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ABSTRACT 
Mannil Prem Kumar 
Marketing Health Care In south East Asia 
The Asia /Pacific basin is currently the centre of business 
activity. One particular area in this basin which· has caught the 
attenton of businessmen is the Asean region especia,lly the 
countries of Thailand, Singapore and Malaysia. Investment has 
poured into these nations and there is rapid development. One 
particular business which has developed very rapidly is the 
health care segment. The economies of these countries are 
flourishing and the standard of health cCare management has 
improved. This means there is a ready market for heath care. 
The thesis begins with a brief introduction to the country 
profiles and then moves to the health care system of the three 
countries. The pharmaceutical industry of the three nations are 
highlighted. The manu-facturing base is small in Malaysia but is 
extensive in Thailand and Singapore. Singapore's Economic 
Development Board is luring high technology based industries and 
showering them with generous benefits. Multinationals feel that 
having Singapore as their base they could tap the entire 
Asia/Pacific region. Patent rights has become a major issue in 
Thailand and the relaxed rules has encouraged the mushrooming of 
generics which has threatened the very existence of 
multinationals. 
The d,istribution network of the pharmaceutical industry is 
~ mentioned. Special mention is made to the G.P.O in Thailand which 
acts as a major purchasing, manufacturing and distributing unit. 
The various drug regulations in the three countries are 
published, with special mention given to the registration 
exercise which is being conducted in Malaysia. The advertising 
code, O.T.C products and self medication has found a palce in the 
thesis. The cross country analysis throws light on the 
pharmaceutidal business in the three nations. The emergenc~ of 
Japan as a future source for pharmaceutical technology is 
explained briefly. The conclusion and the mention of Singapore 
as the venue for the pharmaceutical business takes us through the 
last pages of the thesis. 
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PHARMACEUTICAL MARKETING RESEARCH 
1 The Asia I Pacific region excluding Japan, currently accounts for 
17% of the world wide pharmaceutical sales and represents the 
world's fastest growing pharmaceutical market. In contrast to the 
bankcrupt economies in certain countries of Africa and the 
escalating inflation in South America, the Far East is enjoying 
genuine and rapid economic growth at present with incomes and 
living standards rising faster than anywhere else in the world. 
Asia has changed its outlook all together. This is not the 
continent ages back which was colonised by the West. The outlook 
projected then was a backward and neglected area. Things have 
changed now. Asia has become a leading producer of o11, natural 
resources and boasts of industrialised countries. The economies 
of many Asian countries are comparable to that of Europe, U.S.A 
and Canada. 
Once reknown for cholera, leprosy, typhoid, and malaria and a 
region which had a poor health care system, modernisation has 
moved into the continent. Phatmaceutical and medical supplies 
were shipped into the continent from th~ West. Health care system 
became a necessity and a market developed. During the past 
decade, the value of world consumption of drugs at current prices 
has increased dramatically. In 1976 it amounted to U.S$43 billion 
and in 1985 it reached U.S$94.1 billion which saw an average 
annual increase of 9.1%. 
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lg 1 WORLD CONSUMPTION OF PHARMACEUTICAL BY REGION U.S$ BILLION 
EX MANUFACTURER'S PRICE 
North America 8.761 28.141 
W.Europe 13.111 22 
E.Europe 6.197 9.6 
Japan 4.020 14.038 
Oceania 0.480 0.7 
Latin America 3.689 5.6 
Africa 1.268 2.7 
Asia 2.920 6.6 
China 2.6 4.7 
( W.H.O, Geneva 1988 ) 
The health care system in North America and Europe·has developed 
to a stage which will ultimately become saturated. Multinational 
pharmaceutical companies have become uneasy. New markets have to 
be found. The Latin American economy is in bad shape. Brazil, 
Argentina, Mexico and Venezuela have huge debts and their 
economies are in shambles. Africa has not improved that much 
either. It is still poverty stricken and famine has rocked the 
land. Only a handful of African nations have strong economies. 
On the whole the entire region is neglected and the dark 
continent will still remain as such. 
Thus, what remains is Asia. An ~ver ready market which has proved 
to the Western investor an alternate region for investment and 
trade. 
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PHARMACEUTICAL MARKET SIZE PACIFIC AREA 
KOREA 
TAIWAN 
INDONESIA 
1986 LOCAL 
CURRENCY 
MILLION 
W927,300 
NT18,942 
Rp528,000 
PHILIPPINES P8,175 
THAILAND 86,640 
MALAYSIA M$270 
HONG KONG HK$594 
SINGAPORE S$92 
Pacific, October 1987 ) 
1986 US$ GROWTH 
IN IN 
MILLION L.C 
1053 +3 
493 +17 
419 +11 
374 +15 
255 + 3 
108 +8 
76 +6 
44 +5 
GROWTH 
IN 
U.S$ 
+2 
+22 
-4 
+7 
+2 
+3 
+6 
+5 
South Korea leads the region with a pharmaceutical market size 
of U.S$1.05 billion, although its growth has slowed down 
tremendously. Taiwan has overtaken Indonesia in the number 2 
spot, with the most impressive growth rate in the region in 1986 
with 22% in U.S$ terms. Indonesia's lag is largely due to the 45% 
devaluation of the Rupiah it suffered in 1986. The Philippines 
is back to where it was in 1983 at U.S$374 million. The remaining 
countries showed marginal growth. 
Zeroing down to a special region is Asean (Association Of South 
East Asian Nations). Three of the countries, Thailand, Malaysia 
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and Singapore have become centres of success. Singapore the 2.5 
million populated country has become a newly industrialised 
nation, Malaysia has proved to be the world's largest producer 
of tin, rubber and palm oil, and finally Thailand which has 
gathered enough attention to be the centre of investment for 
Asia and is no more the "Sick Man Of The Asian Continent". 
Pharmaceutical companies seeking new opportunities for sales and 
profits in the face of maturing markets in the Western Hemisphere 
and disillusionment about the prospects in other developing 
countries are incresingly looking to the Far East for significant 
rewards in the next few decades in return for investments being 
made now. 
The objective of the research is to establish that Thailand, 
Singapore and Malaysia have become the focal point of investment 
and also comprise a region which could be utilised by 
international health care companies to market their products. 
This is a region whose health care system has improved 
tremendously and which has enormous potential for the major 
pharmaceutical companies. 
This research also looks into the marketing policies adopted by 
pharmaceutical companies in Singapore, Thailand and Malaysia. The 
format for this thesis has been broken into 3 categories that is 
1) Malaysia 
2) Singapore 
3) Thailand 
The resources for the write up have been tapped through library 
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references, interviews and newspaper reports. 
For Malaysia, the interviews were conducted with personnel 
directly involved in the business. People interviewed work for 
Ciba Geigy, Astra, and Johnson & Johnson. The Malaysian Medical 
Council was contacted for material information. The Ministry's 
library, Malaysian Industrial Development Authority, New Straits 
Times and other institutions have graciously provided valuable 
information. 
In Singapore, Johnson & Johnson, The Ministry Of Health, and the 
research company I.M.S were visited for materials. It has been 
observed that no real write up on the pharmaceutical industry has 
been conducted except for extracts from United Nations reports 
which had been tabled years ago. Newspaper reports were a source 
of information but they were b~ief. 
Pharmaceutical companies were reluctant to part with the 
information they had and research companies that conducted work 
charged the companies high rates. Their information was based on 
samples and not on the population as such. 
In Thailand, 
Pharmaceutical 
Johnson & Johnson, Olic. Thailand and the 
Products Association provided valuable 
information. In addition to these sources, The Drug control 
Authorities of the 3 countries provided skeletal reports on the 
pharmaceutical industry. The Drug Control Authorities Of 
Thailand, Malaysia and Singapore are still in their infant stages 
and depend on the U.S, U.K, Sweden,Japan and Australia for vital 
.,.. 6 -
information. 
Thus, it is seen that unlike the West where ready information is 
available, in South East Asia, it is an uphill task to gather the 
material. 
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THE ASEAN PROFILE 
2 The 1980 E.S.C.A.P conference (Economic Commission For Asia And 
The Pacific, 19-23 May 1980) in Bangkok in its findings showed 
a very heterogenous character within ASK\N countries ranging from 
population disparity among the 5 members ie. Thailand, Malaysia, 
Singapore, Philippines and Indonesia. Today the newest member in 
ASEAN is Brunei. 
With a population of 233 million in 1976, a great disparity is 
evident. Singapore, is the smallest, and is represented only by 
. 
1% of the population. Indonesia is represented with 56%. 
Philippines and Thailand shared 18.5%- 18.6% of the population 
and Malaysia recorded 5.7%. 
The number of ailments episodes per year was 700 million cases. 
Indonesia's share of ailments over its population share 
represented 63.7% of the total ailments, and Singapore recorded 
only 0.8% 
~ Requirements of drugs expressed in terms of population needs was 
estimated at U.S$2,750 million at retail price. Share 
requirements was found tQ be : 
Thailand - 14.8% 
Singapore 1. 4% 
Philippines - 25.3% 
Malaysia 3.8% 
Indonesia - 54.7% 
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Actual drugs consumed in 1976 in ASEAN was about U.S$1 billion 
at retail price. Indonesia and Thailand shared the same amount 
of 33% of the total drug consumption in the sub region despite 
their population disparities .. Singapore consumed 3% of the total 
value. Drug consumption in the Philippines and Malaysia was 16.8% 
and 9.8% respectively. 
Local production which is mainly of a formulation nature in 
ASEAN, totaled US$686 million in retail price. Indonesia 
accounted for 40.1%. Thailand and Philippines totaled an equal 
amount between 22.1% - 22.7%. Singapore was found to be 9.8% 
with Malaysia's share being only 5.4% of the total production 
value. 
4 At C. I. F value on the import of drugs in ASEAN countries the 
amount stood at U.S$266 million. 
Thailand 
Philippines 
Singapore 
Malaysia 
Indonesia 
16.1% 
16.7% 
19% 
16.1% 
32.1% 
5 Among the ASEAN members, Singapore had the highest expenditure 
on health with U.S$87. Indonesia accounted for U.S$6.7, Thailand 
U.S$ 17, Malaysia U.S$24.5 and Philippines U.S$9.6. 
Major ailments in the ASEAN region as a whole were 
Upper respiratory 
Dental conditions 
652% 
562% 
• 
Parasitosis 
Anemia 
Skin infection 
Diarrhoeal disease 
47196 
313% 
i87% 
94% 
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6 Together these ail~ents account for more than 50% of the 
morbidity of the region and mostly require simple drugs. To treat 
the various ailments in the region in terms of equivalent of 
active principles, the leading drugs were :-
7 
Paracetamol 9,008 tons 
P.A.S 4,620 tons 
Ferrous sulphate 1,213 tons 
Metamizol 880 tons 
Ferrous gluconate 879 tons 
Peperazine 800 tons 
Aspirin 495 tons 
In terms of dollar value the leading drugs were 
Propanolol U.S$166 million 
Ferrous gluconate U.S$130 million 
P.A.S U.S$77 million 
Penicillin G-sodium U.S$63 million 
Streptomycin U.S$54 million 
Together these 5 items account for U.S$500 million representing 
18% - 20% of the total requirement. 
The distribution of drug consumption by its pharmacological class 
in 1976 was led by antimicrobials 30%, vitamins and nutrients 
10%, analgesics and antipyretics 9%, hormones 8% , and 
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respiratory drugs 7.8% adding to 65% of the total consumption. 
Within the antimicrobial class, the therapeutics group of anti -
biotics was the leading one. 
For Thailand the consumption of psychotherapeutics was increasing 
in average at 187% annually followed by antihelmintics, hormones 
and vitamins which were all increasing at about 80% per year. 
Antibiotics and cardiovasculars was estimated to grow at a rate 
of 70% and 61% respectively. 
In the ASEAN countries the production of drugs could be divided 
into manufacturing of active principle of raw materials and 
formulation of dosage forms. At present the pharmaceutical 
industry in ASEAN is gearing slowly towards the manufacturing of 
active ingredients. Indonesia was the pioneer in this region. 
Active ingredients are still acquired from Western Europe, Japan 
and the U.S 
In 1976 there were 708 producers, with 0.7% being state 
enterprises and 89% nationally owned and 10% foreign companies 
or joint ventures. Of this total of 708 producers, Thailand 
accounted for 183, with Singapore, Philippines, Malaysia and 
Indonesia accounting for 10, 266, 12, and 239 respectively. 
Of a total production at the wholesale price of U.S$686 million 
approximately 40% of this value was produced by Indonesia, 22.7% 
by Thailand, 22.1% by the Philippines and 5.4% by Malaysia. 
Singapore had the most remarkable position with a population 
representing 1% of the region, it accounted for 10% of the total 
output. The structure of 
pharmacological group is 
-ll-
local pharmaceutical production by 
led by antimicrobial, vitamins and 
nutrients, analgesics and antipyretics. The issue regarding 
production and degree of self reliance could highlight the fact 
that ASEAN countries still depend on imports and finished 
products from abroad. Importation to ASEAN countries are from 
West Germany, U.S.A, Switerzland, U.K, and Japan. 
8 MALAYSIA 
In its 1980 report on pharmaceuticals in ASEAN (ASEAN 1980 -
UNIDO) , it was mentioned that the number of formulation plants 
then was 12. The main formulation centre is the Government 
Pharmaceutical Stores in Petaling Jaya.' 81.5% of the raw 
materials were imported. The most significant drug requirements 
in terms of monetary value were : 
Chloroproparnide 
Penicillin 
Metformin 
Chlorothiaz'ide 
Erythromycin 
Hydralazine 
Methyldopa 
Propanalol 
Ampicillin 
9 The drug dosage forms which was commonly used were tablets and 
capsules. The leading drugs in terms of weight which was used 
were : 
Paracetamol 
Tetracycline 
Penicillin 
Ferrous Sulphate 
Ferrous Fumarate 
Aspirin 
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Comparision of requirements and consumption showed gaps. Four 
drugs were overconsumed namely Methyldopa, Ampicillin, 
Tetracycline and Gelusil. There were many drugs found to have 
requirements in excess of consumption such as Chloropropamide, 
Penicillin, Metformin, Chlorothiazide and Erythomycin. U.N.I.D.O 
in its 1980 report found that diabetics mellitus and hypertension 
were undertreated. However, it was seen that psychotherapeutic 
drugs and vitamins were grossly overconsumed. 
PRICE STRUCTURE 
There is no price control on pharmaceuticals in Malaysia. The 
usual mark for retail sales of pharmaceuticals is about 30%. 
Manufacturers and wholesalers have more variable profit margin 
depending on the type of preparations. In general, brand products 
have higher profit margins than generic preparations, only a 5% 
profit is expected by retail pharmacists from the sales to 
doctors. 
SINGAPORE 
In the Republic the basic drugs consumed were 
Antimicrobials 
Analgesics and antipyretics 
Vitamins 
Nutrients 
Respiratory 
Psychotherapeutics 
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W Drugs sold in Singapore by value, dosage unit and weights were: 
RANK $ VALUE DOSAGE UNIT WEIGHT 
1 Chlorpropamide Imipramine Tolbutamide 
2 Chlorothiazide Chloropropamide Acetylsalicylic 
Acid 
3 Imipramine Tolbutamide Chlorothiazide 
4 Tolbutamide Acet ylsa li •:.:ycl i c Chloropropamide 
~~cid 
5 Hydrallazine Haloperidol Paracetamol 
6 Methyldopa Phenobarbitane Methyldopa 
7 Propanolol Chlorothiazide Mag.Trisilicate 
8 Indomethacin Phenytoin .~luminium 
Hydroxide 
9 Acetylsalicylic Chlorpromazine Ampicillin 
Acid 
10 Thioridazine Thioridazine Primidone 
PRICE STRUCTURE 
Given below is the price structure build up and the price to the 
consumer: 
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Material cost 
Other manufacturing cost 54% 
Full factory cost 10096 
Manufacturers mark up 
Price to wholesaler I agent 125% 
Wholesaler I agent mark up 
Price to retailer 15096 
Retail mark up 5096 
Price to consumer 200% 
Thus from the calculations shown it is seen that the price to the 
consumer is 200% from the initial material ~ost of 46%. 
DISTRIBUTION 
The sale of drugs is controlled by legislation under the poison 
act and rules. Generally, drugs which are patented and with toxic 
effects if taken indiscriminately are classified as poisons and 
can only be ~old by registered pharmacists and also dispensed and 
prescribed by doctors. Drugs not included in the poison list can 
be freely sold anywhere. Amongst these, over the counter (O.T.C) 
drugs are vitamin preparations, cough and cold remedies and 
common analgesics like Aspirin and Paracetamol. 
O.T.C items can be dispensed through grocery stores, 
supermarkets, Chinese druggist etc. The major portion of the 
drugs get dispensed through government hospitals, clinics or 
health centres, private hospitals, private clinics and dentists. 
THAILAND 
The 1980 U.N report shows that upper respiratory infections was 
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found to be the leading group disease accounting for 25.8% of 
total cases. The top 5 diseases and symptoms are completed with 
. fever, diarrhoea, headache and intestinal infection adding up to 
51%. It is clear that th'ese are common ailments which require 
simple drugs. Nutritional d~ficiencies, dental diseases 
' 
immunizable diseases, backaches and parasitosis follow. These 10 
diseases account for 655 of the total cases. 
In terms of monetary value, the requirements were led by 
antibiotics, analgesics, antianemics an<~ antiasthmatics. 
Considering the growth of each drug consumption individually some 
drugs show a high rate ranging from 100% 190% eg. 
psychotherapeutic drugs, anesthetics, diuretics and hormones. The 
comparison of requirements and consumption show gaps both for the 
total value and for some individual drugs such as P.A.S which if 
accepted as .standard treatment would have requirements much 
greater than the actual consumption. Paracetamol gives the 
opposite results which means great overconsumption of the drug. 
Regarding production it has been established that the local 
industry has grown tremendously considering the growth in number 
of producers in the industry and the value of the output. Local 
production of drugs under the pharmacological categories are anti 
- microbial drugs, vitamins and other nutrients. Imports of 
pharmaceuticals were mainly from the U.S. A, Germany, Switzerland, 
U.K, and Japan. 
The pharmaceutical industry in ASEAN countries is a formulation 
one with almost all of intermediates and raw materials imported 
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from foreign countries. It is also an industry where multi 
national corporations are active due to the nature of this 
industry which requires high investment. 
11 There are approximately 700 producers in the ASEAN pharmaceutical 
industry. Of this number about 10% or about 70 producers are 
foreign companies and joint ventures. This number, even if 
relatively low is a good indicator of the low degree of control 
by foreign companies. More appropriate indicators should be 
further studied, such as the degree of concentration by overall 
market and sub market concentration. 
It is also the case that profits in the drug industry made by 
M.N.C's in developed countries, such as the U.S.A is higher than 
any other industries. Also transfer pricing in developing 
countries mostly occurs due to the dependency on raw materials 
and intermediates. Evidence in Colombia and India are good 
examples. This transfer pricing is a heavy burden to consumers. 
To this extent developing countries need to set up appropriate 
policies on prices, according to the cost of drugs. Developing 
countries also need to improve their national capacity to solve 
the problem of transfer pricing. 
It is also arguable that in many countries production of basic 
drugs may not be feasibl~ due to the limited economies of scale. 
But the ASEAN pharmaceutical industry, with an existing market 
of U.S$1 billion, shows an appro~riateness of its market size for 
local basic production. Also the appropriateness of purch~sing 
power level in this sub - region, strongly supports this. It is 
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a strategy of basic production to be adopted as M.N.C's would be 
required in order to reach the objectives of an increase in the 
capacity of basic and intermediate production. To promote 
stronger domestic industry, domestic ownership participation is 
an important factor and the improvement of local ownership is 
strongly envisaged by the governments in the countries researched 
in this thesis. There remains the problem of transfer pricing, 
dependency on raw materials and intermediates of the ASEAN 
pharmaceutical industry and the political will to start basic 
drug production and related programmes; 
ASEAN countries, still require many drugs which have to be 
acquired from foreign markets. Essential drugs which would serve 
the need of the majority of the population may be considered 
suitable to set up a local basic production. In any case there 
would still be drugs for which basic drug production could not 
begin and import of raw materials and intermediates would still 
be required. In this case, transfer pricing would be inevitable 
if the procurement system is not improved. 
Bulk drugs purchasing for the sub region is another possible 
option to solve the problem of transfer pricing. 
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SINGAPORE 
The Reptlblic of Singapore consists of Singapore island itself 
and 54 islets. The Republic is situated at the Southern tip of 
the Malay Peninsula and is separated from Malaysia by the Straits 
Of Johore. The island is some 14 miles wide and 26 miles long and 
the total area is 621 square kilometers . 
The island lies 77 miles North of the equator and the climate is 
Equatorial. Temperature varies daily from 7 5 to 80 degrees 
Fahrenheit. It has a relative high humidity and no defined wet 
or dry seasons. 
_____ The-main-r-acial-gr-oups-i-n-the-country are the Chinese 7-1%-, Mal-ays-
15% and the remainder being mainly Indians and Europeans. The 
official languages are Mandarin, Malay, Tamil and English. The 
principal religions practised are Taoism, Buddhism, Islam, 
Christianity and Hinduism. 
Military service for 30 months is compulsory and was extended to 
cover all adult males in 1985. The Singapore armed forces 
numbered 55,000 in 1985, and the defence budget was S$2,173 
million for 1987 ~ 1988. 
Singapore is a member of the Association Of South East Asian 
Nations (A.S.E.A.N), The Commonwealth, the Colombo Plan, I.M.F, 
U.N, the World Bank and W.H.O. 
Burma 
Andaman 
Sea 
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THAILAND 
Location 
Thailand is a South East Asian Kingdom almost equidistant from 
China and India. 
The Kingdom has a population of 55 million is the approximate 
size .of France and shares borders with Burma to the West and 
North, Laos to the North and North East, Kampuchea to the East 
and Malysia to the South. 
Thailand is divided into four distinct regions, the mountainous 
North, the semi arid North East plateau, the Central Plains which 
is the world's most fertile rice growing areas and the lushly 
tropical Southern isthmus. 
Climate 
Thailand has 2 distinct climates ; a tropical savanna climate 
from the Gulf Of Thailand to the North and a tropical monsoon 
climate to the South. There are 3 well defined seasons, the hot 
season (March and April), the rainy season May through October 
I 
and the cool season November through February. Average 
temperatures are about 83 degrees F. 
People 
Over 85% of the population is ethnic Thai anp the balance are 
Chinese, Malay and Indian origin. 
·- 22-
Religion 
Theravada Buddhism is the professed religion of more than 90% 
of all Thais and casts strong influence on daily life. Thais have 
always subscribed to the ideal religious freedom and sizeable 
minorities of Muslims, Christians, Hindus and Sikhs pursue their 
respective faiths. 
Language 
Spoken and written Thai remain largely in-comprehensible to the 
casual visitor. However English is widely understood particulary 
in Bangkok where it is almost the second commercial language. 
National Leaders 
The Head of State is King Bhumibol Adulyadej. His majesty King 
Bhumibol was coronated in 1950 and is the 9th king of the Chakri 
Dynasty. 
General Chatichai Choonavan is the present Prime Minister who 
heads the government. Chatichai won a mandate in the 1988 general 
elections to take over from General Prem Tinsulananda who stepped 
down. 
On the whole, King Bhumibol provides focus for the majority of 
Thais. There are some chronic military problem~ along the borders 
with Kampuchea and Laos and occasional problems with Muslim 
separatists along the Malaysian border. 
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MALAYSIA 
Projecting from the Isthmus Of Kra down South is the Malay 
Peninsula now called West Malaysia. East Malaysia has carved out 
a sizeable portion of 'the Island of Borneo. East and West 
Malaysia are. separated by the' South 
immediate neighbours are Indonesia, 
Philippines. 
China Sea. Malaysia's 
Singapore, Thailand and 
Total land area is 329,293 sq. km and the population is 17 
million to be exact. The official religion is ~slam but all major 
religions are represented. 
Malaysia has a constitutional monarchy system similar to tha-t of 
the United Kingdom. The King or the Yang Di Pertuan Agong is the 
Head Of State of the country. 
Of the 17 million people, the majority of them are Malays who are 
Muslims. The Chinese come in second and they are Buddhists, 
Christians or Taoists. There are also some who have converted to 
Islam. The Indians form the minority and they are either Hindus, 
Christians or Muslims. 
Malaysia's main exports are manufactured goods, petroleum, sawn 
logs, rubber, palm oil and liquefied petroleum gas. The country 
has a labour .force of 6.3 million. 
Overall the country is stable and threat from the communists are 
-25-
minimal. Unlike many nations which have introduced National 
,. 
Service, this system is not practised in Malaysia. Malaysia is 
a member of the U.N, GATT, Commonwealth and the ASEAN. 
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12 STATISTICAL PROFILE I THAILAND 
General 
Land area :514,000 sq.km 
Climate 
Monsoonal. Normal temperature ranges from 20 degrees C to 38 
degrees c. Mean annual rainfall varies from 1,000 mm in the North 
East to 5,000 mm in the South. 
Population 
53.8 million in 1987 with average annual growth tate of 2%. Life 
expectancy is 63 years. 
Relig.ion 
Over 90% Buddhist. Strong Muslim presence in the South. Other 
major religions also represented. 
National Leaders 
Head of state is King Bhumibol Adulyadej. The Prime Minister is 
Mr.Chatichai Choonavan. 
Economic 
G.N.P 
US$43.8 billion in 1987,estimated US$46.8 biLlion in 
1988. Per capita income is US$8'93. 
- 27 l.. 
Economic Growth Rate 
6.6% in 1987, estimated 7% in 1988. 
Currency 
Baht, 25.78 Baht to US$1, 42.3 Baht to Pound ~terling, 14.3 Baht 
to 1DM, 17.9 Baht to 100 yen, 17 Baht to Swiss Franc, 10.2 Baht 
to Malaysian $1, 12.3 Baht to Singapore $1, 3.3 Baht to H.K$1. 
Budget 
1987 I 1988 government revenue was 226 billion Baht, government 
expenditure ~as 270.5 billion Baht. Of total expenditure 20.3 
billion Baht was on agriculture, 0.9 billion Baht was on industry 
and minining, 14.2 billion Baht was on transport and 
communications, 1. 9 billion Baht was on commerce and tourism, 1. 5 
billion Baht was on science, technology energy and environment, 
48.8 billion Baht was on education, 11-.9 -bil-lion Bah-t- on_p_ubl_ic 
health, 9.4 billion Baht on social service, 49.9 billion Baht on 
national security, 34.8 billion Baht on government administration 
and 66.4 billion Baht for loan repayment. 
Trade 
1987 total exports was 296.5 billion Baht. Major exports were 
textiles 13.9%, rice 7.7%, tapioca products 6.7%, rubber 6.5%, 
gems and jewellery 3.9%, integrated circuits 4.9%, canned seafood 
4.3%, maize 1.4%, prawns 1.&%, sugar 3.2%, canned pineapple 1.1%, 
tin 1%. 
Total imports w.ere 349.1 billion Baht. Major imports were capital 
goods 32.9%, intermediate goods and raw mat_erials 34.6%, consumer 
- ' 
googs 9. 63;, .fuel and lubricCJ.nts 12.. 7%, others 10.1%. 
Major trading partn_efs-w~re -qapan, U.S; West G~rma:py, U.K, Hong 
---00 • •• -: 
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Ko_ng, Singapore, Malaysia. 
Balance Of Payment 
Trade deficit 45.5 billion Baht in 1987,current account deficit 
of 14.9 billion Baht, net surplus and unrequisted transfers 30.6 
billion Baht, total balance of payments in surplus of 18. 2 
billion Baht. International reserves at end of 1987 - gold 
U.S$1.2 billion, S.D.R's U.S$60.4 million, foreign exchange 
U.S$3.9 billion, reserve position in the I.M.F U.S$40.8 million. 
Total foreign res~rves U.S$5.2 billion. 
Interest rates average domestic rates as at end of 1987 :-
bank rates 8.0 , ceiling loans 15, repurchase rates ( 3 days ) 
5.31, interbank call rate 7.08, BIBOR {7 days) 6.41, MCR 11.5, 
MOR 11.5, fixed d~posits ( 1 year) 7.25, savings deposits 5.54. 
Manufacturing 
1987 production :- 9.9 million tonnnes of cement, 10.7 billion 
litres of petroleum products, 15,334 tonnes of tin metal, 
119,319 toriiles of tin plat~, 29,333 passenger cars, 68,815 
commercial vehicles, 302,195 motorcycles, 171,666 tonrie-s of 
galvanised iron sheet , 97,293 litre tonnes of beer, 23,373 litre 
tonnes of liquor, 1.6 billion bottles of soft drinks. 
Mining 
1987 estimated production of 341,145 metric tonnes of Zinc ore, 
178,655.6 million standard cubic feet of natural gas, 5.5 million 
barrels of condensate and 6.1 million barrels of crude oil. 
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Agriculture 
1987 I 198·8 estimated production of 18.6 million tonnes of padi, 
2.3 million tonnes of maize, 19.5 million tonnes of cassava, 910 
million tonnes of rubber, 2. 6 million tonnes of fishery products. 
Prices 
Average wholesale prices of commodities per ton as at end 1987 
was padi No.1 at 3,015 Baht, rice (5%) 5,073 Baht, maize 2,501 
Baht, tapioca pellets 2,582 Baht, rubber ( grade 3) 18,939 Baht, 
tin concentrate 113,732 Baht, black matpe bean 6,370 Baht. 
Power 
Current total installed generating capacity over 6, 700 MW of 
which 30% hydro, 13~ 1ign-ite,27% natural gas and 30 % fuel oil 
and disel. 
Resource 
Estim~ted potential oil and condensate reserves 179.1 million 
barrels, estimated natural gas resources 12.9 trillion cu.ft. 
Infrastructure 
104,000 km roads, 4,450 km'of rail track. Major port is Bangkok. 
The other ports are at Phuket, Songkla, Sattahip, Mab Ta Phut and 
Laem Chabang. International air'ports are at Bangkok, Phuket, 
Songkla and Chiang Mai. There are 5, 900 km. of rivers and canals, 
of which only 1,000 km are usable. 
Banking 
Total commercial bank deposits at end of 19'8c7 wa·s 7~6. 6 .billion 
- - . ~~! .,_ • -· 
___) 
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Baht. Estimated money supply (Ml) at end 1987 was 131.1 billion 
Baht, (M2) 805 billion Baht. The Central Bank of Thailand is the 
Bank Of Thailand 
Foreign Investment 
Estimated direct foreign capital investment was 4. 55 billion 
Baht in 1987. 
Investment Policy 
Foreign investment welcomed in specific sectors at government 
discretion. Tax incentives, includes corporate income tax and 
import duty relief. 
Tourism 
Estimated 3. 5 millio-n visitors in 1987 with 49 billion Baht in 
receipts. 
Social 
Labour force :- 28 million in 1987 with an unemployment rate of 
I 
4.1 %. Of the total employed 62% were in agricultur-e, 8.9% in 
manufacturing and 25% in other related fields. 
Health 
13 hospital beds and 1.5 doctors per 10,000 population. 
Military 
Army 166,000, navy 42,000, air force 48,000, ·reserves 500,000 
. - ::· -'~ 
; •."• 
. · .. ·, . 
Country Risk 
Chronic miiitary problems along the b9rd~rs with Kampuchea and 
Laos, and occaf;lional Muslim separatists along the Malysian 
border. King Bhmnibol provides stable focus for the majority of 
Thais, offsetting a general lack of strength in the gove_rnment. 
Economically the country is heading towards N.I.C Status. Asian 
Business rating for the next 12 months (one to five stars 
4 stars. 
. -
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STATIST,olCAL PROFILE :MALAYS:IA 
13 Land Area 
329,293 sq.km. 
Climate 
Hot and Equatorial. Temperature ranges from 22.2 degrees C to 
32.6 degrees c. Mean annual rainfall is 2,500 mm. 
Population 
17 million with an ann~al growth rate of 2.50 %. Life expectancy 
in Peninsular Malaysia is 70 years, Sabah 63 years and Sarawak 
66 years. 
Religion 
Islam is the national religion but all major religions are 
represented. 
National leaders 
The Head Of State is The Yang Di- Pertuan Agong. Prime Minister 
since 1981 and the Home Affairs Minister is Data Seri Dr. Mahatir 
Mohamad Deputy Prime Minister and National and Rural 
Development Minister is Abdul Ghafar Baba; Foreign Minist~r 
Dato Abu Hassan bin Haji Omar; Defence Minister Tengku Data Ahmed 
Ritba~dd'en Tengku Ismail; Finance Milfister Datuk Paduka Daim 
Zainu(jdin; Tr(lde and Ind:Us>try Minis-ter Da:tin Paduka Rafidah A;z;iz: 
Transp9rt: Mip:ifli:er f)ato pr. Ling Liang Sik; Pub~j.g-W,o~ka ftfinis·ter 
' •• ' .~ •• -~ • • • • ~ ·~ - • - - ' c • • ~-- ~. • • -' ·- " -- • 
, ____ .. 
Yaik; Tel;ecornmqnic9tions and Post Minister P~rto Samy Velu; Land 
and RegioncH Development Mirt,ister Da,tuk Dr. Haji Sulaiman; 
Agriculture Minister Dato Ser:i_ Sanusi Junia; Science and 
Technology Minister Datuk Arilar Stephen Yong Kuet Tze; Education 
Minister Encik Anwar Ibrahim. 
Next election :- before 1992. 
Economic 
Currency: Malaysian ringgit (M$); 2.62 to U.S$1 
G.N.P (at current prices) M$69.7 billion in 1987, estimated 
M$75.3 billion in 1988. 
G.D.P (at current prices) M$75.2 billion in 1987,estimated at 
M$81.2 billion in 1988. 
Per capita G.N.P : M$4,412 in 1987. 
Personal income tax ceiling 40% 
Economic growth rate : 4.7% in 1987, estimated 6% iri'1988 
Inflation rate : 0.8% in 1987, estimated 2% in 1988. 
Budget 
198.8 .for_e_Gft.S't, __ f~9.~!"~1 government revenue M$20. 8 billion, 
operating expenditure M$21.2 billion, development expenditure 
(net) M$5.9 billion. Overall deficit M$6.3 billion. 
Trade 
19.87 exports M$45 .1 billion - comprising M$20. 2 billion in 
manufactured goods, M$6.3 billion in petroleum, M$4.3 billion 
in sawn logs, M$·3. 9 billion in rubber; M$3. 3 billion fn palm oil, 
M$1.7 billion in liquefied natural gas (L.N.G), M$1.7 billion in 
Sf1Wfi tiiil}:)~r, t1S8'4Q IlltliJ"()n ~p t·i·n, M$4·-42 ~i~lion ·in P~}m ~ern~l 
oi'l and-·I-f.S.t~-~- J)f~'r-ion·: 
". ";' • .. ·, ·i. ·- .;;._ '-.. ·-,~ 
:".· ' .-;:;' -~-";': i ;_--c.; __ .•.• i- ~-
Impor.ts :- H$29. 8 billio:q: machinery and tt"ansport equipment 
M$14. 3 billion , manufa·ctured goods M$7 billion, ch.emicals N$3. 3 
billion, food beverages and tobacco M$3.1 billion, mineral fuels 
and lubricants M$2. 4 billion, crude materials M$1. 3 billion, 
others M$530 million. 
Balance of payments: 1987 actual overall balance M$2.9 billion. 
Current account M$5.9 billion, merchandise balance M$14.7 
billion, services balance 1"1$9 .1 billion, net transfers M$358 
million, net long term capital M$1.1 billion, basic balance M$ 
4.8 billion. 1988 projected current account surplus M$2 billion. 
Total external debt end 1987 M$51 billion. External debt services 
ratio in 1987 was 15.2%. 
Manufacturing 
Estimated 1987 production - 699,500 cubic meters of plywood, 36 
million litres of paint, 4.1 million tyres,' 3 million tonnes of 
cement, 644,360 tonnes of iron and steel bars/rods. Malaysia 
assembled 9, 000 passenger cars, 31, 000 motor cycles and processed 
2.-1 mil-lion --tonne,;;; of .,palm _QiL 
Mining And Energy 
1987 produc~ion - 30,400 tonnnes of tin, 498,000 U.S barrels of 
petroleum a d~y 1 5.9 million tonnes of L.N.G and 1271987 tonnes 
ot copper. 
Agriculture 
19'87 produption 4. 4 million tonnes of pa:J,m oil, 1. 6 .million 
tolihe~:r;"'9t •L~-t>.b_er 1 . 1 • 6-'~IJI':t} lrdfi· 'tqn}·(e~'s Of J)QQ~ 1 8Qc~fc6'1(?, tonnes Of 
~4;~:ID:~_·:.~ ~-~;nG1 __ •fz~:~:f 1:~.-;~ftJ_~;~~§~~~-~b:~}~- pt~b~~t-~~~}:9;~-~-;:~·~:~.h. ·.:t{;~~--e ___ <_.:·r __ • _-._."~j- _ •. >• 
.
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Services 
Value added to the service sector by wholesale and retail trade, 
hotels and restaurants was M$6.3 billion. Finance, insurance and 
real estate was M$5. ~ billion, 
communications was M$4 .1 billion, 
being M$1.1 billion. 
Banking 
transport, 
electricity, 
storage and 
water and gas 
Bank Negara is the Central Bank. The total international reserves 
as at end 1987 was M$19.4 billion. Money supply as at the end 
of January 1988 -(M1) M$16 billion, (M2) M$57.1 billion. 
Foreign investment The total capital investment was M$3. 9 
billion. 333 applications were approved with potential employment 
of 59,779 workers. Major investors were Japan, Singapore and 
Taiwan. 
Investment incentives : Tax free pioneer status for up to 10 
years, investment tax allowance of up to 100% , tax abatement 
of up to 50% depending on the level of export. Firms with less 
than M$2. 5 million in shareholders funds are exempted from 
applying for a licence under the Industrial Co-ordination Act, 
and are exempted from having to comply with any condition with 
regard to equity, employment, distribution network and export. 
Foreign firms can hold up to 100% equity depending on levels of 
export. 
Tourism 
1987 arrivals . (Peninsular Malaysia) : 3.146 million, bringing 
revenue of M$1.73 billion. Forecast for 1990 ( visit Malaysia 
year ) is 3. 84 million arrivals, bringing revenue of M$3. 05 
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billion. 
Social 
Labour force : 6.3 million, total employment 5.7 million. The 
unemployment rate is 9.5%. 
Health 
17 hospital beds and 3.2 doctors per 10,000 population. 
Military 
Army 90,000 Navy 9,000 Air force 11,000 Reserves 350,000. 
In spite of lingering suspicions about the underlying strength 
and purpose of the government, tensions are considerably eased 
from a year ago, and the Mahatir administration has shown itself 
to be firmly in charge. No external threats; problems with 
communist insurgents minimal. 
Asian Business rating for the next 12 months (maximum five 
stars):- 4 stars. 
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STATISTICAL PROFILE SINGAPORE 
14 General: 
Land area : 621 sq.km. 
Climate : temperature ranges from 24 degrees C to 31 degree~ C. 
The 1986 annual rainfall was 2,5~6 mm. 
Population : 2.6 million in mid 1986 with an annual growth rate 
of 1~. Life expectancy is 68 years for males and 74 years for 
females. 
Religion all major religions represented. 
National Leaders 
President Wee Kim Wee, Prime Minister Lee Kuan Yew, First Deputy 
Prime Minister Goh Chok Tong, Second Deputy Minister Ong Teng 
Cheong, Minister For Foreign Affairs And Minister For National 
Development S.Dhanabalan, Minister For Finance Dr.Richard Hu, 
Minister Of Trade And Industry Brig. Gen Lee Hsien Loong, 
Minister Of Labour Lee Yock Suan, Minister For Education Dr.Tony 
Tan. 
Economic 
G.N.P : S$39.2 billion in 1986, S$41.7 billion in 1987. 
Per Capita G.N.P : S$13,088 in 1986, S$13,938 in 1987. 
Economic growth rate : 1.8% in 1986, 6.5% in 1987. 
Corporate tax base rate :33% 
Currency : Singapore dollar , S$2.11 to U.S$1 
Budget : 1987/1988 government expenditure S$18. 7 billion {S$9 
billion recurrent, S$7 billion development) . Of total expenditure 
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29% is on public housing, 15% public debt servicing, 10% defence, 
8% land development, 18% grants, subsidies and other services. 
1987/1988 government revenue was S$15 billion. Of total S$4.6 
billion is tax revenue of which 42% is from income tax. 
Trade 
1986 total imports was S$55.55 billion. Major imports were 
machinery and transport equipment (37%}, mineral fuels (19%}, 
manufactured goods (13%}, miscellaneous manufactured articles 
(8%}, food (6%} ,chemicals and chemical products (5%). 
Major suppliers :-Japan (34%), U.S.A (14%), Malaysia (13%), 
China (5%), Taiwan (4%}. 
1986 total exports was S$49 billion. Major exports were machinery 
and transport equipment (38%), mineral fuels (20%), manufactured 
goods (7%), chemicals (5%1, miscellaneous manufactured articles 
(8%), food (5%}. 
Major markets :- U.S.A (29%), Malaysia (10%), Japan (10%), Hong 
Kong (6%), Thailand (3%). 1987 imports S$57.8 billion and exports 
being S$51.7 billion. 
Balance of payments : Surplus of S$1 billion in 1986. Total 
foreign reserves at end!of 1986 being S$28.2 billion. 
Manufacturing 
1986 production of 96,008 tonnes of vegetable cooking oil, 
167,000 tonnes of animal fodder, 152 million kilo litres of soft 
drink, 51 million sq. meters of plywood, 35,381 kilos of paint, 
22,753 tonnes of soap, 1,691,000 television sets, 12,824,000 
radios, 7.4 million cu. meters of broken granite, 162 million 
bricks, 1,897,000 tonnes of cement. 
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Agriculture 
1986 production :- 20,279 tonnes of fish, S$7.9 million worth 
of day old chicks, S$10.3 million worth of cut orchids exported. 
Power 
19!6 electricity production was 10.6 billion kwh, consumption 
being 9,475 kwh. Of total consumption, 84% by industry, 16% 
domestic sector. 1986 gas production 577 million kwh, consumption 
549 million kwh. Of total consumption, 53% by domestic sector, 
44% commercial sector, 1% industrial sector. 
Infrastructure 
2,686 km of roads, 72 post offices, 1.2 million telephones, 236 
primary schools, 157 secondary schools and pre - universities, 
junior colleges, 15 technical and vocational institutes, 3 
polytechnics, 1 institute of education, 1 university. 
Sea ports handled 112.8 million freight tonnes in 1986, airport 
handled 352,808 freight tonnes. 
Banking 
Total deposits of non bank customers at commercial banks S$30.6 
billion. Money supply at end of 1986 ( M1) S$9.8 million, ( M2) 
S$30.95 billion. 
Foreign investments 
Foreign investment commitments in 1986 estimated S$1.4 billion. 
Major investors were U.S.A, Europe, Japan. Major invested areas 
were in industries producing electronic equipment components and 
·computer related products. 
-~-
Investment policy 
Government provides various investment incentives including 
pioneer status, accelerated depreciation allowance, tax 
excemption on interest on approved foreign loans, concessionary 
tax, infrastructure is also upgraded to encourage foreign 
investment in capital intensive/ higher technology industries. 
The government has entered into double tax agreements and 
investments gurantees with coun~ries that have trading and other 
interests with Singapore. 
Tourism 
1986 tourism arrivals was 3,191,058 with about S$4 billion 
receipts. About 61 hotels with 22,080 rooms' at end of 1986. 
Social 
Labour 1.2 million at end of 1986 with an unemployment rate of 
6.5%. Of total work force, 23% are in commerce and services, 25% 
in manufacturing, 22% in other services, 8% in construction and 
0.7% in agriculture and fishing. Average weekly earnings S$196 
for agriculture and fishing, S$224 foe manufacturing, S$205 for 
construction, S$248 for transport and communications, S$194 for 
financial and business services. 
Health 
9,974 hospital beds, 1.06 doctors per 1,000 population. 
Military 
Army 45,0DO ( 30,000 conscripts ) , navy 4,500, air force ~,000, 
reserves 150,000. Also 7,500 police/ marine police, 30,000 home 
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guards. 
Country risk 
There are no immediate external threats to Singapore, but 
instability in either Malaysia or Indonesia could threaten 
harmony among the different races and religons. The major threat 
to internal security, now that the recession has bottomed out and 
business confidence is returning, is dissension within the P.A.P 
and a power struggle among the young guards. 
Asian Business rating for the next 12 months ( maximum five full 
stars): 4 1/2 stars. 
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THE MALAYSIAN HEALTH SERVICE 
15 In the year of independence, 1957, the Malaysian Government 
inherited a health service in which facilities and manpower were 
unevenly distributed in terms of service sect9rs and geographic 
coverage. Since independence the Government has been working 
towards the expansion, improvement and redistribution of 
facilities. 
The various mortality rates which are commonly used as indicators 
of a country'~ health status has increased significantly and the 
health services have shown marked improvement. The increase in 
the number of rural health centres and in specialised units in 
hospitals has been impressive. At the same time demand for health 
care has increased as people became more aware of the importance 
of health. 
The Malaysian Medical Association in its publication says that 
. 
in 1970 the median age in Malaysia was 17.3 years with 64.1% of 
the population below the age of 24 and 44.9% below the age of 
14. Tfie population of Malaysia is predominantly rural, although 
over the last 20 years it has witnessed a ~arge increase in size 
of the urban population. As mentioned earlier, the infant 
mortality rate is a general indicator of the general health 
status of a country. The figure below throws some light from 1947 
till 1976. 
16 
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TYPE OF MORTALITY 1947 1957 1967 1976 
Infant mortality 102 75.5 45 30.7 
Maternal mortality 7 2.9 1.7 0.8 
Neonatal mortality 40 30 24 19 
' 
Toddler mortality N.A 11.0 5.0 2.6 
The infant mortality rate declined from 102 in 1947 to 30.7 in 
1976 while the toddler mortality rate, which i~ sometimes used 
to ind~cate the nutritional status of a country has declined from 
11 in 1957 to 2.6 in 1976~ Similarly the maternal mortality rate 
has declined significantly from 7 in 1947 to 0.8 in 1976. However 
the improvements in the general health status are not enjoyed 
equally by all parts of the country. The less advanced states 
reveal mortality rates which are much higher than the average 
figure for Peninsular Malaysia as well as the more advanced 
states suggesting a poverty mortality relationship. The 
difference between the advanced states such as Selangor, Penang 
and Malacca and the less advanced states such_as Kelantan, Kedah 
and Trengganu are highlighted. 
17 MORTALITY RATES BY STATES, PENINSULAR MALAYSIA - 1976 
STATES INFANT MATERNAL TODDLER 
KELANTAN 38.68 1.23 4.01 
KEDAH 33.69 1.54 3.09 
TRENGGANU 36.01 1.07 4.59 
PA,HANG 31.84 1.45 3.01 
PERL IS 31.19 0.52 2.82 
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SELANGOR 28.87 0.41 1. 76 
PERAK 30.59 0.72 2.82 
PENANG 26.72 0.51 1. 38 
MALACCA 26.55 0.36 1. 81 
N.SEMBILAN 27.22 0.54 2.03 
JOHORE 28.76 0.51 2.15 
PEN. MALAYSIA 30.74 0.78 2.56 
CROSS NATIONAL COMPARISONS 
Cross national comparisons of health indices among several 
selected countries show that Malaysia compares quite favourably 
with countries in the same group, but in some respects is behind 
the high incbme countries. In the ASEAN region, in particular, 
Malaysia's state of health is not favourable as that of 
Singapore's but is better than that of Indonesia, Thailand and 
Philippines (please refer to page 49). 
It has been ·observed that the broad base of the population 
pyramid has become narrower and the age dependency ratio lower. 
Population growth rate has stabilised. Child mortality has 
declined. Health indicators on infant, toddler and maternal 
mortality rates show that a higher level of health all round and 
life expectancies have lengthened . 
18 Disease patterns show a definite shift :from diseases of 
urtderdevelopment to diseases of developed countries. Heart and 
cardio - vascular diseases have been the leading causes of death 
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since 1980. Other problems which have assumed importance are 
neoplasms and accidents. 
19 Major killers such as Malaria, Pulmonary T.B, Gastroenteritis, 
Pneumonia and other infectious diseases have declined as causes 
of death. People no longer die of deficiency diseases such as 
beri - beri anymore. However, diseases of early infancy are still 
significant causes of death and bronchopneumonia and Gastro 
enteritis remain important causes of infant and toddler deaths. 
20 In terms of ethnic differentials, the Chinese enjoy better health 
than the other two ethnic groups ie. the Malays and Indians. 
This is because most of the Chinese households dominate the urban 
population and enjoy higher incomes, and spend more money on 
I 
medical and health services than the other races. 
21 In a study conducted by Dr. Abdul Khalid Saban, the Director 
General Of the Ministry Of Health, it is seen that the higher 
morbidity rates are : 
1) In certain states ( Kelantan, Trengganu, Kedah, Perlis and 
Pahang). 
2) Among Indians. 
3) Income below M$300 to M$1,000. 
4) Among agricultural, forestry and fishery workers followed 
by fa9tory workers. 
5) Unsatisfactory water supply. 
6) Children under 5 and elderly over 55. 
In the case of self medication, Dr. Khalid says that 61% of the 
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people who were ill and did not use services (government or 
private) were using self medication. 
22 ILLNESS RELATED VISIT 
1) 1.27 visits I person I year to private clinics 
2) 0.57 ·visits to government hospitals I urban clinics 
3) 0.44 visits to government rural clinics. 
Generally persons with lower household income use government 
rather than private facilities. 35% with house hold income less 
than M$300 use private facilities. 25% with household income 
M$2000 - M$4999 use government facilities. 94% with household 
income below M$1000 and 76% with household income M$1000 - M$1999 
were admitted to government hospitals. 
23 COST 
Payments on the average - government hospital M$2.60 
- government clinic M$1.50 
In the case of private clinics most patients paid a sum of MS5 
to M$14 as medical charges. 
24 METHOD OF PAYMENT 
It is estimated that nearly 48% of the patients pay their medical 
bills out of their pockets. About 13% are compensated by their 
employers or insurance. The remaining are believed to enjoy free 
medical treatment. 
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25 COMMON CAUSES OF MORTALITY AND MORBIDITY IN PENINSULAR MALAYSIA 
( 1947 - 1976 
The common causes of mortality between the post war years and 
independence were IJlainly communicable diseases such as 
tuberculosis, malaria and gastro - enteritis. Those diseases have 
been commonly associated wi t'h underdevelopment and poverty. 
However, in the 1970's the common causes of mortality are 
reflecting diseases, that are more related to development and 
modernization such as cardiovascular and heart diseases, 
neoplasms and motor accidents. 
A striking feature of the system of health delivery in Malaysia 
is the rigid sep-aration of g-overnment health services from those 
rendered by the private sector. Government health services are 
often inconvenient and time consumuing to use whereas private 
services are expensive for many people. 
The growth of the private sector in medicine has been striking, 
lagging only slightly behind the government sector. Between 1957 
and 1976 the number of private doctors increased from 456 to 
1,110 marking an increase of 2. 45 times. The corresponding 
increase of doctors in the government sector was from 401 to 1401 
an increase of 3.49 times. For 1976, the ratio of private to 
government doctors was 1 : 1.26. It has been estimated that of 
the 1,401 doctors in the government service in 1976, 70% were 
young doctors under compulsory service. The older and more 
experienced doctors have moved into the private practice. Th~ 
26 
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major part of the National Health Budget goes into curative 
medical and health care father than preventive medicine. Nearly 
3/4 of the total current expe,nditure in 1973 was spent on 
curative care. 
Malaysia has developed a comprehensive rural health system of 
main and sub health centres as well as mid wife clinics - cum 
quarters. In the delivery of health care, this very extensive 
rural system plays a primary role. 
The rural health system relies to an overwhelming degree on the 
paramedics and physicians often act more in a supervisory rather 
than operational capacity. 
---
EXPENDITURE 
In Malaysia the expenditure incurred by the government on health 
is lower than that of other essential services. 
Fig 3 MINISTRY OF HEALTH FINANCIAL APPROPRIATION 
YEAR TOTAL % TO NATIONAL % GNP PER CAPITA 
BUDGET ALLOCATION 
1961 M$112,663,747 7.97 2 13.45 
1965 M$142,660,938 5.94 1.92 15.20 
1970 M$183,033,101 5.64 1.51 17.39 
1975 M$405,011,250 5.78 2 0 3c9 33.97 
1980 M$895,579,857 5.27 3.53 66.65 
198:5 M$1, 25.6, 33'3, 300 4.3 2.23 80.13 
19.86 M$1,273,622,440 4.13 . 2.14 79.13 
-·--.;"'" '-· -~· ·-. ~.:.- -
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In comparison with her ASEAN counterparts, : Malaysia 1 s health 
budget as a percentage of the national budget was second only to 
Singapore in 1975, ~nd perhaps equal with the Philippines for 
which no fig~res are available. 
Fig 4 HEALTH BUDGET AS A PERCENTAGE OF NATIONAL BUDGET 
1975 FOR ASEAN 
Malaysia 5.9 
Singapore 10.77 
Indonesia 2.0 
Thailand 3.14 
Philippines (1971) 5.63 
While the allocation for patient care services under the 3_rd 
Malaysia pl-an as collfpared to the 1st Malaysia plan increasesd by 
34%, the allocation for public health services rose by 121% 
showing the increasing attention of the government towards the 
promotional and preventive aspects of health. The most important 
component of the public health sector is tll!l rural hea-lth 
service. Investment in the rural health services has a vital 
role in the New Economic Policy. 
The health of her people is a natipn 1 s most important investment, 
followed by education. Recognition of the need to sustain the 
health services by ensuring an adequate and reliable supply of 
both qualified professionals as well as paramedics to meet an 
increasing population needs is being met by increased allocations 
for training programmes und-er the first, 'second ana third 
Malaysi'a pl-ans. CQ~parcttively I p6pulation and family health 
-. .-:. .. · 
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programmes receive more allocations than training programmes. 
28 MANPOWER 
As the years progressed a greater percentage of Malaysians have 
joined the medical profession. Till the 70's only the University 
Of Malaya was producing doctors but now the University Sa ins 
Penang and the University Kebangsaan in Bangi have been 
graduating physicians. The housemen or "freshies" as they are 
called ,have a bad taste of the Malaysian Medical System. They 
work 48 hours non -stop at times and are normally on call 3 times 
a week. Furthermore they are poorly paid. The recent economic 
conditions forced the government to abandon plans to recruit 400 
doctors from the local and foreign universities. The Deputy 
Health Minister then, Mr. Pathmanaban, took the issue to the 
Public Service~ Co~~ls~i6n and finally won approval to get the 
400 to work for the government. Most doctors wait to complete 
their housemanship and the 'required 3 years of government service 
before leaving for: the private praptice. But with the economy in 
bad shape and many doctors in private practice, bu~ine~-~ h_(l~ 
indeed become dull. Thus these doctors prefer to stay around for 
the time being. The smarter ones sit for M.R.C.P or F.R.C.S exams 
to have additional qualification or migrate to the u.s or U.K. 
The many reasons for leaving the government are :-
1) no proper incentives. 
2) unsatisfactory promotional prospects. 
3) unsatisfactory working hours. 
4) lack of opportunities t6 work in " one's " choice of, 
specialisation. 
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5) need to pass the Bahasa Malaysia exams. 
6) inadequate training opportunities. 
7) frequent transfers. 
8) poor relations between superiors and subordinates. 
9) rural posting. 
10) lack of opportunities to participate in administration 
decision making. 
11) special treatment for the Malays. 
In addition to these many doctors emigrate due to the following 
reasons. 
1) uncertain future. 
2) childrens education. 
3) training opportunities. 
4) fi-nancia-l reasons . 
Nobody wants to work for the Government for the rest of their 
lives. In terms of monetary gain one would retire from the 
government on a M$3,000 I month salary but in the private sector 
! ,--'--- - - -
--
tfie flgure rang~s from M$3,000 to M$10,000 a month. 
Thus with the brain drain taking place the: Malaysian Medical 
system is going to face a manpower crisis. Malaysia's loss would 
be a gain for Canada, U.K, Australia and New Zealand. 
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HEALTH SERVICES IN SINGAPORE 
29 The Ministry Of Health provides the curative, preventive and 
rehabilitative health services. Its organisation comprises a 
headquarters with 8 main divisions and individual operational 
institutions, departments and units. 
Curative services are provided by the hospitals, five of which 
are general hospitals. The other five hospitals specialise in 
obstetrics and gynaecology, psychiatry, dermatology and 
venereology, infectious diseases •and children's rehabilitation. 
The general hospitals provide multi - disciplinary inpatient and 
specialist outpatient . services and a 24 hour accident and 
emergency service. The hospital services are supplemented by a 
network of gener_al outpatient and dental cli-nics. 
Health education and preventive health services are provided 
through the Maternal And Child Health, School Health and School 
Dental services and the Training and Health Education Depar.tment. 
Support- services of the Ministry include BT-ome-dical Englr1eering, 
blood transfusion, Computer information, pathology and 
pharmaceutical services. The School Of Nursing undertakes the 
training of nurses to serve the needs of both the public and 
private sectors. Administrative support is provided by the 
Planning and Development, Finance And computer Services, and 
Personnel And Administrative Divisions. 
30 STATE OF HEALTH 
The general health status of the people in Singapore remained 
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good in 1986. There were no major outbreaks of communicable 
diseases. The estimated mid - year population was 2.59 million, 
reflecting a growth of 1.1% over the previous year. By age 
groupings, 23.9% of the population were below 15 years, 68.1% 
between 15 to 59 years and 8% who were 60 years and over. 
The crude birth declined from 16.~ the previous year to 15.2 per 
1000 population in 1986. The crude death rate and the infant 
mortality rate have remained fairly stable over the past few 
years at 5.0 per 1000 population and 9.1 per 1000 live births 
respectively. 
The main causes of death continued to be heart disease, cancer, 
cardiovascular disease, pneumonia and accidents. The pattern of 
morbidity ~mong hospital patients also re~ained unchanged. 
Amongst males, the main causes of hospitalisation were accidents 
and diseases of the circulatory and digestive systems. For 
females, othe.r than pregnancy and childbirth, the most common 
causes of hospitalisation was diseases of the genito-urinary 
system. 
Tuberculosis remained the most frequently notified communicable 
disease with 1,765 new cases reported compared with 1,952 cases 
the previous year. The other main communicable diseases were 
viral hepatitis (730 cases), malaria (180 cases) and typhoid and 
paratyphoid fever (158 cases). 
31 PRIMARY HEALTH DIVIS.ION 
Pr~mary medical care ia avc:dlable to the public at the Division's 
; ·- '··: ~ 
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25 outpatient clinics; preventive health care for mothers and 
children at the 24 maternal and child health centres and health 
care for the school children and the elderly by the School Health 
Service and the Health Service for the elderly respectively. The 
Division's Training And Health Education Department, is 
responsible for the planning and co-ordination of all health 
education activities, the provision of health education over the 
mass media and group educational activities for specific target 
groups in the community. 
Attendance at the outpatient clinics totalled 2, 344,081 for 
medical consultations and minor surgical procedures. During the 
year, the clinics served a total of 645,500 persons. The common 
medical condi tiona seen in the clinics are upper respirat_Qry 
tract infections, hypertension and diabetes mellitus. In April 
an epidemic of influenza lasting six weeks occurred in Singapore. 
The number of attendances of such cases rose to a peak of 34,000 
per week compared with the average of 12,000 per week normally. 
Special venera! disease screening and superv:j..sed outpa-tient 
treatment of hiberculosis were also conducted in the clinics. 
At the maternal and child health clinics, attendances by women 
for ante - natal and post - natal care and family planning were 
282,657 and ~Y new born infants and pre - school children for 
medical and developmental assessment and immunisation was 
483,262. In all about 76% of all babies born in 1986 attended the 
maternal and child health clinics. Postpartum nursing, follow up 
of at risk babies and defaulter visiting amounted to 187,069 .. The 
number of home visits SQO~~d a decline O·f 19% compared with the 
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previous year as more mothers who defaulted from follow up care 
were contacted through the telephone. 
During the year, the School Health Service provided full medical 
examination for 118,446 school children at Primary 1 and 4 and 
secondary 4 levels. Another 295,933 students received medical 
f 
examination for various 'specific conditions. The immunisation 
programme for school children and the reinforcement of the 
message of heal thy living to school children were also undertaken 
by the School Health Service. Besides giving talks to school 
children, three health fairs were conducted during the year. 
Children with specific medical problems were followed up at the 
School Health Specialist Clinics. The common health problems 
identified among school children were visual defects ( 42. 9%) , 
obesity (10.4%), minimal scoliosis (6.2%), asthma (2.5%) and 
cardiac disorders (1.4%). 
Health education activities and programmes were stepped up. It 
was estimated that 1.6 million people had participated_in t~e 28 
exhibitions, 1,343 talks, 11,936 film shows and 388 displays and 
demonstrations organised by the Training And Health Education 
Department (THE). During the year, about 2,000 different types 
of health education materials were produced. "T.H.E" also 
developed and offered training courses and workskops for teachers 
and·factory nurses on family life education and co-ordinated the 
abortion counselling training for nurses. 
32 DENTAL DIVIS-ION 
. 
The Dental Division provides a comprehensive de.n·tal pr:~~rramme to 
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render and maintain school children dentally fit. It also 
provides routine and specialised dental treatment to the public 
and trains dental auxi-liaries for public service. A 24 hour 
emerg~ncy dental service is also available. 
In 1986 a total of 1,165, 610 attendances and 1, 910,525 procedures 
were carried out, an increase of 0.1% and 4. 9% respectively, 
compared to the previous year. The school dental health programme 
extended its coverage of school children by 5. 3% to 251,254 
children in primary and 86,909 children in secc;mdary schools. 91% 
of the school children were rendered dentally fit. The emphasis 
continued to be on preventive dentistry. 
Attendances at the five hospital dental clinics were 1.~9_,_999 and 
-------- - -- -- --- - ---·- - ----
196,960 procedures were carried out, reflecting increase of 7.1% 
and 7.8% respectively, over the previous year. 
The community dental clinics recorded 1a5,193 attendances and 
2.44, 258 procedures re.f-1-ectf,ag deereases of-- 25.7% -and-- 22;9% 
respectively, compared with the previous year. The leasing out 
of another 2 community dental clinics to private dentists caused 
these reductions. 
Fifteen student dental nurses, 7 assistant nurses (dental) and 
2 dental technicians were trained by the Dental Training 
Department in 1986. 
. ·-~ ' 
• c ·- ., ·'·." 
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33 ATTENDANCES AT DENTAL CLINICS :1980, 1984 -1986. 
Dental clinics 
School 
Hospital 
Community 
Total 
19,80 
539,459 
201,638 
356,957 
1,098,054 
HOSPITAL PHARMACIES 
1884 
660,597 
146,949 
325,721 
1,133,267 
1985 1986 
750,157 804,504 
146,949 159,999 
264,542 201,107 
1,164,031 1,165,610 
The dispensing service was extended and since April, a 24 hour 
dispensing service is available in 4 general hospitals ie. 
Singapore General, Tan Tock Seng, Toa Payoh and Alexandra 
Hospitals. Computerisation of the Inventory Control System in 
these 4 hospitals and the Kandang Kerbau Hospitals was 
implemented in stages and completed in June. A notable feature 
of the system is a direct order entry to the Pharmaceutical 
Department to improv~ productivity and cut down paper work. 
HOSPITAL DEVEL0PMENT PLAN 
The Ministry has adopted a target provision 0f 4. 0 beds per 1, 000 
population for 1990 and 4.2 beds per 1,000 population for 1995. 
over the next decade, the·~xisting hospitals will be redeveloped 
to meet the demands for better quality accomodation and to 
provide additional support facilities which are currently 
lacking. More class A, 81 and 82 beds will be provided. The major 
hospital developments over the next 4 to 5 years include the 
following : 
a) Wopdbridge Hospital will be redeveloped into a 2,560 bedded 
hospital. 
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b) Tan Tack Seng Hospital will be renovated and redeveloped to 
1,200 beds with about 350 Class A and B1 beds. 
c) Tba Payoh Hospital will increase its beds to 560 with about 
145 Class A and 81 beds. 
d) Kandang Kerbau Hospital will have about 390 Obstetrics and 
Gynaecology beds and 86 neonatal beds, and with about 180 
class A and 81 Obstetrics and Gynaecology beds. 
e) An additional 200 bedded Community Hospital will be built in 
Ang Mo Kio. 
34 PERSONN.E·L AND ADM-INISTRATION DIVISION 
A9 at December 1986, the Ministry had a total staff strength of 
12,7 33 comprising 12,649 monthly rated and 84 daily rat:~_q 
employees-. Thi-s rs a decre-as-e of 214 over the precvio.us year, due 
mainly to the reduction of recruitment of Division 4 staff. 
35 MAJOR DEVELOPMENT PROJECTS 
a) SKirt Disease Centre : commenced construction in May 1986. It 
cost S$19 million and is expected to be completed at the end 
of 1987. 
b) College Of Medicine Butlding : Renovations began in November 
1985. It cost S$14.42 million and is expected to be completed 
by February 1987. 
c) National Blood Centre building works started in October 
1986. It cost S$34. 3'4 million and is expected to be completed 
in e(lrly 198'.8. 
d) Toa Payoh aJ:ld JurQ!lg East Polyclin-i~s 
._ .o:"': 
., __ ·, ~ 1'-
• -..-- '- o< ~ _,,_ ,.;:i' ' .. -;-"'"'-. 
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Payoh Polyclinic commenced in June 1986 and cost S$2. 4 
million and is e~pected to be completed tn August 1987. 
Construction of Jurong East Polyclinic coll!menced in August 
1986 and cost S$2.5 million. The project is expected to be 
completed in October 19~7. 
e) Woodbridge Hospital : Principle approval for redevelopment was 
received in June 1986. The project cost S$170.8 million and 
is expected to be completed in December 1990. 
f) National University Hospital : The develo~ment ~ork has been 
fully completed. Officially inaugrated on 17 June 1986 and 
cost S$293. 72 million and is expected to be fully commissioned 
in 1987. 
36 STAFF STRENGTH 
Dcicto~s linclud1ng housemen) 
Dental officers 
Nurses 
Dental nurses 
Administrative, executive, statistical and 
clerical staff 
Engineering, scientific and other professio~al 
staff 
Medical ancillary and tech~ical staff 
Health attendants 
Other general workers 
Daily rated employees 
Total 
1,086 
97 
4,967 
321 
802 
93 
890 
3, 229 
1,164 
84 
12,733 
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37 RECURRENT EXPENDITURE AND REVENUE 
The Ministry's total recurrent expenditure in FY 1986 was S$374 
million representing a decrease of S$41 million or 9. 9% less 
than FY 1985 expenditure. The reduction in health expenditure was 
due mainly to the wage restraint policy. Expenditure on manpower 
accounted for S$271 million or 72.5%. This was S$33 million or 
10.9% less than the expenditure in FY 1985. 
The hospitals continued to be the largest user of health budget, 
consuming S$258 million or 69% of the total recurrent 
expenditure. Support services accounted for S$48 million (13%) 
of the recurrent expenditure. Primary Health Care and Health 
Education Division accounted for S$36 million or 10% and the 
Dental Division accounted for S$15 million or 4%. 
The Ministry collected S$129. 7 million in revenue in FY 1986, 
an increase of S$6. 7 million or 5. 5% over the previous year. 
This was due mainly to more patients opting for higher class 
w.ards with the extension ot Megi~SAY~- to __ pay the full- C-lass A-
bills from January 1, 1986. The bulk of tpe revenue collected, 
S$108. 7 million ( 83. 8%) came from hospitals. Total revenue 
collected represented 34.7% of total recurren:t expenditure. 
The basic split in the health care provision is between primary 
health c~re services and hospital services rather than between 
public and private. 
Primary care is widely available, provided m~,~nly by private 
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Private COIJipanies often provide medical benefits for their 
employees for primary care. Government clinics and dispensaries 
also provide primary care~ Charges are considered reasonable. 
Hospital services are supplied mainly by the government. Although 
there are equal numbers of private and public hospitals, private 
hospitals provide only 21% of the beds. Hospitalisation charges 
are covered by the Medisave savings scheme and by limited private 
insurance. 
There is an adequate number of doctors but a shortage is seen 
among nurses and dentists. The government aims to increase the 
number of the latter and decrease the ratio of "population" 
versus "doctor". 
A considerable number of traditional Chinese physicians practice 
mainly in the less populated areas. Singapore has a fairly 
uncontrolled pharmaceutical market as the 1975 Medicines act has 
not QE!.en fullY implemented. Only the regula-ticon -o-f advert-i-si-ng, 
promotion and clinical trials and the registration of pharmacies 
has been enforced by 1987. However in response to requests from 
the local industry a product registration procedure and licensing 
of manufacturers, importers and wholesalers are being introduced 
from 1987. 
Singapore has an active local manufacturing industry and is a net 
exporter of pharmaceuticals. Imports of medical equipment in 1983 
reached U.S$34 million, of which it is estimated that up to.50% 
may be re - expo:rted. Th~ local i:nqustry is sma,ll _bl;l,t g-rowJ-ng. 
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38 HOSPITAL S·ElRVICES 
The cost of hospital treatment is covered by the Medisave scheme. 
Medisave is pa.rt of the Central Provident Fund. All employees 
make a compulsory contribution from their salary to an account 
in the c. P. F. This contribution is matched by their employer. The 
account attracts interest at 6. 75%. Apart from Medisave the C. P. F 
is designed to help the account holder to finance the purchase 
of housing and to see them through retirement or permanent 
incapacity. An amount equal to 6% of salary goes to the 
employee's Medisave account, up to a maxium total of S$360 per 
month. The self - employed (who pay 6% of their income) are 
encouraged to join. The account is used to pay hospital expenses 
incurred by the account holder or their immediate family (spouse, 
children, parents or grandparents). 
Medisave covers all expenses which are incurred during 
hospitalisation at government establishments, including ward 
charges, operational fees, pharmaceuticals and x - rays and has 
been expanded to include some expensive minor surgery which (,i_Q~_s 
- - -· _. -- ------ -
not involve hospitalisation. Since 1986, it can also be used to 
cover hospitalisation at private hospitals, subject to a daily 
maximum (which depends on the illness). 
Medisave does not cover certain investigative or laboratory 
procedures, nor outpatient services from hospitals, except the 
minor surgery mentioned above. 
If hospital expenses exceed the amount in the account, the 
patient must pay the difference. overdrawn accounts are paid back 
'_: __ ~ ,. __ 
·,;:_,'·''· ,._ 
63 
by future contributions, but may incur charges at C.P.F rates 
until the balance is positive again. 
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HEALTH SERVICES IN THAILAND 
39 The administration of the Public Health Services is under several 
government agencies and administration namely the Ministry of 
Public Health, The Ministry Of University Affairs where all the 
university hospitals belong, Armed Forces and Police Medical 
Services, an~ local authorities, particulary various provincial 
municipalities and The Bangkok Metropolis. University hospitals 
are the largest and not only possesss the most sophisticated 
facilities, but also are leading institutions for training of 
medical specialists of all major and minor sub- specialities. 
There are at present 8 university hospitals. All health services 
up country are under the office of the Permanent Secretary of 
the M. 0. P. H, whereas in Bangkek, -hespitals are -under the· 
Department Of Medical services of the same ministry. Medical 
services outside Bangkok are under the Provincial Health Officer. 
The health service system of the country covers all the essential 
.. -~ -
eTE:mients of primary health care with the addition of mental 
health and dental health activities to be included in the primary 
health care setting. The health infrastructure reaches down to 
the Tambon (sub district) level. There are at present 7, 542 
health centres at the Tambon level. 482 district hospitals and 
72 general hospitals plus 15 regional central hospit.als at the 
provincial level. In the ~illages, 419,304 health volunteers are 
promoting good health. This helps to make the basic services 
I 
available to almost every village. 
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40 MEDICAL EDUCATION 
The number of medical schools remains at 8 but the number of 
doctors produced annually has increased from 510 in 1980 to 
around 700 this year. All newly qualified doctors are still 
required to do 3 years compulsory government service, where 
majority of them are placed " up country". As a result of this 
requirement, the maldistribution of doctors in the country is 
rapidly being corrected. A 1982 study revealed the total number 
of doctors in the country to be 8,644, of this the largest number 
(ie. 5,069 doctors or 59.87% were in Bangkok where the population 
of 5.3 milliori was a mere 11.14% of the whole country. The ratio 
of doctors to the population in the country in 1982 was 1 : 5539. 
As expected Bangkok had the best ratio 1 : 1050.7. Tile QJ:'OV_ince 
in the North East ie. Kalas in showed the worst figure of 1 : 
36,767.05. But when compared with the population 4 years ago it 
became evident that the ratio has decreased considerably, 
particulary in the North East region, where the 1978 figure 
showed the ratio to be 1: ].6_,.2_39. 21 as compar-ed to 1 : 7-, 69!> in 
1982 or a 111.04% decrea~·e over the previous figure. 
Most of the qualified doctors practice in Bangkok and attempts 
are being made to correct tnis maldistribution. There is also a 
maldistribution of other health personnel particulary dentists 
and pharmacists. out of the total of 4,574 pharmacists in the 
country in 1983, 3,477 were based in Bangkok. For dentists the 
total number in the country in 1986 was 2,788 and the majority 
of tham practised in Bangkok. 
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41 · NUMBER OF HEALTH CARE PERSONN,EL IN 1986 
Physicians 
Dentists 
Pharmacists 
Midwives I Nurses 
Midwives 
42 HEALTH S.TATUS 
13,612 
2,778 
6,015 
27,582 
. 8, 821 
Health status of the population can be evaluated by several 
indices which are mentioned below. 
1) Nutritional status 
The best available information on· the nutritional status of 
children of ( 0 -5 years} is as follows 
1982 1984 
, 
% % 
1st degree 35.61 28.53 
2nd degree 13 5.9 
3rd degree 2.01 0.8 
On the average the nutritional status of pre- school children has 
improved ever since the intensive nutritional improvement 
programme started. A significant change can be observed in the 
3rd degree malnutrition which dropped from 2.01% in 1982 to 0.8% 
in 1984. 
',:. · ... , 
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43 INFANT MORTATITY RATES 
The infant mortality rates collected from various sources differs 
considerably. The prime reason for this is believed .to be the 
ignorance of the parents in reporting infant deaths. The figures 
from the survey are believed to be closer to and reflect the real 
situation. 
REGION REGISTRATION SURVEY NSO 
SYSTEM 
1983 1983 1960 
North 16.3 51.8 57.8 
North East 9.7 56.6 52.8 
Central 12.9 35.3 39.0 
---
-
<excluding Bangkok) 
South 10.2 45.2 39.4 
Bangkok 16.9 18.8 26.5 
Whole country 12.4 45.3 47.7 
LIFE EXPECTANCY AT BIRTH 
The life expectancy of both sexes has increased during the past 
10 years. This can be attributed to the improved general health 
status as a result of the economic development, better 
availability of basic education and health services. 
44 
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LIFE EXPECTANCY AT BIRTH 
PERIOD 
1970 - 1975 
1975 - 1980 
1980 - 1985 
LEADING CAUSES OF DEATH 
EXPECTANCY OF LIFE AT BIRTH 
MALE 
57.73 
59.25 
60.77 
FEMALE 
61.57 
63.19 
64.76 
The table shows the 10 leading causes of death for the year 1981 
- 1983. The mortality rates of the 10 leading c~uses of death do 
not differ much from the 1979 figures. It can be said that 
Thailand is now facing problems seen in both developing and 
developed countries. 
As seen in the figures given in the later part of the text, 
government expenditure on health for the year 1980 - 1984 ranges 
from_ 298 .13 t~o 50_6. 4.5 mill~on U.S do~lars or an ~9\.l:!-yalE:)~t of 
5.84% to 6.29% of the total government expenditure. Although the 
figures of the actual expenditures have increased steadily, a 
closer scrutiny reveals that in some years the total government 
expenditure on health compared as a percentage of the total 
government e~penditure apparently is lower than in other years. 
Many factors seem to have contributed to this fluctation 
particulary political and others like the fluctation in the 
national budget. The expenditure of the private sector on health 
is 2. 7 times more than that of the government contribution .. 
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Various foreign governments and international organisations 
contribute health care aid to Thailand. In recent years foreign 
assistance has contributed between 1 - 3% of the Thai health 
care expenditure. 
As a rapidly developing country, Thailand is facing problems 
experienced by both underdeveloped and developed societies. There 
are at present an insufficient number of almost all categories 
of health personnel as well as maldistribution. Total 
expenditures for health services and medical care have grown 
rapidly in real terms in recent terms years ie. 3.5% of the G.N.P 
in 1979 to 4.6% in 1983. Per capita expenditures on health in 
Thailand between 1979 and 1983 increased at an annual rate of 
expenditure are financed by private.sources mainly by households 
and corporations. In 1979, private expenditures were 66% of the 
total expenditures increasing to 69% in 1985 .. Furthermore, 
I 
private expenditures are mainly for curative servic:e!l· W;l,t;.b. a 
society rapidly changing to~ards: "Western" standard, the demand 
for health services will definitely increase at an equally rapid 
pace. 
"} 
. :· ~ 
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Fig 5 LEADING CAUS-ES OF DEATH THAILAND 
Diseases of the pulmonary 
circulation and other 
forms of heart disease 
Gastroenteritis including 
acute diarrnoeal disease 
Other accidents including 
late effects 
Homicide and injuries 
purposely inflicted by' 
other persons 
I 
Ma;I.ignant neoplasm of 
other and unspecified sites 
Motor vehicle traffic 
accidents 
Cerebrovascula·r disease 
Pulmonary tqberctilosis 
1981 - 1983 
1981 
29.7 
22.7 
10.3 
26.3 
11.4 
13.8 
10.9 
11.8 
1982 
32.2 
24.2 
17.7 
21.9 
12.8' 
13.1 
11.5 
11.9 
1983 
31.2 
22.3 
20.3 
16.6 
13.3 
12.8 
12.8 
_' ,,, : ... 
- n-
Diseases of the nervous 
system 10.8 10.6 10.7 
Pneumonia 8.9 9.6 10.0 
Other diseases 
Total 504.2 510.2 510.7 
..... 
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46 Fig 6 HE-AbTH EX,PENDITURE CONTRIBUTION 
ADJUSTED TO 1983 CURRENCY VAbUE IN % 
Ministry of I Other Government Household 
Public Health Organisations and private 
Enterprise 
1979 20.27 13.00 66.30 
1980 17.70 13.00 69.00 
1981 18.10 14.00 67.60 
1982 18.50 12.00 68.70 
1983 19.20 12.00 68.00 
Projections 
1984 1-2-.-10 - fi.-90 70.00 
1985 18.30 11.70 70.00 
1986 18.50 11.60 69.90 
1987 18.80 11.40 69.80 
..... 
1988 19.00 11.30 69.70 
-· 
. 19'89 19.20 11.10 69.60 
1990 19.50 11.00 69.50 
1991 19.70 10.90 69.40 
- . . . .. -~ '.. . .- .._.·. 
Fi:g 7 
'MARKET .SHARE BY .THERAF.',EU':f;IC iCLA'SS 
~ . . . ~ 
~--------------------------~~----
+-------~------------------~-~~-------------~------------------------------------------+ 
l Th~r:'~peuti c: Class . l M~l aysi a . l Incfq~esi ~ :Philippines : Si ng~p.or:e l Thai~ and 
: -----------------------1--~---~---- 1-----:--~-----1------------: ----------- :------------
I I 1 I 
• t I I I 
1 .. Anti-infec:t·ives l 157. : 30.:37.- : 25.27. : 15.27. 
l . 
·: 2. Cardiovascular 8c l :13.5/. l 7.6~ l 5.7'1. l 12.3'1. 
: l . diuretics · 
I 
·I 
1 3. Ne~;.lro-musc:ular ·s.. CNS l '13.5'1. 1 11.utt. : 10.21. l 13.27. 
'I I 
. I 4. Re,sp1iratory l 12.4'1. l · 10.~7. l 18.1'1. l 11.57. 
I 
1 .. 
5. De.rmatologic:als l ·12.37. l 7.4% l 4.97. l 11).1/. 
I I I 
I • I I 
6. Gastro-Intestinal l 9.87. : 18.6'1. : 17.1'1. : 21.1'1. 
I 
7. Vitamins & Minerals : 4.87. I 2.9% l 7.4'1. I 2.5'1. 
8. Eye, EarL Nose I 2.9'1. l 1.8t : 1.7'1. l 2.1'1. 
I I 
I I 
9 E . d • I ? 4"1 I ... 1"~ I 1 7"/ I 1 -:<"•/ • n·OC:rlne I -• t. 1 -'• ';• t • '• I .~,. 
10. qenito-Urinary 8-. l 1. 8/. l 4 •. 41.. l 3. 1/. I 4. 7/. . 
·sex -hormones 
! 
(:1986) : (1987;) l (19.86) l (1987) 
21.8/. 
6.3/. 
16.6% 
11. 4/. 
9/. 
10.4/. 
11/. 
s. 5./. 
( 1984> 
I 
I 
·I 
I 
+----------------------~---------------------~-----------------------------------------+ - . I 
Source :. Ministry of Public Health 
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Market Segmentation 1987 
+------------------------------------------------------+ 
I 
I Therapeutic Cla~s 
I 
1------~-----------------------
1 
Alimentary T & Metabolism 
Blood & B. Forming organ 
Cardiovastular System 
I 
Dermatologicals 
I 
I G.b. system'& Se~ Hormones 
I 
I Systemic Hormones 
I-
I System!-c-An-t-i,;;.irYfeft:~iv-es--
Cytostatic~ 
MuscOlo - SWeletal System 
Parasitology 
~~spiratory System 
I Sensory Organs 
I 
I Various 
I 
I 
1· . Total Madtet 
I 
I 
I Market 1qe7 
1------------~~--~------
1 B + 000 I X 
--------~----1--------~ 
r 
I 
I I 
I 
I 
I 
I 
I 
I 
I~ 
I 
I 
I 
I 
I 
I 
I 
756,773 I 
I 
73,200 I 
I. 
111,185 I 
I 
423,993 I 
I 
134,184 I 
I 
30, 030" I 
.L 
457,BQO I 
I 
1,355 I 
I 
146p540 I 
I 
868.,·505 I 
I 
39,489 I 
652, 1_99 
70,283 
108,918 
1---,:...-..,.. ... _____ _ 
I 3,874,4:52· l=====i======== 
19.5 
1.9 
2.9 
10.9 
3.5 
0.8 
J_ 
1.8 I 
I 
0.0 I. 
I 
3.8 I 
I 
22.4 I 
I . ~ 
LO I 
16.8 
1.8 
2.8 
+-------------------------------------------~-------~--+ 
-:.;,_ ,·,7, 
,-; 
.• 
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47 TOTAL HEALTH CARE EXPEND~TURE, ACTHAL AND"BROJ'.Eec!RED 1979 - 1991 
ADJUSTED TO 19,83 CURRENCY VALUE 23 BAHT EQUALS U.S$1 
Year Total Expenditure Per Capita 
Expenditure G.N.P % u.s s 
1979 1268.83 3.5 27.52 
1980 1349.43 3.8 29.04 
1981 1492.22 4.1 31.43 
I 
1982 1651~6~ 4.5 3,4. 52 
19,83 1816.13 4.6 36.74 
Projections 
1984 2008.09 4.8 - 4.9 39.96 
1985 2220.35 5.0 5.3 43.52 
- --- ~- - -~-----·--·- - --- --- -
-- ~--
19,86 2455.04 5.2 - 5.6 47.35 
19,87 2714.52 5.5 - 6.0 51.52 
1988 3001.48 5.7 - 6.4 56.09 
19,89 3318.74 5.9 - 6.9 61.00 
1990 3669.52 6.2 7.3 66.44 
---- - --··-
1991 4057.39 6.4 - 7.9 72.26 
o( 
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48 BASIC INFORMATION 
1980 1981 1982 1983 1984 
Total government 298.13.! 355.19 419.10 470.37 506.45 
expenditure on 
·health 
(million U.S$) 
Total government 6260.87 6086.96 7000.00 7695.65 8347.83 
expenditure 
(million U.S$) 
Gross national 
- . 
29236.52 33233.87 35641.74 3B994.78 41756.74 
Population 46.45 47.49 48.49 49.46 50.39 
735.04 790.17 823.52 
Total government 6.25 5.84 5.99 6.11 6.07 
expenditure on 
health as a % of 
total government 
exp·endi ture 
G.N.P 
Mihist:ry <;)f J?u~lic 4.12 3.96 4.13 4. 46" 4.49 
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as a % of total 
government 
expenditure 
Total government 1.02 1.07 
expenditure on 
health as a % of 
G.N.P 
Per capita 6.42 7.48 
government 
expenditure on 
health (U.S$) 
Private 
expenditure on 
health 
(million U.S$) 8·25. 52 976.43 
Per·capita 2.82 
private 
expenditure on 
health as a % 
o-f G.N. P 
Ratio of per 112.72 
capita governl'!lent 
expend;i t ur.e on 
' .. ' ':f''" 0 -~ '' • - ·-~ • 
2.94 
112.75 
1.17 1.20 1.21 
8.62 9.48 10.05 
1171.09 1344.39 1496.57 
3.29 3.44 3 .• 58 
112.79 112.86 112.96 
18 
capita private 
expenditure on 
health 
Government 3.84 4.01 4.46 4.64 4.79 
and private 
expenditure 
Ministry of 0.67 0.73 0.81 0.88 0.90 
Public Health 
expen(jiture 
as a % of 
G.N.P 
-~- ... 
. ~ ~ · ... ;... -· '. '"'·"" .. -
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MARKETING OF PHARMACEUTICALS 
49 During the period from 1930's to 1940's when sulphonamides and 
penicillins were first introduced, the pharmaceutical companies 
had to just sell them. Features like product concept, trial 
launch, promotional mix, organising seminars were unheard of. 
Today the scenario has completely changed. Company image, 
marketing concepts, marketing plans, detailing cycle, journal 
advertising, seminar sponsorship, promotional gifts are some of 
the methods adopted by multinational companies. These days 
multinational companies which are involved in R & D cannot 
compete on price alone. 
Image and trust, people (medical representatives), promotion 
activities, communication channels are all currently being used 
to get that market share. 
50 IMAGE AND TRUST 
This has been capitalised by multinationals who are engaged in 
R & D. Efficacy, safety and quality of products has been much 
' 
emphasised as attributes. ' The question on pricing is related not 
to how cheap or expensive the product is but that the products 
give good value for money. any c ompanies build their image and 
service b sgonsoring semi nars and international conferen~es for 
the medical profession. Some have gone further by engaging in 
activities that sno th~i concern for he welfare oi the total 
community and country . 
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51 PHARM~CEUTICAL TRADE 
The current world market for drugs and pharmaceuticals is 
estimated to be over U.S$130 billion with the U.S and Japan as 
the leading markets. The U.S pharmaceutical industry continues 
to invest heavily in research and development of new drugs. 
Cu:rrent estim~te of R & D expenditure is U.S$4.5 million, which 
represents 15% of U.S pharmaceutical sales. The estimated cost 
for developing and marketing a new drug in the U.S is close to 
U.S$100 million. 
·For most of Asia, poor or affluent, the drug business is 
flourishing. Sales of pharmaceutical products are growing at a 
fast pace and ~rejections are for even higher growth rates. At 
present Asia (excluding industrialised Japan) is the world's 
I 
-tourth- fargest ph~r~aceutl.cal market. Europe is in third place. 
Industry analy-sts estimate that 'developi.ng Asia will overtake 
Japan by the year 2000 to become the second largest market, only 
5% smaller than North America. 
52 In the poorer countries of the region such as those in the sub-
I 
continent ( India, Bangladesh and Pakistan ) where health gross 
expenditure are less than 1% of the G.N.P (or around U.S$1 per 
head per year), compared with Japan, with U~S$200 , there is 
enormous scope for expansion of cheaper and common disease 
combating drugs in the rural areas while the urban centres will 
continue to be highly l;'eceptive to more expensive preparations 
such as diet pills, stimulants, depressants, vitamin combinations 
and tonics. 
- 81 -
Many countries in Asia have no allocation or plans for developing 
a pharmaceutical industry of their own. Where there is an 
industry, it mainly consists of formulating and packing. Patents 
are a sensitive subject for international companies and 
governments of developing countries alike. Drug companies argue 
that the vast sums of money spent in research and development can 
only be fully recouped through patent protection. This allows the 
company to determine prices indexed to market place acceptance. 
Many countries in Asia respect the patent laws, though generic 
copies continue to sli:p through. For instance Smith Kline & 
French's best selling anti ulcer drug sells for about HK$12 (U.S 
$1.54) a tablet in Hong Kong while generic copies made by various 
Taiwan companies are available through doctors for third of that 
price of the patented compound. 
All the world's leading drug companies are represented in Asia 
either as joint ventures or full subsidiaries. Foreign firms have 
the lion's share of the retail market in m6st Asian'markets. 
Japan is the only Asian nation which has a well developed 
pharmaceutical industry, and it is seeking to internationalise 
further to reduce its dependence on the domestic market. 
53 MARKETING IN THE SOUTH EAST ASIAN ARENA 
As multinational health care companies consider opportunities for 
expanding sales and profits, they often turn to Asia. Asia is 
composed of many different countries, however, each with its own 
requirements for successful market entry. Multinationals these 
days are focusing on Asia's least known or understood area, South 
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East Asia. 
When most health care managers in Asia hear "South East Asia", 
' . 
they think of the ASEAN nations. The Association Of South East 
Asian Nations (ASEAN) was formed in 1967 in response to military 
and political ramifications of the Vietnam conflict. Today, six 
ASEAN nations ie. Indonesia, Malaysia, Philippines, Singapore, 
Thailand and Brunei - share trade as well as political and 
military alliances. 
Among the ASEAN nations, Indonesi'a has the largest population, 
followed by the Philippines, Thailand, Malaysia, Singapore, and 
Br~nei. Drug consumption statistics, however, are much harder to 
determine. 
First of all industry audits exist in only three of the five 
nations - Indonesia, Thailand, and the Philippines although 
I ._M. S, the research company based in Singapore nas indicated that 
·-· .. 
it may begin audits of Malaysia and Singapore in 1988. Despite 
margins of error, a relative indication of the sizes of certain 
market segments and therapeutic classes can be achieved by 
examining both I.M.S audits and industry association reports. 
When conducting business in South East Asia, more important than 
understanding the varying nature of the region's distinct health 
care markets. Most important of all is to refrain from trying to 
fit ASEAN nations into the Western concept of health care 
marketing and instead to understand the basic differences among 
ASEAN nations .. Their markets can be categorised in several ways -
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prescription based, doctor - dispensing, O.T.C - ethical, and 
consumer health care - and then discuss the implications for 
these markets. 
54 PRESCRIPTION BASED MARKETS 
Only one market, the Philippines, fits the American mould of 
health care marketing to ~ny degree. In the Philippines, doctors 
write prescriptions that pharmacies fill. These are many 
exceptions of the rule, however. 
The economy being what it is, Philippine physicians find strong 
motivation to' supplement their income by selling_samples that 
they receive from health care companies. The class A general 
practitioner in the Philippines can see 25 ~ 30 pharmaceutical 
sales representatives a day, so sampling can quite believably 
become a major additional and non taxed source of income. 
Samples are also given to patients in the "free clinics" funded 
by the Philippines government. Because representatives tend to 
visit doctors in their private clinics, however, samples probably 
reach paying patients in private clinics more frequently than 
patients in free clinics. 
Indonesia is a prescription based market, although physicians not 
near pharmacies tend to dispense~ Thailand, Malaysia and 
Singapore are physician dispensing markets too, although 
Singapore is clearly moving towards becoming a prescription based 
nation by the end of the decade. 
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When this happens, presssure will fall on Malaysia to follow. At 
least 10 years will pass, however, before Malaysia gains a 
sufficient number of pharmacists to support a prescription based 
system. 
Although Thail&nd has a large number of pharmacists, physicians 
there depend heavily upon profits from clinic dispensary sales. 
Thai doctors, therefore, probably won't accept becoming 
prescribers - certainly not within the next decade. 
55 O.T.C ETICAL MARKETS 
O.T.C ethical markets are those in which patients obtain 
prescription drugs either from the doctor or directly from the 
pharmacies. In Malaysia, Indonesia and Singapore, a person can 
obtain many kinds of llleaication by signing a registration book 
at a registered pharmacy. 
In Malaysia and Indonesia, however where supplying medicines to 
"•' 
rural areas presents substantial problems, one quickly realizes 
that these are "open" markets. Medicines that should only be 
dispensed through a registered pharmacy are in fact readily 
available without a prescription. 
Chinese and Malay medicine and sundry shops in Malaysia often 
sell such registered medications, a few pills at a time, in 
unmarked plastic bags. Indonesia has apotiks - apothecaries or 
pharmacies - and drugstores that sell medicines but do not employ 
registered pharmacists. Indonesia also has "Toko Obats", which 
can be any retail outlet, from a sidewalk drugstore to a crate 
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on a bicycle, where medicines are purchased in relatively small 
quantities and at highly competitive prices. 
Although Singapore also ~an be classifed as an o. T. C ethical 
market, it is placing increasingly strict controls on 
pharmaceutical purchases without prescriptions and most likely 
will be the next nation to convert to prescription only status. 
56 DOCTOR DISPENSING MARKETS 
Paralleling the O.T.C ethical markets are the doctor dispensing 
markets. In Thailand, Malaysia, and Singapore, doctors typically 
dispense their patients medications. Although this might appear 
an efficient system, the profit motive behind it has become a 
significant ethical problem. Physicians look for cheap generic 
substitutes for expensinve products from research based 
companies. Their objectives are to either cut costs ~hen 
medication is included in the consultation fee or to maximise 
profits when patients pay for medications separately. 
I n most instances, doctors do not write med ication names on 
conta i ners when they dispense, pr i mari ly bec ause they do not want 
patients to know what they are dispensing. They believe tha t 
pa t i e nts might self diagnose their illness the next time around 
and purchase the drug directly from a pharmacy. The doctors would 
t h e n lose subsequent consultation inc ome. 
Consequently, dispensing doc t ors prefer med icines that are 
unmarke d b y c ode numbers or brand names a nd l ack d istinctive 
tabl et or capsule s h apes o r colours that wou lq a l low p a t ien t s and 
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pharmacists to identify which drugs have been dispensed. 
57 CONSUMER MARKETS 
Of the five major ASEAN nations, Thailand probably has the truest 
consumer oriented health care market. Despite the Thai 
government's intentions of controlling drug dispensing, virtually 
any pharmaceutical product is available there without a 
prescription. 
Thailand has also taken perhaps a strict approach to controlling 
marketing efforts. The governments screens all print and 
broadcast media carefully and critically. Almost no therapeutic 
claims may be made by the products that use T.V, radio or print 
advertising. Nor may they make any direct brand comparisions. 
Even so , it is truly a buyer's market in Thailand. For example 
many years ago antibiotics were advertised through mass media. 
Although this is no longer permitted, direct - to - cq~sumer 
sales of antibiotics are still growing. 
Despite such cases, unit and price values of the Thai 
pharmac~utical market a:t;"e in fact declining. The main reasons for 
this decline are threefold. First, Thailand's Government 
Pharmaceutical Organization (G. P. 0) has made a point of producing 
its own generics to compete with all other companies and has a 
virtual monopoly on government hospital businesses and government 
funded clinics. 
Lack of industrial rights' in Thailand permits G. P .0 to rapidly 
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copy new drugs. In some cases, G.P.O and local generic 
manufacturers have even .beaten the brand originator out of the 
market. Consequently, multinational companies that have depended 
on hospital sal~s elsewhere must in Thailand either enter the 
generics price war or diversify into the more lucrative O.T.C 
market to su~vive. Some companies, such as Merrel Dow, which 
depended on Government sales of Rifampin products, have had 
prices so severely undercut that they have thrown in the towel 
on tender business altogether. More companies can be expected to 
follow suit. 
The second reason for Thailand's decline in unit and price values 
is the plethora of generic companies that have complete freedom 
to produce and market pharmaceuticals in Thailand without the 
regulatory and operati-onal constraints placed on their Western 
counterparts. Thailand lacks not only patent protection but also 
trademark and other forms of industrial protection. 
Pfizer, in fact, is spearheading the industrial rights movement 
in Thailand. This is hardly surprising, considering that its 
Feldene piroxicam has more than four branded· generic 
competitors, most of which were introduced within a year or two 
of Pfizer's launch. 
Roche recently decided to move att ethically positioned topical 
antifungal into the Thai O.T.C sector. It spent a huge amount of 
effort and funds on the,direct- to- consumer campaign, only to 
find that at least eight new branded generic competitors w,re 
ready t6 jump in within three weeks of Roche's launch campaign. 
- 88 -
These competitors had created almost identical packaging and 
brand names to capitalise on Roche's promotional investment. 
The third and perhaps most critical reason for the decline in the 
total value of the Thai pharmaceutical market is a dirct result 
of changes in the nation's economy. Hard times are causing many 
Thai consumers to change from the traditional purchase of two to 
four pills at a time to one to two pills. So while treatment 
incidence is on the increase, the length of each course of 
therapy is shortening and decreasing in value. 
The other nation that has a " consumer " health care market is 
Indonesia. Indonesia is much like that of Thailand, especially 
in the rural areas, which support 80% of lts population. The 
Indonesian gover_nment has drug marketing controls that rival 
those in Thailand and is making more and more of an effort to 
control promotion and distribution of drugs. 
Indonesia, like Thailand, is directly involved in production of 
generics. The Indonesian market is still relatively competitive, 
however. The biggest marketing problem there is the difficulty 
multinational companies have in obtaining new drug registrations. 
This is easier for Indonesian companies, and so local companies 
can rapidly produce generics and often beat the original product 
to market. 
One such case in Indonesia was the 1986 launch of Rantin 
( ranitidine ) by a local manufacturer before Glaxo could get 
Zantac registe~ed. In both Indonesia and Thailand, the increase 
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in branded and unbranded generic competition has created 
additional pressure to distribute and sell drugs through direct 
consumer channels wherever and wheneve r possible. 
58 TRENDS AND ADAPTATIONS 
What marketing implications do these varying circumstances in 
South East Asia create for U.S companies, and what ~rends and 
changes confront those who enter South East Asian markets ? 
PACKAGE SIZE 
One company marketing a leading analgesic in Indonesia in boxes 
of 2 strips of 10 found that in fact consumers were not buying 
20 tablets at a time, but 2 tablets 10 times over. By 
converting to packs of fours, volume and sales in rural areas 
increased significantly. 
This finding is consistent with those in nations such as Thailand 
and Malaysia, where consumers usually purchase no more than one 
day's therapy, or perhaps even a single dose at a time .. ~gain, 
the reason is related to the basic economy. When the per capita 
annual spending on drugs is less than U.S$5, it indicates tha~ 
consumers maintain no inventory of medicine but b uy only when and 
what they need as cheaply as possible. 
For marketers considering a move into the O.T.C sector in South 
East Asian markets, this pattern of retail purchasing means that 
s~aller pack sizes a an be critical to consumer trial and repeat 
purchase. Dist~ibution must also efficiently r each mass markets; 
otherwise, any O.T.C efforts will probably not be cost effective. 
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A study conducted in the Philippines by Eduardo Roberto, 
Professor at The Asian Institute Of Management in Manila and 
President of E. R Associates, examined consumer purchasing changes 
during economic downtrends, especially in the health care 
industry. One change was the middle size packs, dropped in 
popularity. Purchasers instead bought smaller packs, as discussed 
earlier, or larger ones, where trade offers and quant ity 
discounts were significant. 
This creates its own problems, however, when companies push 
retailers to trade up to bigger packs. One problem is a high rate 
of returnea goods. Especially in the hot and humid climates of 
South East Asia, large bottles or open packs of medicines may not 
be stored or handled properly, and products · simply do not hold 
up well. 
In some countries, such as Malaysia, this has also caused an 
estimated two year market inventory level. Offering such trade 
incentives will appeal to companies less and less as problems 
with collections and returned goods mount. 
59 CONSUMER APPEAL 
In all markets, we are seeing more and more effort among major 
companies to attract consumers by developing packaging that 
encourages repeat purchases - even if a consumer originally 
bought the product from a dispensing doctor. Distinctive 
packaging , point of sales materials, and better retail servicing 
are becoming the hallmarks of successful companies in South East 
Asia. 
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60 O.T.C VERSUB ETHICALS 
More companies are looking for 0. T. C products to introduce, 
because these are factors and perhaps easier to register. They 
also suffer less from generic competition compared to some 
ethicals and may not suffer as much from direct government 
competition and de facto price controls. 
The major problem here,· however, is the naivete of ethical 
companies that view consumer health care products as solutions 
to their growth problems. The companies that are already 
entrenched in the consumer health care field :are big and highly 
competitive. Their level of marketing expertise is also far ahead 
of ethical based companies that newer entrants to the 0. T. C 
market will likely have a painful and costly learning experience. 
American companies are also pained to find they are years behind 
European and British firms in penerating markets like Malaysia, 
Singapore, and Indonesia and that a reputation as a leading 
American O.T.C brand loses its advantage there. 
61 EUROPEAN DOMINATION 
In most pharmaceutical markets, a handful of companies control 
the lion's share of the market. But in South East Asia, American 
companies are in for a shock. The companies in control may be 
regional ones, such as the giant United Laboratories, based in 
the Philippines: British based firms ( Glaxo, Welcome'); Swiss 
based (Roche, Ciba Geigy, Sandoz); German (E. Merck, Schering 
A.G , Hoechst, Boehringer Ingelheim ) ; or Swedi~h ( Astra ) . The 
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Americans are not well represented. 
Distribution, which is absolutely critical to marketing success 
in South East Asia, is also dominated by a few non American 
companies. F.E. Zuellig or Diethelm, both Swiss based 
distribution giants in South East Asia, have approaches to 
management that probably ensure that they will stay in the lead. 
This means that manufacturers must work closely and co 
operatively with their distributors to compete with other 
companies represented by the same distributor. American companies 
tend to want exclusivity in a distributor, which is not feasible 
for most distributors in South East Asia. 
A more common criticism of American companies is that they are 
too short term. Their managers change jobs frequently - they stay 
an average two to three years, compared to European managers who 
stay four to five years, or even longer. Another criticism is 
that American managers do not involve themselves in local 
business communities .during such short assignments. Asian, 
European, and British managers, on the other hand, take great 
pride in maintaining their company's reputation, programmes, and 
approaches to the markets they participate in. 
B.Braun, for example, was the first Western company to build a 
complete suture and surgical supplies manufacturing centre in 
South East Asia - Penang, Malysia. Managers from the company's 
German headquarters came to work in the region with a minimum 
five year contract. On a short term, say 10 year basis, an 
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American firm probably would find the investment unacceptable. 
But B. Braun's inroads in the market penetration have already 
surpassed its expectations, and the investment has indeed been 
.,;, 
worthwhile. 
Unlike any other area of the world, pharmaceutical marketing in 
South East Asia is made even more highly competitive by the 
presence of Japanese and other Asian companies. Inroads made by 
these companies make competition for even minor market share more 
intensive. Some of them for exa~ple in the Philippines the 
" United Laboratories " with its branded generics: Japan's 
Meishi, with its antibiotics; and Eisai, with its range of 
ethicals and vitamins; Singapore's Guardian Pharmacies, with its 
dominance in retail pharmacy market and its entry into wholesale 
distribution and house brand manufacture; and Malaysia's Sime 
Darby, the government backed corporation that has made a goal of 
controlling Malaysia's pharmaceutical market. 
·-' 
62 DISTRIBUTORS 
South Est Asia is experiencing a clear trend towards using 
distributors, unlike a decade ago, when companies explored self 
distribution. The reasons for this trend are varied. 
In Indonesia, for example the government 
I 
forbids direct 
distribution by manufacturers in most cases. In other ASEAN 
countries, however, distributors are sought to help with 
tremendous inventory control and collection problems. Government 
and retail accounts often have receivables of 120 - 180 days or 
longer, which is unacceptable to most Americ~n firms, who look 
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at 90 days or even 60 days in horror .. 
Furthermore, ASEAN markets such as Thailand, Malaysia and 
Singapore are relatively small. There is questionable cost 
effectiveness in maintaining individual marketing, sales and 
distribution in these countries. 
Finally, the big distributors in each of the ASEAN markets are 
becoming more and more sophisticated. In particular, distributors 
like F.E Zuellig and Diethelm enable companies to appoint and 
manage a marketing and sales team dedicated to their own product 
line but working within the nucleus of the distributors 
organizations. For example, medium sized companies such as Les 
Laboratories Servier of France or Lederle of the United States 
would have a marketing manager and a few sales representatives 
with their own offices inside F.E.Zuellig's office complex. 
Technically such dedicated marketing and sales teams would be on 
·-· .. 
F. E. Zuellig' s payroll, but they, would report to the regional 
marketing directors of Servier and Lederle located elsewhere. 
Marketing and sales team costs are incorporated in the terms of 
distribution, which works well for both distributor and 
principal. 
In making distribution policy, companies should understand that 
no one distributor effectively handles all of South East Asia's. 
trade. F.E Zuellig is the strongest in the Philippines, and is 
also strong in Thailand, Malaysia and Singapore, and Hong Kong. 
The company is establishing itself in Taiwan. Diethelm is strong 
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in Thailand, Malaysia and Singapore but less so elsewhere. 
Other distributors, to name are Summit in Thailand, Singapore and 
Malaysia; Guardian in Singapore; and Marketlink I Sime Darby in 
Singapore and Malaysia are worth looking into. None, however have 
any presence in Indonesia, where distribution systems are 
completely controlled by Indonesian companies. 
63 CO - MARKETING AND CROSS - LICENSING 
The South East Asian market is highly competitive with its 
increasing regulatory contraints and pressure on profits. A trend 
in South East Asia towards co - marketing and cross - licensing 
drugs is one expected result. Some companies have product lines 
that cannot profitabily support a marketing investment; examples 
are small biotechnology firms with anti - cancer or other highly 
specialised products that are often too sophisticated for general 
use or cater to use by a limited number of specialists. 
These small firms look to companies like Schering Plough or 
Bristol Myers to represent them in South East Asia. Other 
companies like Glaxo,, with good ethical products and marketing 
expertise, look for O.T.C and consumer health care product lines 
to maintain the growth they have come to expect in the region. 
Some companies, such as the Japanese firms 1 will split their 
product lines between distributors or other companies in their 
search for greater ease of registration and market penetration. 
Most current co - marketing and cross licensing arrangements are 
nation and company specific. In some instances two companies that 
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compete directly in one market will team up in another. The key 
to this is personal contacts, which European, Asian and 
especially Japanese firms understand and work at developing. 
American companies don't, by and large. 
64 INCREASED REGULATIONS 
As mentioned, South East'Asian governments will grow more and 
more supportive of generic and local producers, with the possible 
ex~ption of Singapore. It seems likely that lack of patent, 
trademark, and copyright protection, coupled with government 
backed production of drugs for profit or to reduce national 
health care costs as in Thailand and Indonesia will wreck havoc 
on multinational companies that are less to simultaneous 
competition from so many directions. 
In addition, governments will increase their control of prt~e and 
promotion of existing pharmaceuticals. In Thailand ~nd Singapore, 
for example, it is now extremly difficult to obtain necessary 
approvals for ,any drug advertising from the Ministries Of Health. 
Indonesia and Thailand presumably have no price controls, but to 
compete in the government sector would be to sell at a loss. And 
despite the absence of official price control 1 both nations 
control price increase approvals. For example I although the 
Indonesian currency suffered a devaluation of more than 40% in 
September 1986, the government permitted drug price increase of 
only 15%. 
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The governme~ts of South East Asia are also increasingly 
regulating use of their citizens for phase 3 research before 
drugs are approved in major Western pharmaceutical markets. 
Malaysia recently began enforcin9 drug registration based on laws 
enacted in 1986. The laws require free sales certificates 
(FSC 's), which show permission to sell the drug in the home 
nation, for new drug approval. 
Singapore initiated formal drug registration requirements, yet 
refuses hospital formulary approvals unless the drug is already 
sold in Western markets. Thailand and Indonesia require that 
multinational companies - but not necessarily local ones -
provide proof of registration in the home nation as well as FSC's 
from other major Western markets. And registration in the 
Philippines can only be assured within a resonable time frame if 
the product is already registered with the F.D.A in the United 
States. 
In fact a great deal of concern has been expressed in the ASEAN 
newspapers over proposals to allow the export of drugs from the 
United States prior to F. D. A approval. Such publicity will 
probably lead to further incentives to local companies to develop 
drug manufacturing capabilities. This in turn will lead to 
greater control of South East Asian health care markets by local 
companies and less risk to ASEAN nations of control by 
multinationals. 
Even with the above trends, the developing nations of South East 
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Asia will likely take a long time to become sophisticated in the 
ways of medical marketing, compared to their western cousins. 
Technology in South East Asia is changing quickly, but only in 
the major metropolitan areas. Furthermore, marketing technologies 
such as interactive video- discs, direct mail, telemarketing, 
when available, are so costly as to raise questions about their 
feasibility. 
Asian medical sales representatives also need much more training 
to reach even basic skill levels of the newest representatives 
in the Western markets. In most markets, doctors themselves have 
a hard time keeping abreast of new medical technology and are 
leery of sales representatives ability to h~lp educate them. In 
a study conducted in August 1985, it was ~etermined that the 
average time South East A-sian dOctors spent with representatives 
ranged from less than 30 seconds to 2 mini tues. Asked what a 
representative can sell in such a short time, the general 
response was, " Sell ? He's not selling- he's an overpaid sample 
.. ' 
dropper " 
The point is well taken. In South East Asia, the key words in 
pharmaceutical marketing are " back to basics " - and will be so 
for some time to come. 
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OTHER ISSUES 
PATENTS 
Other than Malaysia and Singapore who have established patent 
laws and regulations it was totally impossible to introduce this 
in Thailand and due to this many European and American companies 
lose millions of dollars because of patent ,infringements and 
generics. On the other hand, patent protection only exists on the 
" process " involved for the manufacture of pharmaceuticals. 
65 Smith Kline and French expected its sales in Thailand to total 
U.S$2.7 million in 1986. It could have been U.S$7.6 million if 
Thai manufact~rers were unable to sell compounds patented by SK 
& F in other markets. This was disclosed by SK & F to the Wall 
Street· Journal. 
Over 25 generic versions of Cimetidine ( SK & F's Tagamet ) are 
sold in Thailand with prices as low U. S$0. 34 for one_ ,day • s 
therapy compared with U.S$1.68 for Tagamet. 
Pfizer told the Wall Street Journal that 12 of its U.S patented 
products had revenues totalling U.S$2.2 million in 1984 compared 
with sales of about U.S$4.2 million by other manufacturers. 
Both local and multinational companies believe that Thailand 
will adopt some form of patent legislation for pharmaceuticals, 
althopgh many believe it will be difficult to pass such laws 
because several legislators hold stakes in local drug companies. 
Thailand h&s more than 190 pharmaceutical companies with 1985 
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output of U.S$255 million, compared to U.S$88 million in 1981. 
66 The pharmaceutical industry is fairly optimistic that some form 
I 
of patent protection could be introduced in the next couple of 
years. Several U.S trade delegations, Ambassadors of various 
European countries have raised the issue and have made 
representations to the Thai government. Thailand is one of the 
countries where pharmaceutical patent protection is a problem. 
SK & F and Pfizer have lost revenues because of copying by local 
manufacturers. Pharmaceuticals were specifically excluded from 
the Thai patent law which was introduced in 1979. Processes are 
patentable but this is insignificant in a market where there is 
no chemical synthesis industry. 
67 The United States has decided to remove G.S.P benefits to 
Tha-iland if the nation refused to introduce adequate intellectual 
property protection. U.S trade representative who was in the 
Reagen Administration gave December 15,1988 as the deadline for 
an improvement in the level of protection. The decision to -~mpose 
a deadline was taken by President Reagen during his annual revi~w 
of the G.S.P system. Thai Foreign Minister Siddhi s'avetsila 
planned a visit to Washington in April 1989, so as to ask the U.S 
Government more time to resolve the issue of pharmaceutical 
patents. 
68 On April 28th 1989, an attempt was made in Washington by 
"Thailand to resolve the country's long running dispute with the 
' 
U.S on pharmaceutical patents. The Thai delegation proposed a 2 
I . 
year monitoring system to prevent the copying of new drugs that 
enter the Thai m~rket during the period. It is understood that 
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no laws need to be changed to implement t~e 2 year monitoring 
system which_will prohibit " for safety purposes " the making of 
generic copies from the day a new u.s drug is registered in the 
Thai market .until the Thai Food And Drug Administration gives 
approval of its sale. 
The proposal means that only a foreign drug manufacturer will be 
able to import and sell the new drug at limited places such as 
hospitals. The Thai generic manufacturer during this period must. 
conduct bio - equivalency tests to be approved by the Thai F. D. A. 
The system is in fact a measure to protect new drugs until the 
patent act is amended. Prior to this 2 years proposal, Thailand 
• 
-
had proposed implementation of an 18 month interim measure that 
would protect new u.s drugs entering Thai market. 
Meanwhile, in Thailand private groups indicated that there could 
be a monopolistic practise whereby only a drug producing_~ompany 
be given the sole right to monitor consumer f;Jafety in its dr-ugs. 
The group hinted that the United States safety monitoring 
regulatory system, was an attempt to have Amertcan drug companies 
monopolise the local market with new drugs. It was agreed that 
drug producing firms should not be allowed to monitor consumer 
safety without the participation of a government agency or public 
organisation. Thailand needs to take the patents issue seriously 
and show progress in the talks with the Americans so as to avert 
possible u.s trade retaliation under section 301 of the U.S Trade 
Act. ~·· 
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6~ PATENTS ( SINGAPORE ) 
Pharmaceutical patents are available for both products and 
processes. Patents which are registered in the U. K may be 
registered in Singapore, but registration must be carried out 
within three years of the date on which the patent was issued in 
the U.K. Application must be made by a resident agent and should 
include a certified copy of the specification of the U .K or 
European ( U.K ) patent. ~ 
A patent lasts as long as the corresponding U.K or European (U.K) 
patent I from the date of a Certificate Of Registration. Under the 
compulsory licensing provisions of the Singapore Pat·ents Act, the 
government reserves the right to buy pharmaceuticals from sources 
other than the patent holder, or a licensee, ·for use in 
government .hospitals, inst-itutions and dif?pensaries only. 
70 TRADEMARKS ( SINGAPORE ) 
Trademarks are available indefinitely, subject to the pay~ent of 
periodic renewal fees. A trademark may be withdrawn by the 
proprietor at any time. 
Registration of the trademarks is governed by the legislation 
contained in the Trademarks Act and the Trademark rules 1968. 
Foreign trademarks receive no protection unless registered in 
Singapore. Applications must be m~de through a loc~l resident. 
There are no special provisions -concerning pharmaceutical 
trademarks exclusively. 
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FACTORS EFFECTING THE MARKETING SYSTEM OF PHARMACEUTICALS IN THE 
REGION 
71 PARALLEL IMPORTS ( SINGAPORE ) ' 
To a certain degree we find parallel imports very common in 
Singapore. In the ·Scrip report of June 10/87 a series of 
successful prosecutions by multinational pharmaceutical companies 
of firms parallel importing products into Singapore appears to 
I 
have had the effect of discouraging parallel importers from 
engaging in this practise. It is expected that the new drug 
registration scheme will help reduce the number of parallel 
imports on the market. 
Scrip announced that in early 1987, Glaxo was awarded an 
injunction ' py the Si-ngapore High Court preventing a local 
company, Regent Pharmacy from importing Zantac ( ranitidine ) 
from an undisclosed U.K source. Regent was sued on the grounds 
of patent infringement and the firm undertook in future only to 
purchase Zantac from Glaxo•s local subsidary. 
SK & F was also successful in preventing parallel importing of 
Tagamet and Wellcome also has taken legal actions on the same 
grounds. Under the new product registration scheme an import 
licence will be awarded to any party wishing to import a 
preparation whose product licence is held by any other company 
provided that he can prove the product is in every respect 
identical to that which carries a product licence and that it is 
manufactured by the same manufacturer. Import licences issued 
under these conditions will be granted only on a per consignment 
• 
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basis. Despite the fact there is adequate patent protection in 
Singapore ( any patent granted in the U.K can be automatically 
pe registered in Singapore ) there is still some controversy over 
the compulsory licensing clause which is written into patent 
legislation and which allows the government to purchase parallel 
imports or copy products for use in the government maintained 
medical institutions without legal reprisals from the originating 
company. 
The government is required by law to notify the patent holder 
whenever it imports a product from another source, but the law 
does not specify what information must be provided by the 
government and it is· understood that companies can find it 
difficult to ascertain the source of the product and the price 
paid. Royalties must be paid to the patent holder, but these 
shall in no case exceed 5% of the net ex - factory sale price in 
bulk. 
.. ' 
A letter to The News Straits Times described the compulsory 
licensing clause as " an instrument to circumvent patents mercy 
in order to save money ". While the industry maintains that it 
does not oppose the compulsory licensing legislation in principle 
since it empowers the government to obtain important products 
which for commercial reasons, a patent holder might choose not 
to market it in Singapore it argues that it needs to be kept more 
fully informed by the government in order to guard against 
situation arising in which part of the consignment is diverted 
to the ·private sector. 
-105-
n LABELLING REQUIREMENTS 
With effect from April 1987, the pharmaceutical companies in 
Singapore are required to label certain medicinal products with 
expiry dates under the new medicines ( labelling ) regulations. 
The scheduled products are : 
1) Acetylsalicylic acids and its salts 
2) Alpha Tocopherol and its salts 
3) Anaesthetic Ether 
4) Antibiotics and antifungal agents 
5) Antitoxins 
6) Ascorbic acid and its antifungal agents 
7) Antitoxins 
8) Ascorbic acid and its salts 
9) Blood products 
tOl ChloYcH Hyd~a-t:e 
11) Cyanocobalamin 
12) Ferrous salts 
13) Glyceryl Trinitrate 
·-' 
14) Insulin,s 
15) Nicotinamide 
16) Paracetamol 
17) Parldehyde oral and systemic 
18) Pyridoxine Hydrogen chloride 
19) Retinol and its salts 
20) Sodium Nitrite 
21) Sodium thiosulphate injection 
22) Thiamine I aneurine and their salts 
23) Vaccines 
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Under the new regulations all dispensed medicines must be clearly 
labelled with the following particulars: 
1) Name of patient. 
2) Name and address of the institution where the product is 
dispensed. 
3) Date of dispensing. 
4) Directions for use. 
5) Either generic or brand name. If generic name is used, the 
quantity of active ingredient. 
It is hoped that these measures will contribute to greater safety 
since some doctors have traditonally been reluctant to. provide 
patients with information on the medicines they are taking in an 
attempt to prevent them from purchasing the product elsewhere. 
This had dangerous consequences on occasions such as in the case 
of a-ccidental or suicidal overdose when hospitals have been 
unable to identify the product. 
73 TRIAL TENDERS 
.. ' 
The Singapore government will in future experiment w:lth issuing 
tenders to the private sector pharmaceutical industry to obtain 
supplies of medicines for use.in government maintained hospitals 
and dispensaries. If the new system proves to be economically 
advantageous, government pharmaceutical manufacturing will cease 
to operate. The government's manufacturing facilities have 
reportedly become too small for the demands placed on them, and 
need to be updated. It was therefore decided to .ascertain whether 
purchasing pharmaceuticals from the private sector would be 
cheaper than the costs involved in upgrading the government's own 
plant. 
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While the industry agrees that the new area of business 
represented by the government tenders is of considerable 
importance, it notes that the profit margins are extremely 
slender since the price offered must be low enough to undercut 
parallel imports and generics. The government tender will 
definitely lend to further growth in· the private sector and 
greatly enhance the attraction of Singapore for further 
pharmaceutical investments. 
THAILAND 
74 DRUG ACT AMENDED IN THAILAND 
Thailand's main body of l~gislation controlling pharmaceutical 
provision and the pharmaceutical industry has been amended.· 
Several significant cfi.anges have been introduced but the most 
important is concerning 'the new labelling requirements. Under the 
amended act which comes into effect after 31/12/88 the following 
information must be contained on the product label at the time 
...... 
of the product's entry into Thailand. 
Previously certain items can be added in Thailand before sale 
ie.: 
1) Drug name. 
2) Thqi registration number. 
3) Quantity of the drug. 
4) Name and quantity or strength of the active ingredients of 
the drug must correspond with the drug formula registration. 
5) A humber or letter indicating the time of production or 
analysis. 
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6) Name of the city and country of origin. 
7) The day, month, and year of production. 
8) The words " dangerous drug ", " especially controlled drug", 
" drug for external use ", or " drug for local use ", in 
clearly visible letters. 
9) The words household medicines if applicable. 
10) The words for veterinary use if applicable. 
! 
11) The words expiry date in Thai ( a new requirement and the 
day, month and yea~ of the expiry in the case of 
antibiotics, vaccines and serum products only. 
Another requirement which did not feature in the original act is 
that each imported product must show the name of the importer and 
-
the city where the company is registered. International companies 
will firid the new requirements very difficult to follow, since 
all the imported drugs uniformly produced for ~ale world wide and 
it would be very inconvenient to be forced to produce local 
labels with the expiry date in Thai and to enter all the r~quired 
information on both outer, and inner packaging as well as on very 
small labels, ampoules and vials in the new legislation. 
In its submission to the Thai F.D.A, the P.P.A argues that it 
will be time consuming and costly to open all imported 
pharmaceuticals to add the required details to inner labels and 
that to break the seals will also enable adulteration and illegal 
subtitution of drugs. 
The Thai F. D. A has made new provisions for the fndustry. In 
futtire pha~maceutical c9mpariies will no longer be classified as 
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retail outlets and will therefore be free to move premises 
without being affected by the country's dispensary quota rule. 
The F.D.A has also introduced changes to the Thai Red Cross and 
the G.P.O. At present, these bodies are free to produce, sell or 
import pharmaceuticals without needing to apply to the F.D.A for 
registration. With the new ruling, the G.P.O will be· brought 
within the framework of the law. It is also seen tnat in future 
government hospitals will no longer be permitted to import 
pharmaceuticals which are not registered in Thailand for the 
purpose of clinical trials. 
75 EXPIRED DRUGS 
The Malaysian government takes a very serious stand point on 
drugs. It has banned 7 pharmaceuticals drugs in 1987, but has 
failed in its attempts to prevent expired drugs from being 
channelled to consumers. 
All medic.al drugs sold have a shelf life and it is common in 
Western countries that old or expired stock are destroyed or 
replaced. In fact it is an offence to sell medical drugs past the 
printed expiry date. With proper and tough legislation the 
consumers are protected. But in Malaysia it is a different story 
in medicine shops and pharmacies. The main reason is the fact a 
few giant pharmaceutical companies practise a unilateral 
regulation. All products referred to in the price list are sold 
on a non - returnable basis. The company does not accept the 
return of expired goods for credit or replacement. The poor owner 
or trader in this fiSld is thus saddled with stale medical drugs 
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and where the shelf life has expired. He has to sell them off to 
the unsuspected public to recoup his losses. Unless the 
government takes a positive stand on this, the Malaysian 
consumers will be victims and be ripped of by the pharmaceutical 
giants. 
76 PROBLEM DRUGS 
Many developed countries have banned or restricted the use of a 
number of drug~ that are readily available in the 3rd world. The 
best kn9wn example is-anabolic steroids used to stimulate growth 
or appetite in children. It has been banned in the West because 
of side effects like irreversible virilisation in females and 
liver damage. 
Antibiotics have been used to treat colds and diarrhoea. Medical 
journals have pointed out that they are useless against such 
illness. Colds are caused by viruses and antibiotics are only 
effective against bacteria. According to the British for~¥lary, 
many forms of diarrhoea are not caused by bacteria. But ev~n if 
bacteria is suspected, antibiotics should be avoided in many 
cases because they may prolong rather then shorten the time taken 
to control diarrhoea. 
In Tftailand a virtual 11 drug cocktail 11 is on sale as a popul~r 
cure all. The 11 Yachud Package 11 contains an assortment of 
tablets purporting 
poisoning to V.D. 
to cure a variety of illness from food 
The ~ackage contains Dexamethasone a 
corticosteroid , paracetamol ( an~lgesic ) , an aspirin phenacetin 
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caffeine combination, chlordiazepoxide t'ranquiliser and 
chlorpheniramine and cyprohetadine antihistamines ) . 
Benoxaprofen an anti inflammatory analgesic marketed by Eli Lilly 
as ( Opren ) or ( Oraflex ) has been removed from the U.K because 
of 61 deaths. However the company maintains that the drug is safe 
when used as directed. 
Ciba Geigy's antidiarrhoea drug Entero Vioform ( Clioquinol ) 
has been withdrawn but is still on sale as an O.T.C product in 
Thailand and Indonesia. In Malaysia, where enforcement is slack, 
dumping of sub standard drugs occurs. The former Malaysian Deputy 
Minister Of Health Mr.Pathmanaban warned of the growing illegal 
imports and dumping of poor quality drugs. New regulations 
promulgated in Malaysia last year to control-the manufacture and 
sal~ of d~ugs ~ave yet to be widely enforced. 
77 THE ISSUE OF II HALAL II FOR MUSLIMS 
The Muslims in Malaysia are becoming concerned these days on the 
.. ' 
issue of gelatin and alcohol in toiletries, cosmetics and 
pharmaceuticals. As one is aware, Muslims are forbidden to touch 
pork and alcohol because of religious reasons. Somehow or the 
other products containing gelatin and alcohol reach the hands of 
Muslims and this issue has been having some disturbing effects. 
Sometimes it is unavoidab'le if a person consumes a cough mixture 
I ' 
which contains alcohol, menthol or swallows capsules with gelatin 
coating. Two schools of thought has developed on the issue of 
11 haHtl .. ie. the Egyptian version and the Iranian ideas •. The 
following article published in Cairo with English and Malay 
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MUSLIM BASED TOILETRIES 
Manufacturer/Distributor Branding 
1) Zaitun Industries Sdn Bhd Zaitun 
2) Bristol Myers (M) Sdn Bhd Mawar 
3) As lam (M) Sdn Bhd Safi 
4) Perindustrian Medinah Medinah 
5) Aisyah Aisyah 
6) Pernas Sime Darby Al Murni 
Brand Prodl:lcts 
-
1) Zaitun Talcum Powder, Shampoo, Lotion, Cream 
2) Mawar Talcum Powder, Shampoo, Lotion 
3) Safi Talcum Powder, Shampoo 
4) Medinah Talcum Powder 
5) Aisyah Talcum Powder 
6) Al Murni Shampoo 
Source Johnson & Johnson Malaysia 
' 
Tclnfd, knlnnyn, mlnyak 
wnn~;l. ban - bnunn 
hcrnlkbohol nlnurun yang 
lidnk lllCntiiiiO)'O 
kcwnnglnn dnn scdap, lldnk 
pnlul dikntnlton dorl arok · 
ynn~ dlhnromknn olch · 
!mkumsyarok. 
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Source Utusan Malaysia,_ 4th Feb 1988 
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translations are given below. It was extracted from the Utusan 
Malaysia on February 4th, 1988. The article is self explanatory. 
Zainol Fakir's article says that perfumeries or any kind of 
perfum~d items with or without alcohol can be used by Muslims 
even during prayers. This ruling was made recently by Sheikh 
Ahmad Hassan Mussalam, a member of the Muslim Judicial Council 
( Majilis Fa twa Azhar - is an authoritative Muslim Judicial 
Council ) 
He said that Muslim law stipulates that when the original form 
of liquor or alcohol, is altered, therefore the ruling to it the 
altered liquor or alcohol ) also changed accordingly. It was 
added that it was improper to rule that the liquor or alcohol 
which is mixed with p_erfume oil as " haraln 1·1 ( not acceptable to 
Islam ) because the liquor or alcohol has changed its original 
form. But he mentioned that the liquor or alcohol is " haram " 
for drinking because of its intoxicating nature and this ruling 
is clear in the Muslim Law. 
Sheikh Ahmad· added that perfumeries or items mixed with liquor 
or alcohol, must not be categorised with that type I kind of 
liquor or alcohol which is defined as unacceptable in the Muslim 
law. The issue is more unreasonable when it is seen that 
perfumeries are elements which can kill germs ( harmful to human 
beings ) in t~e air. On the question of prayers, it is mentioned 
that the condition on whether the prayers are acceptable or 
otherwise depend on whether the clothes and the human body were 
free from filth. 
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In relation to this it is seen that perfumeries or alcohol cannot 
be defined as filth. Therefore, prayers performed by someone 
using perfumeries mixed with liquor or alcohol is acceptable. 
It is worth noting that the same;ruling was made by the Council 
a few years agp in Egypt. The same question was posed to Sheikh 
Abu Salam for the benefit of Malaysian Muslims. 
Thus, from this article it can be concluded that to a certain 
extent the rules can be relaxed. Most multinationals, American 
and European are careful in what they produce and sell since they 
do not wish to be caught in the religious issue. 
Many Muslim based companies which have mushroomed these days have 
headed for the toiletries market and are trying to tap the Muslim 
consumers. As 'mentioned earlier the religious issue has still not 
penetrated the pharmaceutical segment yet but it will not be long 
when people will be concerned on alcohol and gelatin in the 
medications they consume. 
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INTER COUNTRY PRICING 
An inter country pricing study was conducted by comparing the 
prices of pharmaceutical products of multinational companies in 
Thailand, Malaysia and Singapore. 
The multinational companies chosen for this exercise were Janssen 
which belon9s to the Johnson & Johnson group of companies, 
Roussel, May & Baker, and Pfizer. The pharmaceutical products 
were picked ~t random from the price lists and were not judged 
from their sales, efficacy or performance. 
The only major criteria involved was th-at their strengths and 
packaging remained the same in all 3 countries thus making the 
calculations much simpler. 
The prices of the drugs were adjusted to Malaysian ringgit from 
Thai Bahts and Singapore dollars. For calculation purposes, 100 
Singapore dollars was fixed as equivalent to Malaysian Ringgit 
$142 and 100 Malaysian ringgit as equivalent to 1110 Thai Bahts. 
Analysis on the pr'ices showed that the prices of pharmaceutical 
products were extremely high in Singapore when compared with the 
3 countries. This is due to the following reasons :-
1) The strong Singapore dollar which makes prices expensive. 
2) The sky rocketing cost of health care treatment in 
Singapore. 
Fig 10 
COMPARATIVE PRICE EVALUATION 
+-----------------------------------------------------------------------~----------------·~ 
Malaysia I Singapore I Thailand 
Pricing : Pricing I Pricing 
Product I Strength IPa~kagingl M$ :----------------------------------~: 
S$ M$ Baht M$ 
:----~-----------------------------------------------------------------------------------: 
JANSSEN 
IDAKTACORT 
·I CREAM 
ISTUGERON 
IMOTILIUM 
tHISMANAL 
ROUSSEL 
ISOFRA-TULLE 
lTOPICORTE 
lSI<IN CREAM 
lTOPIFRAM 
!SKIN CREAM 
lPROCTOSEDYL 
!SUPPOSITORIES 
IPROCTOSEDYL 
lruN~E~ 
IRYTHMODAN CAPS 
ISOFRADEX E/E DROPS 
15gm I I 
I 
I 
25mg I I 
I 
I 
10mg I I 
I 10mg I 
: 10cmx lOcm I I 
I 
I 
I 
I 
15g I I 
I 
I 
I 
I 
15g I I 
I 
I 
I 
I 
100mg I I 
I 
I 
8ml I I 
TUBE I 13.45 . 
I 
I 
250's I 54.00 I 
I 
I 
500's I 159.66 I 
100's I 53.33 I 
50's I 40.00 I 
I 
I 
I 
I 
I 7.38 I 
I 
I 
I 
I 
I 7.70 I 
I 
I 
I 
I 
12's I 6.60 I 
I 
I 
I 
I 
15g I 7.29 I 
I 
I 
lOO's I 46.40 I 
I 
' I 5.05 I 
I 10.30 I 14.63 I 43 I 3.87 I I . . 
I I I I 
. I I . 
I 42.00 I 59.64 I 497 I 44.77 I I I 
I I I I 
I I I I 
1100.00 1142.00 I 1000 I 90.09 I I 
I 40.00 I 56.80 I 450 I 40.54 I I I I I 
I. 35.00 I 49.70 I 375 I 3:::: .• 78 I I I 
I I I 
I I I 
I I I 
I I I 
. : 6.40 9.09 I 66 I 5;95 I I 
I I 
I I 
I I 
I I 
I 7.00 9.94 I 72 I 6. 4·9 I I I 
I I I 
I I I 
I I I 
I I I 
6.00 8.52 I 44 I 3.96 I I 
I I 
I I 
I I I 
I I I 
6.60 I 9.37 I 44 I 3.96 I I 1 
I I I 
I I I 
46.40 ' 65.89 I 360 I 32.43 I ' I 
I I I 
I I 
' 4·. 60 ' 6.53 I 44 I 3.96 I I I 
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Even though Singapore has a duty free port status it has not 
helped much to reduce the cost of drugs. 
Malaysia comes in second after Singapore as far as prices are 
concerned. Thailand happens to be the cheapest of the 3 
countries. This shows that with a broad based pharmaceutical 
industry and the government promoting more of generics, the 
prices of drugs are low and remain within the reach of the lowest 
wage earner. 
78 PRICE CONTROL 
A sub committee on drugs and medical supplies has been set up in 
Thailand as part of the government's price fixing and 
antimonopoly policies. The industry is concerned that this may 
be precursor to the private sector price controls in what has 
been until now a relatively free market. 
The main area of responsibility of the new pricing commit tee 
Hould be to study and analyse pharmaceutical prices and the 
conditions giving rise to them with a view to introducing 
"controlling measures". While rigorous price controls exist for 
products on Th~iland's National List Of Essential Drug the extent 
of control on prices in the private sector has traditionally been 
! 
restricted to exhortations on the part of The Ministry Of Public 
I ' Health for companies not to be excess1ve when implementing price 
increases. 
Many industry executives argue that the price system has actually 
resulted in increased government pharmaceutical spending, since 
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companies whose products would have suffered very radical price 
cuts withdrew from N.L.E.D leaving only local generics which 
under the new system were permitted considerable price rises. 
In Malaysia, eventhough the Ministry of Health has introduced 
registration requirements through the Drug Control Authority the 
Ministry has not done much on price controls. For example the 
price range for brands of paracetamol ( an analgesic ) sold in 
Malaysia shows a seven times difference between the cheapest and 
the most expensive. Thus because of this price difference, the· 
Consumer Association of Penang has called on the Government to 
fix a level for prices of essential drugs needed for primary 
health care and related raw materials. The C.A.P also wants the 
Government to ensure that all raw materials cm_d packaging_ 
materials are of an acceptable quality and are procured from 
international sources at competitive prices. 
79 Pri vatisation 
The Malaysian government is considering the privatisation of the 
pharmaceutical laboratory and store. The government intends to 
hand over the responsibility of buying and storing medicines for 
its hospitals and health centres to a private company. In this 
way the government hopes to save money which would otherwise has 
to be tied up in supplies which it has to maintain. The general 
medical store supplies M$70 million worth of drugs and other 
medical items to government hospitals, clinics and health 
centres. Of this only 10% - a variety of drugs, ointments and 
solutions are manufactured by its own laboratories. Tb.e res.t 
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come from private companies which import 50% of the items 
supplied and manufacture the remaining 40%. 
The plans for privatisation of the government medical store has 
sent shock waves through the pharmaceutical industry. It is 
believed that the profit motive of a private company taking over 
the store would mean an increase in the price of the medicines. 
At the same time the existing industry is left out. More than 
half the local manufacturers will have to close up as they rely 
mainly on Government purchases. The company which has been chosen 
to privatise the medical store is United Engineers Malaysia, 
which is owned by U.M.N.O the main component party of Barisian 
National which rules the.country. It is believed that such a 
privatisation move could discourage foreign investment in this 
field arid would cripple the many 11 Bumiputra " firms tender to 
supply drugs. These " Bumiputra " firms were established in line 
with the New Economic Policy. Thus the Government should 
seriously think about its .privatisation policies before_ ,it is 
implemented. One wrong move could damage the nation Is 
credibility. 
80 DUTIES AND SURCHARGES ( Malaysia ) 
The continuing duties and surcharges levied on both active and 
inactive proces$ materials result in a disincentive against more 
local drug manufacturing investment. Only very few raw materials 
are available locally. Imported finished products are duty free 
while for raw materials there is a 5% surtax on some formulations • 
categorised as non - poisons. Other items such as flavouring 
agents , food, cplouring and glass containers are taxed 5%, 25%, 
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and 50% respectively. Other Government structure.s also trouble 
the industry such as a revision to th~ the patents legislation 
in 1983 that enables the government to waive patents in tendering 
for public health supplies. 
According to the Managing Director of Sterling Drug, Mr. Burt 
Nyberg the abolition of import duties on raw pharmaceutical 
materials may provide a powerful impetus for the growth of the 
. 
local pharmaceutical industry and also help local pharmaceutical 
companies to be more competitive. Mr. Nyberg said, like other 
local pharmaceutical companies Sterling Drug imported nearly 100% 
of its raw materials. Furthermore the pharmaceutical industry in 
Malaysia is in an infant stage and the local market is too small 
to justify the heavy capital investment in manufacturing them 
locally. Sterling Drug on ~~e o~-!I~_r_hAn<!_h.ct~_Q_jlJLtur_ed_ major share 
of the pharmaceutical market. Its major products such as Panadol, 
Cor tal and Eye Mo controls some 60% of the respective pain 
relief, medicine and eye drop markets while Breacol is still the 
leader in the local cough mixture market cqntrolling 40%. 
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THE MALAYSIAN PHARMACEUTICAL INDUSTRY 
Cl The pharmaceutical industry in Malaysia was worth M$350 million 
in 1985 which jumped by 66% from a figure of M$210 in 1981. It 
is expected in 1988 the business will be worth more than M$400 
million. Growth during the past few years has been between 10% 
to 15%. It has been reported that the per capita spending on 
drugs has increased from $15 in 1980 to $23 in 1985. This figure 
is still below the Japanese capita spending of.$184 in 1984. Thus 
there is room for growth in the Malaysian pharmaceutical 
industry .. 
According to the Malaysian Industrial Development Authority, 
pharmaceu~icals ~ncomp_ass an extremel.y wide ~ange of- -products 
from human to veterinary medicaments, and includes cosmetics, 
toiletries and certain borderline agriculture products. 
There has been some conflicting reports as far as manufacturing 
is concerned. According to M.I.D.A the industry produces some 
M$50 mill-ion ringgit wprth of pharmaceuticals per year but the1 
Permodalan Nasional report speculates the pharmaceuticals 
manufactured to be worth M$155 milllion in 1985, a significant 
improvement from M$62 million in 1980. Malaysia definitely lags 
behind Thailand, Indonesia and Taiwan by 10 -20 years in terms 
of pharmaceutical technology and manufacturing capabili~ies. As 
it is seen, the pharmaceutical processing is termed as secondary 
manufacturing. 
About 2/3 of the local drugs and medicines in Malaysia ·are 
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imported. However, significant increase in production has 
improved the percentage of local production to import from 26.4% 
in 1980 to 37% in 1985. Based on average growth rate of 10% per 
annum the pharmaceutical industry is expected to grow from M$600 
million in 1990 to M$1 billion in the year 2000. 
8 2 THE . MARKET 
There are about 20,000 different drugs available in the market. 
This information was issued by the Consumer Association of 
Penang. They can be classified under 19 categories. 
Pharmace4tical Market Share(%) 
Classification 1977 1980 1983 
1) Alimentary system 2.88 5 ._7? 9 .• 59 
2) Cardiovascular system 4.88 8.68 8.52 
& diuretics 
3) Respiratory system 7.27 9.83 8.61 
4) Neuro Muscular system 25.61 16.96 16.66 
5) Endocrif:te d:rug 1.05 1.71 1.45 
6) Contraceptive agents 2.38 1.46 1.19 
7) Antibiotics 17.43 18.13 16.62 
8) Other Chemotherapeutics 9.37 9.49 4.19 
9) Genito urinary system 1.15 1.82 1.5 
10) Metabolism 0.77 1.38 0.26 
11) Vitamins & minerals 4.00 4.75 7.60 
12) Nutritions 6.83 3.69 5.67 
13) Eye,ear, mouth/throat 4.40 2.43 6.16 
14) Dermatologicals 8.90 11.66 8.34 
15) Anaesthetics ~local & 1.43 0.63 0.56 
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general 
16) Diagnostic aid & test 0.64 0.84 0.46 
preperation 
17) Antidotes & immunologi- 0.30 0~26 0.96 
cals 
18) Intravenous solutions 0.11 0.36 1.l9 
19) Miscellalleous 0.60 0.20 0.47 
Total 100.00 100.00 100.00 
As indicated in the table the market share for circulatory 
ailment drugs has increased from 41.79% in 1977 to 43.60% in 
1983. The increase highlights the changes in disease pattern in 
the last decade, which moved from infectious disease to gi~ea~e 
of the circu1atory system. These changes have necessitated the 
introduction of new drugs tailored to counter these ailments. 
Thus, the demand for drugs used in the treatment of circulatory 
system ailments is expected to increase further. .. ' 
Pharmaceuticals and medicines can be broken down into 2 major 
~ategories ie. prescription or ethical drugs and over the counter 
medications (O.T.C) 
PHARMACEUTICAL 
O.T.C ETHICAL 
In Malaysia it is normal for doctors to dispense drugs .. The 
percentage of prescrip~ion and over the conter (O.T.C) drugs in 
1985 was 60% and 40% respectively. 
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However the situation could turn around in the year 2000 when 
. 0. T. C would grab about 60% of the market. The growing trend 
towards self medication could probably be the answer for the 
O.T.C's growth. Self medication is more popular among the 
populace because it is cheaper and more convenient than seeking 
treatment in clinics and hospitals. In developed countries self 
medication accounts for 60% of the total drugs consumed as 
compared to 40% in Malaysia. The other factors that could 
contribute to the reversed scenario are 1) population growth 2) 
improved economic conditions 3) improved lifespan 4) increase in 
the number of drugs given O.T.C status. 
- -
83 TRAD-ITIONAL DRUGS 
In Malaysia and rest of Asia it is not peculiar to see 
traditional medicines being preferred to Western medication. In 
Malaysia· traditional drugs preferred by Malaysians are largely 
. ' 
influenced by their ethnic origins. 
The traditional drugs of the Malay-s are made from the mixture of 
herbs, leaves etc. and is in powdered form. The composition are 
kept strictly within the family. In addition to these in the 
rural areas there is the "Pa Wang" who heads a village and the 
rural folks especially the Malays look towards him for help 
during natural calamities. If there is an outbreak of cholera 
the "Pa Wang" has spiritual powers to stop it. Next to the "Pa 
Wang" there is the "Tok Bomoh" who is somewhat like the African 
medicinal· man. He is more or. less a farmer and in most instances 
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his expertise with traditional medicine is unbelievable. Last 
of all there is the "~iorence Nightingale" of the village who is 
the village nurse or the "Bid~n". Her services are sought during 
child birth and she takes care of the mother and child after the 
delivery of the baby. 
The Chinese community prefer their traditional Chinese drugs. 
These medications are sold by Chinese druggist who number about 
3,500. They supply roots, herbs, ginsengs etc which are from 
China and Korea. No wonder it is surprising that the Chinese 
community in Singapore reacted strongly' to the governments 
proposal to regulate the traditional drug business in the 
repub'lic. 
The Indians on the other hand rely on their Ayurvedic medications 
which are impoJ?ted di-rectly from India. 
84 THE DRUG COMPANIES IN MALAYSIA 
The P.A consulting services carried a major research on the 
industry with the help of the MPTMA (Malaysian Pharmaceutical And 
Tr:aae Manufacture'rs Association) . In its report for 1986, Glaxo 
was the top company with a total sales of $13.~ million. Astra 
came in second with $12.1 million in sales and Pfizer was third 
with $10.8 million sales. For the first quarter of 1987, Glaxo 
remained at the top with $4.4 million in sales, Sandoz was second 
with $2.0 million and Astra was third with $1.8 million. 
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TOTAL MARKET. SHARE OF COMPANIES OPEN REPORT 
85 COMPANY 1987 (QUARTERLY) 
$ % 
1) Glaxo 4440491 24.25 
2) Sandoz - Wander 2029192 11.08 
3) Astra 1871041 10.22 
4) May & Baker 1741483 9.51 
5) Ciba - Geig.y 1488021 8.13 
6) Roche 1251977 6.84 
7) Warrick 1050271 5.71 
8) Hoechst 1036451 5.66 
9) Pfizer 1022385 5.58 
10) I. C. I 744932 4.07 
1ll Sterling-Drug 679357 3.71 
12) Johnson &.Johnson 513967 2.81 
13) Cheah & Fam 441082 2.41 
.. ' 
86 TOTAL MARKET SHARE OF COMPANIES OPEN REPORT 
COMPANY 1986 
$ % 
1) Glaxo 13659534 17.98 
2) Astra 12188722 16.05 
3) Pfizer 10846081 14.28 
4) May & Baker 6350742 8.36 
5) Ciba - Geigy 4566200 8.36 
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6) Warrick 4511650 5.93 
7) Roche 4388466 5.78 
8) Hoechst 4308563 5.67 
9) Sandoz - Wander 4041715 5.32 
10) r.c. I 3364378 4.43 
11) Sterling trug 2764723 3.64 
12) Johnson & Johnson 2726797 3.59 
13) Cheah & Fam 2246898 2.96 
Total Sales 75964796 100.0 
Thus Glaxo, the British giant has outshined its competitors. 
Merck Laboratories, one of the world~s · most respected 
pharmaceutical companies has not made its presence f.elt. Even 
Johnson & Johnson, the world's largest health care company has 
not established a firm footing in the Malaysian pharmaceutical 
industry. The pharmaceutical industry comprises of at least 500 
. ' 
establishments ie. manufacturers/distributor~, wholesalers, 
agents, pharmacies and other drug retailers in Malaysia. In all 
there are 68 distributor~ marketing 20,000 different drugs. 
Drugs and medicines channelled through private clinics and 
hospitals are also on the increase. Their share of total drugs 
consumed has increased from 36% to 46.8% in 1985. The growth is 
due to the increase 'in number of medical establishments and 
~ . 
patients seeking treatment. There are 130 private hospitals and 
1,200 private clinics in 1985 as compared to 71 private hospitals 
and 1,166 private clinics in 1981. 
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87 PHARMACEUTICAL MANUFACTURING 
The size of the current drugs and medicine business in Malaysia 
should be able to accomodate twenty manufacturing establishments. 
Pharmaceutical manufacturing can be divided into two stages : 
Primary manufacturing such as the manufacture of penicillin and 
ampicillin (producing raw materials for secondary manufacturers), 
is absent in Malaysia. This is mainly due to the lack Of R & D 
facilities as understandably, the domestic market is small and 
there is keen international competition. Although investors have 
shown interest in the manufacturing of ampicillin, they are 
reluctant to venture into this field due to the foregoing 
factors. 
These shortcomings are surmountable and the country should look 
into the possibility of utilising its abundant resources, such 
as palm oil ~nd petroleum, to form the base for primary 
..... 
pharmaceutical manufacturing. Palm oil is found to be rich with 
vitamin A, C, E, while Paracetamol can be extracted from crude 
petroleum derivaties. 
88 SECONDARY MANUFACTURING 
Secondary manufacturers convert the products of primary 
manufacturers into saleable products. Some characteristics of the 
local secondary manufacturing activity are : 
1) Less than 20 medium and large establishments where the paid 
up capital ·ranges from M$1 million to M$ 10 million. 
2) Dominated by foreign owned.companies. Locally owned 
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pharmaceutical manufacturers are few who manufacture mainly 
generic drugs. 
3) Production is directed to relatively simple products which do 
not require.high technology and sophisticated machines. 
4) Research and development is insignificant. The cost· of 
developing a new drug in the United States and Japan has 
escalated eight times over the last 20 years. The time 
required to develop a new drug has also inceased from 2 years 
in the early 1960•s to 10 -15 years in 19&4. 
The simpleness of the industry in Malaysia is due mainly to 
the high cost of production. Given the tarrif structure, it 
is cheaper to import drugs. The 25% import tarrif on final 
I 
pharmaceutical products will not reduce imports, n~r encourage 
local manufacturing since the import duty on raw materials 
such as injection bottles, is high as 46%. Local producers are 
dependent on foreign manufacturers for the supply of raw 
materials. Hence, the local manufacturers cannot effectively 
I 
compete with non Malaysian manufacturing. 
89 AGEING POPULATION 
Although Malaysia is a relatively young nation, the percentage 
of people above ~5 years of age has grown from 2.7% in 1957 to 
3. 8% in 1984. Despite the low percentage as compared to many 
developed countries, the increase in the ageing population will 
increase the need for medical health care in the future. 
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Number of.new patients receiving hospital and clinical care 
(Government institution) 
New inpatients c•ooa) 
Outpatients ( 1 000) 
Average number of hospital days 
Utilisation rate of hospital beds (%) 
Source Bulletin Perangkaan Sosial Malaysia 
. 
1970 
490 
58 
9 
40.6 
1980 
700 
75 
7 
53.0 
1971 and 1981 
Ratio of elderly (65years and above) to population 
year (%) 
Malaysia 1984 3.8 
Japan 1982 9.6 
U.S.A 1981 11.5 .. ' 
France 1982 13.5 
West Germany 1981 15.4 
Britain 1980 15.1 
Source : Long Term Credit Bank Of Japan, March/April 1985 and 
P.N.B research. 
A survey done in England in 1980 revealed that the elderly 
defined as people of 65 years and above ) were dispensed twice 
as many participants per year as the national average of si~. 
Drugs, to the majority of people are taken to cure diseases. For 
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the elderly, however, druqs are taken to alleviate the symptoms 
of old age such as malfuctioning of the cardiovascular and 
nervous systems. 
90 SOCIETY'S INCREASING LEVEL OF AFFLUENCE 
In the past 14 years, Malaysia's per capita G.N.P has increased 
more than four fold from $1 I 170 in 1970 to $4 1 867 in 1984. 
Malaysians are becoming more health conscious as the level of 
education and standard of living increased. Per capita spending 
of drugs has increased from $15.5 in 1980 to $23 in 1985 1 but is 
still far below than in major developed countries. 
91 FINANCIAL PERFORMANCE OF MARKET LEADERS 
Generally the financial performances of the companies in the 
pharmaceutical industry had improved over the period of 1981 to 
1984. Table summarises the average financial results of, the 
market leaders. 
1981 1982 1983 1984 
Turnover ( $'000 ) 6490 7460 8230 9420 
Profitability ratio 
Gross profit margin (%) -0.18 1.98 3.14 6.92 
Net profit margin (%) -1.06 0.70 1.10 3.49 
Gross return on assets (%) 3.80 5.16 6.97 11.48 
Gross return on capital 
employed (%) 8.42 10.52 10.48 16.30 
Gross E.P.S ($) 
Net E.P.S ($) 
Liquidity position 
Current ratio (x) 
Acid test ratio (x) 
Leverage ratio 
Debt to equity (x) 
Debt to assets (X) 
Activity ratio 
Inventory turnpver 
Asset turnover (x) 
(x) 
Dividends ratio 
Dividend per share (%) 
Net dividend cover (x) 
Dividend yield 
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0.21 
0.08 
1.41 
0.70 
2.95 
0.59 
3.07 
1.32 
13.02 
1. 54 
9.54 
0.41 
0.19 
1.44 
0.74 
2.74 
0.58 
4.77 
1. 48 
13.85 
1.33 
10.69 
0.52 
0.23 
1. 33 
0.72 
2.54 
0.64 
5.02 
1.46 
15.12 
0.36 
12.89 
0.32 
0.17 
1.42 
0.76 
1. 52 
0.53 
4.20 
1.50 
18.69 
1.25 
15.69 
The average turnover of the companies had increased from M$6.49 
million in 1981 to M$9.42 million in 1984. This was due to an 
increase in the number of retail outlets in the country, 
especially in the Klang valley and other major towns in Malaysia. 
The increase in turnover was also due to the entrance of many new 
drugs into the the Malaysian market, coupled with the improved 
advertising performance of many pharmaceutical companies. 
Gross profit margins recorded by those companies also indicated 
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a substantial increase from a negative 0.18% in 1981 to 6.92% 
in 1984. This was due to an increase in wholesale and retail 
business as compared to government purchase. Government tenders 
stagnated at about M$80 million per year for the past few years 
while market size increased at an average of 10% annually. The 
margins from government purchases are much lower than that from 
the private sector, due to the system of tendering adopted by the 
government. 
Figure shows the competitive positions of companies in terms of 
net margin and turnover. A statistical average line indicates a 
growing trend of margin versus turnover. As turnover increases, 
the margin also increases. This is indicative of an infant 
industry in which the market size is expanding. 
Xepa Soul Pattinson Sdn Bhd is positioned at the highest point 
to the margin, while May & Baker Sdn Bhd has the highest 'turnover 
with an im~roved trend in margin. Xepa Soul has an advantage in 
distribution channels, since it is under Apex Pharmacy Holdings 
Sdn Bhd a retail chain outlet. Apex pharmacy has an established 
distribution network throughout the country. However, Apex 
pharmacy has not been recording better margins due to its 
diversification into the.1 sales of various products such as 
toiletries, which yield lower margins. These are, however 
l 
complimentary items sold together with the drugs and medicines 
to attract more customers. 
Return on assets and return on capital employed also showed an 
increasing trend. Figures show that position and trend of ROA and 
ROCE of the companies. 
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Glaxo Malysia, Syarikat Salim and Xepa Soul performed better than 
the others. However an improved trend can be seen in the 
performance of Roche, Sterling Drug and Johnson & Johnson. The 
statistical av~rage line shows a positive slope indicating that 
as asset or capital employed increases, the return will also 
increase. This indicates that the industry is still in its infant 
stage but it is generally efficient in utilising assets or 
capitals. 
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Fig 14 :· 
Figure : ROA vs. Totai Asset 
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MALAYSIA - WORLD'S POTENTIAL VITAMIN E PRODUCER 
92 Having proved in its ability to serve as a viable off shore base 
for the electronic industry, Malaysia will soon stake its claim 
to become the future world centre for the production and 
marketing of Vitamin E. In the process it will establish the fact 
that the palm oil industry not only can contribute to the 
alleviation of the world malnutrition and hunger but also to the 
overall health and vitality of rich and poor alike in many 
countries. A Vitamin E plant pilot has already been 
commissioned in Malaysia and it is the first of its kind anywhere 
in the world. Vitamin E as it is commonly called contains 2 
compounds called Tocopherols and Tocotrienols. Besides its usual 
positive effect on the general health, Vitamin E is known for its 
" anti oxidant '' ability to slow down the ageing process and to 
give protection to chronic degenerative illness as well as to 
promote fertility. 
Vitamin E, which comes from traditional sources such as soya bean 
scum is not enough to meet the world demand, roughly estimated 
at 7,000 tonnes a year. As the world's 2nd largest source for 
fats and oils today, palm oil holds the potential to become an 
alternative or additional source for vitamin E. 
On the basis of the current availability of Vitamin E in 1987, 
the Malaysian palm oil :i,ndustry could earn as much as M$68 
million a year in additional income. This was based on the 
• 
prevailing Vitamin E price of M$1,000 per kilogramme. By the year 
2,000, Vitamin E production from palm oil is estimated to total 
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1,088 tonnes valued at M$108.0 million a year at current market 
prices. The Vitamin E produced at the pilot plant comes from a 
by product of palm oil refining called palm fatty acid distillate 
( PFAD ). The Vitamin E content of PFAD has been estimated at 
0.4% a tonne. Based on the Malaysian palm oil output of 4.5 
million tonnes in 1987, a total of 170,000 tonnes of PFAD can be 
obtained from which some 680 tonnes of vitamin E can be extracted 
annually. 
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PHARMACEUTICAL INDUSTRY IN SINGAPORE 
93 STATISTICS 
There were 31 pharmaceutical companies in 1984, of which 17 
manufactured locally. In addition there were 45 agents holding 
distribution rights for multinational companies. 
Total pro.duction of pharmaceuticals ( by value ) in 1984 was S$ 
.i 
599.3 million of which S$581. 5 million was accounted for by 
exports. In 1982, production was S$109 million of raw materials 
\ 
and S$316.4 million of finished products. 
94 PHARMACEUTICAL TRADE 
About 97% of locally manufactured pharmaceuticals are exported. 
·Most goods, including pharmaceuticals, enter Singapore duty free. 
In 1987, a system of import licences was introduced. Importers 
of products in Category one must obtain a licence by July 1988; 
licences for pharmaceuticals in other categories will follow. The 
license is issued by the Ministry Of Health Inspectorate 
Section and is valid as long as the product licence of the 
products imported, or until a date set on the license. Licenses 
are only issued to companies registered with the Registry Of 
• Businesses and Companies. 
A license is not necessary for the importation of pharmaceuticals 
which are to be·re- exported. However a certificate ·of approval 
will be necessary from the Ministry from July 1988. 
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95 TRADE 
The 1975 Medicines Act contains provisions, not yet enforced, for 
the certification of approval for export of medicines. 
Pharmaceutical exports are generally 1. 5 times the value of 
imports. The main destinations for the pharmaceutical exports 
are Hong Kong, Japan, Pakistan and Saudi Arabia. The main sources 
of imports are China, West Germany, Japan, Malaysia, Switerzland, 
U.K and U.S.A. 
96 CONTROL OF MANUFACTURE 
Licensing of local manufacturers is to be introduced in July 
1988. Applications for licenses are required to be submitted by 
30th September 1987. Application forms are available through the 
Inspectorate Division Of The Ministry Of Health. 
97 PHARMACEUTICAL RESEARCH 
The 1975 Medicines Act requires that clinical trials be approved 
and certified by the Ministry Of Health prior to their 
commencement. 
PHARMACEUTICAL PRICING 
The manufacturer or importer may set pharmaceutical prices 
freely. There is no current government intention to change this. 
LABELLING AND PACKAGING 
Proposed packaging copy and package inserts will be required to 
be pre - cleared at registration, when the product registration 
system is implemented. 
t . 
'\ 
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The following information will be required on the packaging copy; 
trade name, name and address of the manufacturer ( and importer/ 
distributor), chemical name, strength, number of doses, full 
details of excipients, route of administration, dose, directions 
for use, indications, contra indications, side effects, 
warnings, storage instructions, batch number, expiry date, date 
of manufacture, and product license number. Scheduled poisons 
must carry a poisons label, and controlled pharmaceutical drug 
label. 
Package inserts will be required to state the following; trade 
name, chemical name, strength, number of doses, excipients, route 
of administration, dose, directions for use, indications, contra 
- indications, side effects and warnings. 
The New Medicines ( labelling ) Regulations 1986 require that 
an expiry date be displayed on medicines. Initially, this will 
apply only to a specified list of unstable pharmaceuticals 
(including aspirin, blood products, vaccines, antibiotics, 
insulins, certain vitamins, iron salts and others) . This has 
been enforced from April 1987. 
98 PRODUCT REGISTRATION 
The following products are exempted from registration : raw 
materials, traditional medicines, extemporaneous preperations, 
products manufactured for export only and quasi medical 
products such as medicated shampoos. Products imported for small 
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numbers of patients or solely for re - export need not be 
registered but prior approval must be obtained from the Ministry 
Of Health. 
Each application must include the following : pharmaceutical and 
pharmacological data, a summary of the manufacturing process 
not full details ) , certificates of analysis from the 
government analyst or private laboratory, a certificate of free 
sale from the countries of orign, and samples of the packaging 
or labels, draft packaging copy and samples of the product. 
A separate license is required for each strength, colour, shape 
and presentation of the product. A product license will be valid 
for five.years, unless a provisional license is issued for three 
years. 
Applications are required for category one products by September 
1987. It is envisaged that they will all be licensed or withdrawn 
by July 1988. No dates for the remaining categories have been 
issued. Guide books on registration are available from the 
cashier section of the Ministry of Health and application forms 
from the Inspectorate section. During the first phase of drug 
registration, 2,654 products were registered, 2,182 were 
approved, 51 were rejected, 106 were withdrawn and 315 pending 
additional information. Registration of phase 2 was fixed till 
September 30, 1988. Approvals are expected by mid 1989. 
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99 LEGISLATION 
The 1975 Medicines act covers all areas of pharmaceutical 
manufacture and distribution. However, only the parts relating 
to promotion, advertising, clinical trials and the registration 
of pharmacies were being fully enforced by 1987. The Poisons Act 
and The Misuse Of Drugs Act control the importation of some 
drugs. New legislation requiring the labelling of the expiry 
dates of 22 unstable pharmaceutical products was introduced in 
September 1986. This is to ensure that such products will still 
be effective when administered to or consumed by end users. More 
pharmaceutical products will come under this legislation which 
will be enforced from April 1, 1987 to give sufficient time for 
pharmaceutical firms to prepare the necessary labelling. 
100 PHARMACEUTICAL POLICY 
The government is encouraging local manufacture by offering 
incentives to the medical and pharmaceutical industry in the form 
of tax concessions ( for up to ten years ) , financial aid, help 
for support industries and for forign companies free repatriation 
of profits. Meanwhile, the Ministry Of Health intends to expand 
its own pharmaceutical production facilities to cope with the 
increasing demand. 
101 THE PHARMACEUTICAL INDUSTRY 
In 1987, new legislation was introduced requiring companies to 
obtain a license for the manufacture or import of 
pharmaceuticals. They must be obtained by July 1988 and will only 
be given to companies registered with the Registry Of Businesses 
and Companies. 
-149-
The local manufacturing industry is small by international 
standards, but expanding. A number of multinational companies 
manufacture their raw materials locally eg. Glaxo manufactures 
half of its world supply of Ranitidine in Singapore. Much of 
local production is exported, although 80% of domestic needs are 
met by local manufacture. The Ministry of Health owns a company 
which formulates, compounds and packs generics for government 
establishments. 
102 DRUG REGISTRATION 
Following the recent announcement by the Minister Of Health that 
preparations are being made to introduce drug registration in 
Singapore, members of S.A.P.I held a special meeting with the 
officials of the Ministry Of Health on the issue. The Ministry 
officials explained that a separate product licence was required 
for colour, shape and strength of the same presentation of the 
same medicinal product. Thus for example a separate product 
licence will be required for each of the following products : 
1) Inj. tetracycline 
2) Tab. tetracycline 250 mg. shaped round and coloured red 
3) Tab. tetracycline shaped round and coloured green. 
Hqwever different package sizes of the same product in the same 
strength may be sold under one product licence eg. tetracycline 
capsules 250 mg. packing of lOO's, 500's and 1000's need only one 
product licence. Any changes of the colour or shape of tablets 
after product licence has been issued would render the licence 
invalid. At the time of application of product it is necessary 
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to enclose samples of packaging and their respective labels. 
Changes in the label, particularly with new indications for the 
use of the product, should be reported to the Ministry Of Health 
for suitable amendment of the particulars of the product licence 
in question. 
To facilitate processing of applications for product licences, 
applicants will not be required to give full details of the 
manufacturing process, but summaries of such processes. 
103 NEW PRODUCTS 
Products which have not had sale transaction in Singapore prior 
to 30th June 1987 will be deemed to be new products. Products 
imported before that date but with no sale transaction will still 
be considered as new products. 
104 POST REGISTRATION 
Any changes to the information submitted to the Ministry Of 
Health in an appliqation for a product licence must be notified 
to the Ministry, or the licence will be invalidated. 
105 PHARMACEUTICAL PROMOTION 
According to the 197 5 Medicines Act, three year permits are 
required from li¢ensing authorities before pharmaceutical 
products can be prqmoted to the public; this does not apply to 
promotion to doctor~ or to Chinese drugstore owners. Door t'o door 
'• 
' 
sales and street peddling are prohibited. Since many doctors 
: ... 
dispense, bonusing is a common practice. Advertising in most 
'i 
:··· 
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journals and trade advertisements ie. like price lists, 
catalogues and other literature require authorisation. Exemptions 
to these are the medical advertisements issued by public 
authorities or authorised by the Ministry Of Health. Once 
approved by the licensing authority, advertising material cannot 
be amended without written permission. 
106 POST MARKETING SURVEILLANCE 
Following the introduction of product registration, the Ministry 
Of Health intends to carry out random checks on market stocks 
of product~ to ensure quality is maintained. The product license 
holder will be required to report adverse reactions to the 
Ministry Of Health within 7 days of themselves receiving a 
report. 
107 PHARMACEUTICAL MARKET 
The total sales of pharmaceuticals through all outlets in 1986 
was an estimated S$96 million ( U. S$44 million ) at manufacturers 
selling price. The average consumption of pharmaceuticals per 
head of population was U.S$17 for that year. 
108 GOVERNMENT TENDERS 
Tenders must ensure that the medicinal products they offer have 
all been given product 1 icences, information on which may be 
obtained from the Ministry Of Health. 
109 PARALLEL IMPORTS 
An import licence can be given to anyone wanting to import a 
product, the product licence of which is held by another firm, 
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provided that the importer can show proof that his products 
carries a product licence and that it is manufactured by the same 
manufacturer. Such import licences will be given on a per 
consignment basis. Batch numbers must. be specified by parallel 
illlporters. 
VALIDITY OF IMPORT LICENCES 
Import licences issued to persons authorised by the relevant 
product licence holders shall, in so far as each item of product 
in the licence is concerned, be valid for as long as the product 
licence for that item remains valid or up to the validity date 
stated in the import licence whichever is the earlier. If a 
product or a number of products are to be imported solely for re 
- export then no import or product licence is required; however, 
a certificate is required for such purposes. 
VOLUNTARY DEREGISTRATION 
Holders of product licences for products which are manufactured 
in several countries, may apply to the licensing authority to 
deregister any one or more countries of manufacture or may apply 
to deregister certain strengths, colour, shape or packagings of 
such products. 
CERTIFICATE OF ANALYSIS 
Applications for product licences must be accompanied by 
C~rtificate Of Analysis issued by the government analyst or any 
private analytical laboratory in Singapore or any other country. 
Subsequently it is not necessary to submit Certificates Of 
Analysis for each batch to the Ministry Of Health. Random checks 
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by Ministry Officials will also be made on market stocks. 
110 CERTIFICATE OF FREE SALE 
These are issued by the health authorities of the country of 
origin stating that the product is manufactured in the country 
by a licensed manufacturer and that the product is allowed for 
free sale in the country. 
Every application for product licence must be supported by a Free 
Sale Certificate. However if the application relates to more than 
one product, all of which are manufactured by the same 
manufacturer, then one certificate, listing all the products and 
their respective presentations ( tablets, injections, ointment 
etc.) would suffice. If a product happens not to be sold in the 
country of origin, then the reasons why it is not sold should be 
stated in the certificate. All certificates need to be 
authenticated by the Singapore Embassy, Consulate Trade Mission 
or its representative embassy etc.in the countries where they are 
issued. 
When submitting applications for product licences, evidence of 
sale in countries other than the countries of orign, in the form 
of Free Sale Certificates would be helpful but this is not 
mandatory. 
111 MULTIPLE COUNTRIES OF ORIGIN 
Where a product is manufactured by a company with factories in 
several countries where stocks are drawn, only one product 
licence is necessary for such a product, provided specifications 
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for that product remains identical, and Certificate Of Free Sale 
are obtained from the relevant authorities of each of the 
countries where the product is manufactured. If, however 
subsequerit to the issue of a product licence, it is intended to 
draw stocks from factories in other countries not listed in the 
product licence ( ie. new countries of origin ) , then the product 
licence should be submitted to the Ministry Of Health for the 
necessary amendment. 
112 PRODUCT GROUPING UNDER VARIOUS PHASES OF IMPLEMENTATION OF DRUG 
REGISTRATION 
CATEGORY ONE 
1) Hypnotics, sedatives, tranquilisers, antidepressants and 
narcotic drugs. 
2) Cardiovascular drugs and diuretics. 
3) Antibiotics, antibacterials, antivirals, antifungals, 
anticancer drugs, antituberculosis agents, antileprotics, 
antimalarials, antiparasitic agents and sulphonamides. 
4) Vaccines and human blood products. 
CATEGORY TWO 
1) Drugs for alimentary system. 
2) Drugs for genito urinary system. 
3) Drugs for respiratory system. including antihistamines · 
cough and cold preparations ) 
CATEGORY THREE 
1) Hormones, contraceptives and drugs for metabolism. 
•• 
2) 
3) 
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Eye, ear, nose, mouth and throat preparations . 
Dermatological preparations. 
CATEGORY FOUR 
1) Vitamins an~ nutritional preparations. 
2) Analgesic, antipyretic, anti - inflammatory and anaesthetic 
preparations (including an~irheumatic and gout 
preparations). 
3) Other preparations not mentioned above. 
From the schedule it is seen that antibiotics are in category 1. 
If a firm has diffe.rent presentations of the same antibiotics, 
eg. tetracycline in capsules, eye drops, injections etc. then 
applications for these products should be sent in during the 
registration period for category 1 products. However, if the 
application is for only one tetracycline product, namely eye 
drops, then the application is best submitted during the period 
for category 3 products, viz. eye preparations. Where a product 
comes under two categories, it is advisable to liase with the 
Ministry to determine the proper date for submitting application 
for product licence. 
113 DRUGS AND DRUG LIST 
Pharmaceuticals classified as poisons under the Poisons Act are 
theoretically only available from doctors or from pharmacies on 
presentation of a prescription. The list of products classified 
as poisons is regularly updated : blood products were added to 
the list in April 1988 in response to the spread of Aids. 
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• 
Products classified as Controlled Drugs under the Misuse of Drugs 
1973 are subjected to more stringent controls. 
There is the Ministry Of Health Standard Drug List of about 500 
products from all therapeutic classes. This must be used by 
prescribers in government clinics and hospitals. The products are 
selected by a board of consultants and pharmacists and the list 
is updated annually. New products are considered for addition to 
the list when prescribers apply to use them. 
114 PHARMACEUTICAL DISTRIBUTION 
Prescription pharmaceuticals poisons are available from 
doctors, pharmacies and illegally from Chinese drugstores. Non 
prescription pharmaceuticals are available through pharmacies and 
Chinese drugstores. A licence is required from the Ministry Of 
Health to import, store or sell wholesale or retail 
pharmaceuticals. 
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Fig 17 
115 SINGAPORE ASSOCIATION OF PHARMACEUTICAL INDUSTRIES 
ANNUAL SALES TURNOVER SURVEY 1986/1987 
OPEN REPORT 
COMPANY S$'000 
1987 SALES 
1. Roche Singapore Pte. Ltd. 5,470.00 
2. Summit Co. (S) Pte.Ltd 
- Merck Sharp & Dome 5,038.00 
3. Glaxo Singapore Pte. Ltd. 3,870.00 
4. I.C.I Singapore Pte. Ltd. 3,847.00 
5. Ciba Geigy S.E.A Pte. Ltd. 3,708.00 
6. May & Baker Singapore 2,772.00 
Pte. Ltd. 
7. Hoechst Singapore Pte. Ltd. 2,443.00 
8. Asiamed. Pharm. Products 2,389.60 
9. Boots Co. tF.E) Pte. Ltd. 2,210.00 
10. Beechams Pharm. Pte. Ltd. 2,133.30 
11. Essex Asia Ltd. 1,787.60 
12. Far East Drug Co. Pte. Ltd. 1,672.00 
13. Johnson & Johnson Pte. Ltd. 1,553.00 
14. Drug Houses Of Australia i,540.00 
15. Squibb (F.E) Ltd. 1,371.00 
16. Takeda Chemical Industries 1,323.00 
Ltd. 
17. Bristol Myers Singapore Pte. 1,309.00 
Ltd. 
18 .• summit Co. (S) Pte. Ltd. 
19. Boehringer Ingelheim 
20. Searle Representative Office 
21. F.E Zuellig (T) Pte. Ltd. 
22. Cynamid (F.E) Ltd. 
23. Eisai Asi& Regional Services 
977.00 
940.20 
870.00 
554.00 
467.30 
388.40 
S$'000 
1986 SALES 
5,073.00 
4,192.00 
3,657.00 
3,898.00 
3,756.00 
2,307.00 
1.820.00 
1,983.50 
2,229.70 
2,608.90 
1,529.30 
1,603.00 
1,434.00 
1,362.00 
1,231.00 
1,308.20 
1,061.00 
936.00 
828.70 
1,025.00 
218.00 
362.10 
379.50 
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24. Guardian Pharmacy 347.90 
25. Stiefel Laboratories (Pte) 344.00 
Ltd. 
26. Diethelm Singapore Pte.Ltd 332.10 
- Cilag 
27. Cheah & Fam (S) Pte. Ltd 327.00 
- Biochemie 
28. Diethelm Singapore Pte. Ltd 311.00 
- Lipha 
29. Rorer Pharm (S) Pte. Ltd. 244.90 
30. Boehringer Mannheim (F.E) 187.20 
31. K.S Pang Trading Pte. Ltd 164.50 
32. Diethelm Singapore Pte. Ltd. 128.00 
- Swiss Serum 
33. Cheah & Fam (S) Pte. Ltd 123.20 
- Weber 
34. Diethelm Singapore Pte. Ltd 119.00 
- Geitslich 
35. Diethelm Singapore Pte. Ltd. 116.00 
- Luitpold Werk 
36. Diethelm Singapore Pte. Ltd. 70.00 
- Carter Wallace 
37. Diethelm Singapore Pte. Ltd. 65.00 
- Medinova 
38. Cheah & Fam (S) Pte. Ltd. 65.00 
- Sumitomo 
39. Cheah & Fam (S) Pte. Ltd. 35.50 
- Ciech Polfa 
40. Cheah & Fam (S) Pte. Ltd. 23.20 
- Leiras 
41. Guardian Pharmacy - Ciba O.T.C 7.00 
Principals represented by Summit Co. 
Mack 
Merz 
Schwarzhaupt 
Dr. Thilo 
Whitehall Int. 
Nippon Kayaku 
326.80 
95.00 
311.90 
185.20 
259.30 
238.40 
183.00 
104.60 
102.00 
83.30 
251.00 
120.00 
64.00 
73.00 
20.30 
27.50 
10.70 
21.10 
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THE PHARMACEUTICAL.INDUSTRY IN THAILAND 
116 Since the proclamation of the Industrial Promotion Act in 1962, 
the Thai Pharmaceutical Industry has been gearing ahead. The 
number of pharmaceutical plants has increased from 148 in 1969 
to 189 in 1988. Out of these factories more than 20 of them are 
foreign investment or joint ventures. The government of the 
Kingdom of Thailand has two state run plants ie. The Government 
Pharmaceutical organisation G.P.O and the Military 
Pharmaceutical factory. 
The actual pharmaceutical market is worth about 12,000 million 
Bahts. The figure includes 3,500 Million Bahts as imports and 
8,500 million Bahts as local production. 
The government intends to produce and sell house hold drugs/ 
remedies at reduced price so as to prevent the branded 
pharmaceutical items from having a total control of the market. 
The Military Pharmaceutical Factory manufactures and distributes 
most of its production to the military hospitals or health 
centres which are located throughout the country. The 1982 
statistics showed that 700 pharmacists were employed in the 
pharmaceutical manufacturing industry ie. production, quality 
control etc. Eventhough the manufacturing of drugs has not been 
that sophisticated, it is eventually predicted that the industry 
will make a major breakthrough in upgrading itself with the 
latest technology. 
117 
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MANUFACTURE OF PHARMACEUTICALS 
As discussed earlier, Thailand•s manufacturing system is quite 
advanced. Eventhough the industry claims to have a strict code 
of G.M.P that is good manufacturing practice, some·companies do 
not comply to the strict code of ethics. For multinationals it 
has become more of a necessity to manufacture their products 
locally so that it gives them an added advantage of having the 
product sold cheaply and at a competitive price. Companies are 
liable to pay a hefty duty as high as 30% if they import. This 
30% in import duty is a requirement if there exists similar 
products by other companies that have local registration/ 
production. 
If the drug imported is sophisticated and there happens to be no 
competition in the category, then the import duty involved is 
only 12%. Many companies in Thailand act as the sub contract 
manufacturers· for multinationals. One good example is OLIC 
THAILAND which manufacturers pharmaceuticals for Janssen, Cilag, 
Astra, Beechams etc. OLIC THAILAND is part of the Diethelem group 
which has a strong foothold in Malaysia, Singapore and Thailand. 
OLIC has an extensive manufacturing programme which caters the 
following menu : 
1) tablets which could be plain, film coated or sugar coated. 
2) capsules. 
3) Liquid preparations which could be syrups, drops or elixirs. 
4) Creams and ointments. 
5) Sterile product ie. injectable products. 
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t OLIC was planned and constructed with the help of Swedish and 
Japanese experts and is one of the most modern in South East 
Asia. Other than OLIC, Diethelem and F.E Zuellig are the other 
contract manufacturers to name. 
Compared to her Southern neighbours, Malaysia and Singapore, the 
Thai manufacturing capabilities for pharmaceuticals is way 
upfront but it still needs to import drugs from Japan, Western 
Europe and North America. 
A 1987 study by the Department of Business Economics, Ministry 
Of Commerce gave the following figures for imports and exports 
of pharmaceutical products. The figure below shows the 1985 value 
of exports ie. 213.3 million Baht. There was a 8.06% growth in 
1986, and the value recorded was 230.5 million Baht. In 1987, the 
growth increased by 15.9%. Value of exports monitored by the 
Ministry of Commerce was 267.1 million Baht. 
The import of pharmaceuticals into the Kingdom of Thailand for 
the years 1985, 1986 and 1987 showed the import value as 1,739.5, 
1,658.6 and 1,517.4 million Bahts respectively. 
t 
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EXPORT FOR PHARMACEUTICAL PRODUCTS FOR THAILAND 
19 8 5 - 19"8 7 ) 
Value in Millions of 
Bahts 
Growth 
1985 
213.3 
1986 
230.5 
8.06 
1987 
267.1 
15.9 
. Export markets in 1987 were Hong Kong, Singapore, Laos and 
Australia. 
A 1987 survey on the importation of pharmaceuticals show the 
quantity of different pharmaceutical products imported with the 
respe~cti ve values. Vaccines microbial, vitamins, cathartic and 
laxatives, contraceptives and other medicaments formed the 
largest quantity of items to be imported into Thailand in kilo 
weight. On the other hand in terms of value, toxins, toxoids and 
crypts formed the biggest imports. The figure given below gives 
details of the importation of pharmaceuticals. 
118 PHARMACEUTICAL SALES 
It is difficut to assess the extent of the market value of 
pharmaceuticals in Thailand. The Pharmaceutical Products 
Association of Thailand which has 62 member companies under its 
wing has its own research activities to determine the size of the 
pharmaceutical market. The Pharmaceutical Products Association 
is an organisation which tries to promote high professional 
standards and the availability of high quality products to the 
- 163 -
Thai people. In an open sales exchange for the year 1988, Roche 
Thailand amassed sales of Baht 261,666,000 follwed by Hoechst 
Thai, Glaxo, and Merck, Sharp and Dome which cleared the 200 
million Baht mark. Out of the 62 P.P.A members only 54 P.P.A 
companies were represented iri th±s open sales programme. 
The open sales exchange for December 1988 showed that Smith Kline 
and French achieved 91.7% growth in December to rank first but 
in overall sales it was 9th. Abbot laboratories achieved 29.5% 
growth in December only to find itself 41 in the overall sales. 
Given as attachments are the open sales exchange which reflects 
total sales achieved .for 1988. (Please refer to page 167) 
119 NATIONAL DRUG POLICY 
As drugs are one of the most important components for the 
implementation of the country's health services leading to 
11 Health for all by the year 2000 11 , the Ministry of Public 
Health, in April 1981, issued the National Drug Policy 
emphasising the following points : 
1) Supply of safe and good quality drugs at reasonable price 
right up to the rural areas with special stress on primary 
health care. This will include the improvement of the 
logistics of drug supply and promotion of local drug 
production both in private and public sectors. 
2) Wastage of drugs will be curbed by strict adherence to the 
National Formulary and Essential Lists and dissemination of 
comprehensive informations to the Medical profession 
regarding drugs and treatment regimens. 
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3) As an important component of the quality assurance scheme, 
augmentation of drug analytical facilities, including the 
testing of biological and im~unological products and 
development of a responsible organisation for drug 
standards, drug analysis and reference substances will be 
carried out. 
4) To survey the indigeneous raw materials available in the 
country and to investigate the possibility of developing 
bulk drug production utilising local resources. 
5) Explore intensively the therapeutic potential for 
traditional drugs for safe and efficacious use, especially 
in the field of primary health care. 
120 FACTORS AFFECTING THE THAI PHARMACEUTICAL INDUSTRY 
There are many factors affecting the progress of the 
pharmaceutical industry in Thailand. 
1) Raw materials 
As most of the raw materials are imported, the manufacturers 
have to pay higher prices due to the transportation cost, 
import duty and taxes. The inventory must be kept high 
enough to cover the lead time which usually takes about 3 
months. This will build into the cost of the goods where by 
reducing the competitiveness of the pharmaceuticals produced 
in Thailand. 
2) Technology and Quality 
For the foreign investments and the big local factories, 
technology and qauality are considered acceptable and 
comparable to the products produced by the developed 
countries, due to the lack of modern equipment and research 
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and development activities. The outputs from these factories 
may not measure up to the international standards but they 
must comply with the standards set. 
3) Market 
The size of the domestic market is quite limited. The same 
type of the product may be produced by many manufacturers 
causing a lot of competition in the market. Distribution of 
drugs from the manufacturers to the government units and 
hospitals which are under the control of the Ministry Of 
Public Health can be done only through the G.P.O if the 
payment for the drugs come from the budget provided by The 
Ministry of Public Health, but there is exception in some 
cases. These problems may lead to suspension in investment 
in the local pharmaceutical industry. 
-
4) Pricing 
Due to the strong competition in the pharmaceutical 
business, pricing varies from one another. The manufacturers 
who produce the drugs of quality at high cost will face a 
problem in terms of selling their products. 
121 PROTECTION 
The local industry is quite protected by laws and regulations. 
First of all there is a 30% tarrif duty on import of finished 
pharmaceutical goods. For production they receive investment 
promotion previleges from The Board of Investment such as tax 
holidays, duty free imports of machinery and raw materials. It 
is well recognised that if a high degree of protection is given 
to the domestic industry for a lengthy period of time it can give 
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rise to inefficiency in production as well as low profit margins 
to producers due to lack of competition from foreign supply. It 
can also be seen that a comparison of the retail prices and C.I.F 
price at full factory cost shows a high level of mark up which 
partly reflect high profit margins. The inefficiency in the 
pr6duction pattern is clearly related to the nature of trade and 
inv.estment policies. From the point of view of an industrial 
\ 
development strategy there is now an increasing awareness within 
the official circles that high levels of protection given to the 
domestic industry have to be reduced so that efficency in 
prod~ction will be improved so that industries can be competitive 
in the international market. 
' 122 Fig 18 
RANK 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
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OPEN SALES EXCHANGE ( 1988 ) 
COMPANY SALES (BAHTS) 
Roche 261,666,000 
Hoechst 250,956,000 
G1axo 230,372,000 
Merck Sharp & Dome 230,566,000 
Thai Otsuka 167,666,000 
Ciba Geigy 139,976,000 
Sandoz 139,056,000 
Schering 135,004,000 
Smith Kline & French 133,812,000 
Warner Lambert 125,433,000 
Astra 119,917,000 
Pfizer 118,775,000 
Westnont 118,725,000 
Eli Lilly 116,187,000 
Squibb 116,036,000 
Richardson Vicks 112,387,000 
Boots 109,520,000 
May & Baker 109,501,000 
Janssen 103,817,000 
Cyanamid 103,314,000 
Bayer 102,392,000 
Paiboon Watane 99,410,000 
Bristol Myers 90,526,000 
Well come 90,451,000 
Boehringer Ingelheim 84,404,000 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
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Organon 
Farmitalia 
I.C. I 
Merrel Dow 
Up john 
Medimpex 
Beecham 
Sterling Drug 
Roussel 
Essex 
G.D Searle 
Les Lab Servier 
Boehringer Mannheim 
E.Merck 
A.H. Robins 
Abbot 
Sanofi 
Hausmann 
United A.Pharma 
Syntex 
Mack 
Biomedics 
Degussa 
Unichem 
Eisai 
Stuart 
Carter Wallace 
Pliva 
Menarini 
84,012,000 
81,589,000 
80,807,000 
78,904,000 
70,891,000 
65,015,000 
62,892,000 
55,018,000 
54,678,000 
54,477,000 
50,738,000 
47,183,000 
41,598,000 
35,895,000 
34,744,000 
30,606,000 
30,071,000 
29,814,000 
29,684,000 
27,513,000 
27,400,000 
27,322,000 
26,713,000 
23,253,000 
23,069,000 
12,312,000 
6,121,000 
4,320,000 
2,079,000 
123 
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Fig .19 IMPORTATION OF PHARMACEUTICALS 1987 ( THAILAND ) 
1) 
2) 
3) 
4) 
5) 
6) 
CLASSIFICATION 
Blood plasma medical 
Serum from normal blood 
Organs therapeutic glands 
or other dried extracts of 
glands 
Sera Antisera 
Vaccine Microbial 
Toxins, toxoids, crypts 
antitoxins 
Other microbial cultures 
QUANTITY 
KG ) 
257 
176 
1,457 
604 
139,437 
~16 
1,721 7) 
8) 
9) 
Quinine 92 
Other medicaments & chemical 8,794 
products for malaria 
10) Medical & pharmaceutical 
preparations with alcohol 
11) Vitamin B complex for 
injection 
12) Vitamin Bl for injection 
13) Vitamin B1 tablets 
14) Vitamin C tablets 
15) Other Vitamins 
16) Turbutamol tablets 
17) Anesthetics 
18) Sedatives & Hypnotics 
19) Anticonvulsants 
9,213 
950 
141 
456 
3,090 
180,685 
26 
35,071 
12,399 
3,628 
C. I.F VALUE 
( BAHT ) 
289,610 
660,291 
7,457,984 
5,070,673 
290,164,961 
1,716,212 
3,599,747 
250,000 
11,290,314 
11,966,687 
324,024 
365,734 
1,129,762 
634,684 
46,338,622 
29,008 
20,254,743 
20,572,731 
4,573,939 
20) Salicylate - Cuicophen 
Group 
21) Pyrazolon Derivative 
\ 
l 
- 170 -
22) Para - Aminophenol Deriv. 
23) Psychosedative drugs 
24) Tranquilizers 
25) Pyridine derivatives 
26) Minor group of C.N.S 
27) Adrenergic Blocking drugs 
2~) Skeletal muscle relaxants 
29) Cardiac glycosides 
30) Drugs depressing cardiac 
31) Antihypertensive drugs 
32) Intravenous fluid therapy 
33) Diuretics 
34) Antacids 
35) Cathartic & laxatives 
36) Digestants 
37) Drugs for gall bladder 
disease 
38) Antihistamines 
39) Antitussives 
40) Drugs for anemia 
41) Anticoagulant drugs 
42) Coagulant drugs 
43) Thyroid, antithyroid drugs 
44) Estrogens & progestogen 
45) Androgens 
46) Insulin 
48,222 
1,658 
12,247 
7,410 
774 
90 
278 
30 
2,812 
3,387 
776 
10,195 
5,476 
1,616 
32,424 
238,042 
4,718 
1,130 
34,520 
324,254 
23,202 
2,302 
94 
354 
84 
20 
14,990 
9,5"08,365 
879,059 
7,044,983 
10,338,113 
1,035,387 
30,340 
560,903 
574,569 
4,380,897 
6,479,354 
1,962,140 
31,735,993 
1, 342, 8.82 
3,912,045 
5,012,632 
21,602,359 
3,752,624 
234,336 
19,489,367 
24,870,749 
5,005,760 
4,916,391 
373,361 
992,504 
546,617 
31,119 
42,242,503 
- 171 -
47) Drugs acting on the uterus 909 1, 667' 787 
48) Other hormones 1,208 4,733,609 
49) An.ticancer 10,001 58,558,133 
50) Contraceptives 242,291 93,929,214 
51) Anti infectives 87,532 165,013,608 
52) Anti leprosy 574 2,444,984 
53) Antituberculosis 1,705 6,976,669 
54) Other antibiotics 19,864 46,185,994 
55) Antifungus 17,150 19,037,773 
56) Other medicaments 1,931,059 752,821,062 
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DISTRIBUTION IN MALAYSIA 
As depicted in the diagram, distribution of pharmaceuticals in 
Malaysia is more or less similar to that of Singapore. The source 
of pharmaceutical supply is the manufacturer itself. Manufacture 
of pharmaceuticals is still in its infant stage in Malaysia. Most 
of the manufacturers are based overseas and are represented in 
Malaysia by their affiliate companies. The remaining 
manufacturers have local distributors to take care of their 
interest. 
There are a few companies that do some small scale manufacturing. 
They produce o~T.C items ie. paracetamol tablets, cough syrups 
and eye drops. They distribute the products themselves or have 
appointed agents. 
There are agents who solely involve in tendering activities. 
These agents have set up companies on joint venture basis. They 
have the ,local Malays to head the com~any so as to have access 
to government officials to win government contracts which runs 
into millions of dollars~ The multinationals which have affiliate 
representation and local distributors also vie for go~ernment 
contracts. 
The government has established a small manufacturing unit which 
produces geheral items like cough mixtures, paracetamol tablets 
and elixirs which are distributed to all government hospitals and 
I 
\ 
health centres. 
173 
Flow of the pharmaceutical business in Mal~ysia 
I Dven;~e.::H:l Supplit-!r·s l 
' 
Local L.cJca 1 
I 
Tender-ing· 
Sec: qni::l a ry · IHst:.ributor Agemts 
t1i:u·tu f ac: tu re rs 
I I .. t•lhol esC\ 1 ers 
1 J I •I ---l 
Druc;} Privat.:e 
" 
GP Gclver··nmen t. 13Dvernment 
Stor-es Hospi t:a 1 s Cl.i.n.ics Hosp.i tal s t·1ed ica 1 Stores 
I I I . I 
I ' I . . : I 
.L _____________ L _____________ l_- Pharmac: ies - ___ _L ____________________ J 
Pr- i.ma t-y 
Secondary 
Source: Basic: Marketing Data 1985, Malaysian Pharmaceutical Trade and 
Manufacturers Association, and PNB Research 
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Drugs and medicines are distributed through two important 
channels ie.1) through public government hospitals and 
institutions 2) private hospitals, clinics, pharmacies and other 
retail outlet. 
Public hospitals and the institutions obtain their supply from 
the government medical stores which procure through tenders. In 
addition these hospitals have certain budgets which they could 
use to buy certain drugs from the pharmaceutical companies 
directly. 
The private hospitals and clinics obtain their supply directly 
from distributors and wholesalers. The volume of pharmaceutical 
products sold to public hospitals has declined from 40% of total 
sales in 1980 to 22% in 1985. 
124 This decline has been attributed to the significant increase in 
the volume of business done through the private sector. The share 
of the private sector has increased from 60% in 1980 to 78% in 
1985. This notable increase is recorded by pharmacies and other 
retail outlets which increased their share from 24% M$48 
million ) in 1980 to 31.2% ( M$109.2 million ) in 1985. The 
increase is closely associated with the growing popularity of 
O.T.C drugs with consumers 
The pharmacy industry which grew at an average rate of 10% 
annually in the last decade is expected to develop further. 
Pharmacies currently operate in major towns where the population 
is large enough to support their business. In addition to the 
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popularity of O.T.C drugs sold through these outlets, growth of 
this sector is also expected when the separation of the right to 
prescribe and to dispense medicine is finally adopted. Thus, in 
the future, pharmacies will have to expand their business to 
smaller towns to serve the rural population. 
On the whole, Malaysia is a dispensing market and the bulk of the 
drugs are distributed through the G. P clinics and government 
hospitals. The government health care system has improved 
substantially and most of the people seek treatment on an 
outpatient treatment basis. 
Because of the dispensing activity pharmacies seem to lose out 
to the dispensing doctors and government hospitals. It will 
definitely take some time before the pharmacies establish 
themselves as a force behind the pharmaceutical distribution. 
Most of the pharmacies are only active in business in the major 
towns and cities. In the rural areas the Chinese druggists 
replace the pharmacies in dispensing o. T. C i terns and herbal 
medicines. 
-176-
DISTRIBUTION IN THAILAND 
~ At present there . are about 450 importers and about 189 
manufacturers in Thailand. Out of these 189 manufacturers, some 
export and their value is about 350 million Bahts. 
The 450 importers or wholesalers form a channel of distribution 
to the private hospitals and clinics which account for about 10% 
of the distribution. At times the manufacturers themselves 
service the private hospitals. 
The next category are the pharmacies which account for about 60% 
of the distribution. The wholesalers, manufacturers and the 
general pharmaceutical organisation ( G.P.O ) which is state run 
supply the pharmacies. 
The government hospitals and health stations get their supply 
from the state run G.P.O, wholesalers and the manufacturers. The 
state run G.P~O at times imports sophisticated drugs which they 
don't produce through the wholesalers/importers. 
The armed forces factory imports certain essential drugs and 
supplies the rest from its own facility to the army hospitals and 
army units. The G.P.O and army hospitals account for about 30% 
of the distribution. 
Private clinics and hospitals account for 10% of the 
distribution. At this junction we can see that even though it has 
been established that Thailand is a " dispensing market " where 
( ' -
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1 
I 
I 
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the initial distribution of the drugs is done through doctors, 
the patients follow up and get their supply from the pharmacies. 
Thus it is evident that the 55 million population can purchase 
drugs and medicines from the private hospitals and clinics, 
pharmacies, government hospitals and health stations and finally 
the army hospitals and army units. 
126 The local pharmaceutical factories export to countries such as 
Malaysia, Philippines, Laos, Burma, Kampuchea and Hong Kong. Thus 
with these exports, Thailand has been able to save valuable 
foreign exchange. Each year sales of Thai made medicines total 
about U.S$10 million dollars. 
The pharmaceutical industry in Thailand is still dependent on 
imported raw materials. Each year the country imports roughly 80% 
of the raw materials required for production of pharmaceuticals. 
The value of these raw materials has increased from U. S$22 
million in 1982 to the current figure of U.S$100 million in 1987. 
Among these imported raw materials antibiotics and other 
chemotherapeutics are worth about 40% of the total raw materials 
while vitamins~ minerals and antipyretics, and analgesics share 
about 10% each. 
Today some of the raw materials are available locally such as 
refined sugar, sorbitol solution, glycerin, aluminium hydroxide, 
chloramphenicol, kanamycin, rifamicin etc. The possibility on 
local manufacture of some essential raw materials like 
acetaminophen powder, aspirin and ampicillin are being carried 
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out. 
127 Production and sales of drugs in Thailand is partly monopolistic 
and competitive. There is competition in the marketing of 
medicine which are produced by a large number of plants. Because 
they are mass produced by many concerns, the section of the 
industry manufacturing and marketing them is highly competitive. 
Each manufacturer can only claim a small percentage of the market 
for these drugs. 
Most of the packaging materials are available locally such as 
glass bottles, plastic bottles, aluminium tubes, paper boxes and 
cartons. Private factories still have ample capacity for all 
dosage forms. By average they are running at about 50 - 60% of 
their capacity. In 1981, it was estimated at approximately U.S$ 
300 million dollars. 
GOVERNMENT PHARMACEUTICAL ORGANISATION 
Of particular importance in the process of selling 
pharmaceuticals to the government hospitals is the G.P.O. The 
G.P.O was established in 1941 to produce certain essential drugs 
and import I supply other drugs to government hospitals and 
cl~nics. The G.P.O's production capacity being only 2 - 3% of the 
market for pharmaceutical products but they have become the 
largest importer of drugs to the Kingdom. 
The G.P.O also acts as an importing agent for hospital equipment 
and supplies. The G.P.O coll~cts 5% commission for its services. 
It purchased about U.S$5 million in non pharmaceutical hospital 
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t products in 1985. This situatio.n was unchallenged until last year 
when the Prime Minister's office issued a regulation on April 
14,1986. The issue has inspired a more competitive spirit on the 
part of the G.P.O. Now the government's procurement procedures 
can be summarised as follows: 
128 For drugs and medical supplies produced by the G.P.O 
Government organisation must buy from the G.P.O if the G.P.O 
prices do not exceed 3% of the median prices specified by The 
Ministry of Health. Military organisations must buy from Army 
Pharmaceutical Factory under the same conditions. 
L29 For drugs and medical supplies not produced by the G.P.O 
Government organisations can buy from either the G.P.O or 
directly from a supplier. If the price from the G.P.O is equal 
to or cheaper than any other supplier the Government must buy 
from the G.P.O. 
Another point to consider is that all drugs must be registered 
in the Essential Drug List. In a report issued by Scrip Magazine 
there was a decline in sales by the Thai Government's 
Pharmaceutical organization in 1987. This shortfall was due to 
the introduction of the new hospital purchasing regulations in 
1986. Overall G.P.O sales fell by 16% to 1,396 million Baht, 
(U.S$55.4 million) of which 767 million Baht was-accounted for 
by sales of its own products ( an increase of 21.7% } and 626 
million Baht by third party sales, a decline of 49.5% compared 
with 1986. G.P.O sales account for 15% of the total market in 
Thailand. 
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In Thailand most principal companies distribute the products 
themselves but at times the third party manufacturer will 
distribute the pharmaceutical items on the principal's behalf. 
Fig 20 
·I 
. I 
I Zuellig F.E 
!distributes for 
Abbot 
Boehringer 
Byk Gulden 
Ciba Geigy 
Dispersa 
Gruenthal 
Imex 
Lederle 
Mack 
May & Baker 
Nattermann 
Norgine 
Organon 
Oxochemie 
Protochemie 
Rotta 
Sanofi 
Schering 
Servier 
Servipharm 
Zyma 
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DISTRIBUTING AGENTS 
Diethlem 
distributes for 
B.D.F 
Beecham 
Bencard 
Eisai 
Eli Lilly 
Janssen 
Luitpold 
Nestle 
Parke-Davis 
Roche 
SK&F 
Sandoz 
Searle 
Sterling 
Wander 
Well come 
TIMS, Vol 17, No 2, July 1988 
Berli Tucker 
distributes fori 
B.Braun 
Duphar 
Eurand 
Fissions 
Fujisawa 
Haismann 
Kali-Chemie 
Medinova 
Nutricia 
Robapharm 
Syntex 
Thilo.Dr. 
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Fig 21 
YEARS DOMESTIC PRODUCTION IMPORTS 
VALUE IN MILLIONS OF VALUE IN MILLIONS 
u.s $ OF u.s $ ( c.r.F > 
1972 75 35 
1973 85 37 
1974 110 41 
1975 120 43 
1976 135 44 
1977 170 50 
1978 200 50 
1979 220 54 
1980 250 64 
1981 290 69 
1982 290 75 
1-983 295 80 
1984 300 83 
·1985 310 86 
1986 325 90 
1987 340 95 
Imports including drugs for veterinary use I dental products 1 
plasters and sutures 
Source OLIC Thailand 
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MAIN CHANNELS OF PHARMACEUTICAL DISTRIBUTION 
IN SINGAPORE 
MANUFACTURERS 
AGENT/ 
DISTRIBUTOR 
~ Market covered by SPA·: 70% 
OWN 
DISTRIBUTION 
RETAIL 
DRUGGISTS 
CONSUMERS 
HOSPITALS 
GOVERNMENT 
As shown in 
manufacturers. 
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DISTRIBUTION IN SINGAPORE 
the figure, 
Comparing 
the 
with 
distribution begins 
its neighbours 
from the 
Thailand, 
Philippines, Malaysia and Indonesia, pharmaceutical manufacturing 
is very much in its infant stage but is growing. Since Singapore 
has a duty free status for its port, pharmaceutical products can 
be imported without tax. Most of the manufacturers have their own 
distribution but others still maintain agents or distributors. 
In a survey conducted by the Singapore Pharmaceutical Authority, 
59% of the drugs are channelled to dispensing doctors, 23% 
through retail stores, druggists, pharmacies etc. and about 18% 
to government and private hospitals. 
The end users who are normally the consumers get 59% of their 
medication from dispensing doctors, 13% from retail stores and 
druggists, 8% from pharmacies, 2% from others. The government 
hospitals dispense 15% to the consumers and the remaining 3% is 
supplied by the private hospitals. 
130 The total pharmaceutical market in Singapore amounted to U.S$44 
million in 1986. This represented only 0.04% of the world market, 
and 3. 2% of the South East Asian market in 19·86, showing no 
change in figures for 1985. However, local production accounted 
for 0.017% of the world market. 
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~ 131 MINISTRY OF HEALTH 
Government establishments obtain their supplies 
Pharmaceutical Department of The Ministry 
(pharmaceuticals, chemicals and surgicals). This 
through the 
Of Health 
department 
manufacturers or purchases by tender all government supplies. 
132 PRIVATE DISPENSING DOCTORS 
At the primary care level, most of the dispensing of 
pharmaceuticals are carried out by doctors. Private doctors buy 
their pharmaceuticals from wholesalers or directly from 
importers. 
133 PHARMACIES 
The bulk of prescriptions dispensed through pharmacies come from 
private doctors, particulary specialists, who do not dispense and 
from government establishments when they do not have a prescribed 
product in stock. Non - prescription products account for a high 
proportion of pharmacy business. Most pharmacies are situated in 
the more affluent areas of Singapore. Pharmacies buy their 
supplies from wholesalers or direct from distributors I 
importers. There were 98 retail pharmacies and several hundred 
Chinese drugstores. Generic preparations account for about 50% 
of the prescription market. 
134 CHINESE DRUGSTORES 
Singapore's Chinese drug stores are located in rural and low cost 
housing areas. They are normally family business run on small 
profit margin and a fast turnover. They cater mainly for the 
lower income groups. Some of these shops are run by 11 Sinsehs 11 
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There are estimated to be more than 1,000 traditional Chinese 
Physicians practising in the country. Drugstores sell traditional 
Chinese herbs and are permitted to trade in non - prescriptions 
preparations. These include Western - type pharmaceuticals as 
well as Chinese patented medicines imported from China and Hong 
Kong. However, substantial amount of the business of these 
outlets consists of channelling goods to neighbouring countries 
and 11 under the counter 11 sales of prescriptions pharmaceuticals. 
· 135 HOSPITAL PHARMACY 
All hospitals have pharmacies, under the control of the 
Hospital's Director. In the case of government hospitals, this 
is indirectly controlled by The Director Of Pharmaceutical 
Services Of The Ministry Of Health. Hospital pharmacies 
manufacture pre - package and dispense phiirmaceuticals, and 
provide pharmaceutical information and patient counselling 
services. 
Government hospital supplies are obtained primarily through the 
Pharmaceutical Department of The Ministry Of Health. Further 
supplies .may be obtained from wholesalers and occasionally 
through retailers. Private hospitals obtain their supplies from 
distributors I importers or wholesalers. 
Ward charges in government hospitals include pharmaceuticals. 
However, outpatients are charged a flat fee of S$1 per item per 
week, to a maximum of S$3. Private hospitals charge both 
inpatients and outpatients list prices for.pharmaceuticals. 
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.136 WHOLESALERS 
Wholesalers buy their supplies from distributors I importers at 
a discount of 5%. They sell to dispensing doctors, pharmacies, 
Chinese drugstores and private hospitals at the same price as the 
distributors. 
137 PRESCRIBING AND DISPENSING 
There are no official restrictions on which products a doctor may 
dispense although generic prescribing is officially encouraged. 
As most private doctors dispense, their choice of product is 
likely to be influenced by what they have in stock and by the 
practice of discounting and bonusing when purchasing 
pharmaceuticals. 
If government doctors prescribe a product not supplied by the 
Pharmaceutical Department, the patient will have to purchase the 
drug from a pharmacy, paying the full price. Most dispensing 
(about 80%) is carried out by doctors and the remainder at 
pharmacies. The· Ministry of Health provides full labelling 
(generic name and strength) for all medicines given out at 
government establishments. Private doctors, however, prefer not 
to reveal the name of products despensed in order to ensure that 
the patient returns for further consultation. In December 1984, 
The Ministry Of Health passed legislation requiring the labelling 
of all privately dispensed medicines with the product name, 
strength, dosage, patient and dispenser details and direction for 
use. If a pharmacist dispenses an original pack, the label must 
remain visible. 
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Substitution of prescribed pharmaceuticals is not permitted. 
Prescriptions may be repeated up to three times, if writ ten 
permission is given 
138PHARMACEUTICAL ADMINISTRATION 
The Pharmaceutical Department of The Ministry of Health's other 
Medical And Supportive Services Division is responsible, among 
other things, for enforcing all legislation related to the 
distribution and sale of drugs and natural chemicals. 
The Department of Scientific Services of The Ministry Of Health 
provides scientific and analytical services for government 
d~pjtrtments, and is responsible for quality control of drugs 
manufactured or purchased by the Ministry of Health. 
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ADVERTISING 
Unlike consumer products which can be readily advertised through 
television, cinemas, radio, magazines and videos, pharmaceutical 
products don't enjoy the same p~evilege except in certain 
categories which are mentioned below. Malaysia, Singapore and 
Thailand have their own set of regulations but implemented 
strongly in Singapore. Pharmaceutical products are divided into 
2 sections ie. ethical and O.T.C. 
·Ethical drugs can only be advertised in medical journals ie. 
11 DIMS 11 , which is an authoritative guide to ethical preparations 
available to the medical profession in Malaysia and Singapore. 
In Thailand it is called 11 TIMS 11 • Advertising can also take 
place during medical seminars and also in selected health care 
publications with the consent of the Ministry Of Health. 
O.T.C items enjoy the same preferences as consumer items and are 
advertised extensively. Cough mixtures, paracetamol tablets, de -
worming agents are some examples of 0. T. C i terns. It is not 
necessary that a drug which has O.T.C status in Thailand should 
enjoy the same status in Malaysia and Singapore. 
MALAYSIA 
Drug advertising is controlled by the Medicines ( advertisement 
and sale Ordinance 1956 and Trade Descriptions Act 1972. 
Advertising of prescription and dangerous drugs are prohibited 
in all mass communication media except in professional journals. 
Pharmaceuticals and herbal preparations intended to cure or 
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alleviate certain diseases such as cancer, diabetes, veneral 
diseases etc. shall not be advertised in the mass media except 
in medical publications. All O.T.C drugs should be approved by 
the Government Board to make sure that they are genuine before 
approval can be granted. The common advertising media are 
newspapers, T.V, magazines, radio broadcast, pamphlets, cinemas 
and posters. Among the above, T. V has proven to be the best 
method for urban areas and radio broadcasts are best for rural 
areas for the promotion of O.T.C items. 
139 SINGAPORE 
The objective of the control on advertisements is to ensure that 
medicines so advertised will not jeopardise public health. After 
the commencement of Medicines (Medical Advertisements) 
Regulations 1977, no advertisement or sales promotion for medical 
products, medical devices, apparatus, instruments or contrivances 
shall be published unless a permit for such advertisement has 
been obtained from the Licensing officer, Ministry of Health. 
However, approval is not required for the publication of price 
lists and catalogues which make no recommendations for the use 
of these substances and information pamphlets intended solely for 
the distribution to the relevant professionals. These are 
described as 11 trade advertisements " and " reference 
advertisements " respectively in the regulations. 
For purpose of this control, " advertisement " includes every 
form of advertising whether in print, light or sound; and" sales 
promotion" means any sales campaign { including door to door 
sales ) , exhibition, competition etc. 
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140 CONTENT OF ADVERTISEMENT 
Advertisement should truthfully state the nature, quality and 
properties of medicinal products. Recommendation relating to the 
use of medicines should be accurately stated in moderate terms 
and should be relevant to their properties. 
Advertisements should not exploit the ignorance and credibility 
of the public and should not include scientific data, the 
validity of which cannot be ascertained by the general public. 
Advertisements should not arouse fear in the minds of the public 
nor should they exploit their superstition. 
The use of strong terms, including the following are not allowed: 
1) 11 safe 11 , 11 safer 11 or 11 safest 11 • 
2) 11 very effective 11 11 most effective 11 II scientifically 
proven to be effective 11 , 11 miraculously effective 11 
11 lightning effect 11 etc. 
3) 11 free from side effects 11 , 11 reliable 11 11 dependable 11 , etc. 
4) 11 used in hospitals 11 , 11 recommended by doctors 11 , famous 
throughout the world 11 , etc. 
5) 11 cure 11 11 guaranteed ___ 11 11 money back 11 11 offers 11 etc 
Advertisements should not carry testimonials or recommendations 
by members of the medical, dental, pharmaceutical or nursing 
professions and there should be no reference to any member of 
these professions directly or indirectly. 
Visual and I or audio presentation of doctors, dentists, 
pharmacists or nurses in any advertisement for medical products, 
medical devices, apparatus, instruments or contrivances shall not 
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be allowed. 
No advertisement should carry statements implying that where 
medical treatment has failed, the advertised product would be 
effective. No advertisement should imply or carry claims of 
improved performance in sports or studies. Advertisement for 
medicinal products recommended for slimming, figure control or 
weight control ( ie. weight loss or weight gain ) with or without 
other aids such as diet control, physical exercise etc. should 
not carry statements such as 11 eat as much as you like 11 , which 
by themselves may lead to harmful effects. 
Advertisements should not suggest or imply that the medicinal· 
prc;>ducts offered will promote sexual virility or they are 
effective in treating sexual weakness or sexual excess. No 
reference should be made to premature ejaculation or premature 
ageing. 
No advertisement should suggest or recommend any medicinal 
product for use by pregnant or lactating women. Recommendation 
for " good health 11 should be specific. General terms like 11 good 
for you 11 , 11 for better health 11 or 11 for better living 11 , etc. 
s~ould not be included in medicinal advertisements. Medicines 
available on prescription only should not be adver.tised to the 
general public. 
. Ml PROHIBITED ADVERTISEMENT 
Advertisement of individuals offering medical skill or service 
are prohibited. Advertisements directly or indirectly referring 
to sk:J,ll, service or medicinal products relating to miscarriage 
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in women are prohibited. 
Advertisement for medicinal products, medical device, apparatus, 
instruments or contrivances having any direct or indirect 
reference to the list of diseases and conditions in the first 
schedule to the Medicines Act are prohibited. For easy reference 
the list is reproduced below ·-. 
1) Blindness 10) Hypertension 
2) Cancer 11) Infertility 
3) Catract 12) Insanity 
4) Conception and pregnancy 13) Impotency 
5) Dangerous drug addiction 14) Kidney diseases 
6) Deafness 15) Leprosy 
7) Diabetes 16) Menstrual disorders 
8) Epilepsy or fits 17) Paralysis 
9) Frigidity 18) Sexual function 
19) Tuberclosis 
SALES PROMOTION 
No person shall in conducting any sales promotion, offer any gift 
or prize to promote the sale of any medicinal product. 
APPLICATION FORMS AND FEES 
Application forms are available from the Ministry of Health 
(ground floor), Palmer Road, Singapore 2. 
The fees payable for each permit :-
1) for an advertisement in the form of printed material 
( including stills ) S$25. 
2) for an advertisement using sound S$50. 
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3) for an advertisement using sound and light projection S$150. 
4) for a sales promotion S$50. 
5) for each amendment to an advertisement S$5. 
PERIOD OF VALIDITY OF PERMITS 
All permits shall be valid for three years from the date of 
issues, unless sooner revoked by the Licensing Authority. 
THAILAND 
142 ADVERTISEMENT CONTROL 
This is an activity undertaken by the F.D.A in accordance with 
the provisions of the laws. According to the Drug Act B.E 2510 
( 1967 ) no advertisement is permitted for dangerous drugs and 
specially controlled drugs. The revision of the law in 1979 
includes additional requirement for drug advertisement to be 
approved by the F.D.A. This is to avoid incorrect and misleading 
claims of informations made by the drug manufacturers or 
distributors. Food advertisement is also subjected to be approved 
by the F.D.A prior to its execution. At the early stage of 
development in the field of advertisement control there are a 
number of obstacles ie. administrative and technical. 
For the other controlled substances such as cosmectics and toxic 
substances the F.D.A is implementing a surveillance programme 
which involves regular inspection of all advertisements made in 
various media. Exaggeration claims, misleading or misbranded will 
be failed and reviewed by the agencies concerned and legal action 
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may be taken on serious cases but it is most likely that the 
firms will be warned formally by the F.D.A on the first 
encounter. 
The following jurisdiction of Advertisement Control is stipulated 
in the following legislative measures : 
1) Drug Act 1967 ( as amended by the Drugs Act No. 3, 1979 ) 
2) Food Act 1979 
3) Cosmetic Act 1974 
4) Poisonous Substance Act 1967 
5) Psychotropic Substance Act 1975 
6) Narcotic Drug Act 1979 
The advertisement for the sale of drugs must : 
1) Not boast that a drug or its ingredient is capable of 
miraculously or absolutely treating, relieving, curing or 
preventing diseases or illness or use other words having 
similar meaning. 
2) Not exaggerate or falsely declare the properties of a drug. 
3) Not· create the understanding that a drug contains any 
medicinal substances or ingredients which in fact it does 
not contain or if it does, in quantity other than which it 
is understood to contain. 
4) Not create the understanding that the drug is abortifacient 
or strong emmenagogue. 
5) Not create the understanding that the drug is an 
aphrodisiac or for birth control. 
6) Not state the properties of dangerous or specially 
controlled drugs. 
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7) Not include testimonials by other persons as to the drug's 
properties. 
8) Not state as the property of a drug that it is capable of 
treating, relieving, curing or preventing the diseases or 
disease symptoms notified by the Minister under Section 
77. 
Drug advertising by means of radios, amplifiers, television, 
slides, movies or printed matter must : 
1} have the texts, sound or pictures used in advertising duly 
approved by the licensor. 
2) comply with conditions prescribed by the licensor. 
3) it shall be prohibited to advertise drugs by song or by 
showing the suffering of a patient. 
4) it shall be prohibited to advertise the sale of drugs by 
offering premiums or giving lottery prizes. 
5) The Secretary of The Food And Drug Administration shall 
have the power to order in writing suspension of any 
advertising deemed to be violating this Act. 
6) Any person who advertises drugs in violation of Sections 
88, 89 and 90 is liable to a fine not exceeding hundred 
thousand Baht. 
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COMPARATIVE ANALYSIS ON PRODUCTION, MARKETING & 
DISTRIBUTION IN MALAYSIA, SINGAPORE AND THAILAND 
ETHICAL DRUGS 
The 3 countries comprising of Malaysia, Singapore and Thailand have 
" many things in common. They belong to ASEAN and all 3 share a vibrant 
economy. The main differences seen are in their population 
distribution and geographic sizes. Singapore is an island with a 
million people distributed evenly. Malaysia is split into East and 
West Malaysia and the population is spread into an urban and rural 
network and in Thailand the population is spread along the various 
provinces but many converge into Bangkok to make a living. When we 
compare the total population of these 3 areas, it totals to 72 
million. 
If we view the population of the 3 countries on the marketing 
perspective it is found that Thailand with its 55 million people 
presents a very substantial market to concentrate on. Malaysia's 15 
million population looks appealing and Singapore with its 2 million 
people presents marketers with a small but lucrative market. 
Most pharmaceuticals companies in Thailand concentrate in Bangkok. 
In Malaysia the centre of business is Kuala Lumpur. Major 
pharmaceutical companies sometimes take care of the Singapore 
operations from Malaysia. 
I 
As we are aware the local or traditional medicines still command 
respect as far as treatment is concerned. In Chinese dominated 
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Singapore the Chinese herbal medicines Ginseng's are still sought 
as cures for various ailments. In Malaysia where 3 major communities 
make up the population, the Malays look towards their "Tok Bomoh" or 
medicine man for treatment in the form of herbs, barks, roots and 
leaves. The Chinese druggist serve the Chinese and the Indians look 
towards to the indigenous system of Ayurveda. In Thailand, traditional 
medicines are also in demand. 
Eventhough the Thai economy is picking up, it is not as vibrant as 
the economies of Malaysia and Singapore. As such price has been a 
major determining factor in the marketing of drugs. Of the 55 million 
Thai population only a small proportion can afford expensive ethical 
drugs. Thus this has paved way for the generic drugs to mushroom. To 
the astonishment of multinationals tbe Thai Government has a relaxed 
attitude towards patent rights. Branded drugs like Zantac and Tagamet 
can be acquired easily. With the F.D.A pressurising the Thai 
administration, it is believed that the administrators in Bangkok will 
bow to u.s. pressure to implement patent rights. 
Unlike Thailand, Malaysia and Singapore have implemented patented laws 
but generics still exist. Those. branded drugs which have lost the 
patent rights over the years have many generics to compete with. In 
Thailand the Government encourages the generics, that it is the 
Government's intention that the common man in the streets will be able 
to afford Western medicines. The Government has many steps in hand to 
reduce or control the price of the drugs. Its view is that all single 
ingredient formulations should be sold under the generic or 
pharmacopoeia name. This is likely to result in more competition, 
minimum brand loyalty among customer§, minimum promotional efforts by 
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the manufacturers. All these aspects will help drastically reduce 
the price of drugs and thus the government's objective that the 
consumers will benefit by which a wider section of the society could 
reach out for the drugs. Another route which Thailand may adopt is 
similar to what is done in India i.e. the introduction of the policy 
of differential pricing. Drug formulations in rural areas, may be 
supplied.in bulk packaging and in urban areas the existing system may 
continue or still better and costly packaging may be introduced, and 
accordingly the price be differentiated for both the areas. 
In Malaysia and Singapore differential pricing policies have not been 
implemented yet but the governments are purchasing drugs under the 
tender scheme. Thus with the tender policy, drugs are purchased in 
bulk at the lowest price and distributed to the government run 
hospitals, clinics and health centres. In Thailand the G.P.O. or 
Government Pharmaceutical Organisation takes the lead role in calling 
for tenders. It has been observed that the vast majority of essential 
drugs are well established mul tisource drugs. These could be 
purchased by world wide tendering. The mechanism used for 
international tendering are 
1) the list of drugs to be procured with relevant information is 
advertised in the press. 
2) tender specifications sent to foreign diplomatic missions. 
3) list be sent direct to generic suppliers to ensure their 
participation in competitive bidding. 
In Singapore the government has decided to test "trial tenders" so 
as to obtain supplies of medicines for use in the Government 
maintained hospitals or dispensaries. If the new system proves to be 
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economically advantageous the government's pharmaceutical 
manufacturing will cease to exist. This is because the government's 
own manufacturing facilities have been reported to be too small for 
the demand placed on it. 
143 Many developing and third world countries look towards manufacturing 
of drugs within their borders. But before they can explore the 
potential of manufacturing these drugs they should analyse the 
following points. The-pharmaceutical industry is based upon highly 
sophisticated disciplines 
1} Sciences - medicine, pharmacology, chemistry, bio- chemistry. 
2} Technology- synthesis, production, fermentation, sterilisation, 
packaging. 
3) Economics - costs, prices, marketing and advertising. 
4) Legal affairs patents, licensing, import and export 
regulations. 
5) Fiscal affairs - import duties, taxes, royalties. 
6) Education and training of professional personnel and skilled 
labour. 
Since most developing countries lack the necessary sophistication in 
these disciplines, they find it very difficult to establish a 
pharmaceutical industry. However, quite strong reasons exist for 
developing countries to e~plore their possibilities for establishing 
this industry. The reas9ns are 
1) to reduce dependence upon the external supply of needed drugs. 
2) to save foreign exchange. 
3) to industrialise. 
A pharmaceutical industry in a developing country should be 
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established in ac.cordance with its growth in the above mentioned 
disciplines; therefore the desired transfer of technology must be 
accompanied simultaneously with corresponding development of the other 
disciplines. U.N.I.D.O. which is part of the U.N is among other 
organisations and agencies assisting and advising the developing 
countries, and its view is that a continous exchange of experience 
among their countries may encourage the es·tablishment of new projects. 
In 'fhailand, manufacture of dr:ugs i.e. local production in terms of 
Bahts is 8,500,000,000. Bulk of the manufacture is done by the G.P.O. 
or Government Pharmaceutical Organisation and the Armed Forces. The 
G.P.O. tends to serve the whole nation whilst the Armed Forces serves 
the network of army installations. The G.P.O. was established in 1941 
to produce certain essential drugs and import/supply other drugs to 
government hospitals and clinics. 
f4 Given below are some of the drugs produced in Thailand. 
1) anti microbial drugs. 
2) analgesic - antipyretics. 
3) vitamins. 
4) gastrointestinal drugs. 
5) sympathomimetic drugs. 
6) topical drugs. 
7) blood fluid and electrolytes. 
8) cardiovascular drugs. 
9) hormones. 
10) histamines and antihistamines. 
11) parasiticides. 
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The industry' still depend on imported raw materials and much of it 
comes from Germany, Italy, Japan, U.S.A. and U.K. Some of the raw 
materials which are available locally are refined sugar, sorbitol 
solution, glycerin, aluminium hydroxide, chloramphenicol, kanamycin, 
rifampicin etc. Most of the packaging materials are available locally 
including glass bottles, plastic bottles, aluminium tubes paper boxes 
and cartons. In a study conducted by Kum Chomcin Chantrasakul it was 
seen that private factories still have ample capacity for all dosage 
forms. By average they are running at about 50% - 60% of their total 
capacity. 
.. 
Unlike Thailand, the Malaysian pharmaceutical manufacturing sector 
is still in its infant stage. Raw materials are imported from Japan, 
U.K. and the U.S. The finished product churned out by Malaysia's small 
drug industry are cough and cold syrups, paracetamol tablets, eye 
drops, vitamins, certain injections, ointments and antacids. Given 
in the Appendix section are those companies that have been approved 
to manufacture pharmace1;1tical i terns. The National Pharmaceutical 
' Laboratory in Petaling Jaya does manUfacture certain pharmaceutical 
I 
items and is too small to compare with the G.P.O. in Thailand. 
Singapore has followed Thailand's footsteps to establish a major 
pharmaceutical operations in the Island Republic. Leading 
international pharmaceutical and health care product companies such 
as Baxter international, Becton Dickinson, Beecham, Glaxo, Kanegofuchi 
have been able to enhance their competitive advantage by serving their 
regional and international markets from Singapore. Singapore free-
.. 
enterprise policy allows foreign companies the freedom for 100% 
ownership of its operations in Singapore, the freedom to repatriate 
- 204 -
profits and capital and to recruit skilled personnel. The availability 
of skilled trained chemists, biochemists, ·pharmacists, engineers, 
laboratory and process technicians has enabled many companies in the 
industry to undertake manufacturing product development and testing 
activities in Singapore. Many pharmaceutical and health care product 
manufacturers in Singapore have received the seal of approval of the 
U.S. Food and Drug Administration (F.D.A.). This reflects the high 
level of quality consciousness on the part of the management as well 
as the workers personal discipline and commitment towards maintaining 
high quality standards. 
145 Marketing news in its article dated 24th April 1987, has analysed that 
consumers can be classified into the following 9 groups: 
1) Quality minded - those who look for the best health care at any 
cost. 
2) Ready users - those eager to receive care. 
3) Independently healthy - those involved in self care. 
4) Clinic cynics - those skeptical about organised health care. 
5) Avoiders - those who stay away from health care. 
6) Naturalists - those seeking alternatives to regular health care. 
7) Family oriented - those who think children are important and are 
interested in nutrition, wellness and family. 
8) Generics those who see no difference between health care 
facilities. 
9) Loyalists - those who find a source or approach and stick with 
it. 
Thus it is seen that physchographic segmentation can help health care 
organisations identify consumer needs and tell them about their 
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services and programmes. People have different buying habits, 
attitudes, opinions, desires and wishes and these things appeal to 
different market segments. Once you know the groups, you can target 
the serv~ces and your marketing efforts more effectively. 
Psychographic segmentation is very new to Malaysia, Singapore and 
Thailand. To start with the psychographic segmentation could be used 
in the O.T.C. market where it could be used effectively. One thing is 
for sure marketers can identify and target markets on a cost effective 
basis. 
O.T.C. ITEMS 
Multinationals in Thailand believe if they don't make a break through 
in the tender category, it would be safe and profitable to concentrate 
-
on the O.T.C. segment. Most of the O.T.C. products are backed by heavy 
advertising through all types of media, quite a good number of O.T.c. 
drugs are sold on the basis of specific benefits which they claim to 
provide. In Singapore and Malaysia, the languages used in newspaper 
advertising are English, Malay, Mandarin and Tamil. On T.V, O.T.C. 
advertisement in Singapore is in Mandarin and English, while Malay, 
Mandarin and English are used in Malaysia. In Thailand, Thai and 
English are widely used. O.T.C. status for drugs varies from country 
to country. Thus a drug which is classified ethical in Thailand might 
be considered O.T.C. in Malaysia and Thailand. Thus drug regulations 
change from country to country in South East Asia. 
Since O.T.C. drug items are categorised with food and other consumer 
non edible durables the drug companies can distribute their product 
into any type of outlet by class which are listed below 
1) grocery stores 
2) mini markets 
146 
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3) supermarkets 
4) departmental stores 
5) super stores 
6) pharmacies 
i 
Retailers provide the crucial link between the producers of goods and 
the ultimate consumers. The retailing business is inherently 
widespread and its gr~wth is virtually assured as it is positively 
related to the growth of the population. Retailers in Malaysia, 
Singapore and Thailand can be broken into grocery stores, small shops, 
coffee shops and small stalls on sole family proprietorship. 
Classification of retail outlets. 
Type of Size Number Turnover Catchment 
outlet by class sg ft of items $/year area (km) 
Grocery stores 1,200 2,000 250,000 2 
Mini markets 2,500 5,000 1,500,000 5 
Supermarkets 15,000 15,000 8,000,000 40 
Dept. stores 20,000 5,000 10,000,000 40 
Superstores 40,000 20,000 20,000,000 60 
There is little difference between a grocery store and a mini market 
since it is relatively easy for an operator to convert a grocery shop 
into a mini market. Unlike the grocery store, the mini market operator 
enchances his operation by efficiently utilising retail space or shelf 
space hence incr~asing the number of items displayed on the shelves. 
There is however an obvious difference between a mini market and 
supermarket, since the latter is bigger in size, display more items 
on sale and has larger catchment area. While a mini market is normally 
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situated in "shop lots", a supermarket is mainly situated in big 
shopping complexes. A departmental store by definition only sells 
consumer d4rables and non food items although some do retail food as 
an additional business. A superstore differs from a departmental store 
mainly in size of retail space. Another important distribution point 
for O.T.C. items are the Chinese medicinial shops which ~re involved 
in selling, g~nsengs, herbs, leaves, liquor etc. These shops are 
prominently involved in servicing the Chinese population. They are 
found in Malaysia, Singapore and Thailand which have sizeable Chinese 
population. 
Thus it can be seen that O.T.C. items can be distributed through any 
of the retail outlets. Paracetamol tablets, cough syrups, cough drops, 
vitamin tablets, tonics, eye drops, ointment for muscular pains and 
other products can be channelled through without trouble. 0. T. c. 
business is big and it is seen that more drug companies are attracted 
to this category. Drug companies can advertise without restriction on 
T.V. which draws maximum attention from the consumers. O.T.C. business 
is very much similar in Malaysia, Singapore and Thailand. Companies 
involved in O.T.C. business distribute themselves or make use of large 
distributing houses like Zuellig, Diethelem, Harpers and Boustead. For 
marketing system to be effective, distribution channel plays a very 
important role. It ensures that a range of products is available at 
the right time and at the right place with the minimum cost incurred 
! 
to consumers of all types. Firms have to take certain specific 
decisions relating to market coverage, transportation cost, 
commissions and credit etc. Most pharmaceutical compqnies maintain 
multi level distribu~ion system i.e. in between the manufacturer and 
ultimate consufl!er, there are 2 or 3 intermediaries in the form of 
• 
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wholesalers and retailers. Multilevel distribution is costly but 
considering the services rendered by the middlemen in terms of 
stocking, transportation and dispensing, thus higher distribution 
cost may not be justified. 
PHARMACIES 
Pharmacies in Malaysia, Thailand and Singapore act as outlets for the 
distribution of ethical drugs and O.T.C. items. In all 3 countries 
the pharmacies are manned by qualified pharmacists. In Thailand there 
is a slight exception since pharmacies are classified as 1st class 
and 2nd class. The 1st class pharmacies have a pharmacist while the 
2nd class pharmacies can be run by anyone. In comparing the 3 
countries, Thailand still has the maximum number of pharmacies i.e. 
3,450 1st class and 5,385 2nd class outlets: Malaysia ·currently has 
237 pharmacies and Singapore has 98 to serve the island population. 
The doctors in the 3 countries still practise dispensing and the 
pharmacies still have not achieved the prominence they so do deserve. 
In Malaysia and Singapore the pharmacists are negotiating with the 
Medical Association to allow them (pharmacists) to dispense and the 
doctors _to prescribe. The pharmacies still feature as the major 
distribution outlet for drug companies where ethical drugs are passed 
I 
through to consumers. 
MARKETING TO AND THROUGH THE MEDICAL PROFESSION 
The majority of doctors in the 3 countries prescribe and dispense 
drugs. Thus these professionals have the fin~l say in what drugs to 
prescribe. They could prescribe both ethical and generics. 
Pharmaceutical companies concentrate their marketing activities on 
doctors. In most cases doctors purchase their drugs directly from 
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pharmaceutical companies. At times these doctors prefer to pull stocks 
from pharmacies. In Malaysia and Singapore the "Guardian'' and "Apex" 
pharmacies are a chain of outlets which serve the consumers and 
doctors. 
Successful marketing by pharmaceutical manufacturing companies to 
members of the medical profession is greatly determined by a good 
understanding of the various factors that influence their purchasing 
behaviour. Acceptance of a scheduled pharmaceutical product by doctors 
is a " sine qua non " for its success. While patients portray the 
roles of both buyers (they pay for the product) and users; they have 
little or no influence on the actual choice of product or brand. The 
doctors role as deciders is the crucial one. ·It is therefore hardly 
surprising that the bulk of the marketing eff-orts of manufacturers of 
scheduled pharmaceutical products or ethicals is directed at medical 
practitioners. In a research study conducted on the factors 
influencing product prescription decisions the following results were 
obtained. 
Fig 22 
Factors Influencing Product Prescription Decisions 
1) 
2) 
3) 
3) 
Personal experience with the product. 
Recommendations made:by colleagues in informal 
discussions. 
Sales calls made by pharmaceutical company 
representatives. 
Seminars, conferences, lecturers organised by 
Mean 
Influence 
Score 
4.7095 
3.6095 
3.2381 
2.9905 
4) 
5) 
6) 
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pharmaceutical companies. 
Advertisements in journals and magazines. 
Sales promotional material received from 
pharmaceutical companies, such as samples, 
calenders, diaries, pens, note pads. 
Direct mail advertising. 
2.3476 
2.3286 
1.9524 
Mean influence score is the average score on a 5 point scale, where 
1 = no extent, 2 = limited extent, 3 = moderate extent, 4 
considerable extent, 5 ~very large extent. 
It is clear that the most dominant influence on prescribing behaviour 
l 
is the previous experience with the product and the mean score of 
4.7095 suggests that, on average, it is perceived by respondents to 
influence prescribing decisions to a "very large extent". 
Recommendations made by colleagues in informal discussion is the 2nd 
most important determinant of prescribing decisions. Thus it is 
observed that the two points mentioned above exert the most influence 
on prescribing decisions and are both of an interpersonal/ 
organisational nature and not directly: controllable by the 
pharmaceutical firms marketing strategy of promotional tools. Sales 
calls by pharmaceutical firms sales representatives are perceived to 
be the most influential. It is informative to note that 
seminars/conferences/lectures arranged by pharmaceutical firms are 
regarded as being more influential than advertising and sales 
promotional material. The other factors which influence doctors 
prescription decisions are :-
148 1) scholarly articles by specialists in scientific medical journals. 
2) product availability. 
3.) credibility and reputation of the company. 
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4) price of the product to the patient. 
5) ease in remembering the brand name of the product. 
In Malaysia, Singapore and Thailand all the factors mentioned above 
influence the physicians. Of the marketing tools available, sales by 
sales representatives is the most powerful. Sales calls in Malaysia 
and Singapore. is conducted in English. In Thailand both Thai and 
English are used to communicate to the doctors on the benefits of the 
drugs. Thus personal selling can play a key role in ensuring 
pharmaceutical marketing success through its direct, as well as 
indirect, influence on prescribing decisions. Pleas for more highly 
skilled and better qualified salespeople should not go unheard and 
perhaps it is time for pharmaceutical sales management to give greater 
emphasis to quality of sales calls, rather than quantity. 
DISTRIBUTION 
Distribution of the drugs to doctors and pharmacies is from the 
factories, if the pharmaceuticals are manufactured within the country, 
or the drug companies warehouses if the drugs 
overseas or from the distributor/wholesaler 
are imported from 
warehouse if the 
pharmaceutical companies have appointed distributors. Orders are taken 
by the sales force and the drugs are delivered. Credit facilities of 
45-60 days are extended to the doctors in private practise, pharmacies 
and private hospitals. Government purchase is through tenders. Goods 
are usually transported by road in Malaysia, Singapore and Thailand. 
In remote provinces of Thailand and East Malaysia the pharmaceutical 
goods are air freighted. In .,Thailand and Malaysia due to the vast 
areas, the pharmaceutical representatives cover selected area and do 
follow up calls frequently every month. In Singapore, due to the small 
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size of the Island Republic the sales force is at a bare minimum. 
149 PRODUCT MANAGEMENT CONCEPT 
Most major pharmaceutical companies now have classically structured 
marketing departments which espouse the product management concept 
(P.M. C.) pioneered by the consumer packaged goods marketers. The 
pharmaceutical manufacturers are adopting marketing oriented 
practices, relying less on pure selling and price competition. Whilst 
this concept is structurally embedded in the international subsidaries 
of pharmaceutical marketers, the full theoretical value of the concept 
remains unfulfilled. A study reports on an investigation into the 
future of the product management concept in the South African 
pharmaceutical market. The pharmaceutical market in South Africa is 
a representative microcosm of other international markets. The 
findings in the study showed that product management concept will 
remain an integral feature of the typical pharmaceutical marketing 
organization in the year 1990. Top management support will be given 
to the system. The product manager of the 1990's will be considered 
an information centre for his range of products. His understanding 
of the financial aspects of his products will be reasonable, while it 
is unlikely that he will spend more time in direct contact with the 
market. There is reasonable optimism about the strategic abi 1 i ty of 
the product manager in the future, but this is qualified by hesitancy 
in respect of permitting the product manager a portfolio approach. 
It has been stated that the product managers are expected to stay 
longer in their jobs and will be better academically qualified and 
will probably have spent a period in the sales force. In summary, it 
appears that the product manager of 1990's in the pharmaceutical 
industry will perform information providing, co-ordinating and 
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boundary spanning roles will not exercise line authority over critical 
p~oduct decisions. Thus it is evident that the product management 
. 
concept will gain more steam in Malaysia, Singapore and Thailand where 
pharmaceutical companies compete for market share . 
. • 
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SELF MEDICATION 
~ 
Self medication has always existed in the medical system. If we 
inflict ourselves with a cut which needs minor treatment, we 
would rather go for a box of Band Aid and cover the cut. If there 
is a rising temperature "paracetamol tablets" or rather 
"Panadol" is the remedy. Self medication exists ::i.n ·both the 
higher and lower income group. The higher income group seems to 
have a larger percentage of educated people and they feel that 
they are capable of treating themselves. But once the situation 
changes and they fall very sick, they are seen rushing to the 
nearest clinic or hospital for treatment. In the case of the 
lower income group it becomes necessary at times to treat 
themselves or seek help from the traditional druggist because 
they are poor. 
THAILAND 
In Thailand, ~elf medication was on the rise in the rural areas 
in the 70's. 51.4% of the population were seen using self 
medication or buying drugs for own use. This figure gradually 
fell to 42.3% in 1979. In 1985, a survey showed that self 
medication was only 22.3%. As the government improved its health 
care system by opening up new hospitals most of the rural poor 
were attracted to these government establishments. Thus the 
government hospitals which served only 11.4% of the population 
in 1970 jumped to 32% in 1985. 
150 
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PERCENTAGE OF UTILISATION OF HEALTH CARE SERVICE 
1970, 1979, 1985 ) 
SOURCES OF HEALTH CARE SERVICES 
Self medication or buying of own 
drugs. 
Health care centres 
Government hospitals 
Private hospitals and clinics 
Traditional doctors 
Do not seek any treatment 
Health reporters I health volunteer 
Maternal and child health care centres 
1970 
51.4 
4.4 
11.4 
22.0 
7.7 
2.7 
1979 
42.3 
16.8 
10.0 
20.4 
6.2 
4.2 
1985 
22.3 
13.3 
32.0 
20.8 
2.4 
6.3 
2.1 
0.8 
151 MALAYSIA 
It has come to that extent in Malaysia especially in the rural 
areas for the people to think that doctors are "semi gods". The 
people dont ask questions nor do they demand for information 
about the drugs that are prescribed to them. As a result it is 
fully justified that the layman remains ignorant about health 
matters. Over time the ignorance is perpetuated because doctors 
who are seldom questioned tend to neglect their basic 
responsibility towards patients. 
In public hospitals where the majority of patients come from 
lower income group, doctors are almost never queried about 
anything. There is always the assumption that doctors never make 
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mistakes. 
In private clinics and public hospitals it is quite common for 
doctors to overprescribe or in medical lingo practise " poly 
pharmacy " or prescribing without full diagnostic procedures. 
Studies overseas show that when a doctor does not take the 
trouble to explain the nature of the patients illness, patients 
fail to comply to instructions. Mr. Liew Kee Hooi, Director Of 
Pharmacy Division in The Ministry of Health says that it is not 
unusual to hear patients who stop taking medications when they 
do not get better. Research has also shown that when patients are 
given too many drugs they tend to forget when and how much they 
should be taken within given period of time. Some patients stop 
taking the medications a~ S()()n ~hey teel better, not realising 
that more resistant strains of the bacteria may develop once they 
do that. Another common practice is the sharing of medication. 
When two people appear to have the similar symptoms and only one 
goes to the doctor, there is always the tendency for two to share 
the medication prescribed for one. 
According to Associate Prof. Dzulkifi Abdul Razak of the 
University Science Penang, that not enough has been done to 
educate the public on drug use and misuse. Nor are advertisements 
on drugs a good source of information because they naturally 
accentuate the positive and eliminate the negative. It has been 
pointed out that certain advertisements on antacids are said to 
carry a cooling effect when they are consumed. 
Knowing how easily drugs can be misused the government has 
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insisted that stickers with addresses of the pharmaceutical 
companies be placed on all O.T.C drugs. Till date this regulation 
appears effective. The Drug Control Authority will begin 
registration of 0. T. C drugs soon. Medical professionals are 
hoping when this happens, such items will no longer be sold like 
11 sweets II It is very normal for Malaysian doctors in the 
private practise to dispense their own drugs and because of this, 
community pharmacists still do not play a major role in 
dispensation of drugs. Pharmacists insist that they are better 
trained to dispense and explain the effects of prescribed drugs 
to patients. Pharmacists still insist that doctors should not 
waste time over drug dispensation and concentrite more on 
diagnosing ailments. In this long standing controversy over who 
should dispense drugs, doctors have always maintained that their 
dispensation are free. It has been quoted that Malaysian patients 
are a little spoilt. If the doctor gives them a prescription and 
they have to go to a pharmacy to get their medicines, they get 
annoyed. In hot and rainy weather it will make some of them 
angry. 
On the other hand pharmacists can always double check with the 
doctor to determine why a certain dosage is very high or too low. 
If a doctor prescribes and dispenses medicine, there will be no 
other professional to check his prescription. 
It is forseen that the new system for drug dispensing could only 
be ready in the next 5 years. This system whereby only 
pharmacists can dispense drugs is likely to be implemented in 
• 
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stages. This system would probabaly be implemented in major towns 
first where there are adequate number of pharmacists. The 
Malaysian Pharmaceutical Society believes if the system can't be 
done by ethics then a legislation will be implemented. The 
Malaysian Medical Association has in general accepted the idea. 
But one thing is sure, till there are ample pharmacists around, 
the system could backfire and collapse. 
The Malaysian Pharmaceutical Society is still confident that the 
scheme would go through. They have drawn up a standard for 
doctors when filling.out prescriptions for patients and have 
delivered it to the Malaysian Medical Association. The M.P.S 
feels that the new form when filled will have many of the 
patients particulars. The form would check the doctors 
prescriptions on certain drugs and dosages. At the same time a 
pharmacist would be able to find out if a particu~ar doctor's 
signature is forged. 
152 The Malaysian Pharmaceuticals Trade And Manufacturers Association 
representing the pharmaceutical industry has been promoting the 
importance of self medication in strengthening the Malaysian 
Health Care system. The role of self medication and its 
contribution within the system can be seen from several 
perspectives. 
1) Self medication is a need and a right of the consumer to 
deal with minor illness. 
2) Self medication plays an inevitable, necessary and 
invaluable complementary role to the health care system 
of the developing and developed countries. 
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3) Self medication is one of the means to maximise an existing 
but scarce medical resource. 
4) Self medication is a means to reduce and contain escalating 
medical costs and initiate more consciousness in the need 
for personal responsibility in the health care system. 
5) Self medication will release, acute and chronic illness as 
well as in the disease prevention and health care planning. 
According to the M.P.T.M.A a sizeable population of adults self 
medicate. Therefore it is imperative that regulatory agencies, 
health professionals, consumers and the pharmaceutical industry 
fulfill their obligations and shoulder their responsibilities in 
ensuring responsible self medication. 
The M.P.T.M.A has recommended the following : 
1) The industry, health care professionals and the government 
form an advisory committee on O.T.C products. 
2) A national drug policy on self medication be drawn up. 
3) An information education campaign on self medication be 
developed. 
4) Emphasis be placed on adequate product labelling and 
ethical advertising. 
5) A strict code of marketing practice is to be reviewed and 
adhered to by the industry. 
SINGAPORE 
In Singapore, due to excellent health care facilities, the 
citizens still seek treatment at the government and private 
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hospitals. There is not much room for self medication. Even though 
the country has a dispensing market, the number of registered 
pharmacies in the Republic was 98 as of March 1988. It is 
difficult to analyse the self medicated population in Singapore 
but there is strong possibility that there could be a swing 
towards self treatment in the upper class strata. 
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O.T.C. ITEMS 
153 In many ways,· the O.T.C sector represents the 11 consumer 11 market 
side of the pharmaceutical industry. The much larger prescribed 
sector operates in highly regulated fashion. Within the O.T.C 
sector, drugs operate as virtually standard consumer market, 
complete with manufacturers advertising in the mass media, and 
a few restrictions on consumer purchasing. 
In calculating the market size of O.T.~ pharmaceutical, it has 
been divided into the following groups -
1) cough and cold treatments. 
2) analgesics and other pain relievers. 
3) digestion remedies. 
4) vitamins and dietary supplements. 
5) plasters and dressings. 
6) medicated skin care p~oducts. 
7) a range of minor 11 other 11 market sectors including 
haemorrhoidals, eye and ear care treatments, rheumatic 
treatments, pregnancy testers and condoms. 
In the United Kingdom for that matter, new legislation acts have 
accelerated this mood with radical changes. The government wishes 
to see the burden of The National Health Service eased by the 
consumers taking greater degree of personal responsibility for 
their welfare. 
In terms of the developments the following has been noted : 
1) The cost of chargeable prescriptions has been rising ahead 
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of inflation. 
2) Few chargeable prescriptions are being dispensed. 
3) Deregulation of certain pharmaceuticals has transferred a 
number of more effective drugs away from a purely 
prescribable status and into the O.T.C market. 
4) The emphasis is upon the pharmacist as a community health 
advisor. 
With regards to point 4, the pharmacists in Malaysia have 
requested the Malaysian Medical Association greater autonomy for 
dispensing on behalf of the doctors but the transition process 
is going slow. In Singapore, there are approximately 98 
pharmacies and people are looking towards the local pharmacists 
as a source of medical advice. In Thailand, the community look 
towards pharmacies to avoid visits to the doctor which often 
leads to lengthy waits in the uninspiring surroundings. 
The results from the consumer surveys in the U.K show that 69% 
of the sample of adults claimed to have suffered from a cold and 
56.6% from a cough. This shows that cough and cold treatments are 
the largest category of the O.T.C market. The second most common 
complaint after cold is headache where analgesics are the second 
largest product category. 
Supply of O.T.C items in Malaysia, Singapore and Thailand are led 
by multinationals ie. Glaxo, Sterling Drugs, Boots, Reckitt & 
Coleman, Warner Lambert, Bayer, Wellcome, Richardson - Vicks, 
Beecham and others. 
- 223 -
In the cough and cold category, Sterling Drugs leads the rest 
of the pack with its paracetamol tablet called " Panadol ". In 
the vitamins category Sanatogen { Fissions ) and Boots are trying 
to claim the market for themselves. In the other segments for 
example the adhesive plasters, the market is competitive with 
Elastoplast { Smith & Nephew ) and Band Aid {Johnson & Johnson) 
dominating the sector. The sales of condoms- in Malaysia has 
picked up with the " Aids " scare and women adopting the rubber 
because of the reluctance to take the " pill ~ 
154 Advertising of O.T.C items is on the increase eventhough no exact 
data is available on the dollar value invested. In the U. K 
through M.E.A.L'S ( Media Expenditure Analysis ) it is seen 65-
70 % was spent in 1987 on O.T.C advertising. 
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DRUG REGISTRATION IN MALAYSIA 
155 Till November 1985 there was no proper control of the flow of 
drugs and medicines into Malaysia. At that point of time it was 
believed that there was about 25, 000 - 30,000 preparations 
available in the market. The figure was an assumption and was 
given by consumerist groups. In October 1985 the Deputy Minister 
of Health Mr. Pathmanaban made a press statement saying that the 
new drugs with the exception of "latest discoveries" will not be 
allowed into the Malaysian market. This rule came under the 
control of Drugs And Cosmetics Regulation of 1984. 
Immediately on 1st November 1985 the newly formed 8 member body 
called the Drug Control Authority under the Director General of 
Health oversaw the implementation of the regulation which 
required the 6,800 pharmaceutical preparations listed under the 
poison ordinance 1952 to undergo registration. 
As of December 31st 1987, a total of 3, 908 pharmaceutical 
preparations had been registered in Malaysia from 36 different 
coutries. The overall number of applications received was 7,274. 
Of which 1,670 was rejected by the D.C.A, 140 were withdrawn by 
the companies concerned while 1,304 appeals were lodged against 
the D.C.A's decision. Of these 218 were approved, 115 were still 
pending, and the remainder were rejected. Up to the end of 1987, 
23 manufacturers licences, 88 importers licence, 155 wholesalers 
licences and 4 clinical trial import licences had been granted. 
156 Those drugs rejected were on the grounds that they were 1) toxic 
2) formulations were not rationale 3) the drugs were not used 
in the country of origin 4) dangerous side effects. Thus the 
first phase saw the registration of poison or scheduled drugs. 
Mr.Liew Kee Hooi, The Director of The Pharmaceutical Division, 
• 
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announced that the pharmaceutical services division was now ready 
for the second phase of the registration exercise which will 
cover the non scheduled items or O.T.C products. 
The third phase of the programme will cover traditional medicines 
and the fourth stage will complete the exercise by looking into 
cosmetics. The registration of the first phase was not conducted 
instantly and the Ministry of Health gave the importers and the 
wholesalers a grace period to comply with the new regulation. 
Most of the drugs that passed the drug control tests were 
examined at the National Pharmaceutidal Laboratory in Petaling 
Jaya. The Ministry of Health did mention that if the 
manufacturers and wholesalers had endorsements of their products 
by internationally acknowledged institutions like the F.D.A of 
the U.S.A or similar institutions in the U.K, Sweden or Canada 
it would be an added advantage for processing their applications. 
The pharmaceutical magazine "Scrip" in its article in May 1987 
complimented the Malaysian drug system a "model scheme" for the 
developing countries. The drug companies in Malaysia did complain 
during the exercise that too much was required under tne new law 
but registration was flexible in some re~pects. Malaysia is one 
of the few countries where the industry ·association has 
formulated two codes of pratice ie. one for ethical products and 
the other for O.T.C items. Malaysia is also one of the few 
countries in the developing world to have set up an advertising 
standards board and to have introduced controls. 
157 Consumerist groups are quite vocal in Malaysia, especially the 
Consumer Association of Penang. For example the C.A.P has been 
pressing the Ministry of Health to ban vitamin Bl5 and B17. The 
reasons behind this anxiety is that B15 causes cancer while Bl7 
It 
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when taken in large quanti ties with certain fresh fruits and 
uncooked vegetables, could release cyanide. Both the products 
have been banned by the Singapore Government. In 1986 the 
Pharmaceutical Service Division conducted raids to flush out 
158 those processing scheduled poison for sale without licences. They 
raided 851 premises in 307 towns and found that 477 premises 
possessed scheduled poison for sale. 9,684 types of scheduled 
poisons including psychotropic pills, valued at $1.53 million 
were seized. 
As the Drug Control Authority goes ahead with the 2nd and 3rd 
phases of registration of O.T.C items and traditional medicines, 
the Pharmaceutical Services Division has received mixed 
responses. Many feel that cosmetics should be registered sooner. 
This would allow Muslims to identify whether the cosmetics were 
free from gelatine, lard and placenta before they are used. 
Coming to the traditional medicines, the exercise is going to be 
tough as with regards to the language problems in labelling of 
traditional medicines. It is believed that herbs used in 
traditional medicines were safe. On the other hand some Chinese 
druggists feel that there will be some difficulty in identifing 
the components of tr&ditional medicines. As a result of the new 
drug registration system parallel imports have virtually 
disappeared from the Malaysian market . 
. 1159 CONTROL OF DRUGS AND COSMETICS REGULATIONS 1984 
PRELIMINARY 
1. 1) These regulations may be cited as the Control Of 
Drugs and Cosmetics regulations 1984. 
2) These regulations shall come into force on such date 
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as the Ministry may appoint by notification in the 
Gazette and the Ministry may : 
a) appoint a commencement date for drugs and a 
different ~ommencement date for cosmetics, or 
b) appoint different commencement dates for different 
groups of products, or 
c) appoint different commencement dates for different 
provisions of these regulations, or 
d) appoint different commencement dates for different 
• parts of the Federation. 
e) adopt any combination of the foregoing alternatives. 
2 In these regulations unless the context otherwise requires 
" Authority " means that the Drug Control Authori'ty 
established under regulation 3. 
~ 
" Clinical Trial" means an inv.estigation or series of 
investigations on persons conducted by or under the 
direction and supervision with scientific training of 
experience for the purpose of finding out or determining 
the safety, effectiveness and other effects of any product. 
"Contract manufacturer" means any person who manufactures 
any product on the order of another person to whom a 
manufacturer's licence has been issued under these 
regulations. 
"Cosmetic" means any substance or·preperation intended to 
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be used or capable or purported or claimed to be capable 
of being used in or for cleansing, improving, altering or 
beautifying the complexion, skin, hair or teeth and 
includes soap, 
perfumes. 
toilet preparations, deodorants and 
~ 
~ 
"Dental practitioner" means a person registered in the 
register under the Dental Act 1971. 
"Drug" has the meaning assigned to it in the ordinance but 
does not include a herbal remedy. 
"Fully registered medical practitioner" means a person 
registered under section 14 of the Medical Act 1971. 
"Herbal remedy" means any drug consisting of a substance 
or a mixture of substances produced by drying or crushing 
without subjecting to any other process, a natural 
substance or substance of plant, animal, or mineral origin 
or any part of such substance or substances. 
" Licenced " means any of the licences issued under 
regulation 12. 
" Licenced importer " means a person to whom an import 
has been issued under these regulations. 
" Licenced Manufacturer " means a person to whom a 
manufacturer's licence has been issued under these 
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regulations, and includes a contract manufacturer. 
" Licenced Wholesaler " means a person to whom a 
wholesalers licence has been issued under these 
regulations. 
" Manufacture " in relation to any product includes 
a) the making or assembling of the product. 
b) the enclosing or packing of the product in any container 
in a form sui table for administration or application and 
labelling of the container. 
c) the carrying out of any process in the course of any of 
the foregoing activities. 
" Pharmacists 11 means a person registered under the 
Registration of Pharmacists Ordinance 1951 . 
. 
. , 
" Product 11 means a drug in pharmaceutical dosage form, or 
a cosmetic, having a singular identity, composition 
characteristics and origin. 
I 
11 Registration Certificate " means a registration 
certificate issued under regulation 8(8}. 
11 Registration Product 11 means a product currently 
registered in accordance with the provisions of these 
regulations. 
" Secretary " means the Secretary to the Authority 
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appointed under regulation 3 (6). 
THE DRUG CONTROL AUTHORITY 
3. 1) An authority to be called the Drug Control Authority 
is established for the purposes of these regulations. 
2) The Authority shall consist of the following members 
ie. a) The Director General of Health b) The Dirctor 
of Pharmaceutical Services c) The Director of The 
National Pharmaceutical Control Laboratory d) Five 
members to be appointed by the Minister. 
3) Members appointed under sub -regulation (2) (D) shall 
be the following persons : 
a) a consultant physician in public service. 
b) a pharmacist in the public service. 
c) three persons from any local universities with 
expertise in pharmaceutical sciences. 
4) Subject to sub regulation ( 5) , a member appointed under 
sub regulation 2 (~) shall, unless he sooner resigns, 
hold office for a period of 3 years but shall be 
eligible for reappointment. 
5) The Minister may at any time and without assigning any 
reason, suspend or terminate the appointment of any 
member appointed under sub regulation 2 (D). 
6) The Minister shall after consultation with the 
Authority appoint a pharmacist in the public service 
to be secretary to the authority. 
7) The secretary shall not be a member of the authority. 
8) Any appointment to or suspension or termination of 
membership under these regulations shall be published 
4. 1) 
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in the gazette. 
The Minister may appoint in respect of each member 
appointed under regulation 3 (2) (D) an alternate 
member who shall be similarly qualified as the 
substantive member as provided in regulation 3 (3). 
2) An alternate member attending any meeting of the 
Authority or acting for the substantive member under 
sub regulation (2) shall be deemed for all purposes 
to be a member of the Authority. 
3) An alternative member attending any meeting of the 
Authority or acting for the substantive member under 
sub regulation (2) shall be deemed for all purposes to 
be a member of the Authority. 
5. 1) Subject to sub regulation (2), The Director General Of 
Health shall be the Chairman of the Authority and shall 
preside at all meetings of the Authority. 
2) The Director of Pharmaceutical Services shall be the 
alternate Chairman and shall preside at meetings of the 
authority in the absence of the Chairman. 
3) The Chairman of a meeting shall have an original vote 
and, in the event of an equality of votes, a second or 
casting. 
4) Four members of the· Authority including the Chairman 
shall form a quorum. 
5) The Authority shall meet at such times and places as 
the Chairman may determine. 
6) The Authority may invite any person appointed under the 
regulation (6) or any other person to attend any 
6 
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meeeting of the Authority but such persons shall have 
no right to vote at the meeting. 
7) TheY may be paid to the members of the Authority, to 
the Secretary, to persons invited under sub regulation 
(6), to attend any meeting of the Authority and to 
persons.appointed under regulation (6) such allowances 
and other expenses as may be approved by the Government 
from time to time and such allowances and expenses 
shall be payable out of the general revenues of the 
government. 
8) Subject to this regulation, the Authority shall 
regulate its own procedure . 
9) No action or proceeding of the Authority shall be 
questioned on the ground 
a) of the existence of any vacancy in the membership 
or any defect in the constitution of the Authority. 
b) of any omission, defect or iregularity in procedure 
not affecting the merits of the case. 
The Authority may appoint a person or persons as it 
may think necessary as advisors for the purpose of 
giving it advice when discharging any of its functions. 
REGISTRATION AND LICENSING 
7. 1) Except as otherwise provided in these regulations, 
no person shall manufacture, sell, supply or 
import any product unless 
a} the product is a registered product. 
b) the person holds the appropriate licence required 
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and issued under these regulations. 
2) The requirement of 1 (B) does not apply to the sale 
or supply of any product by a retailer. 
3) The provisions of sub regulation (1) relating to 
importation do not apply to any person arriving in 
the Federation from a place outside the Federation 
who imports, as part of his personal luggage, any 
product meant solely for his use or for the use of 
his family in a quantity not exceeding that which 
may be reasonably required for one month use by one 
person, or to any officer of the Government 
importing any product in the course of his duty, or 
to any person who in accordance with the written 
consent of the Authority, brings any product into 
the federation in transit. 
4) In sub regulations ( 3) " in transit " means taken 
or sent from any country and brought into the 
Federation by land, air or water, whether or not 
landed or transhipped in the Federation for the sole 
purpose of being carried to another country either 
by the same or another conveyance. 
8. 1) The Authority may on application made in such a 
manner or form as it may require, register any 
product subject to such conditions as it may impose. 
2) Every application for the registration of a product 
shall be accompanied with a processing fee for M$250 
and with such documents, items, samples, particulars 
or information as the Authority may require. 
3) The Authority may charge any applicant such costs as 
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it may incur for the purpose of carrying out 
laboratory investigation prior to the registration of 
any product. 
4) The processing fee and such costs as may be incurred 
by the Authority under sub regulation (3) shall not 
be refundable in the event of the application being 
rejected under regulation (11). 
5) Any change in any document, item, sample, particulars 
or information in sub regulation (2) shall be notified 
in writing by the applicant to the Authority within 
14 days from the date of such a change. 
6) Subject to regulation 17, the period of registration 
of a product shall be as specified in the 
registration certificate issued under sub regulation 
(8) and where so specified the registration shall be 
valid till the end of the specified period. 
7) Subject to sub regulation (17) where the period of 
registration of a product is not specified the 
registration shall be valid until it is cancelled. 
8) Upon registration of a product the Authority shall 
issue to the applicant a registration certificate 
in the schedule. 
9) Any person who knowingly supplies any false or 
misleading information to the Authority in 
connection with his application for the registration 
of a product commits an offence. 
9. 1) The secretary shall keep and maintain a register of 
the products registered and separate registers may 
be kept and maintained for drugs and cosmetics. 
10 
11 
12. 
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2) The register shall contain 
a) the name under which the producit is registered; 
b) the content and quality of the active ingredients; 
c) the name and address of the manufacturer; 
d) The name and address of the product registration 
certificate holder; 
e) the registration certificate number; 
f) the date of issue and expiry of the registration 
certificate; 
3) Any person may, upon written application to the 
secretary and upon payment of a fee of M$5 inspect 
the register or registers kept under sub regulation 
( 1) . 
The Authority may require any person applying for the 
registration of any imported product to furnish a 
written declaration made by or on behalf of the 
manufacturer of the product that all the legal 
requirements governing the manufacture of such a 
product imposed by the laws of the country of 
manufacture have been complied with. 
The Authority may, without assigning any reason, reject 
any application for the registration of any product. 
1) The Authority may, subject to the provisions of 
these regulations, issue any of the following 
licences subject to such conditions as it may 
impose: 
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a) a manufacturer's licence in Form 2 in the schedule, 
authorising the licensee to manufacture the 
registered products in the premises specified in the 
licence and to sell by wholesale or supply the 
products. 
b) a wholesaler's licence in Form 3 in the schedule, 
authorising the licensee to sell by wholesale or 
supply the registered products from the address of 
the business premises specified in the licence. 
c) a clinical trial import licence in Form 4 in 
schedule authorising the licensee to import any 
product for purpose of clinical trials, not 
withstanding that the product is not a registered 
product. 
d) An import licence in Form 5 in the schedule, 
authorising the licensee to import and sell by 
wholesale or supply the registered products from 
the address of the premises specified in the 
licence. 
2) Provided the drugs and cosmetics are not included 
together in one licence, any number of registered 
products may be included in the licence other than 
a clinical trial import licence, with shall include 
only one product. 
3) Subject to sub regulation (2), the Authority may, 
on application by the licensee, add to the 
registered products included in the licence other 
than a clinical trial import licence, and make 
such addition or amendment to the conditions of 
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the licence as are rendered necessary by the addition 
of the other registered products. 
4) Subje~t to regulation (17), a licence issued under these 
regulations, other than a clinical trial import 
licence, shall be valid for one year. 
5) Subject to regulation (17), a clinical trial import 
licence shall be valid for such a period, not exceeding 
three years from the date of issue of the licence, as 
may be specified in the licence. 
6) Every licence shall be personal to the licensee named 
in the licence and shall not be transferable to another 
person. 
13. 1) An application for a licence under these regulations 
shall be made to such a manner or form as the Authority 
may require and shall be accompanied with a processing 
fee of M$250 in the case of an application for a 
manufacturer's licence M$100 in the case of an 
application for any other licence. 
2) The processing fee shall not be refundable. 
3) The applicant for a licence shall furnish such 
documents, particulars or information as the Authority 
may require. 
4) Any person who knowingly supplies any false or 
misleading information to the Authority in connection 
with his application for a licence commits an offence. 
14) The Authority may, if it finds fit and without assigning 
any reason, refuse any application for a licence. 
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15. 1) Any person who wishes to import any product for the 
purpose of research in a school of pharmacy or a research 
of training institution or in order to obtain samples for 
purposes of registration may on application be exempted 
by the Authority from the provisions of regulation 7 ( 1) . 
2) The requirement of regulation 7 (1) as regards a licenc~ 
to supply or manufacture does not apply to the dispensing 
or the doing of any act falling within definition of 
11 manufacture 11 which is necessary for the dispensing, 
of any drug for the purpose of its being used for medical 
treatment, by the following persons and in the following 
circumstances 
a) a pharmacist or a person working under the immediate 
personal supervision of a pharmacist in a retail 
pharmacy. 
b) a person acting in the course of his duties who is 
employed in a hospital or dispensary maintained by the 
Federal or any State Government or out of public funds 
or by a charity approved for the purposes of section 9 
(1) (b) of the Poisons Ordinance 1952 or in an estate 
hospital and who is authorised in writing as approved in 
the section. 
c) a fully registered medical practitioner or a dental 
practitioner or a person working under the immediate 
personal supervision of such a practitioner if the drug 
in question is for the use of such practitioner of his 
patents. 
3) Regulation 7 (1) (a) shall not apply to any drug 
manufactured by persons and in the circumtances described 
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in sub regulation (2) if the drug is manufactured for the 
purpose of dispensing. 
4) A school of pharmacy or any research of training 
institutions which wishes to manufacture any product for 
teaching and research purposes may on application be 
exempted by the Authority from the provisions of regulation. 
5) Any person who wishes to manufacture any product solely for 
the purpose of producing samples for clinical trials or for 
registration under these regulations may on application be 
exempted by the Authority from the provisions of regulation 
7 ( 1) . 
16.1) The Authority may issue such certification on any matter 
relatin9 to any product where such certification is 
required by any country importing such a product. 
2) A fee of M$25 is payable on the issue of such 
certification. 
17.1) The Authority may, at any time and without assigning any 
reason, suspend or cancel the registration for any product 
or revoke any licence issued under these regulations and 
may amend the conditions to which such licence or 
registration is subject. 
2) Subject to sub regulation (3), any suspension or 
cancellation of the registration of any product under sub 
regulation (1) shall similarly and at the same time affect 
any licence issued under these regulations relating to 
that product. 
3) Not withstanding sub regulation (2), where licence issued 
- 240 -
under these regulations relates to several registered 
products~ the suspension or cancellation of the 
registration of any product under sub regulation (1) shall 
not affect the position of other registered products listed 
in the licence. 
18 Any person aggrieved by any decision of the Authority under 
these regulations may make a written appeal to the Minister 
within fourteen days from the date the decision is made 
known to him and any decision of the Minister made on an 
appeal shall be final. 
MANUFACTURE OF REGISTERED PRODUCTS 
A licenced manufacturer shall ensure that all personnel employed 
at all levels of manufacture 
a) possess suitable qualification required for their jobs; 
b) have adequate experience and are technically competent; 
c) are regularly trained during their employment for the purposes 
of keeping up to date with any advances or changes; 
d) are medically examined regularly; 
20.1) registered products shall be manufactured[ processed 
packed, labelled and tested in premises which are in 
accordance with standards set by the Authority. 
2) Adequate storage areas shall be provided so that all 
starting[ rejected or returned materials or intermediates 
or finished registered products are adequately separated. 
3) Manufacturing premises shall be maintain~d in good and 
sanitary conditions: there shall be a sanitation programme 
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for the maintenance of the premises in these conditions 
and records of the performance of the programme shall be 
kept. 
21.1) Manufacturing and testing equipment~ shall be designed 
placed and maintained in such a way so as to : 
a) be suitable for their intended use; 
b) facilitate thorough cleaning whenever necessary; 
c) minimise any contamination of registered products and 
their containers during manufacture; 
d) minimise the risks of confusion and omission of any 
manufacturing steps 
2) A licenced manufacturer shall 
a) ensure all weighing, measuring and recording equipments 
are maintained in good working conditions and are 
regularly calibrated. 
b) where suitable, have manufacturing steps monitored by 
recording devices. 
c) ensure all manufacturing equipments are thoroughly and 
regularly cleaned in accordance with such written 
specifications as the Authority may determine. 
d) ensu~e records of the matters in paragraphs (a) , (b) and 
(c) are kept and maintained. 
23 Manufacturing operations shall be carried out in accordance 
with such requirements as may be determined by the 
Authority. 
1) A licenced manufacturer shall establish a quality control 
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department under the supervision of a suitably qualified 
person. 
2) A quality control department shall -
a) control all materials used in the manufacturing process; 
b) monitor ·the quality aspects of all manufacturing steps; 
c) control the quality and stability of the finished 
registered products; 
3) For all the purposes of this regulation, a licenced 
manufacturer shall provide such facilities as may be 
necessary for a quality control department to discharge 
its duties. 
24 For the purposes of this part, a licenced manufacturer shall 
conduct regular inspections of his manufacturing and quality 
control activities. 
25 A licenced manufacturer shall maintain proper records of 
every batch of finished registered products distributed to 
enable the complete and rapid recall of the registered 
products if necessary. 
MISCELLANEOUS 
26. 1) Any officer or inspector may, at all reasonable times, 
enter any premises used or connected with the 
manufacture, sale, supply or import of any product for 
the purposes of inspecting 
a) the product with which the premises are concerned; 
b) the premises and the operations carried out in the 
premises; 
c) any licence, registration certificate, record or document 
27.1) 
- 243 -
required under these regulations and every licenced 
person and every agent and servant of the licenced person 
shall afford every assistance required by the officer 
or inspector and shall, on demand by the officer or 
inspector, produce any product or any licence, 
registration certificate, record or document required 
under these regulations. 
2) Any officer or inspector may seize any product in 
respect of which he reasonably believes that an offence 
under these regulations, or any breach of the conditions 
subjected to or affected, has been or being committed, 
and any plant, equipment, book, document or other article 
which he reasonably believes would furnish evidence of 
the commission of such offence or breach. 
Every licenced wholesaler and importer shall maintain 
proper records of each transaction involving a registered 
product, showing the particulars specified in the 
registration, for a period of not less than five years 
from the date of transaction. 
2) In the case of a licenced wholesale, the records shall 
show the date of sale or supply, the name and address of 
the purchaser, the name and quantity of the registered 
product sold, the registration reference of the product 
and the number of the invoice or delivery order. 
3) In the case of a licenced importer, the records shall 
show the date of importation, the name and address of the 
supplier, the name and quantity of the registered product 
imported, the number of the bill of landing, the date of 
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any sale or supply made and the name and address of the 
purchaser. 
28 A licenced manufacturer, a licenced wholesaler, a licenced 
importer or the holder of a registration certificate in 
respect of any product shall inform the Authority of any 
adverse reactions arising from the use of the registered 
product immediately after he recieves notice of such adverse 
reactions. 
29.1) The Authority may issue such instructions to any person 
as it thinks necessary for the better carrying out the 
provisipns of these regulations and which may in particular 
relate to the recall of any registered product from the 
market and the disposal of any registered product. 
2) Any person who contravenes any directions issued by the 
Authority under sub regulation (1) commits an offence. 
30.1) Any person who contravenes any of the provisions of these 
regulations or any condition of any licence issued under 
these regulations or any condition subject to which a 
product is registered under these regulations commits an 
offence. 
2) Any person who commits an offence under these regulations 
shall be liable on conviction to a fine not exceeding 
M$1,000. 
31 The Minister may, offer consultation with the Authority, 
exempt any person or class of persons by notification in the 
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Gazette from any of the provisions of these regulations 
subject to SUGh conditions or reactions as he may impose in 
such exemption. 
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GOVERNMENT PHARMACEUTICAL SERVICES 
160 The Pharmaceutical division of the Ministry of Health has many 
objectives and strategies. A detailed report is given below. 
The objectives of the programme are : 
1) To strengthen the supply system to meet pharmaceutical 
and other health needs in the health programmes at 
minimal cost. 
2) To provide an efficient an effective pharmaceutical 
service in hospitals and health centres. 
3) To increase the range and volume of pharmaceutical 
products manufactured by the government. 
4) To ensure quality, efficacy and safety in the use of drugs 
and other pharmaceutical products and safety in the use of 
traditional medicines and cosmetics. 
5) To ensure proper procedures in the importation, management 
and sales of drugs and other pharmaceutical products. 
6) To ensure rational drug utilisation. 
Strategies to achieve the objectives : 
The following strategies are planned to achieve the above 
objectives: 
1) To ensure continuous and adequate supply of 
pharmaceutical products and other products of quality 
by: 
expanding and improving storage facilities in all 
institutions to meet the increasing demand. 
establishing a network of new regional medical stores. 
fully implementing the integrated store system in the 
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medical stores of General and District hospitals. 
modernising the store inventory control management 
system and communication through computerisation. 
purchasing products of assured quality. 
strengthening transport systems to meet increasing 
demand. 
to improve the hospital pharmacy services to an efficient 
and effective level by 
a) expanding and improving existing manufacturing 
facilities in pharmacy units and establishing 
facilities for preparing extemporaneous and sterile • 
preparations. 
b) ensuring rational drug utilisation through 
implementing drug information services, patient 
counselling services, prescription screening, 
labelling of drugs with generic names and cautionary 
labels and " units of use " supply system. 
to increase the production and quality of pharmaceutical 
products by 
a) better maintenance of production equipment to reduce down-
time. 
b) increasing productivity through better organisation and 
utilisation of manpower. 
c) improving in-process quality control techniques to 
ensure the quality of finished product. 
d) improving end product quality assurance by establishing 
quality control facilities at hospitals. 
e) establishing standard formulary and procedures for use in 
-~-
all hospital manufacturing units. 
f) ensuring efficacy and safety in the use of drugs and 
cosmetics regulations 1984. 
To improve the enforcement of pharmacy legislations by : 
a) strengthening of enforcement units at Ministry and State 
levels~ 
b) formulating new legislations, reviewing and amending 
existing ones whenever necessary. 
c) increasing the scope and frequency of enforcement 
activities through raids and inspection of licenced and 
unlicenced premises, private clinics and customs entry 
check -points. 
to ensure adequate qualified and trained personnel to 
manage and operate the expanding services by : 
a) identifing the grades and categories of personnel 
required. 
b) providing formal courses and on the job training. 
c) conducting seminars and workshops etc. for the staff. 
PROGRAMME OPERATION 
1) Procurement and distribution 
The procurement and distribution of supplies operate 
through a central procurement and purchasing system of 
pharmaceutical laboratories and store, Petaling Jaya and 
a distribution infrastructure which distributes supplies 
to user units. State Medical Stores and bigger institutions 
are allowed to make local purchase subject to certain 
provisions for non standard items and during 
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emergencies. 
The pharmaceutical laboratories and store is an unallocated 
store which operates through a revolving fund. The management 
system of this store and its branch in penang has been 
computerised since 1985. This computerisation has 
facilitated and improved the inventory control, procurement, 
distribution and accounting activities. 
2) Hospital Pharmacy 
Hospital pharmacy includes the following activities 
dispensing to out-patients. 
monitoring of prescriptions. 
patient counselling. 
drug information service. 
production of pharmaceutical preparations. 
drug supply for in-patients. 
Recently great emphasis was placed on the utilisation of 
the pharmacist's professional knowledge to increase the 
effectiveness of patient treatment. In dispensing, 
emphasis is given to screening of prescriptions to detect 
polypharmacy, incompatibilities, interactions and 
contraindications, to labelling of dispensed medicines with 
generic names and cautionary labels and to patient 
counselling to increase compliance. Production activity 
stresses on Good Manufacturing Practice through the use of 
standard formulary, work sheets and procedures. In ward 
pharmacy, the unit of use supply system is being promoted. 
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PRODUCTION 
Pharmaceutical preparations manufactured by the Pharmaceutical 
Laboratories- And Store, Petaling Jaya, include tablets 
injections, intravenous fluids, galenicals reagents. In 
hospitals, the types of preparations are limited to galenicals 
and drops prepared for home consumption and for health centres 
in the district. Some hospitals with facilities also produce 
intravenous fluids. 
High speed production equipment and machinery together with 
advanced production technology are used to meet the increasing 
demand for various preparations. The concept of in process 
quality control and good manufacturing practice are used to 
ensure products of quality. 
QUALITY CONTROL 
To control the q~ality of products, traditional medicines and 
cosmetics in the market. 
The Contr61 Of Drugs And Cosmetics Regulations 1984 was enforced 
in November 1985. These regulations require the registration of 
all medicines including traditional medicines· and cosmetics. The 
implementation of these regulations is scheduled in phases, 
·' beginning with pharmaceutical dosage form followed by traditional 
medicines and lastly cosmetics. 
The evaluation for registration is ·done by the Drug Control 
Authority based on the evaluation of documentations, end product 
testing and evaluation of manufacturing premises and 
manufacturers. As a result of this registration procedure,the 
licensing of importers, wholesalers, manufacturers and importers 
of drugs for clinical trials are also enforced. 
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ENFORCEMENT 
Legislations cu.rrently enforced are : 
- The Registration Of Pharmacists Ordinance 1951. 
- The Poison Ordinance 1952. 
- The Dangerous Drug~ Act 1952. 
-The Medicines (advertisement and sales) Act 1956.: 
- The Sale Of Food And Drugs Ordinance 1952. 
The above legislations control the practice of pharmacy, the 
importation, exportation, sale and manufacture of drugs including 
traditional medicines and cosmetics. The control is through the 
registration of pharmacists, the licensing of premises, the 
issuing of import and export permits, and screening of medicines 
and other substances claiming therapeutic value. Inspection or 
raids on licenced and unlicenced premises,·private clinics and 
customs entry check points are carried out both at Ministry and 
State levels. 
Any dealings with dangerous and psychotropic substances requires 
statistical reports of sales and usage. As a signatory to the 
Single Convention 1961 and The Psychotropic Convention 1971 
annual statistics on stocks, production, usage and importation 
of narcotic and psychotropic substances for the whole ·country are 
collected and reported to the respect'i ve authorities at the 
United Nations as required by the above conventions. 
Pharmaceutical substances including traditional medicines and 
cosmetics are monitored to ensure that they do not contain 
poisonous substances and heavy metals which are dangerous to 
health. Testing of samples are done at the National 
Pharmaceutical Control Laboratory, Petaling Jaya. 
Advertisements of medicines through the mass media and other 
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means are screened to ensure that they conform to the provisions 
of Medicine (Advertisment And Sales) Act 1956. 
DRUG INFORMATION 
To promote rational drug utilisation, The National Drug 
Information Centre was established at the · The National 
Pharmaceutical Control Laboratory. The centre is responsible for 
collecting, keeping and distributing information on drugs to the 
dru9 information centres in government hospitals and also 
professionals and the public. The . centre also monitors the 
incidence of adverse drug reactions. 
TRAINING 
This programme also involves the training of the pharmacy 
assistants and pharmacy laboratory assistants. After a year of 
training in the Trining School in Petaling Jaya, trainee pharmacy 
assistants are posted to hospitals and health centres to undergo 
practical training for two years before they are appointed to the 
public service. Pharmaceutical laboratory assistants after three 
years 'of .training are posted at production or quality control 
laboratories. 
This programme in addition to providing in service training 
courses for its staff also participates in teaching of University 
. . 
Science Malaysia students in Forensic Pharmacy. Training of pupil 
' 
pharmacists are also conducted at selected institutions. 
ADVISORY AND CONSULTATION SERVICE 
Senior officers of this programme participate in several national 
anq international activites in matters relating to drug 
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information, usage of drugs, formulation and enforcement of drug 
legislations, drug abuse, custom tarrif, quality control 
standards and list of essential drugs. 
The Pharmaceutical Services Division is headed by the Director 
of Pharmaceutical Service and assisted by a Deputy Director. The 
division is responsible for : 
implementation of policies on pharmaceutical services and 
medical supplies services. 
- implementation of the pharmacy and supplies programme. 
- overall management of pharmaceutical services ie. 
1) pharmacy services in hospitals, polyclinics and rural 
health centres. 
2) pharmaceutical manufacturing service at central and 
ho~pital level. 
3) logistics and supplies facilities from Central Medical 
store, regional store and integrated stores. 
4) quality control services. 
- procurement and distribution of drugs, pharmaceuticals and 
medical equipment to health facilities under the Ministry Of 
Health. 
- Quality control and standards of drugs manufactured I issued 
by the Ministry of Health. 
- quality and standards of drugs imported into the country. 
- evaluation, improvement and expansion of pharmaceutical and 
supplies service in line with the needs of Health Services. 
- development of expertise in pharmacy and related fields in 
The Ministry Of Health. 
- acquisition of personnel for the operation supply, 
production and other activities under the division. 
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- monitoring of licit movements of narcotis in the country and 
enforcenment of the ordinance and related regulations. 
- liason with other related Ministries I agencies eg. anti-
drug task force, customs, police, Ministry of Trade And 
Industry, etc. 
The body acts as a secretariat to : 
1) The Poisons Board established under the Poisons Ordinance. 
2) The Pharmacy Board established under the Registration Of 
Pharmacies Ordinance. 
3) The Medicines Advertisement Board established under the 
Medicines (advertisement and sales) Act. 
4) Drugs and equipment evaluation committee, pharmaceutical 
laboratories and store, Petaling Jaya. 
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DRUG REGISTRATION IN SINGAPORE 
161 Drug registration is a system provided under the Medicines Act 
1975 whereby all medicinal products for human use must be 
licensed by the Ministry of Health prior to any sale. The local 
manufacturers, wholesalers and importers of medicinal products 
must also be licensed before they can conduct their business. 
The objective of drug registration is to ensure that medicines 
are safe, efficacious and of good quality before they can be 
offered for sale. 
Current control system only restricts dealings of potent products 
by listing them in the Poisons Act or Misuse Of Drugs Act. 
Licences for import, sale and distribution of these substances 
are given to individuals who possess the required qualification 
or expertise. The system of control originated many years ago and 
is being phased out in many countries. The modern concept of drug 
control is through drug registration, each product will be 
evaluated for safety, efficacy and quality before licences are 
issued. 
The authority to licence medicinal products intended for human 
use rests with the Ministry of Health. Toilet preparations, food 
and disinfectants sold without making reference to medicinal use 
are exempeted. 
" Medicinal product" is defined in the Medicines Act to mean any 
substance which is to be used for administration to human beings 
a~d apimals for diagnosis, prevention or tteatment of ailments 
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including preparations intended for the promotion of health, for 
anaesthesia or for contraception. ( Raw materials used for the 
. 
manufacture of medicines fall within this category). Excluded 
from this definition are : a) medical instruments, apparatus or 
appliances b) medicinal products not included for general sale 
but intended for researc~ or testing purposes c) substances used 
for filling dental cavaties d) bandages and surgical dressings 
which are not medicated to provide any therapeutic or palliative 
action. 
New medicinal products are those introduced into the market on 
or after the commencement of drug registration. 
EXEMPTIONS 
The medicines act exempts several groups of products from 
~egistr~tion. These are ; 
- medicines dispensed in accordance with prescriptions. 
- extemporaneous preparations and small scale preparations made 
for use within the health institution I pharmacy. 
- herbal remedie~ of plant(s) original only. However herbal 
remedies with added chemical components or in injection dosage 
form will not be exempted. 
The following groups of items will not be included for 
registration during the initial stages of drug registration 
- traditional medicines. 
- homoeopathic medicines. 
- raw materials. 
- locally manufactured products solely for export. 
- products imported for specfic treatment of individual persons 
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only. However prior approval must be obtained from the Ministry 
of Health before import of such products. 
- products imported solely for re-export only. However a 
certificate must be obtained from the Ministry of Health prior 
to such import. 
- Quasi- medicinal products such as medicated shampoo ( eg. anti 
dandruff shampoo) and medicated soap. 
TYPE OF LICENCES AND CERTIFICATES 
The licences involved are : 
- product licences. 
- import licences. 
- wholesale dealer's licence. 
- manufacturer's licence. 
CERTIFICATES 
- Certificate for exporter of medicinal products. 
- Certificate for product imported solely for re-export. 
SUBMISSION OF APPLICATIONS 
Applications for licences/certificates must be submitted in the 
prescribed forms issued by the Ministry of Health. (Application 
forms for the various types of licences and certificates are 
available free of charge from the inspectorate section, Ministry 
of Health ) . Applicants are advised to read this guide book and 
the explanatory notes carefully before completing the relevent 
applications forms. 
The time schedule for the submission of applications for various 
licences will be announced. Applicants are advised to submit 
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their applications for licences as early as possible. 
Applications for certificates to import medicinal product soley 
for re- export may be made prior to each import. Certificate for 
export of medicinal products may be applied as and when required. 
PRODUCT LICENCES 
The onus of applying for a product licence shall rest with the 
firm responsible ·for the introduction of the product into the 
Singapore market namely : 
a) in the case of an imported product the manufacturer's local 
representative or its sole agent. 
b) in the case of locally manufactured product, the manufacturer 
of the product. 
The following information is required for application of product 
licences : 
a) full product formula including inert ingredients. 
b) evidence of sale before date of commencement of drug 
registration. 
c) registration certificate/certificate of free sale from the 
country of origin. 
d) finished product specifications with certificate of analysis. 
e) specimen sales pack, label and pamphlet. 
f) summary of manufacturing and quality control facilities if the 
product is manufactured overseas. 
For new products the following information is needed 
a) full formula including inert ingredients. 
b) detailed manufacturing procedure. 
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c) finished product specifications with certificate of analysis. 
d) method of analysis of active ingredients. 
e) registration certificate /certificate of free sale from the 
country of origin. 
f) free sale certificates from other countries. 
g) document from health authority of the country of origin 
certifying that the manufacturer concerned is a licensed 
manufacturer. 
h) specimen sales pack, label and pamphlet. 
i) summary of the clinical trial papers on the product. 
After the product has been licensed any subsequent change in the 
particulars relating to the product ( eg. change of formula, 
composition/ingredient, recommended use) may render the licence 
invalid unless prior approval of such change has been obtained 
from the licensing authority. 
Product licence holder should report to the Inspectorate Section, 
Ministry of Health, as soon as possible or within one week, of 
any adverse reaction for the product. 
IMPORT LICENCES 
Importers who do not hold product licences may apply for import 
licences to import medicinal products which have already been 
given product licences. 
IMPORT LICENCE FOR AUTHORISED AGENT OF PRODUCT LICENCE HOLDER 
This type of import licence will be issued to importers who are 
authorised by the product licence holders to impor~ licensed 
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products on their behalf. 
IMPORT LICENCE FOR NON AUTHORISED AGENT 
Such import licence will be required for each i tern in each 
consignment. Importers should provide evidence, to the 
satisfaction of the licensing authority, that the products to be 
imported are identical to the products already registered in 
Singapore. It is the duty of such importers to ensure that 
provisions made under the trade marks and the patents (compulsory 
licensing) act have been complied with. 
For importation of products under the authorisation of the 
Singapore product licence holder, applicant should submit a copy 
of such authorisation from the product licence holder. For 
importation of products identical to a licenced product, the 
importer should provide a copy of the certificate of analysis 
from the manufacturer for the particular batch to be imported and 
enclose a copy of the invoice from the manufacturer to the 
exporter and from the exporter to the local importer 
respectively. 
For medicinal products imported under the authorisation of the 
product licence holders, the relevant product licence numbers 
should appear on the labels and packages accompanying the 
products. For products imported otherwise labelling of the import 
licence number should be done in place of the product licence 
number. 
Non authorised agents holding import licences should report to 
the Inspectorate section, Ministry of Health, within one week in 
relation to any adverse drug reaction received for the products 
for which they hold the import licences .The validity of an import 
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licence in respect of each medicinal product to be imported shall 
be subjected to the continued validity of the corresponding 
product licence for that product. Any suspension, revocation or 
variation of the product licence shall equally apply to the 
import licence in respect of that medicinal product. For import 
licences which are on per item basis, importers should return the 
relevant licences to the Licensing Authority for cancellation 
within seven days after completion of re-export. 
WHOLESALE DEALERS LICENCES 
Except for the licensed manufacturer and the holder of a product 
licence, any person selling medicinal products to others for 
purposes of resale will have to apply for a wholesale dealer's 
licence. The requirement for the wholesale dealer's licences also 
apply to the supply of commercial samples of medicinal products 
in like manner. In application for a wholesale dealer's the 
applicant should supply a list of medicinal products to be dealt 
with by way of wholesale, completed with the names of 
manufacturers, 
licence numbers 
countries of manufacture, Singapore product 
and expiry dates of product licences. Any 
amendment to the above mentioned list should be reported to the 
licensing authority and a new updated list of all products which 
the wholesaler will deal with by way of wholesale should be sent 
to the licensing authority to replace the old list. The validity 
of a wholesale dealer's licence in respect of each medicinal 
product to be dealt with by way of wholesale shall be subjected 
to the continued validity of the corresponding product licence 
for the product; and any suspension, revocation or variation of 
the product licence shall equally apply to the wholesale dealer's 
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licence in respect of that medicinal product. 
MANUFACTURER~S LICENCES 
In application for a manufacturer's licence the applicant should 
state the pharmaceutical dosage forms to be manufactured and 
submit a layout of the factory and other important features. 
Sanitary facilities should also be indicated. A list of equipment 
for manufactriring, assembly and quality control should be 
submitted together with a summary of the manufacturing processes. 
CERTIFICATES FOR PRODUCT IMPORTED SOLELY FOR RE - EXPORT 
Importers should apply for such facilities for each item in each 
consignment prior to each import. Products imported under such 
authorization are prohibited for local sale. 
FEES FOR LICENCES AND CERTIFICATES 
Fees will be charged for the following licences and certificates 
1) product licence (each product) 
provisional 
ordinary 
new product 
2) import licence 
3) wholesale dealer's licence 
4) manufacturer's licence 
5) certificate for export of medicinal products (per 
certificate) 
6) certificate for product imported solely for re-export (per 
product) 
7) amendment fee (per occasion) 
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FORMAT FOR RECORD KEEPING 
All licence holders and holders of certificate for product 
imported soiely for re-export must keep records of their 
transactions for a period of five years from the date of the last 
entry. The · following information must be included in such 
records. 
1) Name of product 
2) Batch number 
3) Date of manufacturing 
4) Expiry date 
5) Packing 
6) Product licence number 
7) Date of transaction 
8) Delivery order /invoice number /production ticket number. 
9) Name and address of purchaser /supplier 
10) Quantity received 
11) Quantity sold 
12) Stock balance 
13) Analytical results (for products manufactured locally ) 
PRODUCT RECALL 
When such an action is necessary after deliberation by the 
Ministry, it is the responsibility of the product licence holder, 
import licence holder and wholesaler to recall all the products 
which are imported /distributed by them. 
GENERAL SALE LIST 
When the whole process of drug registration is completed, a 
general sale list will be printed which will include products 
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allowed to be sold over the counter. Products not listed in the 
general sale list may only be supplied from pharmacies or on 
. 
prescriptions only. 
SUSPENSION, REVOCATION OR VARIATION OF LICENCES AND CERTIFICATES 
The licensing authority may suspend, revoke amend the details in 
any licence or certificate. He shall serve on the licence or 
certificate holder a notice giving particulars and reasons for 
such suspension, revocation or variation. Any person who is 
aggrieved by such a decision may appeal to the Minister for 
Health whose decision shall be final. 
ENQUIRIES 
Enquiries concerning drug registration should be made to the 
Inspectorate Section, Ministry of Health (Headquarters). 
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162 DRUG CONTROL AUTHORITY ( Thailand ) 
FRAMEWORK OF THE AUTHORITY 
Planning and implementation, on the legal basis, of any 
activities concerning pharmaceutical control by means of 
1) establishment of criteria, procedure and condition in 
relation to the manufacturing, sale, importation and 
registration. 
2) licensing for manufacture, sale or importation. 
3) inspection of the premises (newly applied or modification/ 
correcting the old premises) 
4) evaluation and issuance of certificate of registration for 
pharmaceutical products. 
5) issuance of the licenses for the manufacturing or 
importation of the drug sample (both traditional and 
modern). Such samples are intended only for utilization 
in registration process. 
6) studying, researching and compilation of the data I results 
to be used as information in the process of standard and 
quality establishment. 
7) implementation of the process of suspending, withdrawal or 
modifying of licenses and certificates. 
8) training and advising on control procedures for the 
personnel concerned. 
9) co-operating with the related authorities or institution 
of both national and international levels in order to 
exchange and update the existing information. 
10) conducting and organizing the meeting of the drug 
committee. 
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DRUG REGISTRATION IN THAILAND 
Drugs which require registration fall into the following 
categories 
1} Drugs which are not listed in the pharmacopeias notified by 
The Minister ie. drugs in various trade names such as 
Metaplex tablet. 
The pharmacopoeias are : 
a} Thai Pharmacopoeia, First edition ( 1987 } volume 1 
part 1. 
b) International Pharmacopoeia, 3rd edition. 
c) British Pharmocopoeia 1980, volume I and 2. 
d) British Veterinary codex 1985, and supplements. 
e) The United States Pharmocopeia, 25th revision 1985 and 
supplements. 
f) The National Formulary 16th edition 1985 and 
supplements. 
2) Drugs of which their formula are not listed in the above 
mentioned pharmacopoeias. Most of them are new drugs or 
drugs in combination eg. analgesics and antipyretics 
combined with antihistamines. 
3) Drugs which are listed in the above mentioned pharmacopeia. 
4) Drugs of which their formulas are listed in the 
pharmacopoeia. 
Drugs which do not require registrations 
1} pharmaceutical chemicals or semi finished pharmaceutical 
chemicals which are not readily packed ie. pharmaceutical 
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raw material. 
2) herbal remedies eg. roots, leaves, fruits and flowers. 
3) drug samples which are permitted to be manufactured or 
imported for registration. 
SOME INFORMATION ON DRUG REGISTRATION 
1) Registration is categorised into 
2) 
3) 
a) registration for modern drug 
1) human use. 
2) animal use. 
b) registration for traditional drug 
1) human use. 
2) animal use. 
Certificate for drug registration are categorised into : 
a) certificate for registration of manufactured drug. 
b) certificate for registration of repacked drug. 
c) certificate for registration of imported drug. 
The manufacturers and importers of both modern and 
traditional drugs must have the certificate of registration 
of each drug before they can be produced or imported. Before 
applying for drug registration, the following steps should 
be followed. 
a) In applying for the permission to produce samples, the 
manufacturers must submit two sets of documents 
containing the application form for sample production, 
labels and inserts. After receiving the permission, 
then the samples can· be produced. In this case the 
manutacturers can produce only the samples that are 
permitted. 
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b) The importer must submit two sets of documents 
consisting of application forms for sample importation, 
labels and inserts in order to request for the 
permission to import the samples for registration. 
c) For traditional drugs, the manufacturers or importers 
also have to follow the same procedures as those of 
modern drugs before thy can produce or import the 
samples of drugs to be registered. 
d) In requesting for the permission to import the samples, 
if the original manufacturers have never applied for 
the drug registration in Thailand or have not yet 
received the permission to register their products, 
their factories must guarantee as meeting the standard. 
In this case the Food And Drug registration would 
request the Ministry of Foreign Affairs to inform the 
Thai Embassy in those countries to send their officials 
for inspection. Alternatively, the agencies may receive 
the forms from accredited overseas suppliers and send 
them to be certified by their government or authorities 
as well as the Thai Embassy or the Pharmaceutical 
Manufacturers Association of those countries. 
e) The importers who need to import any new drugs which 
are not listed in the pharmacopoeia and dont have the 
certificate for drug registration must submit the 
certificate of free sale issued by their government 
together with other documents mentioned above. 
Combination drugs with new formulas are also included 
in these cases. 
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PROCEDURE IN DRUG REGISTRATION 
1) Four sets of documents in accordance with the application 
form for drug registration must be submitted. The 
application forms for production of modern drug or 
traditional drugs, samples as well as as those for sample 
importation which have been already certified must be 
attached with the submitted documents in each case. The 
documents to be submitted should contain : 
a) Product's name. 
b) List of active and inactive ingredients as well as 
their contents. 
c) Packing. 
d) standard method of analysis for modern drugs. In those 
cases when these methods are not stated in the 
pharmacopoeia notified by the Minister, the method 
should be able to give the identification and assay 
of the active ingredients. It should also give details 
of the finished products, unofficial ingredients, 
percentages, limitations and references. 
e) Labels must also show products name, contents, name and 
quantity of active ingredients, batch and control 
numbers, name of manufacturer and address, 
manufacturing date etc. 
f) Inserts or accompanying literature. If it is presented 
in a foreign language, translation into Thai is needed. 
g) The insert should contain product's name, 
identification and direction for use, content of the 
package and dosage. 
2) For registration of ne:w drugs, report of the study in 
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animals and clinical trails must be attached. This report 
should be published with reliable refrences. Therapeutic 
efficacy, side effects and toxicological data should be 
presented. In addition, certificate of free sale from the 
manufacturer's government must be submitted. 
3) Samples of drug to be registered must be submitted. 
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THE GATEWAY TO SOUTH EAST ASIA I SINGAPORE 
163 The 1987 economic indication showed the G.D.P growth percent for 
. 
Thailand, Malaysia and Singapore as 8.3%, 7.4% and 9%. The 
economies of the 3 countries has been striking and investors have 
been drawn to the region. Brunei, Indonesia and the Philippines 
also showed improved G.D.P% but not as spectacular as the other 
3 countries. Eventhough all these six countries form ASEAN, which 
has been designed on the same frame work of the E.E.C, the group 
has had many disagreements. Indonesia and the Philippines have 
political instability and Brunei is too small to be taken 
seriously. To the marketer who will concentrate in the ASEAN 
basin it would be best to go regional and concentrate on the 
Thai, Malaysian and Singapore markets first and get a strong 
foothold. To attack these 3 markets it would be advisable to move 
from a central location. Between Istanbul and Perth (Australia) 
and between Johannesburg and Hong Kong, Singapore serves the 
logical choice to establish a regional headquarters. 
After its break up with Malaysia, Singapore moved ahead under the 
close scrutiny of Mr. Lee Kuan Yew. Today, Singapore is one of 
the 4 N.I.C's of Asia. Lee has transformed the Island Republic 
to be the country which has the· " lowest risk " as far as 
investments are concerned. Investment commitments in 1987 was 
S$1.7 billion reflecting u.s, Japanese and European corporate 
investors unflagging confidence in Singapore's economy and 
competitiveness. Foreign investors in Singapore earned an income 
of S$3.7 billion in 1987 from their investments an increase of 
17% over 1986. 
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Singapore is heading towards high tech and the Lee 
. 
administration intends to make Singapore the centre of business 
for the Asia - Pacific region. The City State has one of the 
world's highest per square meter concentrations of M.N.C's 
(Multinational companies ) from the U.S, Japan and Europe - some 
3,400 subsidiaries and joint ventures including about 600 large 
manufacturing operations. Today, Singapore offers :-
1) Entry into local and regional markets. 
2) Market test bed opportunities. 
3) Economic, social and political stability. 
4) Conducive pro - business environment. 
5) Managers, professionals and workers with traditional and state 
of the art industrial and corporate service skills. 
6) Advanced transport and communication infrastructure. 
7) Good standard of living. 
Thus it can be seen that this Global City has become integral 
mode in the international network of economies because of its 
well developed trading, marketing, transport and communication 
links and international financial network and services. 
Due to its small size and other features such as 
industrialisation, high income per capita, favourable geographic 
location, high literacy rates and skill labours, Singapore is now 
classified among the newly industrialised countries. Thus 
Singapore can play a complementary role in the development of the 
pharmaceutical industry in the region, serving as a centre of 
finance, skilled labour, scientists as well as the centre for 
trade and distribution within the sub- region. In other words, 
ASEAN economic co-operation would depend very much on the role 
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Singapore will be allowed to play in Intra - ASEAN trade and 
external trade of the sub - region. In fact, the Intra - ASEAN 
trade already exists, according to available statistics. When the 
ASEAN package of industries come on stream the Intra ASEAN flow 
of these products, mostly fertilizers for the time being, trade 
among ASEAN partners should increase sharply. 
Singapore has already shown its ability to penetrate the 
international market, not only within ASEAN but also in Europe, 
America and elsewhere. Therefore, ASEAN industries including 
pharmaceuticals which require a higher technology can actually 
be competitive worldwide, as Singapore's experience has shown. 
' Consu~tations among the ASEAN countries should lead to avoiding 
competition in the chemical and pharmaceutical industry. As 
mentioned an optimal location of study of a pharmaceutical site 
to economize transport and other economic variables is required. 
Due to the high value of imports as well as the higher value of 
exports on hand and the relative low level of local consumption 
of pharmaceutical products, it is seen that many of these 
products have been merely transferred from one country to 
another. The movement of pharmaceutical products from one place 
to another may create a problem of quality assurance of drugs, 
since some of these drugs might be stocked for a long period of 
time before being exported to other countries. 
From the results of the U.N.A.P.D.I study it was found that 
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Singapore was a very exceptional economy in the field of 
pharmaceuticals. Standing in a much better off position than 
ASEAN neighbours, it is emphasised that Singapore could play a 
vital role in helping to contribute to other ASEAN countries. 
Such possible contributions could include as different aspects 
of distribution of local products, assisting and co- operating 
in training ( eg. fermentation technology ) , personnel, financing 
etc. 
SINGAPORE'S CONDUCIVE OPERATING ENVIROMENT 
Leading international pharmaceutical and health care product 
companies such as Baxter International, Becton Dickinson, 
Beecham, Glaxo, Kanegafuchi, Japan Medical Supply and 3M have 
been able to enhance their competitive advantage by serving their 
regional and international markets from Singapore. 
They are among the more than 600 leading companies from the 
United States, Europe and Japan who have invested more than S$ 
12 billion in Singapore to manufacture and provide related 
technical support services, along with some 2,800 other foreign 
companies and financial institutions based in Singapore. 
A world leader in the production of semi - conductors, computer 
disk drives, refrigerator compressors, petroleum and other 
products, Singapore actively encourages and welcomes foreign 
investments, many of which have found Singapore's pro- business 
environment extremely favourable for continued growth, expansion 
and diversification. 
Its free enterprise policy allows foreign companies the freedom 
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for 100 percent ownership of its operations in Singapore, the 
freedom to repatriate profits and capital and to recruit skilled 
. 
personnel from any source. 
Singapore's modern infrastructure, among the best in the world 
includes :-
1) an active seaport that works round the clock 365 days a year 
and provides turnaroun9. time of eight hours for a container 
ship. 
2) an efficient airport, served by 47 international airlines, 
which clears arriving passengers in 15 minutes. 
3) state of the art telecommunication links with the world, 
includes direct dialling facilities to 164 cities. 
4) wide range of international banking and financial services 
provided by more than 220 banks and finance companies. 
5) immediate availability of fully serviced industrial 
buildings and facilites enable companies to start up or 
expand their operations quickly. 
The availability of skilled trained chemists, biochemists, 
pharmacists, engineers, laboratory and process technicians in 
Singapore has enabled many companies in the industry to undertake 
manufacturing, · product development and testing activities in 
Singapore. The Institute Of Molecular And Cell Biology which was 
opened in 1987 undertakes research in cell regulation, infectious 
and genetic di~eases and plant genetic engineering. 
Many pharmaceutical and heal thcare product manufacturers in 
Singapore have received the seal of approval of the U.S Food and 
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Drug Administration ( F.D.A ) . This reflects the high level of 
quality consciousness on the part of management as well as the 
workers personal discipline and commitment towards maintaining 
high quality standards. 
THE PHARMACEUTICAL AND HEALTHCARE PRODUCT INDUSTRY IN SINGAPORE 
Singapore has a 170 year history of mercantile trading with both 
its regional partners and the world. Many leading manufacturers 
of pharmaceuticals and medical equipment have established 
marketing and distribution facilities in Singapore to better 
serve their Asia pacific markets. 
In the early seventies, the industry was given a boost when 
Beecham of the United Kingdom established a wholly owned 
subsidiary in Singapore to produce semi - synthetic penicillin 
for the Japanese market. 
The industry has since grown significantly over the years as 
companies achieved full production while others expanded into 
other product· areas. The industry's output grew from S$316 
million in 1980 to S$825 million in 1986, while gross fixed asset 
investments by the industry increased from S$119 million to 
almost S$400 million during the same period. 
PROFILES OF SUCCESSFUL COMPANIES 
Baxter Healthcare began their operations in Singapore in 1978 
with the manufacture of infusion sets. The facility, now equiped 
with gamma ray sterilisation capability, is one of Baxter's most 
advanced plants in the world and has been approved by the U.S 
FDA. A second plant to manufacture sophisticated hospital and 
laboratory equipment, such as aspheresis, intravenous flow, renal 
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therapy and diagnostic equipment, mainly for the.American market 
will be operational in 1988. At the same time the company is 
planning to undertake product and process development in 
Singapore. Fixed asset investments which total S$70 million in 
1987 will reach S$110 million by 1981. The existing highly 
efficient facility has earned the company numerous awards from 
its parent company. These include 11 Best Plant 11 , 11 Plant of the 
Year 11 , 11 Award of Quality 11 , 11 Most Improved Plant 11 
Beecham's plant in Singapore was set up in 1970 to produce semi -
synthetic penicillin products for export to Japan. Since then, 
various expansions have been undertaken resulting in the 
company's investments in Singapore reaching S$130 million in 
1987. Today, the range of products manufactured in Singapore 
includes Amoxil, Ampiclox, Orbenin, Penbri tin in oral and sterile 
forms and the recently introduced new antibiotics Augmentin and 
Timentin for various markets such as Japan, China, The Middle 
East and Africa. 
Becton Dickinson has invested S$100 million in a Singapore plant 
to be operational by the second half of 1988, to manufacture a 
wide range of disposable syringes and hypodermic needles for 
world markets. The latest addition to Singapore's medical 
industry, this world scale plant will capitalise on Singapore's 
locational advantage to better service the Asia Pacific 
markets. 
Diagnostic Biotechnology Pte. Ltd established in 1985 with 
venture capi tai funds is engaged in bio medical research and 
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development, production of diagnostic kits and custom made 
peptides and providing reference laboratory services. The 
company, which has a technology transfer agreement with Biotech 
Reseach Laboratories of the U.S.A, is located at the Singapore 
Science Park. Products on the market include Enzyme Immuno Assay 
kits and Western Blot Assay kits for each of H1 V1, H1 V2 and 
HTLV1. At the same time the company is developing rDNA 
diagnostics for H1V1 and Hepatitis B and a diagnostic set to 
detect H1V 1 and 2 in one assay. 
Glaxo established its S$120 million plant in 1982 to manufacture 
bulk ranitidine hydrochloride, the new anti gastric ulcer drug 
which has become the world's best selling ethical drug. The 
availability of fully serviced industrial estates enabled Glaxo 
to start up its first ever rani tidine hydrochloride plant in 
Singapore speedily. 
Japan Medical Supply, encouraged by Singapore's cost 
competitiveness, set up its second overseas manufacturing 
facility in Singapore in 1980 to produce infusion and transfusion 
' 
sets, blood collection bags, syringes, fistula needles ~nd CAPD 
continuous ambulatory peritoneal dialysate for markets 
outside Japan. The company will be expanding its range of 
products manufactured in Singapore and is constructing its own 
S$10 million factory building extension. The Singapore operations 
have been of strategic importance in the Company's business 
expansion worldwide. 
Kanegafuchi selected Singapore to set up its plant to produce 
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amino acids and hydroxyl - phenyl glycine ( HPG ) used in the 
manufacture of antibiotics. The Singapore facility, Kanegafuchi 1 s 
only HPG manufacturing ~lant~ uses the unique high yield 
fermentation process. The HPG is exported to the United States, 
Europe, Japan and other Asian countries. The numerous advantages 
of manufacturing in Singapore have assisted Kanegafuchi to 
achieve and maintain world leadership in the HPG business. 
Pacific Biomedical 1 s facility was set up in 1987 to design, 
develop and manufacture high quality but affordable heart valves 
and cardiac care devices and disposables. The plant in Singapore 
was a result of American entrepreneurship and Australian funding. 
Siemenls subsidary in Singapore manufacture behind the ear and 
custom made within the ear hearing aids for the Asian markets, 
while hearing aid sub - assemblies are produced for its sister 
companies in other countries. Another Siemen 1 s subsidiary 
operates a medical and dental equipment servicing and training 
centre in Singapore to service its customers in the Far East 
(including Japan and The Peoples Republic of China) and the 
Middle East. The centre has a staff of 16 engineers. 
Spectramed ( formerly Gould Medical produces thermodilution 
catheters and pressure monitoring accessories in their FDA 
registered, class 10,000 clean room facility in Singapore for 
markets in Japan and Europe. It is also developing new products 
such as multi lumen catheters and blood sensors with local 
hospitals and academic institutions. The plant in Singapore is 
Spectramed 1 s most significant facility outside the United States. 
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Stiefel's Singapore facility manufactures ethical topical 
dermatological products for the Asian Pacific and African 
markets, and intends to undertake research to adapt its products 
to these markets. 
3M's intra ocular lens manufacturing plant in Singapore 
established in 1987, supplies lenses to the Asia Pacific market. 
The highly competitive manufacturing costs of its lenses in 
Singapore has enhanced 3M's marketing efforts to enlarge its 
market share in the Asia Pacific region. 
Sinqatronics and Wearne's Technology, both locally owned 
. r 
companies, have successfully developed a digital blood pressure 
monitor and an electro therapy equipment respectively. Both 
products have enjoyed considerable market acceptance locally and 
elsewhere. 
WHY SINGAPORE ? 
Singapore is strategically located at the crossroads of 
international trade routes and has enjoyed political, economic 
i 
and social stability. Her pragmatic government has always adopted 
a pro business approach and maintained'an open door policy since 
her independence in 1965. These, coupled with her highly 
developed and sophisticated infrastructure in telecommunications, 
port and airport facilities, availability of ready built fully 
serviced factory buildings and industrial parks and modern 
offices, skilled and well trained work force, and the presence 
of well developed supporting industri~s, all contribute to 
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Singapore as an ideal location for investment. 
Location 
Situated in the heart of South East Asia, a resource rich region 
of some 300 million people and more than 3,400 for~ign com~anies, 
I 
Singapore offers to investors a strategic location well placed 
to serve the markets in the region including India, Japan, China, 
Australia and New Zealand. Her unique time zone and 
telecommunications network allow its financial institutions and 
other businesses to conduct transactions with any part of the 
world all within an 8 hour working day. 
International travel is equally convenient. Hong Kong is a mere 
3 1/2 hours away; Tokyo, just over 6 hours; Sydney less than 8 
hours; London, Los Angeles and San Francisco within 15 hours from 
Singapore. Her highly efficient airport at Changi, voted one of 
the top three in the world, clears air travellers in as fast as 
15 minutes. 
BUSINESS DEVELOPMENT 
Singapore's pragmatic government has created an attractive and 
conducive business climate for companies to invest here. Her open 
door policy allows the more than 600 international companies 
here, who have set ~P manufacturing and technical support service 
operations to enjoy freedom of business activity. There are no 
restrictions on : 
Foreign ownership. As there is no local ownership 
requirement, foreign companies are allowed 100% ownership 
of their businesses in Singapore. This enables companies to 
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have full control of proprietary technology. 
Movement of capital. Companies can freely repartriate their 
profits and capital as there are no foreign exchange 
controls. 
Free port. There are no import duties on industrial raw 
materials, equipment and machinery. Companies are therefore 
free to move their goods in and out of a truly free trade 
country. 
Employment. There is freedom to employ qualified staff from 
all sources. 
These together with her sophisticated infrastructure, readily 
available skilled labour and her strategic location have led to 
an increasing number of companies to use Singapore as a regional 
marketing and distribution base, and as a centre for product 
design and development work. A number of companies have also 
established and set up their ·operational headquarters in 
Singapore, to undertake a full range of business activities 
including management of their subsidiaries and group financing 
in this region. 
STABILITY 
Apart from her open door policy and her strategic location, 
Singapore has a unique record of political, economic and social 
stability. The tripartite co - operation between the government, 
employers and unions in meeting economic objectives has enabled 
Singapore to achieve a stable and conducive environment for 
business. In the last eight years, virtually no man days were 
lost due to industrial actions. This co - operation was evident 
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in the prompt response by employers and unions to the 
government's call for wage restraint to ensure that Singapore 
I 
retains its international competitiveness. 
Political stability and consistency of Government policies 
provide the backdrop for the country's rapid economic 
development. Her G.D.P has grown from S$2 billion in 1960 to 
S$42 billion in 1987. Inflation averaged less than 2% in the 
last five years; in terms of per capita income, Singapore ranks 
19th in the world and is the second highest in Asia after Japan. 
The Singapore dollar has remained strong and stable for a record 
period of time. 
Expatriate executives and their families have easily adjusted to 
and enjoy living in Singapore. Excellent healthcare, ample 
educational facilities and moderately priced executive homes are 
readily available. A well developed infrastructure, municipal 
efficiency and an English speaking population all combine to 
provide a comfortable and secure living environment for these 
expatriate families. 
INDUSTRIAL INFRASTRUCTURE 
As a business and financial centre, Singapore continually 
enhanc~s its efficient and sophisticated infrastructure to serve 
the changing needs of business. Both the airport and port 
comparable to the world's best, are highly efficient and 
competitive in terms of facilities and services. 
Telecommunication services are modern and comprehensive and offer 
among the lowest rates in the world. 
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Changi International Airport - enjoys an international reputation 
for its efficiency and good design was voted one of the top three 
. 
airports in the world. Also yoted the .. best airport for air 
' . 
cargo", at the 13th International Forum for Air Cargo, Changi 
~ 
International Airport currently handles more than 45 
international airlines and 558 scheduled flights per week linking 
Singapore to 90 cities in 51 countries. 
Singapoe Port- the first container port in South East"Asia is 
ranked as one of the world's busiest and is a major global 
warehousing and distribution centre and trans shipment hub. 
Equipped with the latest cargo handling facilities, the port 
operates round the clock to provide extremely fast turn around 
f.or carriers from all over the world. More than 500 shipping 
lines serve Singapore and provide links to some 300 ports 
worldwide. About 30,000 vessels call at the port each year. 
Telecommunication Services 
Singapore's state of the art telecommunication services are a 
boon to international companies and a relief to businessmen 
travelling in the region. A direct dial telephone service links 
Singapore to 162 destinations within seconds. International 
teleconference services are available and businessmen can offer 
simultaneously with up to 9 other parties in different locations. 
International telex and telefax services are avilable to 205 and 
55 destinations respectively.· Sophisticated telecommunication 
services for high speed international data transfer via satellite 
·are readily available at competitive rates. The communications 
infrastructure required by the information age is constantly. 
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being enhanced to maintain Singapore's position as a significant 
node in the global information network. 
DEVELOPED INDUSTRIAL ESTATES 
Ready built modern, fully serviced factories in industrial 
estates are; available for immediate start up operations. These 
factories, fully served by roads, sewers, water and power 
supplies, and telecommunication facilities, are conveniently 
located near housing estates to provide an immediate source of 
manpower. ·similarly, fully serviced industrial lands are also 
available. ' 
BANKING AND FINANCE 
Singapore is also a thriving financial centre served by 192 
commercial and merchant banks, 85 insurance companies, 4 discount 
houses, 8 interna~ional money brokers and 34 finance companies. 
Between them, they provide a full range of services from exchange 
and money market services to trading of gold, financial futures 
and the Asian dollar. 
SUPPORTING INDUSTRIES 
Singapore _offers a wide range of specialised facilities and 
services to meet the needs of pharmaceuticals and health care 
companies operating in the Republic. These include terminal, 
storage, warehousing and transportation services. 
Specialised services such as chemical, biochemical, sterility and 
pyrogen testing and analytical services are available from the 
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Singapore Institute Of Standards And Industrial Research, The 
Department Of Scientific Services, The National University Of 
Singapore, as well as from private inspection and testing 
bureaus. 
Also many international engineering consultancy firms in 
Singapore offer technical services in the design and construction 
of chemical process plants, including automation, in the Republic 
and the region. 
A full range of other supporting services are widely available 
at competitive prices. These include fabrication of pipes, tanks, 
heat exchangers and process ,equipment, mould making, clean room 
and precision plastic and rubber injection moulding, sterlisation 
and manufacturing of electronic components, PCBA printed 
circuit board sub assemblie$ ) and other components. There are 
also companies that provide turnkey manufacturing services. 
SKILLED MANPOWER 
One of the many factors influencing investments in singapore is 
the availability of indust~ious, trained manpower. It is indeed 
one of Singapore's most important assets, apart from her 
geographical location. That is -why each year some 12% of 
Singapore's national budget is-spent on education. 
The Singapore worker has been rated at par with the best of the 
world by various international consultants. BERI 
enviroment risk information ) , for instance has 
Singapore worker best overall in the world for 
business 
ranked the 
attitude, 
• 
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productivity and technical skills for the seventh consecutive 
year. 
Worker training and skills upgrading are constantly undertaken 
by companies and the specialised training institutions to enhance 
worker productivity and to ensure that existing skills are 
relevant to the needs of the industry. 
There is a growing pool of skilled and experienced professionals, 
a readily available source of top and middle management 
personnel, production 
increasing number of 
supervisors and section managers. An 
local and foreign trained graduates 
constantly replenish this pool, stimulating competition that 
sharpens business acumen and keeps marketing know how up to date. 
To maintain a steady flow of highly trained professionals into 
the labour force, The National University Of Singapore ( NUS ) , 
·the Nanyang Technological Institute NTI and the two 
Polytechnics have doubled their student intake at the same time 
maintaining their high standards. At the same time Singapore's 
open door policy allows qualified and experienced foreign 
individuals, ·who can make a positive contribution, to be 
employed. 
RESEARCH AND DEVELOPMENT 
R & D has been chosen as a vehicle for Singapore to move towards 
high technology. Product design and development capabilities will 
be improved and competence in technologies relevant to the 
economic activities will be further developed. 
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The government has set up a 115 hectare Science Park to serve as 
a focal point for industrial R & D and " brain services ". To 
date, some 34 companies with a total staff of 1,061 including 352 
R & D staff, have established R & D facilities in the park. The 
Park's proximity to the National University of Singapore and The 
National University Hospital fosters close interaction and 
exchange of knowledge and ideas between university staff and 
industrial researchers. 
Furthermore the University has recently set on a course to 
establish itself as a centre of excellence in both education and 
research. High quality staff and excellent research facilities 
have enhanced the research environment in the NUS. 
The Institute Of Molecular And Cell Biology IMCB ) was set up 
within the National University Of Singapore ( NUS ) in order to 
strengthen the infrastructure for basic biomedical and 
biotechnological research. When fully operational, the Institute 
will have 21 research teams comprising some 200 scientists led 
by a pool of top researchers from the U.K, the U.S.A and Canada. 
In additional to these, the National University Hospital together 
with some 21 other hospitals undertake ongoing research 
activities while at the same time functioning as hospitals. In 
1986, the National University Hospital's Pathology Department 
alone worked on more than 20 areas of research. 
These institutions together with the Nanyang Technological 
Institute and the two polytechnics will be making an even more 
important and positive contribution towards industrial R & D, 
especially in an environment where emerging technologies are 
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driven by R & D. 
Last year alone, the companies in Singapore spent S$400 million 
on R & D. This expenditure is expected to increase as the 
momentum on R & D is accelerated. 
TAX INCENTIVES 
Singapore's attractive tax incentives allow qualified companies 
in Singapore to maximise their return on investment. According 
to the U.S Department Of Commerce Survey On Current Business 
( August 1987 ), Singapore offers one of the best returns on 
investment. Between 1982 and 1985 the .return on U.S direct 
investments in Singapore averaged 27%, which puts it ahead of 
Ireland, Japan, Hong Kong, South Korea and Taiwan. 
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~4 JAPAN AND ITS ROLE IN ASEAN 
. 
While Western multinationals move towards a more concrete 
approach into marketing pharmaceuticals, ASEAN's leading trading 
partner moves closer to fill the role of" big brother ''. Japan 
has topped the world in the production of new pharmaceutical 
products in 1981 when the industry reached its maturity. By 1990, 
Japan would have reached the same level of high technology as in 
Europe and the U.S. The Japanese will be ever willing to dominate 
their presence in Asia since the economies of most Asian 
countries in particular ASEAN is in the take off period. The 
pharmaceutical industry in ASEAN is still backward but there is 
room for expansion. Japan's role in ASEAN in the context of the 
pharmaceutical industry are :-
1) sharing the Japanese modernisation experience. 
2) transfer of Japanese pharmaceutical industry's high 
devetopment, technology and manufacturing. 
3) extending a co - operative frame work. 
Japan's pharmaceutical industry has.gone through several phases 
to attain.modernisation. Japan has a good system of G.M.P, G.L.P 
and has reached a phase where Japan could produce new 
pharmaceutical products on its own. The Japanese experience can 
therefore provide the guidebook for ASEAN. 
Japan's pharmaceutical industry's capacity to develop new 
products has improved tremendously and will join the rank of 
leaders in the pharmaceutical field. Thus with the high 
technological .development of the Japanese pharmaceutical 
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industry, the trend is to transfer them to the countries and 
areas where the cost is cheaper and it is probably that this will 
be the direction of policy changes in the industry. 
Modernisation of the pharmaceutical industry begins with the 
modernisation of the manufacturing process and the manufacturing 
process begins with the implementation of G.M.P. Japan's 
achievements could be a good lesson. Another area where the ASEAN 
countries could learn is the distribution system adopted by 
Japan. 
The life of pharmaceutical manufacturers is sustained by the 
continuous introduction of new products. Development research 
know how is learnt through the process of new product 
development. The best way for the ASEAN countries to learn could 
be through joint development for mutual benefit. 
The pharmaceutical and electronics'industries are some of the 
areas of growth in the ASEAN region. To modernise, the industry 
requires effort and innovation. The pharmaceutical industry is 
not only modernising but is also facing a lot of challenges and 
problems that needs analysis and solutions. 
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CONCLUSION 
. 
A comparative analysis has already been conducted detailing the 
production, marketing and distribution of pharmaceuticals in 
Malaysia, Singapore and Thailand. As it appears the Thai market 
looks vulnerable to foreign pharmaceutical comapnies. The 
relaxation of patent regulations and the aggresive policies 
regarding generics which have won the Government approval have 
sounded a note of caution for the foreign based manufacturers. 
The only way to survive in the Thai market is to introduce high 
technology based drugs where generics are left stranded or to 
compete in the lucrative O.T.C market. The same rule applies to 
Malaysia and Singapore as well but the generics are not that 
widespread as it is seen in Thailand. Generic prescription has 
some disadvantages and these are : 
165 1) Brand names are often simpler, spelt and remembered than 
generic names. 
2) Quality of generics has claimed to be inferior. 
3) Differing appearences may be a problem for some patients and 
they prefer to be prescribed by the same brand name. 
4) The source of a generic cannot be identified once it has 
been dispensed and it is noted that the implementation of 
the product liability legislation will underline the need 
for dispensing doctors and pharmacists to keep appropriate 
records. 
Thus we have seen some of the problems faced by multinationals 
in this region. Multinationals certainly can overcome generic 
obstacles if they approach the markets through regional 
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operations. Many international companies have traditionally 
handled their worldwide operations as a loose confederation of 
highly autonbmous country units, thus their operations lay closer 
to the differentiated and decentralisation ends of the 
continuums. 
In a study conducted on marketing strategies through regional 
operations, it indicated an example of a manufacturer who is 
dependent on local manufacturing in a European location as a 
means of tapping the market in Europe as a whole. Thus to attack 
on regional basis there are many solutions available to a 
company. 
166 POOLING OF RESOURCES 
The first solution to go on a regional basis is to pool the 
resources available. Resources from a group of company operations 
if the operations are small may be combined to increase efficency 
or to provide services which might otherwise not be available to 
those country level operations. A good example of pooling 
resources is forecasting. 
16 7 FORECASTING 
An area with considerable response in terms of consolidation is 
in monitioring of regional wide economic conditions. Thus it is 
seen with a regional office, multinationals can prepare and 
disseminate information and projections in order to prevent 
costly duplication among the subsidiaries within the various 
countries. Another area is in monitoring region wide regulatory 
developments, particulary those affecting product standards and 
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advertising restrictions. The pooling of resources for 
improvement of sales has a greater advantage for the European 
Economic Community but ii do~s not mean the system cannot be 
adopted in ASEAN where Thailand, Singapore and Malaysia are 
prominent members. 
168 PRODUCT DEVELOPMENT COSTS 
When subsidaries have a history of product development autonomy, 
it is found advantageous to use a regional operation to pool 
product development activities. The high cost of product 
development can be cut down to a minimum with such an activity. 
169 PRODUCT VARIETY 
It is seen when country units made product decisions based only 
on what they could sell within their own country markets, many 
product oppo~tunities which required large scale process 
technology were rejected. The regional group assesses regional 
demands so that, if large enough it will push ~for co- operative 
arrangements among national units. 
170 GOVERNMENT SALES 
Government sales are important when government purchases are a 
high potential portion of sales. This is because government 
purchasers may consider a firm's economic impact on the country 
when deciding whether or not to purchase from it. Since companies 
may operate various subsidiaries within the region, governmental 
authorities may not be aware of the important total impact the 
company is making in the area. A unified external relations 
approach can result in a more complete message than if each 
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subsidiary, each product group or each country group were to take 
on the duties separately. 
171 INTERNATIONAL CUSTOMERS 
Frequently a supplier sells to subsidiaries of the same 
multinational firm in more than one country. By combining 
efforts, the supplier may be able to deal with regional decision 
makers and determine what type of concessions will be needed to 
gain region-wide sales. Such regional control also helps assure 
that one group does not make concessions such as price decreases 
or product modifications, which are inconsistent with other 
corporate entities within the area. 
172 PRODUCT GROUP SYNERGY 
Another approach to regionalisation is to gain leverage among 
customers when two or more products are operating in the area, 
particularly if the product groups have strong bases in different 
countries. 
173 INTERNATIONAL COMPETITORS 
Another aspect where regionalisation has been successful is 
attacking a competitor's strong market. Subsidiaries have been 
seen concentrating to strengthen their positions in relation to 
local competitors, leading them occasionally into new but related 
products. The resources to attack local competitors could have 
been better spent by concentrating on a regional attack strategy. 
174 PREVENTING INTERNAL COMPETITION 
At one extreme, a firm may be able to centralise production in 
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order to reduce costs. At the other extreme, a firm may have 
products where transportation costs are too high to justify 
taking advantage of the scale of economy in production. In 
between these 2 extremes are products for which multiple 
production locations are necessary, but for which there is 
product arbitrage potential when costs move differently among the 
countries due to such factors as inflation rates or an exchange 
rate re-alignment. There is also the potential for price 
competition. among these subsidiaries when there is excess 
capacity. This is the reason where firms have instituted regional 
control in order to prevent sales shifts which could be 
disruptive to their production facilities. 
STANDARDISATION 
175TRANSFERENCE OF INFORMATION 
Because of the growing market homogenity within the region, most 
respondents report a growing ability to predict . success or 
failure for a group of countries on the basis of their experience 
in one of them. Regional management can quickly monitor the 
results from all the countries in the area and communicate ideas 
or directives elsewhere. For example, O.T.C advertisement which 
is successful in Singapore will usually work in Malaysia or vice 
versa. 
The above mentioned points on the regionalisation plan if 
followed by multinational marketers will be useful. Another point 
to consider, other than the regionalisation idea is to conduct 
acquisitions. There are small pharmaceutical enterprises 
available in Thailand and Malaysia and the giant companies could 
buy them up while retaining the local management. This is one of 
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the best methods to have a strong foothold in & country. If the 
acquisitions are not possible then joint ventures should be 
considered f~r implementation. For example in Malaysia the 
government decided to come out with a national car called Proton 
with a joint understanding with Mithsubishi. The local car market 
has been completely dominated by Proton that the other foreign 
car manufacturers have been left struggling behind. Thus the same 
applies to the pharmaceutical industry. 
l76 RESEARCH & DEVELOPMENT 
Research and development plays a major role in the business of 
a company. If more new products are available to a company it 
could mean a competitive edge it would have on its rivals. In its 
research paper, c. C. L ( Cambridge Consultants Limited ) explains 
the need for new product launches through R & D activities. For 
pharmaceutical companies it is necessary to ensure a regular 
stream of competitive timely new products which is the surest way 
to increase the market share and profits. The report has put 
Malaysia and Thailand as followers or starters in R & D 
activities and Singapore has been singled out as independent and 
yearing towards as a centre for R & D activity. A researched 
product is purchased for the benefits it delivers. A researched 
product 
meets customers needs better than its rivals. 
is of a higher quality than its rivals. 
reduces customers costs. 
offers unique features to the customers. 
But unfortunately, C.C.L says that the majority of new products 
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are not superior products and fail due to 
1) inadequate market analysis. 
2) defects· in product-design-quality. 
3) poor product marketing and launch. 
4) higher development and/or manufacturing costs than expected. 
5) competitors strengths greater than expected. 
6) poor timing of introduction. 
7) production problems. 
Many examples can be mentioned on basis of the points mentioned 
above and a good example is Opren an anti - rheumatic drug which 
was marketed by Eli Lily. The product was introduced with much 
publicity throughout the world. It was later seen that some 
patients put on Opren medication died in the U. K and this 
prompted the company to immediately withdraw the product from the 
market. Thus it is seen that limited clinical trials had 
indirectly jeopardised the marketing of the product. 
Appendix 1 
AX INCENTIVES ADMINISTERED BY THE ECONOMIC DEVELOPMENT BOARD !SINGAPORE> 
----------------------------------------------------------------------------------------------------------------+ 
Tax Incentives : Qualifying Activities : Minimum Requirements : Tax Concession 
o Pioneer Status Approved manufacturing and 
service activities 
New activity or one which has: 
been granted pioneer status 
in the past 
1) Exemption of 33% tax on 
profits arising from 
pioneer activity 
2> Tax relief period is 
5 - 10 years 
-----------------------:----------------------------:------------------------------:----------------------------~ 
o Expansion Incentive Approved manufacturing and 
service activities 
Minim'um investment of S$10 
million in new productive 
equipment and machinery (for 
manufacturing activities 
only) 
1> Exemption of 33% tax an 
profits in excess of 
pre-expansion level 
2) Tax relief period of up 
to 5 year-s 
-----------------------:----------------------------:------------------------------:----------------------------: 
~ Investment Allowance 
Incentive 
1) Approved manufacturing 
and service activities 
2> Approved research and 
development activities 
' 3) Approved construction 
operations 
4> Approved projects for 
reducing consumption 
of potable water 
Qualifying period of up to 5 
years within which specified 
investments must be made 
Exemption of taxable income: 
of an amount equal to a 
specified proportion (up tal 
50%} of new fixed 
investment 
------------------------------------------------------------------------------------------------------------------+ 
Source Economic Development Board Singapore 
Appendix 2 
TAX INCENTIVES ADMINISTERED BY THE ECONOMIC DEVELOPMENT BOARD (SINGAPORE) 
Source : Economic Development Board Singapore 
·----------------------------------~------------------------------------------------------------------------------~ 
Tax Incentives I Qualifying Activities I Minimum Requirements I Tax Concession 
I --------------------- : -------------------- I --------------
·----·-------------------------------------------------------------------------------------------------------------~ 
o Operational 
Headquarters (OHQ) 
Approved headquarters 
operations 
Operational Headquarters 
' 1) should manage related 
companies outside of 
Singapore and 
2) must provide approved 
headquarters services to 
related overseas companies' 
from Singapore 
------------------------1----~-----------------------i------------------------------
o Post-pioneer 
Incentive 
l 
I 
Approved companies enjoying 
pioneer status or export 
incentive where the export 
incentive is a follow-up 
to the pioneer status 
previously awarded 
Companies must be enjoying 
pioneer status or export 
incentive on or after 1 April 
1986 and should incur 
additional investment 
1) Income arising from the 
provision in Singapore 
of approved services 
will be taxed at 10% 
2) Other income from 
overseas subsidiaries 
and associated companies! 
may also be eligible fori 
effective tax relief 
I 
! 
----------------------------1 
Corporate tax rate of 15% 
for up to 5 years on 
expiry of pioneer or export 
incentive 
I 
I 
------------------------:----------------------------:------------------------------:----------------------------
o Approved Foreign 
Loan Scheme 
o Approved Royalties 
1 
! 
Approved manufacturing 
and service activities 
Approved manufacturing and 
service activities 
1) Minimum loan of S$200,000 
from a foreign lender for 
purchase of productive 
equipment 
2) Tax relief should not 
result in an increase in 
tax liability in the 
foreign country 
Tax relief should not result 
in an increase in tax 
liability in the foreign 
country 
Exemption of withholding 
tax on interest 
50% or 100% exemption of 
withholding tax on 
royalties 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975) 
Appendix 3 
In pursuance of Regulation 6 (2) of the Medicines (Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------·------------------------------------------+ 
l Serial lCer·tificate : 
No : No l Name & Address of Pharmacy l Pharmacist-In-Charge lDate cf Registration: 
~---------i------------~-----------------------------------~-------------------------~--------------------~ 
1 0439 
2 0006 
3 0492 
4 0491 
5 0470 
6 0471 
!Advanced Medi Mart 
lBlock 201E~ Tampines Street 23 
1#01-64, Singapore 1852 
:Alcare Pharmaceuticals Pte Ltd 
:400 Balestier Road #01-22 
lBalestier Plaza, Singapore 1232 
'Allied Medic Pte Ltd 
150 Orchard Road #04-06 
Orchard Plaza, Singapore 0923 
American Hospital of Singapore 
321 Joe Chiat Place 
Si ngc.~por e 1542 
Yip Yoke Moi <Ms) 
Chua Chwee Hong <Ms> 
Liam Lay Kheng <Ms> 
Lim York Hwa nee Sim 
<Mrs> 
iApex Pharmacy International Pte Ltdl Monica C K Chan <Mrs) 
1301 Upper Thomson Road #02-01 
lThomson Plaza, Singapore 2057 
lApex Pharmacy International Pte Ltdl Iris Lee Yen Linn <Ms) 
150 Market Street #01-12 
:Golden Shoe Car Park 
:Singapore 0104 
1st January 1988 
1s-;t 3anuary 1988 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
7 i 0472 lApex Pharmacy Int'l Pte Ltd : Chao Ye Peng : 1st January 1988 
!Block 34A, Margaret Drive #01-342 
!NTUC Fair Price, Singapore 0314 
+---------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975> 
Appendix 4 
In pursuance of Regulation 6 C2> of the Medicines (Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+----------------------------------------------------------------------------------------------------------~-
: Serial 
No 
l Certificate l 
No Name & Address of Pharmacy Pharmacist-In-Charge IDate of Registration: 
:---------:------------:-----------------------------------:-------------------------:--------------------: 
8 0473 
9 0474 
10 04-75 
11 0496 
12 0016 
13 0014 
14 0032 
Apex Pharmacy Int'l Pte Ltd 
Block 205, Hougang Street 21 
#01-133, Singapore 1953 
Apex Pharmacy Int'1 Pte Ltd 
Lion City Hotel 
.Commercial Building, Geylang Road 
:Oriental Geylang, Singapore 1440 
IApex Pharmacy Int'l Pte Ltd 
1#03-15/19 Raffles City Tower 
\Singapor-e 0617 
:Apothecar-y Pr-ivate Limited 
119 Tang1in Road #03-26 
lTanglin Shopping Centre 
lSingapor-e 1024 
lAr-cade Medical Hall 
'11 Collyer Quay #02-35 
The Arcade, Singapore 0104 
Asia Pharmacy Private Limited 
257 Selegie Road #02-281 
Selegie Complex, Singapore 0718 
Atrium Pharmacy 
6 Raffles Boulevard #02-116 
lMarina Square, Singapore 0103 
Yew Sok Har· <Ms> 
Chang Yok Ying CMs) 
Doncella Abigail Inglis 
<Ms> 
Tan Siew Tin nee Chew 
(Mrs) 
Chong Lian Hua <Ms> 
' Catherine Lim Swee Gek 
nee Wee CMrs) 
Felicia Ling nee 
Tham Yin Har (Mrs) 
1st January l.988 
1st J am.1~1ry ). 988 
1st January 1988 
:lst January 1988 
1st January 1988 
1st J am.1~1ry 1988 
1 c::·!-
-· ... 
J C:"\ rll.IC:"\ I~ y 1988 
+---------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975) 
Appendix 5 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
: Serial 
: No 
:certificate : 
No Name & Address of Pharmacy Pharmacist-In-Charge :Date of Registration: 
:---------:------------:-----------------------------------:-------------------------:--------------------: 
+----------------------------------------------------------------------------------------------------------+ 
15 l 0431 l Atrium Pharmacy : Chua Lee Cheng <Ms> l 12th JanLtary 1988 
16 0010 
17 0459 
18 0019 
19 0022 
20 0430 
21 0009 
11 Orchard Road #B1-18 
Dhoby Ghaut MRT Station 
Singapore 0923 
Chao Dispensary 
Block 2, Rocher Centre #02-596 
Singapore 0718 
:community Pharmacy 
:1 Jalan Anak Bukit #01-08 
:Bukit Timah Plaza, Singapore 2158 
:Coronation Pharmacy Pte Ltd 
1587 Bukit Timah Road #02-11 
:Singapore 1026 
Dragon Door Medical Hall 
Block 23, Outram Park #01-403 
Singapore 0316 
Federal Pharmacy 
865 Mountbatten Road #01-64 
Singapore 1543 
Freshe Pharmacy Pte Ltd 
80 Anson Road #02-10 
IBM Towers, Singapore 0207 
Choo Tian Hock 
William Woo Tat Meng 
Rosaline Ong Giam Hock 
Neo <Mrs) 
Delia Ong Chiaw Inn 
nee Wee <Mrs) 
Chong Tong Thok 
Albert Tok Gek Song 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
+----------------------------------------------------------------·-----------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975> 
Appendix 6 
In pursuance of Regulation 6 <2> of the M~dicines <Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
l Serial :certificate l 
No l No I Name & Address of Pharmacy I Pharmacist-In-Charge IDate of Registration: 
:---------:------------:-----------------------------------:-------------------------l--------------------: 
22 0023 
23 0026 
24 0/.1.79 
25 0024 
26 0483 
27 0494· 
28 04·78 
29 0456 
lGleneagles Hospital Limited 
14 Napier Road, Singapore 1025 
!Guardian Pharmacy 
1176 Orchard Road #B1-05 
lCentrepoint, Singapore 0923 
!Guardian Pharmacy 
1223 Holland Avenue #01-05 
!Singapore 1027 
lGuardian Pharmacy 
1293 Holland Road #02-12 
lCold Storage Jelita, Singapore 1027: 
Priscilla Toh Pui Chun 
<Mrs> 
Chow Wai Lin CMs) 
Low Hui San <Ms> 
Rufina Lim Chin Hing 
(!"is) 
!Guardian Pharmacy : Ruth Lee Choo Ai <Ms> 
124 Amber Close,. Level 1 
ICold Storage Katong, Singapore 15431 
!Guardian Pharmacy 
13 Mount Elizabeth Road #02-10/12 
!Singapore 0922 
!Guardian Pharmacy 
1300 Orchard Road #B-02 
lThe Promenade, Singapore 0923 
:Guardian Pharmacy 
124 Raffles Place #02-22 
lClifford Centre? Singapore 0104 
Tan Chew Eng CMs) 
Chin Mee Fong <Ms) 
Corrie Koo nee 
Li~w Mei Ling !Mrs) 
1st January 1988 
1st JanLlary 1988 
1st January 1988 
1st January 1988 
lst January 1988 
1st January 1988 
:J.st J anLlary 1988 
1st January 1988 
+---------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975) 
Appendix 7 
In pursuan~e of Regulation 6 <2> of the Medicines <Pharmacy Registration> Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
l Serial 
No 
:Certificate I 
No Name & Address of Pharmacy Pharmacist-In-Charge !Date of Registration: 
:---------~------------~-----------------------------------:-------------------------:--------------------~ 
30 0028 
31 0477 
32 0476 
33 04·81 
34· 0482 
35 0025 
36 0489 
!Guardian Pharmacy 
166 Serangoon Garden Way 
:Singapore 1955 
:Guardian Pharmacy 
180 Marine Parade Road, #Bl-31/33 
!Parkway Parade, Singapore 1544 
\Guardian Pharmacy 
lChangi Airport #B11-43A 
ICar Park Link Tunnel, 
!Singapore 1781 
:Guardian Pharmacy 
:Departure Transit Lounge #021-22 
!Changi Airport, Singapore 1781 
:Guardian Pharmacy 
lBlock 192, Lorong 4 
IToa Payoh #01-674, Singapore 1231 
:Guardian Pharmacy 
1111 North Bridge Road #03-09 
:Peninsula Plaza, Singapore 0617 
!Guardian Pharmacy 
1304 Orchard Road #Bl-05 
lLucky Plaza, Singapore 0923 
Ong Seck Peng CMs) 
Mega Tianadi <Msl 
Saw Pik Kee <Ms) 
Lim 1'1eng Lee 
Heng Siew Ngin (Ms> 
Bharati Ramakrishnan 
<Ms> 
Sit Bee Teen <Ms> 
1st Jar11.1ar·y 1988 
1st January 1988 
1st January 1988 
1st cianua,~y 1.988 
1st J an1.1ar·y 1988 
1st January 1988 
1st January 1988 
+--------------------------------------------·--------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975> 
Appendix 8 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------~-----------------------------------------------------+ 
l Serial l CertiT i cate I 
No l No l Name & Address of Pharmacy i Pharmacist-Irl-Charge lDate of Registration: 
:---------t------------~-----------------------------------~-------------------------~--------------------·~ 
37 0488 
38 0486 
39 0500 
40 0487 
41 0485 
42 0484 
43 0020 
!Guardian Pharmacy 
1252 North Bridge Road #03-09 
lRaffles City Shopping Centre 
!Singapore 0617 
:Guardian Pharmacy 
11 Maritime Square #01-43/44 
!Singapore 0409 
:Guardian Pharmacy 
168 Orchard Road #02-35 
lPlaza Singapore, Singapore 0923 
:Guardian Pharmacy 
1176 Orchard Road #03-11 
lCentrepoint, Singapore 0923 
!Guardian Pharmacy 
11 Claymore Drive #01-08/09 
lOrchard Towers, Singapore 0922 
!Guardian Pharmacy 
1190 Middle Road #01-02 
!Fortune Centre, Singapore 0718 
:Guardian Pharmacy 
119 Tanglin Road 101-1~ 
lTanglin Shopping Centre? 
!Singapore 1024 
Dorothy Sim nee lst January 1988 
Chew Seok Ghee <Mrs) 
K'ng Lay Hoon <Ms> 1st January 1988 
Lee Chay Nghee <Ms> 1st January 1988 
Kwah Peng Muay <Msl 1st Je:1.nuary 1988 
Ho Swee Geok <Ms> 1. st J anLlary 1988 
Chang Siaw Bing <Ms> 1st January 1988 
Yo11g l<am Seng 1st Januar·y 1988 
+----------------------------------------------~----------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975> 
Appendix 9 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration) Regulations, 1981 1 the 
following list of Pharmacies in Singapore registere~ under the said Regulations for the year 1988, 
is published for general information:-
+-----------------------------------------------------------·----------------------------------------------+ 
: Serial :certificate : 
No l No : Name & Address of Pharmacy : Pharmacist-In-Charge !Date of Registration: 
:---------:------------:-----------------------------------:-------------------------:--------------------: 
44 0018 
45 0031 
46 0034 
47 0011 
48 0004 
49 0429 
50 0005 
!Guardian Pharmacy 
12450 Ang Mo Kio Avenue 8 #01-01 
lAng Mo Kio MRT Station 
!Singapore 2056 
:Guardian Pharmacy 
11 Park Road #01-60 
!People's Park Complex 
!Singapore 0105 
!Guardian Pharmacy 
1301 Upper Thomson Road #01-24 
!Thomson Plaza, Singapore 2057 
Tina Choo Kuei Ting 
<Mrs) 
Tan Seng Cheong 
' Ngoi Ming Li <Ms) 
!International Dispensary Pte Ltd I David Boen 
l4-6 Hill Street, Singapore 0617 
!Japanese Association Clinic, S'porel Chow Hsun Cheng CMs> 
1120 Adam Road, Singapore 1128 
'John Little Pte Ltd I Low Giat Ling <Ms> 
277 Orchard Road #01-00 
Specialists' Centre, Singapore 09231 
Jurong Hospital Pte Ltd 
235 Corporation Drive 
Singapore 2261 
Chan Ah Lui nee Tee 
<Mrs> 
27th January 1988 
' 4th 1'1arch 1988 
10th March 1988 
1st January 1988 
1st. January 1988 
1st January 1987 
l.st January 1988 
+---------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975> 
Appendix 10 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration> Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is publi.hed for general information:-
+----------------------------------------------------------------------------------------------------------+ 
Sed al I Certi f i c:ate I 
No : No : Name & Address of Pharmacy : Pharmacist-In-Charge IDate of Registration: 
---------l------------:-----------------------------------:-------------------------:---------------------: 
51 0449 
52 0021 
53 0003 
54 0002 
55 0030 
t:'• ;;JO 0013 
57 0012 
Kimisawa Pharmacy : Moey Siew Peng CMs> 
435 Orchard Road #Bl-01 
Wisma Atria, Singapore 0923 
Liang Court Pharmcy Pte Ltd : Quah Sin Phay 
177 River Va~ley Road #03-35/36 
:Liang Court Complex, Singapore 0617' 
!Majesty Pharmacy : Liew Lee Ching <Ms> 
:Block 86, Marine Parade Central 
l#Ol-670, Singapore 1544 
:Medical Hall 
:9 Battery Road #01-15/16 
:Straits Trading Building 
:Singapore 0104 
:Medical Hall 
l#Bl-14, Dhoby Ghaut MRT Station 
:Singapore 0923 
lMedichem Pharmacy 
:1 Raffles Plac:e #81-12 
IOUB Centre, Singapore 0104 
:Mount Alvernia Hospital 
:820 Thomson Road, Singapore 2057 
Low Kam Fon <Ms> 
Wong Kwai Fong CMs> 
Yoon Lay Hwee nee 
Chua <Mrs> 
Looi Cheng Kui <Ms> 
1st January 1988 
1st Januc:\ry l.988 
1st January 1988 
1st January 1988 
lst MaJ~ch 1988 
1st January 1988 
1st January 1988 
+-----------------------------------------------------~-----------------------------------------------·-----+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 19751 
Appendix 11 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration> Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
l Serial !Certificate l 
No ! No I Name & Address of Pharmacy ! Pharmacist-In-Charge :Date of Registration: 
l---------:------------i-----------------------------------~-------------------------!--·------------------~ 
58 
59 
60 
61 
62 
63 
I 
-' 
0007 
0008 
0001 
0499 
0495 
0442 
!Mount Elizabeth Hospital Limited 
l3 Mount Elizabeth, Singapore 0922 
!Mount Elizabeth Hospital Ltd 
l3 Mount Elizabeth #02-09 
!Singapore 0922 
lMun Dispensary Private Limited 
!442-444 North Bridge Road 
!Singapore 0718 
!National University Hospital 
!Pte Ltd 
13 Lower Kent Ridge Road 
!Service Block, Singapore 0511 
!National University Hospital 
!Pte Ltd 
:5 Lower Kent Ridge Road 
!Main Block, Singapore 0511 
!Orchard Pharmacy Private Limited 
!400 Orchard Road #03-24 
lOr· chard Towers, Singapore 0923 
Chen L.::1i Fun nee Lee 
<lvlrs l 
Wu Siew See <Msl 
Au f<\-Jak Chun 
Li ak Teng Lit 
Lim i'1Ltn i"'oon 
Agnes Tan Pah Chon <Msl 
1 s'l: J anua1~y. 1988 
1st January 1988 
1st January 1988 
1st January 1988 
lst JarlL\ary 1988 
1st January 1988 
64 : 0436 lP Govindasamy Pillai <S> Pte Ltd l Mercy Rodrigues <Msl l 1st January 1988 
150 Serangoon Road, Singapore 0821 
+---------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
(ACT 52 OF 1975) 
Appendix 12 
In pursuance of Regulation 6 (2) of the Medicines (Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
I Serial :certificate I : I 
: No : No : Name & Address of Pharmacy i Pharmacist-In-Charge !Date of Registration! 
l---------1-----~------l------------~----------------------:-------------------------:--------------------l 
+---------------------------------------------------------------------------------------------------------+ 
I 
I. 
I 
65 0440 
66 0015 
67 0444 
68 0441 
69 I 0497 I 
I 
70 I 0017 I 
!Pan-Malayan Pharmacy Private Ltd 
150 Jalan Sultan #02-11/12 & 28/29 
:singapore 0719 
IPharmed Import & Export Pte Ltd 
1149 Rochor Road #81-17 
IFu Lu Shou Complex, Singapore 0718 
!Prime Pharmacy Pte Ltd 
180 Marine Parade Road #81-74 
!Parkway Parade, Singapore 1544 
iPrince Pharmacy 
:1 Park Road, #01-77 
!People's Park Complex 
!Singapore 0105 
!Princeton Pharmacy (S) 
20 Bideford Road #01-02 
Pte Ltd I I 
,Wellington Building, Singapore 09221 
!Regent Pharmacy Pte Ltd I I 
304 Orchard Road #06-51 
Lucky Plaza, Singapore 0923 
Tay Teng Pin 1st January 1988 
Lai Hwei Ching (Ms) 1st January 1988 
Lim Siew Chin (Ms) 1st January 1988 
Tan Kee Guan (Ms) 1st January 1988 
Tan Ah Bee I 1st January 1988 I 
Philip Poon Kin Chye I 1st January 1988 I 
71 : 0445 !Robinson & Co Pte Ltd : Koh Kay Seng : 1st January 1988 
1176 Orchard Road #01-14/17 
:centrepoint, Singapore 0922 
+-----------------------------------------------~---------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
(ACT 52 OF 1975) 
Appendix 13 
In pursuance of Regulation 6 (2) of the Medicines (Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
1 Serial :certificate I 
No I No Name & Address of Pharmacy Pharmacist-In-Charge IDate of Registration: 
I---------l------------l-----------------------------------1-------------------------l--------------------: 
+---------------------------------------------------------------------------------------------------------+ 
72 0469 
73 0443 
74 0434 
75 0435 
76 .0433 
77 0438 
78 0437 
ISatim Pharmacare 
163 Robinson Road #01-02 
lAfro Asia Building, Singapore 0106 
:Shenton Pharmacy 
13 Shenton Way #02-15 
Shenton House, Singapore 0106 
Simedsu Pharmacy 
190 Middle Road #01-09 
Fortune Centre, Singapore 0718 
Sincere Dispensary Pte Ltd 
10-12 Hill Street, Singapore 0617 
Singapore Pharmaceutical Pte Ltd 
Block 433, Clementi Avenue 3 
#01-248, Singapore 0512 
Somedico Pte Ltd 
Block 163, Bukit Merah Central 
#03-3583/5, Singapore 0315 
lSomedico Pharmacy Pte Ltd 
!Singapore General Hospital 
!Block 4, Level 1, Unit 41-02 
:singapore 0316 
Rohana Hussain (Ms) I 1st January 1988 
Chang-Tan Nai Keow iMrsi I 1st January 1988 
Ho Teck Swee l 1st January 1988 
Yeo Koon Kim 1st Januar:y 1988 
Wee Keng Boon 1st January 1988 
Ng Yew Mun 1st January 1988 
!Chang Sok Keng (Ms) 1st January 1988 
+---------------------------------------------------------------------------------------------------------~ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 5.2 OF 1975> 
Appendix 14 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration> Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+-----------------------------------------------------------------------------------------------------------+ 
l Serial :certificate : 
No : No : Name • Address of Pharmacy : Pharmacist-In-Charge lDate of Registration: 
:---------~------------r-----------------------------------:-------------------------:--------------------: 79 046.2 
: . 
80 0467 
81 0468 
82 0498 
83 0029 
:somedico Pharmacy Pte Ltd 
168 Orchard Road #B1-02 
lYaohan Supermarket, Plaza Singapore: 
:Singapore 0923 
lSomedico Pharmacy Pte Ltd 
:301, Upper Thomson r·oad #01-01 
lTh~mson Plaza, Singapore 2057 
lSomedico Pharmacy Pte Ltd 
15 Lower Kent Ridge Road #01-15 
:National University Hospital 
:Singapore 0511 
lSomedico Pharmacy Pte Ltd 
:1 Yuan Ching Road 
lYaohan Supermarket CJurong> 
'Singapore .2261 
. 
Somedico Pharmacy Pte Ltd 
Outram Road #B1-01 
Outram MRT Station, Singapore 0316 
Tian Ai Kian <Ms> 1st January 1988 
Leng Yew Fei 1st January 1988 
Lim Shiu Chin <Ms> 1st January 1988 
Lim Sen Too 1st J am.tary 1988 
Chan Woon Seong 1st February 1988 
84 : 0461 :Supreme Chemist Pte Ltd l Tan Mui Chai CMs> : 1st January 1988 
9 Penang Road #01-07/08/09 
Supreme House, Singapore 09.23 
I 
·' 
+-----------------------------------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
{ACT 52 OF 1975) 
Appendix 15 
In pursuance of Regulation 6 {2) of the Medicines (Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
i Serial :certificate : 
No : No Name & Address of Pharmacy Pharmacist-In-Charge :nate of Registration: 
1---------l-----~------l-----------------------------------:-------------------------:--------------------l 
+---------------------------------------------------------------------------------------------------------+ 
85 i 0460 !Supreme Chemist Pte Ltd i Koh Poh Heo nee Wee i 1st January 1988 
86 0464 
87 0463 
88 0465 
89 0466 
90 0452 
91 0453 
11 Sophia Road #01-35 i {Mrs) 
IPeace Centre, Singapore 0922 
i 
!Supreme Chemist Pte Ltd 
114 Scotts Road #05-89 
!Far East Plaza, Singapore 0922 
lTanglin Pharmacy Pte Ltd 
119 Tanglin Road #03-33 
lTanglin Shopping Centre 
lSingapore 1024 
lThe Pharmacy Private Limited 
ll Scotts Road #03-25 
!Shaw Centre, Singapore 0922. 
!The Pharmacy Private Limited 
130 Robinson Road #07-03 
lTuan Sing Towers, Singapore 0104 
lThomson Medical Centre Pte Ltd 
l339 Thomson Road, Singapore 1130 
!Tong Hin Pharmacy 
1295 South Bridge Road, 
:singapore 0105 
Wong Moei Far (Ms) 
Foong Weng Hon 
George Tung Kooi Yoon 
Ng Ser Hock 
Lim Kok Wah alias 
Lim Kok Hwa 
Lau Kieng Poh 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
1st January 1988 
~-------------------------.--------------------------------------------------------------------------------+ 
Source : Singapore Government Gazette 15th April 1988 
THE MEDIClNES ACT, 1975. 
<ACT 52 OF 1975) 
Appendix 16 
In pursuance of Regulation 6 <2) of the Medicine~ <Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988, 
is published for general information:-
+---------------------------------------------------------------------------------------------------------+ 
: Serial !Certificate l 
No : No : Name & Address of Pharmacy : Pharmacist-In-Charge !Date of Registration: 
:---------:------------:-----------------------------------:-------------------------:--------------------: 
92 O.l!54 
93 0432 
94 0.o.l57 
95 04-93 
96 0033 
97 0451 
!Tong Keng Hong Drug Store 
!11 Collyer Quay #01-21 
lThe Arcade, Singapore 0104 
!Waltons Pharmacy Pte Ltd 
l435, orchard Road #Bl-23 
!Wisma Atria, Singapore 0923 
!Waltons Pharmacy Pte Ltd 
!510 Lorong 6 #Bl-01 
'Tea Payoh MRT Station 
Singapore 1231 
Waltons Pharmacy Pte Ltd 
5 Raffles Place #Bl-37 
Raffles Place MRT Station 
Singapore 0104 
!Waltons Pharmacy Pta Ltd 
1146 Market Street #01-11 
!Singapore 0104 
lWei Fun Sheong Tim 
!150 South Bridge Road #81-12/14 
!Fock Hai Building, Singapore 0105 
T.:m Tek Seng lst .Jt.~nuary 1988 
Si aLl Tew F'hang 12th January 1988 
Yeo Soc:l Lam <Ms) 1st JanLtar·y 1988 
Pr1g Yong l<c.1h 1st Jc:;nLtary :1.988 
Wong Yiam Moi <Ms> 1st January 1988 
Lam Poh Yin nee Ng CMrs> ist .:Jc::nu.::tr·y 1988 
+---------------------------------------------------------------------------------------------------------+ 
Source Singapore Government Gazette 15th April 1988 
THE MEDICINES ACT, 1975. 
<ACT 52 OF 1975) 
Appendix 17 
In pursuance of Regulation 6 <2> of the Medicines <Pharmacy Registration) Regulations, 1981, the 
following list of Pharmacies in Singapore registered under the said Regulations for the year 1988~ 
is published for gene~al information:-
+----------------------i----------------------------------------------------------------------------------+ 
I S • 1 I c t • f • t !\ I 1 l 1 er 1 a 1 er 1 1 c a e 1 
1 
1 1 1 
: No : No ·r Name & Address of Pharmacy : Pharmacist-In-Charge !Date of Registration: 
~---------:------------:-----------------------------------:-------------------------:--------------------: 
98 04-55 :Youngberg Memorial Adventist 
:Hospital 
!309 Upper Serangoon Rood 
!Singapore 1334 
Teo Boon Lie 1st January 1988 
+---------------------------------------------------------------------------------------------------------+ 
Singapore. 14th March 1988 CMH. CHQ)) 36:04/6) 
Source Singapore Government Gazette 15th April 1988 
Dr. Kwa Soon Bee 
Permanent Secretary <Health)/ 
Director of Medical Services, 
Ministry of Health 
Singapore 
UTILIZATION OF GOVERNMENT HEt':iL TH SERVICES 
1980 ' 1984-1986 
Hospital Admi ssi or1 
Hospital Specialist Clinic Attendance 
Accident & Emergency Attendance 
Primary Health Care Attendance 
Dental Clinic Attendance 
1980 
97. 1 
528 .. 3 
156 .. 2 
1660.5 
454.9 
Source : Ministry of Health Singapore, Annual Report 1986 
Appendix 18 
Rate per 1000 Population 
1984 1985 1986 
91.0 89.9 85. 4· 
483.5 478.0 449.8 
185.6 171.3 J.41.5 
1294.:-2 1234- .. .o."f :l231 .. 0 
448.1 455. 1 450.7 
SINGAPORE POPULATION AND VITAL STATAISTICS Append i >' :l. 9 
---------------------------------------------------------------------------------------------------------------
NATURAL LIVE- STILL- INFANT NEONATAL PERINATAL MATERNAL. 
YEAR POPULATION INCREASE BIRTHS DEATHS BIRTHS MORTALITY MORTALITY MORTALITY MORTALITY 
--------------------------------------------------------·-------------------------------------------------------
NUMBERS 
1950 1, 022' 100 34,059 46,371 12,312 807 3,813 1,383 1,668 86 
1960 1,646,400 51' 565 61 '775 10,210 886 2,158 1,093 1 '747 28 
1970 2,074,507 35,217 45,934 10,717 451 942 671 998 15 
1980 2,413' 94·5 28,712 41,217 12,505 264 483 366 556 2 
1984 2,529,100 28,394 41 '556 13' 162 243 365 256 435 5 
1985 2,558,000 29' 136 42,484 13,348 227 394 297 461 2 
1986* 2,586,200 26,579 39,400 12,821 201 359 248 394 2 
RATE OF 
GROWTH ('iO Rate per· 1000 
1950 4·. 4 33.4 45.4 12.0 17. l. 82n2 29.8 35.4 1..8 
1.960 3u5 31.3 37 .. 5 6.2 14. 1 34.9 17.7 27.9 0.4 
].970 1.7 17.0 22.1 5.2 9.7 20.5 14.6 21.5 0.3 
1980 1.2 11.9 17. 1 5.2 6.4 11.7 8.9 1.3. 4 0 
1984· 1.1 11.2 16.4 5.2 5.8 8.8 6.2 10.4 (J. 1 
1985 1.1 11.4 16.6 5.2 5 .. 3 9.3 7.0 10.8 0 
1986* 1. 1. 10.3 15.2 5.0 5. 1 9. 1 6.3 9.9 o. 1 
•Preliminary figure 
* Source : Ministry of Health Singapore, Annual Report 1986 
GOVERNMENT HOSPITAL ADMISSIONS, 1980, 1984-1986 
Hospital 1980 1981.1· 1985 1986 
Singapore General Hospital 58,637 62,310 64,982 65,473 
Tan Tcck Seng Hospital 37,680 38,459 42,987 45,475 
Alexandra Hospital 34,841 33,898 33,255 30,930 
Tea Payoh Hospital 31,937 29,925 29,477 28,070 
Changi Hospital 4,11:::.~ 3,4·66 3,755 L'l' 157 
Sembawang Hospital + 1,076 
Kandang Kerbau Hospital 53,437 48,436 48,442 39,620 
Middle Road Hospital 682 887 738 767 
Middleton Hospital* 6,066 6,587 
Trafalgar Hospital ++ 162 
St. Andrew's Hospital 192 17'-i· 124 158 
Woodbridge Hospital 5,576 5,828 6,056 5?959 
View Road Hospital 103 168 179 130 
Total 234,502 230' 138 229,995 220,739 
+ Closed wef 31.3.83 
* Renamed Communicable Disease Centre and came under the administration 
of Tan Tock Seng Hospital wef 1.1.85 
++ Came under the administration of Woodbridge Hospital wef 1.1.83 
* Source : 'Hinistry of Health Singapore, hmual Report 1986 
Appendix 20 
PATIENTS DISCHARGED FROM GOVERNMENT HOSPITALS 
BY SPECIALITY, 1980, 1984-1986 
Speciality 
General Medicine 
General Surgery 
Obstetrics 
Gynaecology 
Paediatrics 
Neonatology 
Paediatric Surgery 
Orthopaedic Surgery 
Infectious Diseases 
Psychological Medicine 
Psychiatric Medicine 
Renal Medicine 
Neuro-Surgery 
Neurology 
Ophthalmology 
Otorhinolaryngology 
Plastic & Reconstructive Surgery/Burns 
1980 1984 
53,802 50,467 
43,472 39,808 
39,267 37,289 
23,126 16,623 
18,218 17,691 
15,441 15,399 
2,476 
12,919 16' 184 
7' 171 7,315 
5,563 5,914 
865 
3,391 2,732 
737 702 
3,427 3,749 
1,498 3,787 
1,636 1,968 
* Source : Ministry of Health Singapore, Annual Report 1986 
Appendix 21 
1985 1986 
52,031 51,629 
40,457 40,589 
36,435 29,058 
15,637 15,053 
17,064 1.6,800 
15,558 12,685 
2,512 2,657 
16,289 16,887 
3,854 2,958 
96 
6,019 5,781 
933 1,052 
3,315 3,675 
730 699 
4,501 5,859 
4,331 4,349 
1,729 l. ,649 
Append±x 22 
GOVERNMENT HOSPITAL, ADMISSION RATE BY AGE AND SEX, 1985* 
Rate per 1000 population 
Age Male Female Total 
---------------------------------------------------------------
0 - 4 165.5 135.3 151.0 
5 - 9 42.0 27.3 35.0 
10 - 14 34.3 21.1 27.9 
15 - 19 54.6 44.8 49.8 
20 - 24 62.4 121.5 91.1 
25 - 29 57.4 163.0 108.6 
30 - 34 54.5 119.6 86.4 
35 - 39 56.7 79.6 68.0 
40 - 44 63.5 66.7 65.1 
45 - 49 76.7 75.2 76.0 
50 - 54 106.3 85.0 . 95.8 
55 - 59 129.8 92.7 111.7 
60 - 64 159.9 114.1 137.3 
65 - 69 203.4 143.8 172.5 
70 + 364.4 230.7 287.5 
Total 82.4 97.7 89.9 
* 1986 figures not available at the time of printing 
Source : Ministry of Health Singapore, Annual report 1986. 
Appendix 23 
LIST OF PHARMACIES IN MALAYSIA 
+------------------------------------------------------------------------------------------------------------+ 
+---------------------------------------------~-------------------------------------------------------------+ 
Jan Pharmacy : Jecki Medical Supplies Sdn Bhd : Alpha Pharmacy Sdn Bhd 
123 Jalan Sultan Iskandar : 2 lot 9 Block A Ground Floor : Lot 8 Block C kompleks Sentosa 
Ipoh, Perak : komplek Sentosa, Jalan Sutera : No 2 Jalan Sutera Dua, 
Taman Sentosa 80150 Johor Baru, : Taman Sentosa 
Johor : 80150 Johor Baru, Johor 
-----------------------------------·-----------------------------------:-----------------------------------
Ang Pharmacy 
78 Jalan Gelangang 
Mel aka 
Pharmacist : Mr Ang Luan Tak 
Apex Pharmacy 
83-A Jalan Munshi Abdullah 
75100 Melaka 
Pharmacist : Mr Lau Chow Ling 
People's Pharmacy 
5961 Jalan Bendahara P 0 Box 123 
Malacca 
Pharmacist : Mr Chong Ngiap Lye 
:-----------------------------------:-----------------------------------:-----------------------------------: 
Sentosa Pharmacy Sdn Bhd 
122 Jalan Serampang 
Taman Pelangi, 80050 Johor Baru 
Interpharm <M> Sdn Bhd 
Lot 47 TAR kompleks 
Jalan Ah Fook, 80000 Johor Baru 
Negri Pharmacy 
42 Jalan Date Sheikh Ahmad 
70000 Seremban, Negeri Sembilan 
Pharmacist : Mrs koh kian Tee I : Pharmacist : Ms Angeline Lee 
:-----------------------------------:-----------------~-----------------:-----------------------------------: 
Apex Pharmacy Sdn Bhd 
Lot 18-19 TAR kompleks 
Jalan Ah Fook, 80000 Johor Baru 
Pharmacist : Ms Hen Hong Wah 
Farmasi Kluang 
23 Jalan Datuk Tech Siew khor 
kluang, Johor 
Pharmacist : Mr Bernard Lee 
Peninsular Pharmacy 
Plaza Peninsular Shopping Complex 
160 Jalan Templer, Seremban 
Pharmacist : Mr Cheah Eng Shin 
:-----------------------------------:-----------------------------------:-----------------------------------: 
Apex Pharmacy Sdn Bhd 
7 Jalan Mohd Akil 
Batu Pahat, Johor 
Pharmacist : Mr Tan Chin Yau 
Public Pharmacy 
Lot 2.56 Tingkat 2 Wisma Punca 
Emas, Jalan Dato Sheikh Ahmad 
70000 Seremban 
Pharmacist : Mr Chee Swee Leong 
Life Pharmacy 
427 Jalan Date Abd Rahman 
70000 Seremban, Negeri Sembilan 
Pharmacist : Mr Allan Chong 
+-----------------------------------------------------------------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
Appendix 24 
LIST OF PHARMACIES IN MALAYSIA 
+-----------------------------------------------------------------------------------------------------------+ 
Hew Pharmacy l Victory Pharmacy l Apex Pharmacy CKelantan) Sdn Bhd 
No 48/49 Birch Road : 491 Jalan Hilir Market l 789-J, Jalan Gajah Mati 
Seremban, Negeri Sembilan : 15000 Kota Bharu, Kelantan : Kota Bharu, Kelantan 
Pharmacist : Mr Hew Kiang Hean Pharmacist : Ms Susan Tan Pharmacist : Mr Wee Tiang Kiang 
i-----------------------------------:---------------------------------~-~-----------------------------------t 
Lim Medical Supplies 
95 Jalan Banggol, Jalan Terengganul 
20100 Kuala Trengganu, Trengganu 
Pharmacist : Mr Chuah 
Dewma Farmasi 
Lot 120 Wisma Suara Muda 
Jalan Suara Muda, Kota Bahru 
Pharmacist : En Zuekamaini Ismail 
Pahang Pharmacy Sdn Bhd 
51 Jalan Teluk Sesek 
25000 Kuantan, Pahang 
Pharmacist : Mr Lim Chee Beng 
:-----------------------------------:-----------------------------------:-----------------------------------: 
Naina Mohd & Sons 
No 1 Medan Pasar 
56050 Kuala Lumpur 
Pharmacist : Mr Selvamani 
Salim CM> Sdn Bhd 
No 14 Jalan Hang Kasturi 
50050 Kuala Lumpur 
Pharmacist : Ms Khor Siew Huey 
Hew Pharmacy CM> Sdn Bhd 
No 20 Medan Pasar 
50050 Kuala Lumpur 
Pharmacist : Mr Hew Kiang Hoe 
!-----------------------------------t-----------------------------------·~-----------------------·------------1 
S M Sathar Pharmacy 
Shoplot 12A Ground Floor 
Straits Trading Building 
4 Leboh Pasar Besar 
50050 Kuala Lumpur 
Pharmacist : Mrs Kamalia bte Saman: 
Ideal Pharmacy 
36 Jalan Masjid India 
Kuala Lumpur 
Pharmacist : Ms K Wong 
Sri Suyan Sdn Bhd 
59 Jalan 2/90 Taman Pertama 
3 1/2 Miles, Jalan Cheras 
Kuala Lumpur 
Pharmacist : Ms Beh Siew Joo 
:-----------------------------------1-----------------------------------!-----------------------------------
Pantai Medical Centre 
Jalan Bukit Pantai 
Kuala Lumpur 
Pharmacist : Ms Lee Seng Dee 
M S Ally Sdn Bhd 
89 Jalan Bandar 
50000 Kuala Lumpur 
Pharmacist : En ABdul Jadi 
Subang Farmasi Sdn Bhd 
58 Jalan 15/48 
Subang Jaya~ Selangor 
Pharmacist : Mr S Kanesin 
+-----------------------------------------------------------------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
Appendix 25 
LIST OF PHARMACIES IN MALAYSIA 
+-----------------------------------------------------------------------------------------------------------+ 
Wan Medical Supplies l Eastern Pharmacy CM> Sdn Bhd l Himalaya Medical Hall 
62 Leech Street l 72 Theatre Street l 83 Jalan Sultan Idris Shah 
30000 Ipoh, Perak l Ipoh, Perak l 30000 Ipoh, Perak 
Pharmacist : Mr Govindan Joseph Pharmacist : Mr Tan Ah Kee 
:-----------------------------------1-----------------------------------l-----------------------------------: 
Georgetown Holdings Bhd 
Jalan Steser1 
Ipoh, Perak 
Pharmacist : Mr Keh Ghee Sing 
Poh Teik Medical Hall 
78 Jalan Besar 
Taiping, Perak 
Pharmacist : Mr Beh Thian Teik 
Apex Pharmacy 
Lot 11,12 & 13 Kemp Yik Foong 
Jalan Laksamana, Ipoh, Perak 
Pharmacist : Mr Lim Chui Peng 
l-----------------------------------:-----------------------------------:-----------------------------------i 
Ting Pharmac:y 
Lot 319 Wisma Ganda 
Sitiawan, Perak 
Pharmacist : Mr Ting Kong Hing 
l Hovid Pharmac:y 
1 Treacher Street 
Ipoh, Perak 
Pharmacist : Mr Tan Teik Pin 
Public Medical Supplies 
495 Jalan Pasir Puteh 
31650 Ipch, Perak 
Pharmacist : Mr Liew Nyuk Cheong 
:-----------------------------------i----------·------·-------------------l-----------------------------------: 
United Pharmacy 
24 & 24A Tingkat Enam, Ipoh 11 
Taman Ipoh Selatan, Ipoh, Perak 
Pharmacist : Mr Wong Yew Choon 
Kinta Pharmacy 
6 Theatre Street 
Ipoh, Perak 
Pharmacist : Mr Au Yoke Fong 
Fatimah Hospital 
Jalan Date Lau Pak Khuan 
Ipoh Garden, Ipoh, Perak 
Pharmacist : Mr Ang Swee Siew 
i-----------------------------------:-----------------------------------:------------------------------------~ 
Guardian Pharmacy 
Ipoh Garden Plaza, Jalan Tasek 
Ipoh, Perak 
Quinpharm (M) Sdn Bhd 
35 Jalan Theatre 
30300 Ipoh, Perak 
Pharmacist : Ms Angeli Lau Sou Funl Pharmacist : Mr Yeong Lai Yeng 
Apex Pharmacy Sdn Bhd 
377-A Taman Peringgit Jaya 
Mel aka 
Pharmacist : Mr Lim Hang Char 
+------------------------------------------------------------------------------------------------------------+ 
Source Johnson & Johnson Malaysia 
Appendix 26 
LIST OF PHARMACIES IN MALAYSIA 
+---------------------------------------------------------------------~--------------------------------------+ 
Apex Pharmacy <EM) Sdn Bhd l Herk Chung Pharmacy l Apotik Bina Pharmacy 
No 2 Electra House P 0 Box 1055 : No 10 Ban Hock Lane P 0 Box 2688 l 157F Jalan Satok 
93722 Kuching, Sarawak l 93752 Kuching, Sarawak l 93400 Kuching, Sarawak 
Pharmacist : Ms Annie Law Pharmacist : Mr Andrew Liew Pharmacist : Mr Shahari Alias 
:-----------------------------------:-----------------------------------:-----------------------------------~ 
Bath Pharmacy Sdn Bhd 
49 Carpenter Street 
l<uc:hing, Sarawak 
Pharmacist : Mr Wong Sie Sing 
A & C Pharmacy & Lab Sdn Bhd 
25 Padungan Road P 0 Box 2181 
Kuc:hing, Sarawak 
Pharmacist : Ms Kok Hiaw Jin 
United Medical Hall (1979) Sdn Bhdl 
54 Jalan Kampong Nyabar 
96000 Sibu, Sarawak 
Pharmacist : Mr Wong Siong Chiik 
Ms Chai Joon Hiong 
~-----------------------------------1----------------~------------------:-----------------------------------: 
Central Pharmacy Sdn Bhd 
No 024 Sarawak House 
96000 Sibu, Sarawak 
Pharmacist : Mr Chua Toh Jan 
B Y Chan Pharmacy 
29 Jalan Maju P 0 Box 774 
96000 Sibu, Sarawak 
Pharmacist : Mr B Y Chan 
The New Asiatic: Co 
No 1 Channel Road P 0 Box 122 
Si b1..t, Sarawak 
Pharmacist : Mr Steven Kung 
:--------------------·---------------:-----------------------------------:------------------------------------~ 
Min Kang Pharmacy Sdn Bhd 
No 18 Main Bazaar 
97000 Bintulu, Sarawak 
Pharmacist : Mr Vincent Ng 
Miri Pharmacy Sdn Bhd 
16 China Street P 0 Box 449 
98007 Miri, Sa~~wak 
Pharmacist : Ms Annapurna Sengupta: 
Moh Heng Pharmacy Sdn Bhd 
14-A River Road P 0 Box 53 
98007 Miri, Sarawak 
Pharmacist : Ms Sim Ling Ling 
:-----------------------------------1------------------~----------------l-----------------------------------~ 
Ho Dispensary Sdn Bhd 
255A Penang Road 
10000 Penang 
Pharmacist : Mr Ng Ark Yeow 
Naina Mohd & Sons 
12 Beach Road 
Penang 
Pharmacist : Ms Kok Sup Mooi 
Georgetown Dispensary 
39 Beach Street 
Penang 
Pharmacist : Mr Lee Song Hin 
+-----------------------------------------------------------------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
Appendix 27 
LIST OF PHARMACIES IN MALAYSIA 
+-----------------------------------------------------------------------------------------------------------+ 
Fleming Farmasi l Apex Pharmacy Sdn Bhd : Babycare Pharmacy Sdn Bhd 
Lot 1.36 Kompleks Wilayah l 17 Ground Floor, Bangunan Abas Hohl 34 Jalan SS 22/25, Damansara 
Jalan Campbell, Kuala Lumpur l Jalan Barat, Petaling Jaya : Jaya, 47400 Petaling Jaya 
Pharmacist : Ms Thian Peng Pharmacist : Ms Wong Li Choo Pharmacist : Ms Lim Siang Loci 
:-----------------------------------1-----------------------------------:-----------------------------------: 
Guardian Pharmacy <M> Sdn Bhd 
Ground Floor Yow Chuan Plaza 
Jalan Pekeliling, Kuala Lumpur 
Pharmacist : Ms Aileen Chong 
Georgetown Dispensary Bhd 
31 Jalan SS 2/75 
47300 Petaling Jaya 
Pharmacist : Mr Kuan 
Lee Farmasi & Baby Centre Sdn Bhd 
5 Lorang Raja Hassan 
Kelang 
Pharmacist : Ms Chong Chu Li 
~-----------------------------------:-----------------------------------:-----------------------------------: 
' City Chemist Sdn Bhd 
144 Ground Floor, Ampang Park 
Shopping Centre, Jalan Ampang 
Kuala Lumpur 
Pharmacist : Ms Chow Sow Kuen 
Butterworth Pharmacy Sdn Bhd 
4709 Bagan Luar Road 
12000 Butterworth 
Province Wellesley 
Farmasi Wangsa 
12 Persiaran Ampang 
55000 Kuala Lumpur 
+------------~---------------------------------------------------------------------------·-------------------+ 
Source Johnson & Johnson Malaysia 
Appendix 28 
LIST OF PHARMACIES IN MALAYSIA 
+----------------------------------·--------------------------------------------------------------------------+ 
Guardian Pharmacy l Apex Pharmacy CJ) Sdn Bhd l Bukit Mertajam Pharmacy 
Guardian Central Purchasing l Lot 18-19 Ground Floor, Tun Abdul l 251 Jalan Kulim 
187 Jalan Sungai Besi l Razak Complex, 80000 Johor Baru : 14000 Bukit Mertajam 
57100 Kuala LL.tmp1..1r i Jot1or l Province Wellesley 
1-----------------------------------t------------------------------------~-----------------------------------: 
Jaya Jusco Stores Sdn Bhd 
Dayabumi Komplek 
Jalan Sultan Hishamuddin 
50050 Kuala Lumpur 
InterTarm Malaysia Sdn Bhd 
47, 2nd Floor, Jalan Ah Fook 
Tun Abdul Razak Kompleks 
80000 Johor Baru, Johor 
Allin Pharmacy 
43 Jalan SS 22/23 
Damansara Jaya 
47400 Petaling Jaya 
~-----------------------------------~-----------------------------------i-----------------------------------~ 
Naina Mohd & Sons <M> Sdn Bhd 
1, 3 & 9 Medan Pasar 
50050 Kuala Lumpur 
Jecki Medical Supplies Sdn Bhd 
No 2 Lot 9 Block A 
Ground Floor Kompleks Sentosa 
Jalan Sutera, 80150 Johor Baru 
Farmasi Utama 
113 Jalan SS 21/37 
Damansara Utama 
47400 Petaling Jaya 
:-----------------------------------1-----------------------------------i-----------------------------------: 
Salim <M> Sdn Bhd 
14 Jalan Hang Kasturi 
50050 Kuala Lumpur 
Lim Pharmacy 
237 Lorong Tun Ismail 
Kuantan, Pahang 
Howe Cheang Medical Supply Sdn Bhd' 
454 Penang Road 
10000 Penang 
~-----------------------------------1-----------------------------------t-----------------------------------
Apex Pharmacy <Sel) Sdn Bhd 
105 SS 21/lA 
Damansara Utame:1 
47400 Petaling Jaya 
Boon Pharmacy Sdn Bhd 
82-188 Penang Road 
10000 Penang 
Poly Pharmacy Sdn Bhd 
915 Jalan Sultan Badlishah 
05000 Alor Star, kedah 
+----------------------------------------------------------·-------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
.;,< 
Appendix 29 
LIST OF PHARMACIES IN MALAYSIA 
+-----------------------------------------------------------------------------------------------------------+ 
+-----------------------------------------------------------------------------------------------------------+ 
K H Farmasutika Sdn Bhd : City Chemist Sdn Bhd : Guardian Pharmacy (M) Sdn Bhd 
10.7 Persiaran Raja Muda Musa : Lot 6 Ground F:loor, Asiajaya : Bukit Bintang Plaza, Jalan Bukit 
Port Klang : Complex, Loron~ Utara C, P.Jaya : B~ntang, Kuala Lumpur 
1 Allin Pharmacy 
43 Jalan ss 22/23 
Damansara Jaya, Petaling Jaya 
Pharmacist : Ms Chan Lin Heong 
Fleming Farmasi 
Lot 1.36 Kompleks Wilayah 
Jalan Campbell, Kuala Lumpur 
Pharmacist : Ms Thien Peng Sim 
Pharmacist : Ms Yap Kuen Kin 
Apex Pharmacy Sdn Bhd 
, Lot 201 Kotaraya Complex 
Jalan Cheng Lock, Kuala Lumpur 
Pharmacist : Mr Toh Weng Tuck 
Syarikat Asia Pharmacy 
Lot F-059 1st Floor 
Sungei Wang Plaza, Kuala Lumpur 
Pharmacist : Ms Chow Kam Fong 
Guardian Pharmacy (M) Sdn Bhd 
Ground Floor, Complex PKNS 
Shah Alam, Selangor 
Pharmacist : Cik Nor Hayati 
City Chemist Smkt Sdn Bhd 
Bangunan Perkim, Jalan Ipoh 
Kuala Lumpur 
Pharmacist : Mr Jimmy GB Chua 
Ms Fong Oi Leng 
-----------------------------------=-----------------------------------=-----------------------------------: 
Guardian Pharmacy (M) Sdn Bhd 
1st Floor, Jaya Supermarket 
Jalan Semangat, Petaling Jaya 
Pharmacist : Mrs Ong-Oh Hup Ho 
Guardian Pharmacy (M) Sdn Bhd 
Ground Floor, Ampang Shopping 
Complex, Jalan Ampang, K.Lumpur 
Pharmacist : Mrs Tan Kwai Nyok 
Allied Pharmacy Sdn Bhd 
137 Jalan Imbi 
Kuala Lumpur 
Pharmacist : Ms Ho Suet San 
K H Hoe Farmasutika Sdn Bhd 
107 Persiaran Raja Muda Musa 
41100 Port Kelang 
Apex Pharmacy Sdn Bhd 
Lot 17 24-25 OUG Plaza 
Jalan Old Klang, Kuala Lumpur 
Pharmacist : Ms S H Cheong 
Allin Pharmacy 
43 Jalan ss 22/23, Damansara Jaya 
, 47400 Petaling Jaya 
Pharmacist : Ms Chan Lin Heong 
I 
I 
+-----------------------------------------------------------------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
Appendix 30 
LIST OF PHARMACIES IN MALAYSIA 
+-------------------------------------------------·----------------------------------------------------------+ 
Cosmopolitan Marketing Services : Malaysia Pharmacy Sdn Ehd : Georgetown Dispensary Bhd 
<M> Sdn Ehd <Pharmaceutical Div) l 20-6 Jalan Pahang I 31 Jalan SS2/75 
16 Jalan 15/48, Subang Jaya : 53000 Kuala Lumpur : Petaling Jaya 
Pharmacist : Ms Tan Lee Lee Pharmacist : Mrs Jegathesan Pharmacist : Mr Kuan 
1-----------------------------------:-----------------------------------:-----------------------------------: 
Farmasi Utama 
Jalan SS 21/37, Damansara Utama 
47400 Petaling Jaya 
Pharmacist : Ms Hui Lee Lin 
Tri-Op Pharmacy 
312 Jalan Pahang, Setapak 
53000 !<ual a LumpLtr 
Pharmacist : Mr Bernard Woo 
Babycare Pharmacy Sdn Bhd 
34 Jalan SS 22/25 
Damansara Jaya, Petaling Jaya 
Pharmacist : Ms Lin Siang Looi 
1-----------------------------------~-----·-----------~------------------!----------------------------~-------! 
Ling Chemist 
124 Jalan Pahang 
53000 Kuala Lumpur 
Pharmacist : Mr Ling Dang Ming 
Apex Pharmacy <Sel> Sdn Bhd 
105 SS 21/lA, Damansara Utama 
47400 Petaling Jaya 
Pharmacist : Mr Loh Swee Eng 
Lee Pharmacy & Baby Centre S/Bhd 
55 Lorong Raja Hassan 
41400 Klang, Selangor 
Pharmacist : Ms Chong Chu Li 
1-----------------------------------:------------------------------------i------------------------------------i 
Guardian Pharmacy <M> Sdn Bhd 
12th Floor Kompleks Kewangan 
Jalan Raja Chulan, Kuala Lumpur 
' Kuala Lumpur Ph~rm Sdn Bhd 
78 Jalan Eukit Bintang 
55100 Kuala Lumpur 
Pharmacist : Mrs Helen Aw : Pharmacist : Mr Tan Yap 
Syarikat Asia F~armacy 
Lot F-059 1st Floory Sungei Wang 
Plaza, 50250 Kuala Lumpur 
:-----------------------------------,-------------·-----------------------:-----------------------------------: 
Binjai Sdn Bhd 
8th Floor, China Insurance Bldg 
174 Jalan TAR, 50100 Kuala Lumpur 
Pharmacist : Mr S Swaminathan 
City Chemist Sdn Bhd 
City Chemist Emp Sdn Bhd, Sungei 
Wang Plazay 55100 Kuala Lumpur 
Pharmacist : Miss Loh 
Allied Pharmacy Sn Bhd 
137 Jalan Imbi 
Kuala Lumpur· 
Phar~acist : Ms Ho Suet San 
+--------------------------------------------·---------------------------------------------------------------+ 
Source : Johnson & Johnson Malaysia 
LIST OF PHARMACIES IN MALAYSIA Appendix 31 
+-----------------------------------------------------------------------------------------------------------+ 
Guardian Pharmacy l Boon Pharmacy Sdn Bhd : Howe Cheang Medical Supply Sdn Bhd! 
Ground Floor, Penang Plaza I 182 ~enang Road : 454 Penang Road 
Burmah Road, Penang I 10000 Penang : Penang 
Pharmacist : Ms Wong kong Seong Pharmacist : Mr Law Teik Hong Pharmacist ~ Ms Lim Siew Lee 
~-----------------------------------:-----------------------------------·l-----------------------------------l 
Well Pharmacy Sdn Bhd 
KOMTAR Penang Road 
Penang 
Pharmacist : Ms Lim Soo Eng 
Central Pharmacy 
18 Argyll Road 
Penar1g 
Pharmacist : Mr Yang Kong Wah 
Penang Pharmacy Bdn Bhd 
306H Burmah Road 
Penang 
Pharmacist : Mr Chee Say Hean 
:-----------------------------------:-----------------------------------:-----------------------------------: 
Butterworth Pharmacy Sdn Bhd 
4709 Bagan Luar Road 
Butterworth, Province Wellesley 
Pharmacist : Ms Yong Yin Wah 
Bukit Mertajam Pharmacy Sdn Bhd 
251 Jalan kulim 
14000 Bukit Mertajam: P.Wellesley 
Pharmacist : Mr Lim Hoon Ngak 
S P Farmasi Sdn Bhd 
312-P Jalan Bakar Arang 
Sungai Petani 1 Kedah 
Pharmacist : Mr Tan Cheng Chin 
:-----------------------------------~-----------------------------------:-----------------------------------: 
Mice Medical Hall Sdn Bhd 
1537 Jalan Sultan Badlishah 
05000 Alor Star, Kedah 
Pharmacist : Mr Sic Lye On 
Poly Pharmacy Sdn Bhd 
915 Jalan Sultan Badlishah 
Alar Star~ Kedah 
PharmaciEt : Mr Khoc Chong Chye 
Tri-Op Pharmacy Sdn Bhd 
170-B Jalan Tunku Putra 
Kulim, Kedah 
!-----------------------------------:---------------7-------------------:-----------------------------------: 
Tri-Op Pharmacy Sdn Bhd 
150 Jalan f<ota 
Taiping, Perak 
Pharmacist : Mr Wu Tuck Seng 
Yin Woh Tong Medical Hall 
136 Jalan Sultan Iskandar 
30000 Ipoh, Perak 
Pharmacist : Mr Yoong Seng Huat 
K H Hoe Farmasutika <Pk) Sdn Bhd 
59-A Jalan Raja 
36000 Teluk Intan, Perak 
Pharmacist : Mr Wong Toon Lee 
+------------------------------------------------------------------------------------------------------------+ 
Source Johnson & Johnson Malaysia 
Appendix 32 
MPANIES THAT HAVE BEEN APPROVED TO MANUFACTURE PHARMACEUTICAL PRODUCTS IN MALAYSIA 
1 
2 
3 
4 
5 
6 
7 
COMPANY 
The East Asiatic Co <M> Sdn 
Bhd <Dumex> 
Malayan Pharmaceutical 
Factory 
Glaxo <M> Sdn Bhd 
Warner Lambert <mfg> Sdn Bhd 
Sterling Drugs <M> Sdn Bhd 
Asia Pharmaceutical Products 
Sdn Bhd 
Xepa Soul-Pattison Sdn Bhd 
ADDRESS 
1 Road 205 Petaling Jaya 
Ex-TP 
3 Jalan Semangat Petaling Jaya 
Ex-TP 
2 Jalan 51A/221 P B Box 11 
Petaling Jaaya 
EH-TP 
Jalan 13/4A Petaling Jaya 
TGC 
Ulu Klang Kuala Lumpur 
TGC 
Mak Mandin Indsutrial Estate 
TGC 
68 Ayer Kerch Indsutrial Estate 
TGC 
Source : !~laysian Industrial Development Authority 
\ 
OUTPUT 
Antibiotic, vitamins, asprin 
preparations, hormones, anti-
tuberculosis, iron preparation 1 
sulphonamides, tranquilisers, 
antacids 
Antibiotics of all types, bulk 
medicine.s, ointments 
Antibiotics, vitamins, ointment, 
other liquids, tablets, capsules, 
and specialised food 
Vitamins, iron preparation, 
antacids 
Pharmaceutical, toiletry, 
cosmetics, household & industrial 
cleaning products, fly baits 
Pharmaceutical products, cosme~ic 
preparation, veterinary medicam•nts 
Antidiarrhoeal mixture, cough 
mixture, vitamin syrups, anti-
asthmatic syrups, antihistamine 
syrups, sulphonamides syrups, anti-
biotic cream or ointments 
Appendix 33 
OMPANIES THAT HAVE BEEN APPROVED TO MANUFACTURE PHARMACEUTICAL PRODUCTS IN MALAYSIA 
8 
9 
10 
11 
12 
13 
COMPANY 
Pharm Malaysia Sdn Bhd 
Hoechst Pharmaceutical (M) 
Sdn Bhd 
Raza Manufacturing Sdn Bhd 
Ranbaxy (M) Sdn Bhd 
Optisol Sdn Bhd 
Depco United Sdn Bhd 
ADDRESS 
Lot 24 Bakar Arang Indsutrial 
Estate P 0 Box 54 Sungei Petani 
Kedah 
70% KCP 
Pandamaran 
KCP 25% 
16 Jalan 51A/227 Petaling Jaya 
25% CP 
Bakar Arang 
60% KCP 
32A & B Jalan Overseas Union, 
OUG Kuala Lumpur 
50% KCP 
4 Lebuh Kurau Tiga, Chai Leng 
Park, Prai, Province Wellesley 
Penang 
Source : Malaysian Industrial Development Authority 
OUTPUT 
Tablets, capsules, liquids 
Tablets; encapsulated preparations, 
liquids for oral and external use, 
cream, ointments, suppositories 
injectables (approved on 19/11/86) 
Tablets, capsules, ointments, 
cream and liquid preparations 
Pharmaceutical products including 
ampicillin trihydrate, etc 
(approved on 29/4/82) 
Chlorhexidine salts, contact lens 
solution 
Veterinary medicaments, supplements 
for animal feeds and body food 
supplement (vegetable extracts) 
OMPANIES THAT HAVE BEEN APPROVED TO MANUFACTURE PHARMACEUTICAL PRODUCTS 
14 
15 
16 
17 
18 
COMPANY 
Beecham Products (Far East) 
Sdn Bhd 
Chemical International Sdn Bhd 
Modern Chemicals Sdn Bhd 
Ho Yan Hor (Kausing Brand) 
Medical Hall Sdn Bhd 
Malaysian Pharmaceutical 
Industries Sdn Bhd 
ADDRESS 
Petaling Jaya 
Ex-TP 
Ulu Tiram, J'ohor Baru 
50% KCP 
Jalan Kelang, Selangor 
25% KCP 
Ipoh, Perak 
TGC 
Bayan Lepas, Penang 
TGC 
Source : Malaysian Industrial Development Authority 
Appendix 34 
OUTPUT 
(i) Toiletries - hair dressings 
shampoos/bath products, ·~kin 
cream and lotions, talcum 
powder, perfumes/deodorant 
(ii) Medicines - proprietory 
medicines 
(iii) Malted tablets 
Medicaments, cosmetics & 
Pharmaceuticals (approved on 
31/12/73) 
'4-Acetaminophenol' (Peracetamol) 
(approved on 4/11/76) 
Pharmaceutical products 
Pharmaceutical products 
(approved on 26/6/84) 
Appendix 35 
JMPANIES THAT HAVE BEEN APPROVED TO MANUFACTURE PHARMACEUTICAL PRODUCTS IN MALAYSIA 
L9 
w 
~1 
COMPANY 
Medic 2000 Sdn Bhd 
Camden Industries Sdn Bhd 
NV l"'edicophar·ma 
Ex-TP 
T.G.C. = 
= Ex Pioneer Status 
Without Tax Incentive 
ADDRESS 
KP Sari Petaling 
I<CP 50% 
I<P Prai, Pulau Pinang 
TGC 
Subang Jaya, Selangor 
K.C.P. = Investment Tax Credit or Allowance 
Source : Malaysian Industrial Development Authority 
OUTF'UT 
Pharmaceutical products in 
capsules, tablets and granules 
<approved on 12/11/85) 
Pharmaceutical products 
<approved on 10/12/85> 
Pharmaceutical products 
<approved on 4/11/86> 
Appendix 36 
DISTRIBUTORS' DIRECTORY MALAYSIA/SINGAPORE 
-----------------------------------:-----------------------------------:-----------------------------------: 
MARKETLINK (M) SDN BHD 
Lot 19 Jelen 223 
46100 Petaling Jaya 
P 0 Box 1095 
Jelen Semangat 
TEL : 7577233, 7577339, 7577541 
Cable : MACWAT PETALING JAYA 
Telex : MA 37691 
Distributor for : 
Allergen Pharm 
ANB Laboratories 
Biomedica Foscema 
Carter Wallace 
David Bull Laboratories 
Duphar (India) 
Gee 
Karl Engelhard 
Kendall 
Knoll Ag 
Lab for APPlied Biology 
Nordmark 
Pharmacia 
Regal Pharmaceuticals 
Terumo 
PAHANG PHARMACY SDN BHD 
22 Lorong Vivekenenda 
Off Jelen Rozario, Brickfields 
50470 Kuala Lumpur 
TEL : 2743243, 2741134 
Telex : MA 37112 PROCEM 
Branch : 
31 Jalan Teluk Sisek 
25000 Kuantan 
Pahang Darul Makmur 
, Distributor for : 
Alkaloida, Hungary 
Biogal, Hungary 
Chinoin, Hungary 
Egis, Hungary 
Gedeon Richter, Hungary 
Human Inst., Hungary 
Krka, Yugoslavia 
Liorente, Spain 
PREMIER PHARMACEUTICALS (M) SON 
BHD 
1st & 2nd Floor Jalan S13 
Taman Selayang Jaya 
8th Mile Ipoh Road 
68100 Batu Caves 
Selangor 
TEL : 03-6182760, 6182762, 6182573\ 
Telex : MA 31208 Prime 
Dsitributor for : 
Capsulation Services 
Daiwe 
Glisten 
Institute Franco Tosi 
Medicap 
Scendrug 
:-----------------------------------:--------------~--------------------:-----------------------------------, 
MILRIN PHARMACEUTICAL CO (M) 
SDN BHD 
133 Beech Street, 10300 Penang 
TEL : 04-618343, 628182, 611408 
Telex : MA 40921 
Distributor for : 
PFIZER (PTE) L~D 
Lot 4 Jelen 13/'6 
46200 Peteling Jaya 
P 0 Box 333 
Jelen Sultan, 46740 Petaling Jaya 
TEL : 7556833 
Central Pharmaceuticals, USA : Distributor for : 
Carnrick Laboratories, USA \ Pfizer 
B.F. Ascher & Co Inc, USA 
National Pharmaceutical Mfg Co USA\ 
Prodesfarma, Spain 
PROPHARM (M) SDN BHD 
640-A, 4th Mile 
IPoh Road 
51200 Kuala Lumpur 
TEL : 03-6277389 
Telex : MA 36295 
Distributor for : 
Astrapin, W.Germany 
Koltis, W.Germany 
Korea Green Gross Corp 
:-----------------------------------:-----------------------------------:-----------------------------------: 
Source : DIHS, "olume 16 Number 3 October 1987 
Appendix 37 
DISTRIBUTORS' DIRECTORY MALAYSIA/SINGAPORE Source : DIMS, Volume 16 Number 3 October 1987 
:-----------------------------------:-----------------------------------:-----------------------------------
UNITED ITALIAN TRADING CORPN (PTE)l WALETA MALAYSIA SDN BHD 1 F.E. ZUELLIG (MALAYSIA) SDN BHD 
LTD : 9 (1st Floor) Jelen SS2/75 11th Floor Wisma Damansara 
No 66 Jln Mega Mendung : 47300 Petaling Jaya Jelen Semantan 
Komplex Bander : P 0 Box 6564 Damansara Heights 
Batu 5 Jelen Kelang Lama : Kampung Tunku 50490 Kuala Lumpur 
58000 Kuala Lumpur : 47307 Petaling Jaya P 0 Box 10251 
TEL : 7831121, 7834844, 7833680 l TEL : 7760717, 77606777, 7760787 50708 Kuala Lumpur 
7837018, 7815691 : 7760587 I 'TEL : 2545022 
Telex : UITCLKL 37686 l Cable : WALIPHARM l Cable : FEZ KUALA LUMPUR 
Distributor for: :Telex : WALETA'MA 37507 : Fax : 03-2550896 
Commonwealth Serum Lab : Distributor for : : Telex : FEZKL MA 31299 
C P Pharmaceuticals 
Fawns & McAllen, Australia 
Ferring, Sweden 
Fisons 
Fujisawa, Japan 
I. M.S., U.S.A. 
Japan Medical Supply 
Key Pharmaceuticals 
Lifepharma 
Lohmann, Germany 
Dr Madaus 
Newport 
Pharmachiemie-Haarlem, Holland 
Pierre! 
Protea Pharm 
Rosken 
Sigma, Australia 
Sigma Tau 
Smeller 
Tuta Lab 
Zambon 
Apotex Inc 
Ashford Lab 
Bracco Ind Chemica 
Chemapol 
Dentinox 
Dr Falk 
Lek Ljubljana 
Medinova 
1 Mepha 
Optopic Lab 
Remedies 
Rowe 
Soico 
Tanabe Seiyaku 
Viratek 
Walter-Ritter 
Penang : 
410E Jelen Jelutong 
11600 Penang 
P 0 Box 626 
10780 Penang 
TEL : 889100 
Distributor for 
American Cyanamid Co (Lederle Lab): 
Astra Pharmaceuticals 
Boehringer Mannhein 
British Cod Liver Oils-Seven Seas 
Disperse 
Eli Lilly 
Kabivitrum 
Merck 
Merrell Dow 
Nattermann (Hadensa) 
Reckitt & Colman 
A.H. Robins 
Rorer 
Armour 
usv 
3M Riker Lab 
Sanofi 
Les Labs Servier 
Schering Corp, U.S.A. 
Smith Kline & French 
Synthelabo 
Upjohn 
Well come 
!-----------------------------------:-------~---------------------------:-----------------------------------: 
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DISTRIBUTORS' DIRECTORY MALAYSIA/SINGAPORE 
:-----------------------------------:-----------------------------------:-----------------------------------
WELLCOME MALAYSIA SDN BHD 
1 No 7 Lorang SS13/3F 
~ubang Jaya 47500 Petaling Jaya 
Selangor 
TEL : 7332624, 7334350, 7334232, 
7332806 
Cable : TABLO[D PETALING JAVA 
Telex : TABMAL MA 36247 
For Products of 
Burroughs Wellcome & Co 
Calmic Ltd 
Wellcome Foundation Ltd 
NORSE CROWN CO <M> SDN BHD 
No 38 Jalan Tun Sambanthan 3 
Brickfields, 50470 Kuala Lumpur 
P 0 Bo>: 11462 
50746 Kuala Lumpur 
TEL : 2749077, 2749082 
Cable : NORSE PETALING JAVA 
Telex ; MA 33218 N CROWN 
Distributor for 
Lundbeck 
Nordisk Insulin Laboratorium 
Weiders 
WELLMEX SDN BHD 
103 8< 105 Jalan Sibu 
Taman Wahya, 6th Mile Jalan Ipoh 
G.P.O. Box 10655 
Kuala Lumpur 
Tel : 6264088, 62p4941 
Sole distributor for 
Lab Biocodex, France 
British Medical L:ab, Australia 
Lab Cusi, Spain 
Pilva, Yugoslavia 
Rophar~a, Belgium 
Dr Steffen, W. Ge1rmany 
Waldemar Weimer, W.Germany 
1 ORGANON MALAYSIA ~DN BHD 
16, 3rd fl~or 
Jalna SS 1518, Subang Jaya 
47500 Petaling Ja~a, Selangor 
TEL : 7340530 <4 lines) 
7340528 <Direct Line) 
Telex ~ MA 36554 ~RGMAL 
Distributor for : 
Organon 
M & B <MALAYSIA> SDN BHD 
Lot 8 Jalan 19/1 
46710 Petaling Jaya 
P 0 Box 150 
TEL : 7551355 
Tel e>: : MA 37651 
Distributor for : 
1 Institut Merieux 
May & Baker 
One 
P.N. Gerolymatos S.A. 
Pasteur-Vaccins-Institut Merieux 
Rhone Poulenc 
I S.P.E.C.I.A. 
MEDISPEC <MALAYSIA> SDN BHD 
8 Tavoy Close 
10050 Penang 
TEL : 04-360701, 372564 
Telex : MA 40877 INNCO 
Distributor for : 
Biolab Co., Ltd <Thailand) 
Dr Grossmann Ag. Pharmaca 
-----------------------------------:-----------------------------------:-----------------------------------: 
Source : DIMS, Volume 16 Number 3 October 1987 
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DISTRIBUTORS' DIRECTORY MALAYSIA/SINGAPORE 
:-----------------------------------:-----------------------------------:-----------------------------------: 
: PHARMMALAYSIA SON BHD : ROCHE (MALAYSIA) SON BHD : ABBOTT LABORATORIES (S) PTE LTD 
69A/B Komplex Damai : No 1 Jalan SS21/37 : No 40 Jalan 19/3 
Jalan Dato Haji Eusoff : Damansara Utama l 46300 Petaling Jaya, Selangor 
Off Jalan Ipoh, 50400 Kuala Lumpurl 47400 Petaling Jaya l TEL : 7569727, 7569803 
TEL : 4426466, 4416543 : TEL : 7187731 (4 lines) : Distributor for : 
Factory : ' Penang : : Abbott Lab 
Lot No 24 1F Lorong Delima Lima l Ross Lab 
Bakar Arang Indsutrial Estate Island Glades, 11700 Gelugor 
08000 Sungai Petani, Kedah TEL : 04-883525, 880168 
TEL : 04-413011, 413012 Distributor for : 
Cable : MAXIPLEX Evergreen 
Telex : MAXIIN-MA 42225 Roche 
Distributor for : 
Himalaya Drug Co, Bombay, India 
Pharmmalaysia 
-----------------------------------=---------------~-------------------:-----------------------------------: 
APEX PHARMACY 
Sebeh : 
Sandakan Chemist Sdn Bhd 
2 Jalan Pantai 88801 Kota Kinabalu 
TEL : 088-55100 
Distributor for 
Convatec, USA 
Delta West 
Farmitilia Carlo Erba 
KAPS 
Norgine Ltd 
Istituto Serono 
Serono Diagnostics 
Smith & Nephew Pharmaceuticals 
Soul Pattison Lab 
Tops an 
Thamos Laboratories Ltd, UK 
:-----------------------------------
BETAMED (M) SON BHD 
20-6 Jalan Pahang 
53000 Kuala Lumpur 
TEL : 03-4421548 
Telex : MA 32207 BMPTG 
Distributor for 
Arcana, Austria 
Azra, Canada 
Betamed Products 
Delalande 
Forest Laboratories 
Lab Valles Mestre, Spain 
Lek Pharmaceut~cals & Chemical 
Works - Yugoslavia 
Ludwig Heumann 
Marion, USA 
Promedipharm 
Source : DIMS, Volume 16 Number 3 October 1987 
THE BOOTS COMPANY (FAR EAST) 
PTE LTD 
10 Jalan SS 13/6 
Subang Jaya 
47500 Petaling Jaya~ Selangor 
TEL : 7332603, 7337723, 7337727 
Cable : BOOTS CO, KL 
Telex : MA 36253 
Distributor for : 
Boots 
Dupont 
Dupont Critical Care 
Seton 
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I C I INDUSTRIAL CHEMICALS 
<MALAYSIA> SDN BHD 
Distributor for : 
INNOVEST HART DISTRIBUTORS SDN BHD: JEBSEN & JESSEN <Ml SDN BHD 
I C I 
Nipro 
StLlart 
JMD SDN BHD 
Distributor for : 
Germed, German Democratic 
Republic 
Radiumfarma International 
Milano/Italy 
Siam Pharmaceutical Co Ltd 
Thailand 
JOHNSON & JOHNSON SDN BHD 
Distributor for : 
Cilag 
Janssen 
Distributor for : 
Bebelac, Holland 
Camden Industries Sdn Bhd 
Dow Corning, USA 
Kali Chemie, Germnay 
Mallinckrodt, USA 
UPSA Laboratories, France 
KOMEDIC SDN BHD 
Di stri butot~ for 
Antibioticos, S.A. <Spain> 
Avantgarda <Italy> 
Medochemj. e Ltd 
KYOWA HAKKO <M> SDN BHD 
Distributor for : 
Kyowa Hakko Kogyo Co Ltd, Japan 
Cheong Wae Pharma Corp, S Kor~a 
<Anti cancer products) 
Distributor for : 
Becton Dickinson 
Leo Pharm 
Monocional Antibodies Inc 
Novo Industri A/S 
Sci avo 
Synco Inc 
LAM TAT TRADING CO 
Distributor for : 
Hennig Arzneimittel Kg. Main, West: 
Germany 
Towa Pharm Co Ltd, Japna 
Will Pharma, Belgium 
Yung Shin Pharm Industries Co Ltd 
Taiwan 
Dr Hobein & Co GmbH, W. Germany 
Pharmadrug, West Germany 
:-----------------------------------:-----------------------------------:-----------------------------------: 
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DIETHELM MALAYSIA SDN BHD 
Distributor for : 
Abbott <E.Malaysia) 
Beecrram 
Boehringer Ingelheim 
Health Farm 
Lipha Pharm 
Luitpold Werk 
Pfizer <E.Malaysia) 
' Sandoz/Wander 
Squibb 
Stiefel 
Swiss Serum & Vaccine Inst 
Synte~: /Simco 
Warner Lambert/Parke Davis 
(E. Malaysia) 
GERMAX SON BHD 
Distributor for 
Bionorica, W Germany 
Deutsche Chefaro Pharma, GmbH 
\.LJ. Ger-many 
F Trenka, Austr-ia 
Hermal Kurt Herrmann 
Piette International, Belgium 
DUOPHARMA MALAYSIA SDN BHD 
Distributor for : 
A.M. Pharma Hendeis, W.Germany 
Asia Pharma, S Korea 
Chong l<un Dang 
Chung Gui Pharma, S Korea 
Grunenthal 
IBI, Italy 
Il Yang Pharm 
Laboratories Atral, Portugal 
Lomapharm, W Germany 
Ludwig Heumann, W Germany 
Ohta Pharmaceutical, Japan 
Pharma Hamelin, W Germany 
Potter & Clarke Ltd, England 
Rotexmedica, W Germany 
Sinil Pharms, S Korea 
TAD, W Germany 
Tai Guk Pharma, 8 Korea 
Tai Kwang 
Yeong Dong Corp, 8 Korea 
GLAXO MALAYSIA SDN BHD 
Distributor for : 
Glaxo Group Products 
EASTERN FARMASI <M> SDN BHD 
Distributor for 
Vitabiotics Ltd (England) 
EISA! <M> SON BHD 
Distributor fo1~ 
Eisa! 
FL1shi mi Pharm 
Towa Pharm 
EQUIMED (Ml SDN BHD 
Distributor for 
l<yl i far 
Lohmann, W Ger-many 
Macherey, Nagel 
Medefield Pty Ltd 
Nyegaard 
Torrent lab 
HOECHST MALAYSIA SDN BHD 
Distributor for : 
Berrr i. ngwer ke AG 
Behring Diagnostics, USA 
Diamant Lab, France 
Hoechst AG 
Roussel Lab, England 
Roussel Uciaf, France 
:-----------------------------------:-------------------------------------=-----------------------------------
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LUEN WAH MEDICAL CO 
Distributor for : 
Helm 
Luerr Wah 
Otsuka 
Pharmon 
R.P. Scherer 
San ten 
Shigaken 
Taiho 
Takeda 
MALAYSIA PHARMACY SDN BHD 
Distributor for : 
Betamed CM> Sdn Bhd 
Coloplast A/S, Denmark 
Elder Pharmaceuticals Inc, USA 
Stockist for : 
Sunward Chemical Ind Co. Pte Ltd 
SCHMIDT SCIENTIFIC SDN BHD 
Distributor for : 
Byk Gulden, West Germany 
Scherirrg A.G., B:erlin/Bergkamen 
SEARLE CM> SDN BHD 
Distributor for : 
Searle Laboratories 
SOMEDICO SDN BHD 
Distributor for : 
C.B. Fleet Co Inc 
Ci me:< AG/L Td 
Deseret 
Ego Pharm, Australia 
Meiji Pharm 
Busse:-: Pharm 
SAFIRE PHARMACEUTICALS (M) SDN BHDl STERLING DRUG (M) SDN BHD 
Distributor for : 
laboratories Delalnde, France 
Gonoshasthaya Pharmaceuticals Ltd 
Bangladesh 
Cadila Laboratories PVT. LTd, Indi: 
Griffon Laboratories Pvt, Ltd 
India 
P T Pradja Pharmaceutical 
Industries, Indonesia 
Vilco Laboratories Pte Ltd 
Gujarat, India 
Distributor for : 
Breon Lab 
Sterling 
Winthrop 
SUMMIT CO (M) SDN BHD 
Distributor for : 
Alcon Pharmaceutical Ltd 
Ayerst Lab 
Internat Chemical Co Ltd 
Mack 
Merck Sharp L Dohme 
Merz 8-. co 
Nippon Kayaku Co Ltd 
Par Pharmaceuticals 
Pure Lab 
Schwarzhaupt Ag 
Thilo & Co 
Toyo Jozo Co Ltd 
Whitehall Internal Inc 
Wyeth International 
SUNWARD CHEMICAL INDUSTRIES CO 
SDN BHD 
Distributor for ~ 
Lirrx 
Selvi 
Sunward 
'· I 
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SUPREME DRUGS 
Distributor for : 
Alembic Chemical Works Co Ltd 
India 
Bioforce Limited, Switzerland 
Darya Varia Lab/Pharos Chemie, 
Holland & Indonesia 
ECE Chimica Rumania 
Franco Indian Pharmaceuticals 
<PVT> Ltd, India 
Ginsana Products Lugano S.A. 
Switzerland 
German Remedies Ltd, India 
Gohl Pharma S.A. Switzerland 
Laboratories Biofarma Ldn, Lisbon 
Laevosan Gesellschaft GmbH & Co 
KG, Austria 
Lagap S.A., Switzerland 
MD Associates, Inc USA 
Napp Laboratories Limited, England 
Neolab S.A., Switzerland 
F'o-Ho-Co Ltd Switzerland 
PT Pradjn Pharmaceutical 
Industries, Indonesia 
Pharmax Limited, England 
Phyteia AG, Switzerland 
UNAM CORP <M> SON BHD 
Distributor for 
Biomedis 
Imperial Pharm 
Medicr.em 
Pediatrica 
United American Pharm 
~Jest mont 
UNIDRUG HOUSE 
Distributor for : 
Unichem Lab Ltd, Bombay 
Glenmark Pharm, Pvt Ltd, Bombay 
Unichem Distributors Ltd Part, 
Bangkok 
Rio-chemicals GmbH, Germany 
Concept Pharm Pvt. Ltd, Bombay 
Lupin Lab Pvt Ltd, Bombay 
Malaysia Chemist <Pte> Ltd, S'pore 
SUMMIT CD CS'PORE> CORPN <PTE> LTD: 
Di stri bt.ltor fo1r 
Alcon Pharm Ltd 
Ayerst Lab 
Internal Chemical Co LTd 
Heinrich Mack 
Merck Sharp ~ Dohme 
Merz & Co 
Nippon Kayaku Co Ltd 
Schwarzhnupt Ag 
Singapore Biotech Pte Ltd 
Dr Thilo & Co 
Whitehall Internal Inc 
Wyeth Internal 
SUNWARD CHEMICAL INDUSTRIAL CO 
PTE LTD 
Distributor for : 
Linz 
Sunward 
VLI Corporation 
WARNER LAMBERT IS> PTE LTD 
Distributor for 
Parke Davis 
Warner Lambert 
TRANSMEDIC PTE LTD 
Distributor for : 
ANB Laboratories 
Pfrimmer 
Pharmacia Diagnostics/Healthcare/ 
Ophthalmic 
Sifra 
UNI DRUG HOUSE 
Distributor for 
Brttish Pharm 
IDPL 
Lupin Lab 
Unichem Lab Ltd 
UNITED ITALIAN TRADING CORPN !PTE> l 
LTD 
Distributor for : 
Commonwealth Serun Lab, Aust 
CP Pharmaceuticals, UK 
Fawns & McAllan, Australia 
Ferring, Sweden 
Fujisawa, ,Japan 
IMS, USA 
Japan Medical Supply, Japan 
Key Pharmaceuticals 
Lifepharma, Italy 
Lohmann, Germany 
Dr Madaus, Germany 
Morishita, Japan 
Newport, USA 
Pharmachemie - Haarlem, Holland 
Pi errel , Italy 
Protea Pharm, Aust 
Rosken, At.lst 
Sigma, Aust 
Singafrench, France 
Smeller 
Travanol/Hyland, USA 
Tuta Lao, Aust 
Zambon, Italy 
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456 Alexandra Road 
NOL Building #19-03 
S0511 
P 0 Box 1016 
1 Maxwell Road 
S9020 
TEL : 2787366 
Cable : ABBOTLAB-SINGAPORE 
Telex : ABOTLAB RS 23367 
Distributor for : 
Abbott Lab 
Ross Lab 
APOLLO MEDICAL SUPPLIES PTE LTD 
10 New Industrial Road #04-05 
S1953· 
TEL : 2866272 
Telex : RS39250 MRC 
Distributor for 
Mundipharms/Mahakam Beta Farma 
BAYER (S) PTE LTD 
4 Penjuru Lane 
S2260 
TEL : 2654055 
Telex : RS 21721 BAYERSP 
FAX : 2658084 
Cable : BAYERSP 
Distributor for 
Ames 
Bayer 
Cutter Biological 
Miles Products 
BEACONS CHEMICAL 
53 QualitY Road 
S2261 
TEL : 2652336, 2653713 
Cable : BEACONS 
Telex : BEACON RS33378 
, Distributor for : 
Beacons Chemical 
Upha 
CHEAH & FAM (SINGAPORE) PTE LTD 
Ho Seng Lee Flatted Warehouse 
Building 
10-C Jalan Ampas #02-01 
51232 
TEL : 2543255, 2543498 
Telex : RS 50623 KHFAM 
Distributor for : 
Biochemie 
Ciech Polfa 
Ebewe 
Ethitek Pharm Co, USA 
Leiras 
Serotherapeutisches Institut, 
Austria 
Sumitomo 
Weber 
I 
-----------------------------------. 
CFS (S) PTE LTD 
55 Cuppage Road 
#06-07/08 
S0922 
TEL : 7375844 
Distributor for 
Pharmmalaysia 
I 
I 
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APEX PHARMACY INT'L PTE LTD 
104 Boon Kang Road #04-08 
Sl233 
TEL : 2941218 (3 lines> 
Cable : APEXPHARM 
Telex : APEXCO RS 24306 
Fax : 65-2972317 
Distirbutor for : 
Delta West Ltd, Aust. 
Farmitalia Carlo Erba 
Ikapharm 
KAPS 
Norgine Ltd, U.K. 
Norgine Pty LTd, Aust. 
Sereno, Italy 
Soul-Pattinson Lab, Aust 
Thames Lab Ltd, U.K. 
Xepa-Soul Pattinson, M'sia 
THE BOOTS COMPANY <FAR EAST> PTE 
LTD 
5th Floor, Roche Building 
30 Shaw Road 
S1336 
TEL : 2854222 
Cable : BOOTSCO 
Telex : RS 22180 
Distributor for : 
Boots 
Dupont 
Dupont Critical Care 
Seton 
CIBA-GEIGY S.E. ASIA <PTEl LTD 
4 Fourth Lok Yang Road 
82262 
TEL : 2653622 
Di str i l::~utor for-
Ciba 
Geigy 
Servipharm 
Zyma 
:-----------------------------------:-----------------------------------:-----------------------------------: 
ASIAMED PHARMACEUTICAL PRODUCTS 
<S> PTE LTD 
421 Tagore Avenue 
S2678 
TEL : 4596011, 4598832 
Telex : RS 28069 
Telefax : 4590134 
Distributor for : 
Servier 
THE BORNEO CO PTE LTD 
989 Bukit Timah Road 
52158 
TEL : 4698188 
Cable : BORNEO SINGAPORE 
Telex : Rs 50666 
Distributor for : 
Euro-Labor 
F(orer 
Wellcome/Calmic Ltd 
Fisons 
Organor,/Rett/Mul ti 1 an 
DEREK MARKETING PTE LTD 
470 North Bridge Road #04-20 
Singapore Finance House 
50718 
TEL : 3369761 
Telex : RS 24200 ref 
Distributor for : 
Antigen Ltd 
Astrapin 
Medochemie Ltd 
3923 
:-----------------------------------:-----------------------------------:-----------------------------------: 
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DUMEX DIVISION THE EAST ASIATIC 
CO (S) PTE LTD 
360 Orchard Road #06-06 
International Building 
S0923 
Tel : 2350249, 2350401 
Distributor for : 
Con naught 
Dumex 
FREDERICK PORDES AGENCIES PTE LTD 
10 Anson Road, #23-08A 
International Plaza 
80207 
Tel : 2202328, 2202192 
Distributor for 
Immuna 
Dr Remischier & Co 
Ludwig Haumann 
Pfrimmer & Co 
Siam Bheasach Co Ltd 
ICI <SINGAPORE) PTE LTD 
4 Raffles Quay, #09-00 
Finiayson House 
S0104 
Tel : 2243811 
Cable : IMPKEMIX SINGAPORE 
Telex : Rs 21111 
Distributor for : 
ICI 
Stuat-t 
:-----------------------------------:---------------------~-------------:-----------------------------------: 
DUOPHARMA TRADING (S) PTE LTD 
71 Tannery Lane #09-02 
City Industrial Building 
81334 
Tel : 7438283 
Telex : RS 38180 DUOSIN 
Distributor for : 
A M Pharma Handels, W Germany 
Asia Pharma, S Korea 
Chong l<un Dang 
Chung Gui Pharma, 8 Korea 
Grunenthal 
IBI, Italy 
H Yang Pharm 
Lab Atral, Portugal 
Lomapharm, W Germany 
Ludwig Heumann, W Germany 
Ohta Pharma, Japan 
THE GETZ CORPORATION 
100F Pasir Panjang Road 
80511 
Tel : 4759777 
Telex : RS 23554 
Distributor for : 
Boehringer Ingelheim 
Gl a:{ a 
' Ho Yan Hor Pharm 
The Mentholatum Co 
Upjohn Co 
William Ransom 
JARDINE PARRISH 
100-C Pasir Panjang Road 
80511 
Tel : 4751322 
Distributor for 
Abic 
Alpha Therapeutic/ 
G C Pharmaceutical 
Apam/Green Cross . 
Asia-Werke 
Bioc:odex 
Chiesi Farmac:eutici 
De>:o 
Ercopharm/Erco Orion 
Fidia 
German Remedies 
Green Gross/G C Pharmaceutical 
Homburg 
Laboratories Grifois/Green Cross 
Promedica 
Radial 
Simco 
8ynte:·: 
Zambeletti/Eurodrug 
:-----------------------------------:-----------------------------------:-----------------------------------: 
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ANTAH PHARMA SDN BHD 
Dist~ibuto~ fo~ : 
Alpha The~apeutics/G C 
Pha~maceutical 
Apam/G~een C~oss 
1 Asia Pha~m 
Chauvin-Blache 
Chemlewo~k Hombu~g 
E~co O~ion 
ESPE Seafeld Co 
Eu~od~ug 
Fidia/Chiesi 
Ge~man Remedies 
G~een C~oss/G C Pha~maceutical 
Ko~ea G~een C~oss/G C 
Pha~maceutical 
Labo~ato~ies G~ifols/G~een C~oss 
P~omedica 
Radio/Wade Pha~m 
Rotta Pha~m 
APOLLO BETA SDN BHD 
Dist~ibuto~ fo~ : 
Mundipha~ma/Mahakam Beta Fa~ma 
B BRAUN MEDICAL SUPPLIES SDN BHD 
Dist~ibuto~ for ; 
B B~aun Melsugen Ag 
B Braun Medical Industries Sdn Bhd 
BOUSTEAD TRADING (1985} SDN BHD 
Distribute~ for : 
' Fisons 
Hisamitsu 
Mentholatum Pte 
Nicholas Kiwi Int'l Pty Ltd 
Well come 
Zambeletti/Eurodrug : William Ransom 
ATLANTIC ALBORATORIES <M> SDN BHD 
Distributor fo~ 
Atlantic Lab 
BAYER <M> SON BHD 
Distributor for : 
Arne~ Diagnostic Products 
Bayer Human Pharmaceuticals 
Cutter Biological Products 
Miles Products 
BRISTOL-MYERS <MALAYSIA> SDN BHD 
Distributor for : 
Bristol Laboratories 
Mead Johnson 
Westwood Products 
:-----------------------------------:-----------------------------------:-----------------------------------: 
CAMDEN INDUSTRIES <M> SON BHD 
Distributor fo~ : 
Camden Indust~ies 
DRUG HOUSES OF AUSTRALIA CM> SON 
BHD 
Distributor for : 
Cede~roth 
Chugai 
DHA <S'po~e> 
Optisol 
Pharbita 
Trebor <UfO 
CHEAH & FAM MALAYSIA SDN BHD 
Dist~ibutor fo~ : 
Biochemie, Austria 
Ciech Polfa, Poland 
Ebe~~e, ALtst~ i a 
Lei~as, Finland 
Medica, Finland 
1 Sumitomo, Japan 
Weber, West Germany 
DUTCH BABY MILK INDUSTRIES 
<MALAYSIA> BERHAD 
Dist~ibutor for : 
C C Friesland 
Cooperative Company Holland 
CIBA-GEIGY <M> SDN BHD 
Distributor for : 
Ciba 
Geigy 
Servipharm 
Zyma 
DUMEX DIVISION THE EAST ASIATIC COl 
<M> BHD 
Distributor for : 
Apotheker·nes Lab 
Conn aught 
Dumex 
:-----------------------------------:-----------------------------------:-----------------------------------: 
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i JOHNSON & JOHNSON PTE LTD i LUEN WAH MEDICAL CO (S) PTE LTD I NAINA MOHAMED & SONS LTD 
l Distributor for : I Distributor for : I Distributor for : 
Janssen Pharmaceutica I Helm I Alembic Chemical Works Co Ltd. 
Ortho Diagnostics I Malayan Pharm Factory l India 
K H JOHNSON TRADING CO 
Distributor for : 
H9me Diagnostics Inc, USA 
Nordisk Denmark 
Yunglin Korea 
KYOWA HAKKO INDUSTRY (S) PTE LTD 
Distributor for : 
Kyowa Hakko Kogyo Co Ltd, Japan 
LIANG COUR~ PHARMACY PTE LTD 
Distributor for 
Gueat Medical 
Heine 
Macherey-Nagel 
Nycomed 
PHARMACON PTE LTD 
Distributor for : 
Carnrick Laboratories USA 
Carrton (Dalalande) 
Delainndo, France 
Delandale Laboratories UK 
Dubernard Hospital, France 
Forest Laboratories USA 
Furt Laboratories, France 
Marion Laboratories USA 
Mochidan, Japan 
Otsuka i Banyu Pharmaceutical Co Ltd, Japan! 
Pharmon 1 Bioforce Limited, Switzerland 
R.P. Scherer Dale Medical Products Inc, USA 
Rotexmedica Darya Verla Lab/Pharos Chemie, 
Santen Holland & Indonesia 
Scanpharm ECE Ch~mica, Rumania 
Shigakaen Franco Indian Pharmaceuticals 
Taiho {Pvt) Ltd, India 
Takeda German Remedies Ltd, India 
Ginsana Products Lugano S.A. 
MALAYSIA CHEMIST PTE LTD 
Distributor for : 
Elder Pharmaceuticals Inc USA 
Forest Pharmaceuticals Inc, USA 
Malaysia Chemist Pte Ltd 
MAY & BAKER SINGAPORE 
Distributor for : 
Institut Merleux 
May & Baker 
Ono 
Pasteur-Vaccins 
P N Gerolymatos S A 
S.P.E.C.I.A. 
i PFIZER PTE LTD 
I Distributor for 
Pfizer 
PTE LTD 
8¥.-i tzerland 
Gohl Pharma S.A., Switzerland 
1 Lab9ratories Biofarma Lda, Lisbon 
Laevosan Gesellschaft GmbH & Co 
KG, Austria 
Lagap S.A., Switzerland 
Mayfair Laboratories, England 
MD Associates, Inc., USA 
Napp Laboratories Limited, England! 
Neolab S.A. Switzerland 
Pharmax Limited, England 
Phyteia Ag Switzerland 
Po-Ho-Co Ltd Switzerland 
Pt Pradja Pharmaceutical 
Industries, Indonesia 
Prodesfarma S A, Spain 
Rallis India Ltd (T.C.F. Products) I 
India 
G H Zeal Ltd, England 
I I I 
I I I 
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l WALETA SINGAPORE PTE LTD l Y~ELLCOME (SINGAPORE) PTE LTD l PLAZA PHARMACEUTICAL TRADING PTE l 
Distributor for : l Distributor for : I LTD l 
Apotex Inc l The Wellcome Foundation Ltd l Distributor for : l 
Ashford Lab Ltd I Calmic Ltd l Dr Falk 
Bracco Ind Chemica S.p.A. l l 
Dentinox 
Lek Ljubljana 
Medefield Pty Ltd 
Me ph a 
Optopic Lab Ltd 
Pharmochem 
Row a 
Soico Baise Ltd 
Spofa 
Taneba Seiyaku 
Viratek 
Walter Ritter 
WELLCHEM PHARMACEUTICALS 
l Distributor for : 
I Dams Lab 
! Grinsted Products 
UCB 
Nippon Shinyaku 
Pliva 
Hermal 
Tillotts 
(PTE) LTD 
Luxilon Industries Co (Orfit) 
F.E. ZUELLIG (TRADING) PTE LTD 
Distributor for : 
Allergan Iternational, USA 
American Cyanamid Co, USA 
(Lederle Lab) 
Astra Pharmaceuticals Int AB, 
Sweden 
Boehringer Mannhiem GmbH, W Germani 
British Cod Liver Oils Ltd, 
England 
Dispersa Ag, Switzerland 
Eisai Co Ltd, Japan 
Eli Lilly S.A. USA 
Kabivitrum Int AB, Sweden 
Kulzer & Co GmbH, W Germany 
Les Lab Servier 
(Asiamed Pharmaceutical Products 
Pte Ltd) 
Merrell-Dow Pha~m Inc, USA 
E Merck, w Germany 
Nattermann Int'l GmbH, W Germany 
Hadensa (Ireland) Ltd 
Rickitt & Colman Ltd, England 
Lloyd's Pharm 
Riker Lab Pty Ltd Australia 
A.H. Robins Co USA 
Sanofi Pharma Int'l France 
Schering Corp USA 
Smith, Kline & French Lab 
Australia 
Synthelabo Pharmacie, France 
RECKITT & COLMAN SINGAPORE PTE LTDl 
Distributor for 
Lloyd's Pharm 
Roche 
ROCHE SINGAPORE PTE LTD 
Distributor for : 
Reckitt & Colman 
SATO PHARMACEUTICAL (S) PTE LTD 
Distributor for : 
Sate Pharm 
SCHMIDT SCIENTIFIC PTE LTD 
Distributor for : 
Byk Gulden 
Clonmel Chemical Co Ltd 
Douglas Pharmaceuticals Ltd 
Lundbeck 
Rater B V 
Schering A G 
Tidal Pharmaceuticals Co Ltd 
:-----------------------------------!-----------------------------------1-----------------------------------l 
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SHENTON PHARMACY : SINGAFRENCH ENTERPRISE PTE LTD 
Dist~ibuto~ fo~ : : Dist~ibuto~ fo~ : 
Ambix Lab, USA : Laborato~ies Chauvin Blache,F~ance 
App~oved P~escription Se~vices Ltd: Labo~ato~ies Delag~ange (France) 
England : Laborato~ies De L'ozothine France 
Smith & Nephew Pharm Ltd, England : Labo~ato~ies Leu~quin <F~ance) 
SIME DARBY MARKETING 
Dist~ibutor fo~ 
Atlantic Lab 
Anpha~ Rolland 
Biomedica Foscama 
Chinoin 
Dupha~ 
Dupha~ B V 
Egis 
Eian Pha~m 
Engelha~d 
Gea 
Gedeon Richte~ 
~:::endall 
Knoll 
Lab fo~ Applied Biology 
Labo~ato~ies Francais 
Nordma~k 
Rotta 
Labo~ato~ies Vallant-Defresne 
(France) 
Labo~ato~ies Pete~s <F~ance> 
SINGAPORE PHARM GS:PORE> PTE LTD 
Dist~ibuto~ fo~ 
Bieffe SpA <Italy) 
E Denk <W.Germany> 
Farmasimes <Italy) 
Lema Industria F~rmaceutica Italy 
Inte~national Gene~ics <UK> 
Labatex Pha~ma S.A. <Switze~land) 
I Medinat Pha~maceuticals Aust~alia 
Mylan Pha~m <USA> 
Pha~ma Plus <Switze~land> 
Recordati <Italy> 
SOMEDICO PTE LTD 
Dist~ibuto~ fo~ ~ 
C B Fleet Co Inc 
Cent~al Pha~m 
Climex AG/Ltd 
Ego Pha~m, Aust~alia 
Ho Van Ho~ Pha~m 
Meiji Seika Kaisha Ltd 
National Pha~m 
Standa~d Lab 
Sussex Pha~m 
SPOT INDUSTRIES PTE LTD 
Dist~ibuto~ fo~ : 
Asia Pha~m CKo~ea> 
Cadila 
Chung Gei F'harm 
Dong Shin Pha~m 
Elko O~ganisation SRL 
Fujimoto Pha~m Co~p 
Inga Lab 
Yuhan Co~p 
STERLING DRUG (S'PORE> PTE LTD 
Di stl~i but or fa~ 
B~eon Lab 
National Lab 
Nyal 
Ste~ling 
Winthrop 
JEBSEN & JESSEN INDUSTRIES 
SERVICES PTE LTD 
Dist~ibutor for : 
1 Becton Dickinson 
Diset~onic Ag 
Leo Pha~m 
Monocional Antibodies Inc 
Nova Indust~i A/S 
Recordati Spa 
1 Scir1vo 
Synco Inc 
:-----------------------------------:-----------------------------------:-----------------------------------: 
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+-----------------------------------------------------------------------------------------------------------+ 
DIETHELM SINGAPORE PTE LTD 
Lullpold-1'4ork 
May & Baker (OTC products) 
Mcneil 
Medinova 
Nicholas 
Or tho 
Sandoz 
Searle 
Squibb 
Swiss Serum & Vaccine Inst. 
Warner Lambert {Brunei) 
DUOPHARMA TRADING (S) PTE LTD 
Pharma Hamelin, W Germany 
Potter & Clarke Ltd, England 
Rotexmedica, W Germany 
Sinil Pharma, S.Korea 
TAD, W Germany 
Tal Guk Pharma, s Korea 
Tai Kwang 
Yeong Dong Corp, S Korea 
GUARDIAN WHOLESALE 
Blk 60B, #11-03/04 
Singapore Warehouse 
Martin Road 
S0923 
Tel : 7339883 
Telex : RS 56606 GUARD P 
Distributor for : 
Ciba Geigy 
Guardian 
ICI 
Napp 
Pickles 
l-----------------------------------l-----------------------------------l-----------------------------------1 
I DRUG HOUSES OF AUSTRALIA (ASIA) I FAR EAST DRUG CO (PTE) LTD I HOECHST SINGAPORE PTE LTD I 
I PTE LTD I 1 Sophia Road #08-01 I 200 Cantonment Road #16-02 
I 2 Chia Ping Road Peace Centre ' Southpoint 
#09-01 Haw Par Tiger Balm Building S0922 S0208 
No 2 Chia Ping Road Tel : 3378641, 3378349, 3~89095 Tanjong Pagar· P 0 Box 102 
82261 Distributor for : 89108 
Tel : 2652777 Biomedis Tel : 2257227 
Telefax : 2654703 Imperial Pharm Telex : HOESIN RS 21662 
Distributor for : Medichem Fax : 2257228 
Cederroth Pediatrica Distributor for : 
Chugai 1 Therapharma 1 Behringwerke AG 
Dr Grossman AG, Pharmaca United American Pharm I Behring Diagnostics, U.S.A. 
Drug Houses of Australia (Asia) Westmont I Diamant Lab, France 
Pte Ltd I Hoechst Akllengesollshaft 
F.Ahlgrens Tekn. Fabrik A.B.- I Hoechst Veterinaer GmbH 
Lakerol I Roussel Laboratories Ltd, U.K. 
Laboratories Landarian S.A. I Roussel Uciaf, France 
Medicopharma 
1-----------------------------------l-----------------------------------l-----------------------------------l 
Source : DIMS, 1.7olume 16 Number 3 October 1987 
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DISTRIBUTORS' DIRECTORY MALAYSIA/SINGAPORE 
:-----------------------------------:-----------------------------------:------------~----------------------: 
: B BRAUN SINGAPORE PTE LTD : BRISTOL-MYERS (S) PTE LTD : DIETHELM SINGAPORE PTE LTD : 
I 
I 460 Alexandra Road : 50 Genting Lane. $04-01 
#34-03 PSA Building : Cideco Indsutrial Complex 
: S0511 I S1334 
TEL : 2743176 TEL : 7470246 (5 lines) 
I Telex : 56734 BBRAUN Cable : MYTOL SIN~APORE 
Fax : 2737091 Telex : RS 35359 MYTOL SINGAPORE 
Distributor for : Distributor for : 
B Braun Melsungen A G Bristol Laboratories 
B Braun Medical Industries Sdn Bhd Mead Johnson 
UPHA CORPORATION (M) SDN BHD 
No 9 Lorong SS13/3D 
Subang Jaya Industrial Estate 
47500 Petaling Jaya 
Selangor 
TEL : 7334545 (4 lines) 
Telex : MA 36177 
Westwood 
WARNER-LAMBERT (MFG) SDN BHD 
Jalan 13/4A 
46200 Petaling Jaya 
P o Box 87, P.J. 
46710 Petaling Jaya 
TEL : 03-7565011 
Cable : WARNLAM 
, Distributor for : Telex : HALLS MA 37618 
Distributor for 
I 
I 
I 
I 
Beacons Chem 
Upha Pharmaceutical Parke Davis 
Warner-Lambert 
:-----------------------------------:-----------------------------------
Source DIMS, Volume 16 Number 3 October 1987 
34 Boon Leat Terrace 
S0511 
TEL : 4711466 
Telex : RS 36121 DIETCO 
Fax : 4799104 
Distributor for 
Beecham 
Carter Wallace 
Cilag 
Geistlich 
Lipha Pharm 
SYARIKAT WELLCHEM SDN BHD 
928 Jalan 17/38 
46400 Petaling Jaya 
I TEL : 7572449, 7570218 
Fax : 03-7568228 
Distributor for 
Doms Lab 
Nippon Shinyaku 
Richard Daniel & Son Ltd 
UCB 
Wellchem 
Enforcement 
Statistics of national enforcement coverage, 1984 - 1986 
+-----------------------------------------------------------------------------------+ 
Cumulative 
Total 
1984 : 1985 : 1986 : 1.1.78-
31.12.86 
-------------------------------1-----------~-----------:-------------:-------------t 
Prosec1.tt ion 
No of cases prosecuted 
No of cases found guilty 
Total fine imposed ($) 
Control of Medicine 
Advertisements 
No of applications for 
approval 
No of advertisements approved 
Fees collected ($) 
274 149 
266 140 
:293,230.00 1175,300.00 
564 I 2,715 
368 I 386 
28,200.00 l135,750.00 
I. 
I 
229 1,163 
203 1,122 
213,260.00 11,107,670.00 
4,157 
1,247 
207,850.00 
+-----------------------------------------------------------------------------------+ 
Source Pharmaceutical Services Division, Ministry of Health Malaysia 
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Appendix 54 
Enforcement 
Statistics of national enforcement coverage, 1984 - 1986 
+-----------------------------------------------------------------------------------+ 
Cumulative 
Total 
1984 : 1985 : 1986 : 1 • 1 • 78 -
31. 12.86 
-------------------------------~-----------l-----------!-------------1-------------l 
Enforcement 
I I I 
I I I 
Number of premises raided I 447 I 500 I 894 I I I 
Number of premises where 
poisons were found I 252 I 325 I 474 I 1,972 I I I I 
j I : I 
Number of drug items seized I 3,634 I 5,393 j 9,674 I I 
I I 
I I 
Value of drug items seized ($) 1404,349.00 1724,894.00 :1,534,.2.24.00 
I I I 
I I I 
Number of licences issued 
Type A I 425 I 624· I 714 I I I 
Type B I 389 I 462 I 501 I I 
' Type D I 372 I 434 I 457 I I I 
- Type E I 19 I 17 I 17 I I I 
Fees collected ($) I 48,240.00 I 56,580.00 I 60,940.00 I I I 
+-----------------------------------------------------------------------------------+ 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
STATISTICS SHOWING THE PERFORMANCE OF PROGRAMME OPERATIONS 
Procurement and Distribution 
Statistics on stocks handled by the Pharmaceutical Laboratories and Store, 
Petaling Jaya, 1984 - 1986 
+---------------------------------------·----------------------------------+ 
Stocks I 1984 l 1985 l 1986 
:-------------------------!---------------:---------------·~---------------: 
Value of stocks 
received ($) l 47,887,427.00 I 51,713,310.00· l 75,375,385.00 
Value of stocks 
issued CS> l 57,638,510.00 l 60,734,749.00 : 68,217,726.00 
Annual stock turnover 
($) 1105,525,936.00 !112,448,059.00 l143,593,111.00 
.l Stock turnover rate I 1.77 l 2.08 : 2.20 
Value of stock balance 
31st Dec {$) l 31,547,750.00 I 26,801,236.00 I 35,276,592.00 
+-------------------------------------------------------------------------+ 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
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STATISTICS SHOWING THE PERFORMANCE OF PROGRAMME OPERATIONS 
Production 
Production statistics at the Pharmaceutical Laboratories and Store, 
Petaling Jaya, 1984 - 1986 
+-------------------------------------------------------------------------+ 
Type of Product l 1984 l 1985 l 1986 
:-------------------------:---------------:---------------:---------------: 
Small volume I I I 
' ' 
I 
parenterals (units> I 3,594,125 I 3,378,131 I 2,717,803 I I I 
' 
I 
I I 
Multidose parenterals 
<units> I 232,245 I 232,390 I 222,387 I I I 
I I I 
I I I 
Intravenous fluids 
<1.mits> I 678,119 I 611,443 I 614,467 I I I 
I I 
' I I I 
Tablets <unit> I 470,194,700 I 524,387,430 I 702,224,790 I 
' 
I 
Galenicals (kg) I 366,770 I 374,343 I 391,257 I I 
' 
+-------------------------------------------------------------------------+ 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
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Registration of drugs by The Drug Control Authority, 1985 - 1986 
+--------------------------------------------------------------------+ 1985 I 1986 
t--------------------------------------------:---------t-------------1 
Number of applications received 9 6,471 
Number of applications approved 1,842 
Number of applications rejected 852 
Number of applications cancelled 8 
Total Fees collected ($) 12,250.00 11,602,000.00 
+--------------------------------------------------------------------+ 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
QUALITY CONTROL 
Quality control tests done at the Quality Control Laboratory, 
Pharmaceutical Laboratories and Store, Petaling Jaya 
198~ - 1986. 
+--------------------------------------------------------------------+ 
1984. 1985 1986 
:----------------------------------:---------:---------:-------------: 
: Number of samples tested 6,972 : 6,874. : 7318 
+--------------------------------------------------------------------+ 
Quality control tests done at the National Pharmaceutical 
Control Laboratory, Petaling Jaya, 1984. - 1986 
-----------------------------------------+ +--------------------------- 1986 
Analytical Laboratory 
- samples tested 
- tests done 
Pharmaceutical Laboratory 
- samples tested 
- tests done 
Pharmacology Laboratory 
_- samples tested 
- tests done 
Microbiology Laboratory 
- samples tested 
- tests done 
1984. I I 1985 
---------:---------
1,4.60 
8,630 
1,897 
4.,682 
861 
1,070 
1,255 
1,396 
1,559 
9,26.1 
2, 30:8 
6, 21'1 
1,135 
1,579 
1,678 
2,062 
:----------------------------------:---------:---------
: Total samples tested 
: Total tests done 
5,4.73 
15,778 
6,680 : 
19,113 : 
1,570 
9,061 
2,805 
6,655 
1,184 
1,611 
2,081 
2,4.4.9 
7,64.0 
19,376 
+--------------------------------------------------------------------+ 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
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TRAINING 
Statistics on Training Activity, 1984 - 1986 
+---------------------------------------------------------------+ 
1984 l 1985 l 1986 
:---------------------------------1---------:---------:---------: 
Number of pharmacy assistants 
graduated I 91 I 96 I 44 I I I 
Number of pharmaceutical 
laboratory assistants graduated I 12 I 1 I 3 I I I 
Number of pupil pharmacists who 
completed training I 50 I 65 I 68 I I I 
+---------------------------------------------------------------+ PHARMACEUTICAL SERVICES DIVISION 
MINISTRY OF HEALTH 
Source : Pharmaceutical Services Division, Ministry of Health Malaysia 
ROSS-COUNTRY COMPARISON OF SELECTED HEALTH INDICATORS 
COUI\ITRY 
wed en 
• S. A. 
ustralia 
a pan 
. ~(. 
taly 
.s.s.R. 
i ng.;1.pore 
1.1gosl a vi a 
rge.nti na 
~azil 
osta Rica 
lgeria 
1..1ba 
:1ru 
alaysia 
.misia 
ESTIMATED 
MID 1976 
POPULATION 
8.2 m 
215.1 m 
13.9 m 
112.8 m 
55.9 m 
56.2 m 
256.7 m 
2.3 rl1 
21.6 m 
25.7 m 
109.1 m 
2 m 
17.3 m 
9.4 m 
16. 1 m 
12.3 tl1 
5.7 m 
PER CAPITA 
INCOME IN 
BUS (1975> 
8150 
7120 
5700 
4450 
3780 
2810 
2550 
2450 
1550 
1550 
1030 
960 
870 
800 
760 
760 
730 
CRUDE 
BIRTH RATE 
1976 11.9 
1976 14.7 
1976 16.7 
1976 16.4 
1976 12.1 
1976 14.0 
1976 18.5 
1976 18.8 
1976 18.1 
1970 22.9 
1975 37.1 
1976 29.3 
1975 48.7 
1975 20.7 
1975 41.0 
1976 31.7 
1975 40.0 
CRUDE 
DEATH RATE 
11.0 
8.9 
6.3 
6.3 
12.2 
9.7 
9.5 
5. 1 
8.4 
9.4 
8.8 
4.8 
15.4 
5.4 
11.9 
6.2 
13.8 
INFANT 
MORTALITY 
RATES 
8.7 
5.8 
14.3 
9.3 
14.3 
19. l 
27.7 
13.7 
36.4 
59.0 
38.2 
86.3 
27.3 
58.2 
Appendi l< 60 
LIFE EXPECTANCY 
<MALE & FEMALE> 
1975 (72.07 & 77.65) 
1975 (68.7 & 96.5) 
1976 (72.8 & 77.35) 
1976 (72.8 & 77.35) 
1970 (67.8 L 73.8> 
1972 (68.97 & 74.88) 
1972 (64.0 & 74.0} 
1970 (65. 1 ~t, 70) 
1972 (65.42 L 70.72> 
1975 (65.16 L 71.38) 
1970 (57.61 & 61.00) 
1975 <51.7 L 54.8) 
1970 (68.5 & 71.8) 
1965 (52.59 & 55.48) 
30.7 )* 1976 (66.2 & 71.4) 
125.0 1975 <52.5 & 55.7) 
<tracted From The Future of Health Services in Malaysia, Malaysian Medical Association, 1980 
ROSS-COUNTRY COMPARISON OF SELECTED HEALTH INDICATORS 
COUNTRY 
ESTIMATED 
MID 1976 
POPULATION 
PER CAPITA 
INCOME IN 
BUS < 1975> 
CRUDE 
BIRTH RATE 
CRUDE 
DEATH RATE 
INFANT 
MORTALITY 
RATES 
Appendix 61 
LIFE EXPECTANCY 
<MALE & FEMALE> 
-------------------------------------------------------------------------------------------------------
yria 7.6 m 720 1975 45.4 4.8 21.7 1970 (54. 49 ~1. 58. 73) 
. Korea 35.9 m 560 1975 28.8 8.8 - 1970 (63 ~( 67) 
hilippines 43.8 m 380 1975 43.8 10.5 58.9 1975 (56.9 & 60) 
hail and 43 m 350 1975 43.4 10.8 25.5 1960 (53. 6 g~. 58. 7) 
ndonesia 139.6 m 220 1975 42.9 16.9 125.0 1960 (47.5 8t. 47.5) 
*Peninsular Malaysia only Sourr.:e WHO Reports and IBRD Report on Income 
Extracted From : The Future of Health Services in Malaysia, ·~alaysian Medical Association, 1980 
Appendix 62 
Number of Admissions by Selected Common Causes in Government Hospitals 
from 1947 - 1976 in Peninsular Malaysia 
+-~-----------------------------
I 
I CAUSES 
1-------------------------------
:cardiovascular & heart diseases 
I 
I 
!Tuberculosis 
I 
I 
!Malaria 
I 
!Neoplasms 
I 
!Motor vehicle accidents 
!Other accidents 
!Mental Illness 
!Diseases of skin 
!Gastro-enteritis 
:complications of pregnancy 
I 
I 
!Bronchitis 
I 
I 
!Diseases of early infancy 
I 
!Deficiency diseases 
I 
!.Abortion & complications 
!resulting from abortion 
!Other diseases 
I 
I 
I 
I 
--------------------------------------------------------------------------------------+ 
1 9 4 7 I 1 9 5 5 I 1 9 7 6 !Difference in number! 
---------------------1---------------------:---------------------!of admissions in I 
No of 1% of total! No of I% of total! No of 1% of totaliGovernment hospitals! 
AdmissionsiAdmissionsiAdmissionsiAdmissionsiAdmissionsiAdmissionslbetween 1947 & 1976 
----------l----------:-------·---l----------l----------l----~-----l--------------------
4,162 I 1.90 I 8,539 I 3.47 I 28,917 I 4.63 I + 6.95 times 
9,056 
26,189 
1,901 
1,393 
35,395 
2,385 
22,514 
5,954 
5,479 
7,496 
1,820 
926 
1.283 
92,631 
4.14 
11.98 
0.87 
0.64 
16.19 
1.09 
10.30 
2.72 
2.51 
3.43 
0.83 
0.40 
0.59 
43.39 
7' 515 
911 
3,275 
2,407 
23,907 
.;!,762 
12,384 
8,139 
833 
7,192 
3,072 
4,387 
5,198 
138,016 
3.05 
3.70 
1. 33 
0.98 
9.71 
1. 93 
5.03 
3.31 
3.38 
2.92 
1. 25 
1. 78 
2.11 I 
I 
I 
9,139 
7,615 
11' 535 
15,513 
75,329 
21,635 
14,364 
19,685 
26,592 
8,369 
13,011 
10,270 
15,970 
56.05 I 350,607 
1046.00 + 1. 01 times 
1.21 - 3.44 times 
1. 84 + 6.07 times 
2.47 +11.14 times 
12.00 -'- 2.13 times 
3.45 + 9.07 times 
2.29 - 1.57 times 
2.98 + 3.14 times 
4.24 4.85 times 
1. 33 _.._ 1.12 times 
2.07 _.._ 7.15 times 
1.64 +11.09 times 
2.54 +12.45 times 
55.85 3.78 times 
1-------------------------------1----------
----------:---------- ----------1----------l----------:--------------------l 
!Total admissions I 218,584 100.00 I 246,237 100.00 I 627,551 I 100.00 I 
+----------------------------------------------------------------------------------------------------------------------_;._ 
Source : Medical Department - Reports & Hospital Returns 
Extracted from : The Future of Health Services in Malaysia, Ma1ay.sian Medical Association, 1980 
Appendix 63 
No. of nmdi.callv certified and inspectE~d deaths by selected common 
causes as registered with Reqistrar of Births & Deaths in Peninsular 
Malaysia (1955 & 1976) 
+-------------------------------------------------------------------------------
1955 
No o·f : I. o·f . Total 
Causes Deaths* : Deaths* 
Tuberculosis 1,673 7.72 
t·1al a1~ i Et 807 4.20 
Neoplasms 665 ~.). 46 
388 2. (>2 
F'neumon i a 1.. ~593 8.30 
Gastro-enteritis 2.429 12.65 
Co~plications of pregnancy 1 ,090 5.68 
Diseases of early infancy 4,462 23.25 
Cardiovascular ~ Heart Diseases 1.765 9.20 
Motor Vehicle Accident~ 217 1. 13 
Other Accidents 2,484 12.94 
Deficiency diseases 672 3.5 
Other diseases 949 4.95 
1976 
No of : I. of Total 
Deaths* : Deaths* 
750 3.21 
59 (). 25 
2,168 9.28 
249 1. 07 
1,250 5.35 
526 2·.25 
2,964 12.68 
n.a. n. a. 
4,686 20.05 
355 1. 52 
1,869 8.00 
315 1.35 
8176 34.99 
--------------------------------:--------------~-------.----------------------
Total No. of Medically 
Certified & lrispected Deaths 19, 194 : 100.00 : 23,267 : 100.00 
+-------------~-----------------------------------------------------------------
* medically certified ~ inspected deaths 
Source : Annual Report of Registrar of Births & Deaths 
Extracted From : The Future of Health Services in Malaysia; Malaysian Medical Association 
i9BO. 
MALAYSIA PUBLIC DEVELOPMENT EXPENDITURE FOR HEALTH SERVICES, 1981-90 
( ~'!> m i 11 ion) 
Programme 
Patient c:are services 
New hospitals 
Public: health services 
Ruro.\1 health services 
Other public: health services 
Dental health services 
Training 
Applied food and nutrition 
Other health activities 
Population and family health 
Total 
Fourth Plan 
allocation 
1981-85 
471.00 
471.00 
194.21 
190.92 
3.29 
4.04 
18.97 
14.34 
26.86 
46.75 
776.17 
Source : Fifth Malaysia Plan 1986-1990 
Extracted From : Basic Marketing Data, 1987 - MPTMA 
Estimated 
expendi tt..tre 
1981-85 
470.64 
470.64 
194.20 
190.91 
3.29 
4.02 
18.96 
14.33 
26.85 
46.75 
775.75 
Fifth Plan 
allocation 
1986-90 
377.57 
377.57 
234.90 
228.14 
6.76 
13.09 
3.25 
30.00 
26.54 
12.53 
697.88 
Appendix 64 
Appenal.x o:> 
PRINCIPAL CAUSES OF DEATHS IN GOVERNMENT HOSPITALS PENINSULAR MALAYSIA, 1980 - 1984 
1980 1981 1982 1983 1984 
-----------------------------------------------------------------------------------------------------------------· 
art Disease 2,885 ( 16. 56'1.) 2,892 ( 16. 95/~) 2,912 (16.50'1.) 2,787 (15.97'1.) 3,316 <18.73/.: 
seases of Early Infancy 2,596 (14.90'1.) 2,371 ( 13. 90'1.) 2,129 (12.07%> 2,365 (13.55%) 2,314 ( 13. 07'/.: 
cidents 2,290 ( 13. 14i0 2,073 ( 12. 15'l.l 2,373 ( 13. 45/~) 2,302 ( 13. 19'1.) 2,345 ( 13 •. 25/.) 
rdio-vascular Diseases 1,381 (7.93'1.) 1,379 (8.08'/.) 1 '432 <8.12'/.) 1,406 <8.06/.) 1 '571 (8.87%) 
oplasms 1,356 (7.781.) 1,328 <7.78'1.) 1,402 <7.95/.) 1,349 (7.73/.) 1,326 ( 7. 49i: 1 
eumonia 706 <4.05'/.) 650 (3.81/.) 612 (3.47/.) 612 (3.51/.) 518 (2.931.! 
berculosis 543 (3. 12'i0 576 <3.38/.) 503 <2.85'1.) 430 <2.46'1.) 471 (2 .. 66:~;, 
stro-enteritis 326 <1.87/.) 250 (1.47/.) 177 (1.00/.) 104 (0.60'1.) 135 <0. 76/.) 
seases of Liver 290 (1.66/.) 333 (1.95'1.) 297 (1.68/~) :301 (1.72'1.) 279 ( 1. 58/.) 
ficiency Diseases 169 <0. 97/.) 120 <0.70/.) 148 <0. 84/.) 140 (0.80%) 
mplications of Pregnancy - - - - 113 <0.64'/.) 
1 Causes 17,423 17,063 17,641 17,707 
urce : Information and Documentation System Unit, Planning and Development Division, Ministry of Health 
racted From : Basic Marketing Data, 1987 - MPTMA 
Appendix 66 
MALAYSIA : DOCTORS AND DOCTOR-POPULATION RATIO BY STATE, 1980 AND 1985 
1980 1985 
Number of doctors Number of doctors 
------------------------------ ------------------------------
State Government Private Total Government Private Total 
-------------------------------------------------- ------------------------------
Johor 183 168 351 193 273 466 
l<edah 91 67 158 110 116 226 
Kelantan 60 28 88 76 59 135 
Mel aka 62 56 118 84 74 168 
Negeri Sembilan 128 56 184 110 108 218 
Pahang 100 58 158 115 96 211 
Perak 87 311 398 225 356 581 
Perl is 21 8 29 21 10 31 
Pulau Pinang 121 207 328 205 282 487 
Sabah 61 67 128 70 110 180 
Sarawak 111 68 179 140 105 245 
Selangor 104 228 .......... ..::.._.::...:.:. 360 380 740 
Terer,gganu 47 18 65 62 32 94 
Federal Territory 621 377 998 509 511 1,020 
MAU:WSIA 1 '797 1,717 3,514 2,290 2,512 4,802 
Source : Estimates based on Ministry of Health, 1986 
Extracted From : Basic Marketing Data, 1987 - MPTMA 
MALAYSIA : INDICATORS OF HEALTH SERVICES AND 
CONDITIONS, 1980 AND 1985 
Indicator 
Doctors per 10,000 population 
Dentists per 10,000 population 
Acute care hospital beds* per 1,000 population 
Rural population per health centre ( '000) 
Rural population per midwife/rural clinic ( '000) 
Life expectancy+ 
- Male 
- Female 
Infant mortality rate (per 1, 000) 
Toddler mortality rate <per 1 '000) 
Maternal mortality rate <per 1 '00(1) 
Crude birth rate+ <per 1 '000) 
1980 
2.6 
0.5 
1.7 
25.8 
4· .. 3 
66.7 
71.6 
19.7 
1..8 
0.6 
30.9 
Sources : Ministry of Health and Department of Statistics 
Notes : 
* Excluding private health sector beds 
+ For Peninsular Malaysia only 
# Figure for the year 1984 
Extracted From : Basic Marketing Data, 1987 - MPTMA 
Appendix 67 
1985 
3.2 
0.7 
1.7 
20.4 
4.2 
67.6 # 
72.7 :j:~ 
17.5 # 
1. 5 # 
o. 4 tf 
30.7 # 
NUMBER OF RETAIL PHARMACIES AND CHINESE DRUGGISTS 
IN MALAYSIA - 1986* 
State Pharmacies 
Johore 15 
Mel aka 8 
Negeri Sembilan 7 
F.Territory 66 
Selangor 37 
Perak 25 
Penang 3 
l<edah 6 
Perl is 
Pahang 5 
Trengganu 4 
l<elantan 5 
Sabah 30 
Sarawak 26 
TOTAL MALAYSIA 237 
Estimate, Dec: 16, 1986 
Extracted From : Basic Marketing Data, 1987 - MPTMA 
Appendix 68 
Chinese Druggist 
350 
125 
140 
470 
340 
380 
275 
190 
40 
120 
55 
70 
135 
170 
2,860 
10 PRINCIPAL CAUSES OF ADMISSION INTO GOVERNMENT HOSPITALS 
PENINSULAR MALAYSIA, 1980 - 1984 
1980 1981 
---------------- ----------------
Accidents 110,053 (14.92:1.) 103,544 ( 13. 73:1.) 
Complications of Pregnancy 57,001 ( 7.73:1.) 94,440 (12.52:1.) 
Gastroenteritis 31,488 ( 4.27/.) 26,461 ( 3.51:1.) 
Heart Diseases 23,266 ( 3.16:1.) 23,659 ( 3.14:1.) 
Mental Illness 21,493 ( 2.92:1.) 23,131 ( 3.07:1.) 
Diseases of Early Infancy 19,287 ( 2.62:1.) 21,991 ( 2.92/.) 
Diseases of Skin 17,395 ( 2.36:1.) 18,080 ( 2.40:1.) 
Cardio-vascular Diseases 16,503 ( 2.24/.) 18,717 ( 2.48/.) 
Neoplasms 15,711 ( 2. 13/.) 17,264 ( 2.29:1.) 
Pyrexia of Unknow Origin 12,735 ( 1. 73/.) - -
Pneumonia - - 10,295 ( 1. 36:1.) 
Ophthalmic Condition - - - -
All Causes 737,465 754,394 
,t\ppendix 69 
1982 1983 1984 
---------------- ----------------
--------------·· 
106,870 (13.33;1,) 108,174 (14.11:1.) 103,022 ( 12.93: 
84,205 ( 10. 50:1.) 87,.322 ( 11. 39/.) 79,420 ( 9.97:' 
26,444 ( 3.30:1.) 26,969 ( 3.52:1.) 20,281 ( 2. 55~ 
24,905 ( 3. 11 ;1,) 23,806 ( 3.11:1.) 28,679 ( 3.60'; 
23,441 ( 2.92:1.) 22,381 ( 2.92/.) 23,745 ( 2. 98~ 
23,385 ( 2.29/.) 33,914 ( 4.42:1.) 32,039 ( 4.02: 
21,088 ( 2.63/.) 19,593 ( 2.56:1.> 18,014 ( 2.26i 
19,932 ( 2.49/.) 16,954 ( 2.21/.) 19' 143 ( 2.4o:. 
18,521 ( 2.31:1.> 18,160 ( 2.37/.) 18,610 ( 2. 34:/ 
13,958 ( 1. 74/.) 
- - 10,604 ( 1. 38:1.) 
- - - - 11,741 ( 1. 47i: 
801,670 766,698 796,691 
-------------------------------------------------------------------------------------------------------------------· 
Source : Information and Documentation System Unit, Planning and Development Division, Ministry of Health 
Extracted From : Basic Marketing Data, 1987 -i~TMA 
MEDICAL SPECIALISTS IN GOVERNMENT SERVICE IN MALAYSIA l\.S ON 31ST, DECEMBER, 1984 
Type of Specialist 
General Physician 
General Surgeon 
Obstetrician/Gynaecologist 
Anaesthesiologist 
Ophthalmologist 
Orthopaedic Surgeon 
Radiologist 
Paediatrician 
Pathologist 
Psychiatrist 
TB/Chest Physician 
Radiotherapist/Oncologist 
Otorhinolaryngologist 
Dermatologist 
Urologic Surgeon 
Nerosurgeon 
Neurologist 
Nephrologist 
Haemotologist 
Cardio-Thoracic Surgeon 
Plastic Surgeon 
Forensic Pathologist 
Paediatric Surgeon 
Venereologist 
Cardiologist 
Superscale Posts 
Post Filled 
42 
40 
31 
31 
27 
14 
22 
21 
18 
12 
12 
6 
8 
8 
4 
4 
3 
3 
4 
4 
2 
3 
2 
4 
1 
326 
38 
37 
23 
17 
14 
8 
12 
14 
9 
9 
8 
4 
3 
6 
1 
2 
0 
2 
2 
2 
1 
1 
0 
1 
0 
214 
Source : Medical Services Division, Ministry of Health 
Extracted from : Basic Marketing Data, 1987 -MPTMA 
Timesacle Post Filled 
Malaysia 
20 
8 
10 
1 
2 
3 
5 
9 
3 
1 
2 
2 
1 
4 
2 
1 
0 
1 
1 
2 
3 
0 
0 
2 
0 
83 
Non-
Malaysia 
1 
4 
0 
4 
2 
1 
1 
0 
0 
1 
0 
0 
0 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
16 
Total 
21 
12 
10 
5 
4 
4 
6 
9 
3 
2 
2 
2 
1 
5 
3 
1 
0 
1 
1 
2 
3 
0 
0 
2 
0 
99 
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Total No of 
Specialists· 
Employed 
59 
49 
33 
22 
18 
12 
18 
23 
12 
11 
10 
6 
4 
11 
4 
3 
0 
3 
3 
4 
4 
1 
0 
3 
0 
313 
~: .. I, 
j .. • 
..... 
.App~ndix 71 
4-PEAOAGANGAN ANTARA NEGARA-NEGAAA ASEAN 
. ~$~~- . . 
-.4-'-INThA-AsEAN mADE 
' '· US$ mllllorl 
. . 
i 
Perdagangln Antara .,egara-kegaui ASE_AN 
.. 
. ini,;;-ASEAN Trade · · :. ;' · -' 
I 
' 
. ~ .. 
Nager! Thai Btunel Indonesia Malaysia Fll!plna • ;.; sirigajJura 
I 
Btullfll lndorrosla Malays IIi Philippines Slngapori · than and 
'-
., 
' 
·.· ; 
Imparl Eksporl lmpotl Ekspoil Imparl Eksporl Import Eksporl lritport Ekaporl Import l!kspOit 
lmpod '&pod lmpotf Elrj10rl lmpotf ~lrporf lmpotf ' ~tqHHI lnrpo~ ~ tntjJod ~tqHHI 
Brunei 1976 .. N.A • N.A. 13.3 60.0 N.A. . N.A. ' : &l.o ~.il 5.8 . 
lllllmll ' 
- tsO.~ . 1984 .. u 21.7 31.0 0.8 i.2 6-t.e .. 228.11 1&.8 201J.ii 
1986 .. 0.4 IU 29.8 18.11 o.e t&.s ', t47.il ts&.li: I i.e :iii.R 
1988 .. 4.3 0.8 :18.5 i!.f.o t.:J iu •· ted 120.1 20.$ i411.0 
' 
1887 .. 4.0 0.6 1o:i.s u o.li 47.8 .· :i1~t.2. tt9.~ b.t ja1.e 
'• 
' 
lndoneslo 1070 .. N.A. N.A. 8.0. ':i8.o ir.o 28.0 87.0 mi.o u.o ; 
·Indonesia 
j1ol.o 1884 .. N.A. I-I.A. 88.0 9ti.o 18.0 I&S.O 11,128.o 6&.0 98.0 
1088 .. 1.0 N.A. 114.0 77.0 2:1.0 199.0 782.0 1,828.0 68.0 6u 
1988 .. 1.0 i.o 110.0 !lli.O ID.O i lii.ci ii8i.o . o~:h 72.0 &4.0 
. 1887 ..... 1.0 B.O 165.0 ito.o 811.0 i 74.0 4 is.o . t.ol to 84.0 03:0 
I 
I 3~~-d Malaysia 19l0 .. N.A. N.A. 88.0 11.0 u 29.0 ios.o 80.0 18.0 
Malaysia I 
1984 .. t.o 97.0 17~.0 101.0 i 242.0 363.0 l.e31i.o 3,38~.0 4no 486.0 
1905 ... t.o 31.0 139.0 88.0 230.0 . 308.0 !·~18.0 uo.l.o 438.0 1127.0 
1988 .. t.o 35.0 144.0 54.0 bs.o 247.0 1,830.0 u&e.o 429.0 381:0 
1987 .. 1.0 113.0 178.0 147.0 i48.o 323.d j,ll73.7 31283.0 443.q Blt.O 
I 
' 
! 
.fJIIplna 1070 . NA N.A. 30.0 2.0 28.0 • ll.d 7.q . $.0 
PM/pplnes 
1984 .. 55.7 0.6 199.0 0.3 354.9 178.0 it~-· ati.3 80 .• 9.0 
1985 .. 14.9 0.5 J09.8 18.3 390.2 173.7 ,128;8 249.8 65.8 83.1 
1088 .. 13.3 0.8 137.4 27.9 215.1 Dt.O 128.8 t&3.8 ·29.0 88;7 
1987 .. 52.6 0.8 92.1 84.8 233.6 tio.o 237.4 1ti11.4 4.U 124.7 
Slngapura 1970 .. . 33.9 N.A. N.A. 459.0 a4o.o 0.0 4.0 I ,. 4o.o 11.0 
S/ngllpCNB 
1984 195.0 204.0 N.A. N.A. 4,308.0 3,902,0 185.0 207.0 
I 833.0 111!14.0 .. 
1985 .. 245.0 291.0 N.A. N.A. 3,738;0 3,6.30_.0 1911.0 218.0 144.0 04U 
1088 .. 138.0 314.0 1,230.3 '984.4 3,400.0 3.327J) 184.0 . 248.0 
' 
- 737.0 821.0 
1987 .. t31.o 337.0 i,480.0 i.o8o.o- '4,600.0 .4,073:0 178.0 4i8.0 '· i,ott.o uia.o 
. 
·. 
Negerl Thal1970 .. N.A. NA 10.0 18.0 7.0 40,0 3.0 . ·-·-·~-0 40.0 
Thailand 
' 
. 1984 218.8 .. f!.O 79.1 48.9 604.7 350.8 20.~ 23.0 . ~,2.~ 823.$ .. 
lOSs .. ' 330.7 IU 80.8 43.3 547.0. · as4:e 69.8 113.1 888.11 585.8 
1008 .. 179.0 14.8 81.9 117.7 384.8 38ta 70.7 20.0 ioO .• 788.0 
' 1987 
,. 
243.7 15.8 11.1.1 68.11 521.3 38U t40.8 73.0 t.ot2.t t,o2a.O .. I 
. ' 
.. 
' Kurang darlpada ASS I Juta. • le~s lh~ IJSI f mllilotl. · 
Sumber: t'er~aan llaluan Pardagang11n (foenerbltan IMI'}. j. . . • . ' Soilrce: Olrecl/on ol _tmda Slaflsflt:j (IMF l'ubllcallorr] • . 
,· 
-:I 
: 
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1.2-ASEAN: I<EY ECONOMIC DATA 
Rlzab tlisbah Jumlah Hulang luar J'legerl Bekalan Wang' l<al!ar f'ergaluarall Kadar Pertukaran 
l<asar Qayar Balik (% ~adar Pangangguran Parkllangan• Wang (matawang 
Anlarabangsa• Hutqng• partuml>ullan) (% darlpada (% kadar nagar! bagl 
lAS$ jula) Tols/ Exlernsl Debl tenaga buruh) !umfluhan) AS$1 pada 
akhlr !ampoh) 
-
Gross Debl Servicing Money supply• Unemploymttril Msnulsclurltig Elfchange Rate 
lnlemalional Rallo• AS$ rlbu (uta Sabagal% (~ groW(h Rare (" of Production" (nallonsl 
Rsse,Yes" USI billion darlpada KNK rilltt) labour Ioree) (% groWfll currttncy per 
(US$ ni/1/ion) As " or GNp rate) ussr el end 
or period) 
(Brunei Dollar) 
NA Nil NIL NIL NA. N.A. N.A. N.A. 
N.A. Nil Nil t-Ill N.A. N.A. NA. 2.17 
tfA. NIL NIL Nil - 9.8 NA N.A. 2.09 
NA NIL !'Ill Nil -11.3 N.A. N.A. 2.16 
N.A. NIL NIL NIL - N.A. N.A. 1.99 
ru. NIL NIL NIL - N.A. N.A. -
(Aupla!l) 
160 N.A. N.A. N.A. 36.4 N.A. N.A. 378.0 
4.773 190 I 30.3 149.7 6.5 N.A. 8.2 1,074.0 
4,974 19.8 31.0 145.1 So9 N.A. 8.2 1.125.0 
4.051 24.3 37.3 195.2 7.6 N.A. 4.9 1,641.0 
5,592 37.1 44.1 302.6 2.9 N.A. 13.5 1.650.0 
11,304 34.3 48.6 258.4 
-
N.A. 
- -
(Ringgit) 
660 N.A. f>I.A. t>I.A. 8.0 7.5 12.3 3.08 
3.723 JIB 15.3 50.2 - 0.8 5.8 11.4 2.43 
1.912 Hi.O 17.6 58.7 1.7 8.9 - 9.2 2.41 
6,027 18.8 19.4 78.1 2.8 8.3 7.2 2.80 
7,435 14.8 20.4 67.5 13.0 8.2 12.5 2.49 
1,220 
- - - -
IM 
- -
(Peso) 
251 N.A. N.A. NA. 46 4.3 1.8 8.44 
602 23.7 25.4 90.7 3~9 10.6 - 7.2 1978 
615 32.7 26.3 81.7 35.7 II. I - 7.7 19.03 
1.720 34.0 20.3 92.9 42.7 I 1.1 0.8 20.53 
960 35.8 27.9 61.0 52.4 9.6 7.1 20.00 
6_11 
- - - - -
I 
-
~ 
(Singapore 
12j 
Dollar) 
1.012 0.6 0.1 7.9 15.6 60 3.0!1 
10.416 0.4 05 28 30 2.7 7.5 2.1!1 
12.847 2.1 05 2.5 - O.P 4 I ~ 7.3 2.10 
12.939 2.4 0.3 19 11.8 6.6 8.8 21!1 
15.227 1.3 0.2 1.1 12.0 2.8 f7.0 1.99 
-
0,2 ci2 O.JI 
-
2.5 
- -
(Bah!) 
908 I" .A. N.A. N.A. 7.9 I.e) N.A. 20.93 
1,92j 23.6 15-11 37.(J 11.6 j!.2 82 27.11i 
11!.190 I 26.8 17.4 45.3 -:u 2.8 
' 
o.li 26.65 
2.8Q4 l!1.3 IU A3.2 18.8 (J.O IJ.O 28.13 
4.1107 19.!1 17.1! !1.0 - ;!.6 IU 21j.07 
,.,eoe 18,9 ff!.2 ~1.5 - -
- -
1 Malsysle-197fl pr/Cas; Indonesia anq SlngaporB-11175 ptfces; f'hlllppllfttS and Tltallsnd-1900 pr/Ces. 
~ E•porls (.p.b. les• /mpprfs Mf. · 
J (Jross reserves of monetary aulhorftles comprising SDRs, /MF Reserve Posillon, foreign flxcltange minus gold. Data for 1988 refers to June only.----
• Oefinect as service psymenls O/f fiKiem~l debl as a perce(llage of eKporls of goorls Etnd services. · 
1 Comprlslrrg curillf!cy hJ clrr:ule(loq and !lflmatld deposlls. · 
' Data for Malayslil reter11 111 f'flf!/lfsulsr Malaysia only. 
'Esllm~le. 
Source: ./FS, natlom•l raporfs. Wotfd (J&vfllopmen( lnctlcslors llnti Key /ndlcalor, of Oeveloplng ~snr~~r Countrllls of ADB, 
vii 
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f .2-1\sEAN: PERI\NOI<MN EI<ONOMI PEN tiNG 
. luns Bllangnn Parlumbuhnn · kNI< Per l<nplla . Perlumbuhan 
kawosnn PP.nduduk I< ON I( Podo Horga Harga Penggunn 
(kllomoler Oulo) St>benar' Pasarnn Semosa (%) 
pcrsP.gl) (%) (AS$) 
1\ren PopulntiOtt ne11IGDP GNP Per C11pila Growllrln 
(sqliRro (milliorr} Growtlr' elfurnml Consumer Prlcos 
hllomelres} (%} Mmt.el Prices (%} 
(US$} 
BnUNEI ! ~ . 5,765 
Bifi,JNEI 
N.A. N.A. 1!!7~ .. .. 0.156 NA 111~4 
" 
.. 0.216 4.0 NA. 3.0 
1\11!5 .. .. 0222 1.0 N.A. L9 !?P!l .. 0.226 4.0 l5.~oo 0.7 
f907 .. .. , . - 2.0 - 1.7 
1980' .. - Lo - 2.0 
.INboNESIA ,. 1,90(345 
/NQ(JNESIA ' 
jl170 .. .. 119.47 75 74 12.3 
9M .. 160.00 60 520 g I 
j~~5 ;63.40 2.4 476 . 4 . .t 
11'66 i66.7o 32 ~90 9.2 '•' .. .. 
11':lo• · · .. - 3.!J - 9.3 
.. -
!1.0 
-
s.o 
Ml\ll\ YSII\ .. 329,293 
~A~AYSIA 
11170 .. .. 10.40 63 380 1.9 
1901 .. , . 1627 7.8 1.999 3.9 
I91JQ .. ., 1569 -l.o 1,908 0.4 
190'1 .. .. 18.10 1.2 1.583 0.8 
!907 
'' 
16.50 5.2 1,830 08 
1900' .. Hl.92 7.4 t,803 2.!1 
'· 
FllfPINI\ .. 300,000 
PHtltpf'INES 
4.3 !117Q .. .. 3685 
-6.0 190 140 1901 .. .. 53 17 815 50.8 
1905 54.30 -4.3 572 5.7 .. .. 
1986 55.00 1.5 560 - 0.3 .. 
!9~7 57AO 5.1 597 7.5 ,, 
f900' - 11.!1 - 1!.0 .. 
SINoAPU"'I\ .. 621.7 
SINGAPOfiE 
!9iq 2.07 13.7 918 03 .. .. 
1!181 253 8.3 8.916 2.8 .. ,. 
1!18~ 256 - 15 6,890 0.5 
1!106 260 I 8 1:410 -1.4 
1!107 .. 2,61 8.8 7.900 0.5 
f988'. 
-
0.0 
-
1.9 
" 
-
NI!Gf'RI lHAI 51~.000 
rll/lll.(IND 
0~ 1979 .. ~ ! 36.37 89 lBO 
111~4 .. .. ~o-1o 5.5 769 0.9 
IPQ~ ,. 51.30 3.2 73~ 2.f 
9!16 .. .. ~2.60 3.5 810 19 
I~Q7 .. .. 53.60 7.i - 2.~ 
191181 .. 
-
8.3 
-
!1.0 
1 Mnlnysla-hnrga !97811ndonesla dan Slngapttrll-hllrgn 1975; l'nlpln11 dell Negerl Thal-hargn 1980. 
1 Eksporll.o.b. lolulc Import c.l,l. 
lmb .. ngan lmbangan 
A_koun Samasa_ rerdeg~ngan' 
lmbangnn (ASS Jula) 
Purnber,aron 
(AS$ uta) 
Cumml Jlccourrl BIIIIIIICIIol 
Bala11ee ollf!IJ rrnde' 
Balenceol (US S milfton} 
P11ymenls 
(US I mllr1011} 
' N.A. 862.0 
2.648 2.561.3 
2,300 2,328.7 
1;500 1,144.2 
!1,500 499.3 
, .. oo 
-
253 loci.o 
-1.858 8,01JI.O 
-i.923 8.366.0 
-4,004 347.0 
-1,820 6,314.11 
-•,ood 
-
I. 8 
- ,812 
~460 
2,354.0 
- 832 3.145.0 
- 80 3.000.0 
2,452 5,303.0 
t,t11 
.f,323.0 
- 30 - 163.0 
-1,258 - .919.5 
- iii - 737.4 
998 
-
404.3 
- 539 -1,240.8 
-f,soo 
-
I 
- 566 - 907.0 
- 360 -4,597.0 
- 15 -3,425.0 
479 -3.018.0 
533 -3;90:!.0 
i,ooo 
-
- 249 - 669.0 
-2,109 -~.ooi.l 
-1.637 -2,137.5 
247 - 301.6 
- 691 -1,70i.l 
- ell !I -
1 f11tab ko~or lambdgf!·!ombngn kowongnn ynng lordlrl dnrlpadn SOns. kedudtrknn rll11b IMF, pf!rlukoron wang eslng lolnk omas, Oala bngllnh<m 1988 
Pllhlnggo bulan Juii sulinJII. . · 
f P.!lrtk•!fkari sebagnl b~ynrnn perkhldmnlan ko alnA hulnng luar nnporl SP.bngol porglus ek~POII bargngan clan parkhlclm11len. 
• Terdlrl dorlplldn motnwtmg dtolorn odornn dart ~lmpanan SP.mnsn. · 
1 t;>nla unlulc Mulnysln ntllruJuk kopoda Somennnfung Molnysln sohRfa. 
' 1\nggnran. 
Sr:rrr~er: rrs, laporrm-lopornn nogarn, Pelunluk-p~lunJuk rembongunnn Ounlg clan Petur>Juk-pelunJuk Penllng Negora-negara l<eanggoloan 1108. 
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t .3-1\Sl:I\N: kl:WANOI\N. Sl:I<Toh 1\WI\M 
1\S$ I I 
,_j--AsEAN: "untie sEC#nrl FINANe~; 
· I.Js$ mimti/1· ua 
' 
I 
· llosll' Petbolonfnen1 leblhonf • Punca Pamblayd_D!! 
kurengan Sollrcet of f'Tnllncll l<esoluruhan : 
l>rnfnmPri berslh l>l~nmnn bersU• i>u~aan. 
luar Negurl tlalem Negnrf' bek Tunali 
novorru11r Expetrdi1Ut111 0..11r111t Nol t-or11lgrf N11l Oomll;tle IJs11 ol C8m 
Surplu!IIOillelt f1oiTOWirrg 1Jorrowfni1! f111lence' 
nnUNel 
f1nUNEt 
1970 .. .. .. . . N.A. N.A. 
1984 .. .. .. .. 3.:100.1 :1.108.9 
1905 .. .. .. .. 3.aou 1,907.3 
1908 1,5~2A 1,003.9 
·19&7' .• 
.. .. .. 
.. .. .. - -
INOONESII\ 
' tNDONESIII 
1970 .. .. .. .. 951.3 1.219.0 
1984 .. .. .. .. 10.2~8.9 18.711.6 
11105 .. .. .. .. 18.813.4 18.883.9 
1908 .. .. .. 12,820.5 14.231.3 
19071 :: .. .. .. 12,189.1 13,733.9 
MAlAYSfll 
MALAYSIII 
1970 .. .. .. .. 765.5 934.3 
1904 .. .. .. .. IUTo.e 18.000.0 
1885 .. .. .. .. 13;217.8 14.768.~ 
1988 .. .. .. 10,621.9 13.127.:1 
1987' .. .. .. .. 10,800.0 12.020.8 
FIUPINA 
PltlltPPtNES 
1870 .. .. .. .. 753.0 7438 
1904 .. .. .. .. 2.875.8 3.379.7 
190~ .. .. . .. .. 3.623.8 4.210.1 
1988 .. .. .. 3.880.0 5.382.:! 
1907' .. .. .. .. 4,933.8 5,093.1 
SINOIIPiJnA l 
SINGIIPOne I 
1970 .. .. .. .. 443.0 370.6 
1984 .. .. .. .. 6.365.11 4.611 II 
1985 .. .. .. .. 7,030.6 8.611.9 
1906 .. .. .. 8.834.11 6.330.3 
19071 :: .. .. .. 8,432.2 7,105.9 
1-iEOEhl Tillll 
niAILIINtJ 
1870 .. ' .. 902.2 1,180.5 .. .. 
190. .. .. .. .. II,70U 7.037.2 
1965 .. .. .. . .. 6.243.7 8.337.0 
1960 .. .. .. 8,!1112.5 8.5~5.7 
1907' .. .. .. .. 1,462.7 8,817.6 
1 Mef11iomlungl hasQ dan parnberlan yang dllerlmq. 
' J..longamlm'IJI perbelnnJnan don plnlaman lotnll bnrar on bonk. 
1 flr'!l~a-ungl<a dnlnm hmungnn ndalnh plnJomon bnrslh lermosulc 
plnJomnn lunr negerl dan dnlnm nogorl. 
' Unruh Molayslo, lerdlrl dor,Pnda lerlrna11n hhos don parubahon haria. 
' 1\nggaran. 
Nols: K11dar porluhran yor'll dlgunaknn 11dnloh sornn seperil 
· dl Jndual I .2. 
- Sumbar: II'S, laporan·lo!IO'on negnrn don Polunfl•k·pehonjuk Panllng 
Nagnrn-nagnra l<aenggolonn 1\0b. 
.. 
' 
; 
N.A. NIL tl.A. N.A. 
1.193.2 Nil N.A. ~"· 1.097.0 Nil NA .A. 
459.6 Nil N.A. N.A. 
-
NIL 
I 
i. N.A. NA. 
- 287.7 - tt:Jo ~.I 
- 482.8 8IU -:10.8 - 1:1.8 
-
1!50.8 305.7 
-
-au 
-1.810.11 1.5911.0 .. 
-
tU 
-1,584.8 1,504.2 ; . eo.li 
-
- 168.8 -oe 99.~ .to.o 
-b2U 2.160.~ 1.468.8 41U 
-1.&38.8 891.7 f.&OI.7 -este 
-:!.605.4 ~73.8 1.762.11 3888 
-1,948.8 - 1711.3 ·• 3,838.5 -817.8 
i 
u 
- -
-&9.8 
- 6039 . 92.8 Ul.l -
- 606.3 - 7.9 r &94.1! ;_ 
-1.622.2 174~3 1,347.9 
-
- 859.2 272.8 11811.~ -
64.5 - 10~.8 45.1 - u 
763.7 - . 17.4 1,669.7 -:!,308.0 
388.8 - 21.0 1.5553 -1,922.9 
sou -2.064.2 1.569.6 
-
-753.7 
-
402.1 1,155.8 
-
' 
' 
- 258.3 _; 1200.111 117.2 
-1;253.0 17~.8 1,122.4 -4U · 
-:!.093.3 6819 I.:JOU 28.8 
-1,963.2 438.2 I 1;627.0 
-
-1,354.8 202_9. 1;151.11 
-
'. 
1 COtrrpr#Sflt fiiVIIilllfl lind grllniS lfltflfwld. 
1 Cornprls11s IIJrPfllldillllll and l11rfdlng loss repll)'rllllnls. 
1 FlfllltfiS ftJ bt~~chols llrll nel bdnvttfng Including (orwff111 11rrd dom.srie 
borruttflrg.. · 
' f'ot MBieysln, eornprlslls o; ~pecl11l rflc!llpli 1111d ellllrtgll 1rt 11sselt. 
1 Esllntlllll. 
Nola: £Jrdurng11 r11111 uslld fs '"''"" to 1/ral In tabl11 1.1. 
Source: If'S, nol/onlll rilporis drrd f(lly lrtdlc"lors or VeVIIfoplng COIIII· 
lrlos of 11Df1. 
: 
I 
i 
' 
I 
I 
. 
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PHARMACEUTICAL INDUSTRY PROFILE 
+--------------------+-----------------+-----------------+----------------+ 
MALAYSIA SINGAPORE THAILAND 
Drugs per capita 
consumption 
Drugs imports 
U.S.$7 
U.S.$82 Million 
,No. of formulation 
!plants 
l 
!Private MNC Is ( 3) 
Local (15) I 
'Govt 1 
Mark up to W/saler 
Nark up to the 
Public 
PHARMACIES 
IW/sale + 20%-30% 
237 
Chinese Drug Stores 2860 
Govt Hospitals 78 District Hospt 
16 General Hospt 
2 Univ. Hospt 
Private Hospitals 133 
Health Centres 139 (PM) Main H.S 
234 (PM) S.H.S. 
Drug registration Yes 
,required 
INo. doctors (Govt) 2228 (1985) 
',No. of doctors 
~private 
No. of dentists 
2711 (1985) 
555 (Public) 
575 (Private) 
U.S.$23 
U.S.$58 Million 
MNC's (3) 
r,ocal (15) 
1 (Stopped June 
1988) 
CIF + 38% 
W/sale + 33~6 
98 
>1000 
12 
12 
26 
Yes 
1492 (1986) 
1355 (1986) 
97 (Govt) 
U.S.$4.40 
U.S.$165 Million 
189 
- 1 (G.P.O.) 
- 1 (A.R.M.Y.) 
CIF + 20% 
W/sale + 25% 
I 
1st cls.ss 3450 
2nd class 5385 
I 
I 
6614 Traditional! 
I 
I 
15 Central/Regn I 
72 General Hasp. I 
>482 district Hpl 
N.A. 
7666 
Yes 
13612 ( 1986) 
2778 (Govt) 
---------------------------------------------------------------------------+ 
*N.A. : Not available Source : MPTMA, I .M.S. , nO PH Singapore • 
Singapore Medical Council Annual Report, 
D. r. .A. Thailand, MOPH Thailand 
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MALAYSIA 
1985 
M$140 MILLION - 40% 
,_[ _ ___,] .PRESCRIPTION 
MARKET SIZE J.l.1$350 HILLIOO 
~OTC 
M$600 MILLION - 60% 
MARKET SIZE M$1 BILLION 
SOURCE: Pharmaceutical Industry,P.N.B. - Quarterly Econanic And Investment 
Review, January - March, 1986. 
Pharmaceutical Industry : Caoacity &·Utilisation (on basis of 1 shift) ··· ··-··· 
Dosage 
forms 
1 Tablets Utilized 
ex millions) Installed 
Loaded 
2 Capsules Utilized 
ex millions) Installed 
Loaded 
3 Injectable 
Liquid 
C'OOO Lts) 
4 Injectable 
Powders 
(kg) 
5 Oral Liquid 
<Million Lt> 
6 Topical 
Por.-Jder 
(kg) 
7 Ointment-
Cream 
( '000 kg) 
Util.ized 
Installed 
Loaded 
Utilized 
Installed 
Loaded 
Utilized 
Installed 
Loaded 
Utilized 
Installed 
Loaded 
Utilized 
Installed 
Loaded 
Pr-ivate 
3,799 
8,812 
43/. 
612 
2,086 
29/. 
4,241 
8,964 
47/. 
37,004 
88,004 
42/. 
11.03 
27.36 
40/. 
1 '085, 176 
1,824,421 
59/. 
401 
1,265 
32/. 
Sl.lrvey 1 
G P 0 
761 
952 
80/. 
389 
486 
80/. 
344 
430 
80/. 
1. 30 
1. 63 
80/. 
24 
30 
80/. 
Total 
4,590 
9,764 
47/. 
612 
2,086 
29/. 
4,630 
9,450 
50/. 
37,348 
88,430 
42/. 
12.33 
29.00 
43/. 
1,085,176 
1,824,420 
59/. 
425 
1,295 
33/. 
Source : Proceedings 9th Asian Congress of Pharmaceutical Sciences Seoul, 1982 
Estimated 
Installed 
Capacity 
10,740 
2,295 
• 
9,450 
90,000 
32 
2,000,000 
1,500 
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SLlrvey 11 
7,030 
13,214 
53/. 
2,102 
3,086 
bBl. 
10' 162 
17,540 
58'1. 
19,606 
32,430 
60/. 
15.62 
18.62 
30/. 
1,714,000 
3,223,979 
53/. 
2,023 
4,953 
41/. 
Number of Health Facilities and Pharmacies/Manufacturers/Importers 
<Private Sector) December 1987 - Thailand <Source : MOPH> 
+-------------------------------------------------------------------------~----+ 
Category : Bangkok : Up-Country : Total 
:---------------------------------------------~---------~------------:---------: 
11. Health Facilities 
1.1 Modern Health Facilities 
Medical Facilities with beds 
- without beds 
Dental Facilities <without bed) 
Midwife Facilities - with bed 
- without bed 
1.2 Health Facilities <2nd Class) 
- Medical 
Dental 
- t"li dwi fe 
- without bed 
1.3 Traditional Health Facilities 
Medical - with bed 
without bed 
Midwife - with bed 
- without bed 
109 
3,170 
921 
17 
30 
21 
25,0 
10 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
6 : 
58,7 : 
I 
I 
2 : 
2 I I 
199 
4,144 
938 
110 
922 
58 
308 
894 
9 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
299 : 
I 
I 
22 I I 
3 I I 
305 
7,314 
1,859 
127 
952 
79 
558 
904 
15 
886 
24 
5 
+------------------------------------------------------------------------------+ 
Appeno.~x 1~ 
Number of Health Facilities and Pharmacies/Manufacturers/Importers 
<Private Sector) December 1987 - Thailand <Source : MOPH> 
+------------------------------------------------------------------------------+ 
Category : Bangkok : Up-Country : Total 
:---------------------------------------------:---------:------------:---------
l2. Pharmacies 
2.1 Modern 
2.2 Modern <Finished Products> 
2.3 Modern (for Animals) 
2.4 Traditional 
l3. Manufacturers 
l4. Importer-s 
- 1'1odern 
- Traditional 
- Modern 
Traditional 
1 '901 
713 
23 
1,210 
150 
282 
382 
89 
I 
I 
I 
I 
I 
I 
I . 
I 
I 
I 
: 
I 
I 
1 '581 
28 
141 
•+' 865 
38 
418 
27 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
3,482 
441 
164 
6, ()73 
188 
700 
409 
89 
+------------------------------------------------------------------------------+ 
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Export of Pharmaceutical Products 
+---------------------------------------------------------------
Exports of Pharmaceutical :. Total Exports : 
Year : Products (million Baht) : (million Baht) 
:---------:------------------------------:--------------------· 
:l985 213.2 193 '::::.65 
1986 230.4 :~31 ~ 224 
1987 290.5 254, 50(H+ 
Ave. 
+--------------------------------------------------------------
* estimated by NESDS 
Source Thai Trade Monitor 1987 - 88 
1986 MAJOR PHARMACEUTICAL EXPORTS - THAILAND 
- Blood fluids and electrolytes 
- Antibiotics 
- Other drugs 
Source Technical Division, F.D.A 
(Million Bahts) 
58.563 
41.758 
109.172 
25.00% 
18.15% 
47.46% 
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THAILAND EXPORTS COUNTRY OF DESTINATION 1986 
1. Hong l<ong 6. Laos 
2. Singapore 7. Taiwan 
3. Malaysia 8. Burma 
4. Japan 9. Iraq 
5. Australia 10. Iran 
Source Thai Trade Monitor 1987 - 88 
Source 
Number of health professionals 1988 
Physicians 
Dentists - First Class 
Pharmacists - First Class 
Physical therapists 
Medical technologist 
Nurse - First Class 
Midwifery - First Class 
Nurse and Midwifery - First Class 
Ministry of Public Health 
15,074 
3,307 
6,965 
527 
1,962 
17,922 
13,863 
30,863 
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Appendix 84 
Consumer Price Index for Whole Kingdom by Groups 
(1976 == 1000) 
+---~---------------------------------------------------------------------------------------+ 
Line : Weights : 1983 : 1984 : 1985 : 1986 : 1987 
------------------------------:---------:---------:---------1---------:---------:---------: 
1. All Items I 100.00 I 187.9 I 189.5 194·. 1 197.7 I 202.6 I I I I 
I I I I 
I I I I 
2. Food I 40.30 I 185.5 I 183.4 178.9 I 184.1 I I I I 
I I I I 
I I I I 
3. Non-Food I 59.70 I 186.7 I 191.2 202.3 207.5 I 213.0 I I I I 
I I I I 
I I I 
4. Clc>thing I 6.74 I 180.5 184.3 I 196.0 I 201.0 I I I 
I I I 
I I I 
J::' Hc)usi.ng I 24. 13 I 184.7 191.9 . 205. 1 I 216.0 I 223.5 ...Jo I I I I 
I I I I I 
I I I I I 
6. Personal and medical care: 5.48 I 179.6 185.6 192.4 I 194.2 I 197.4 I I I I 
I I I I 
I I I I 
7 .. Tr·anspor·tati on I 9.47 I 232.5 232.9 249.5 I 242.7 I 244.2 I I I I 
I I I I 
I I I I 
8. Recreation, Reading and I 10.27 I 175.8 178.1 182. 1 I 183.5 I 185.8 I I I I 
Education 
I I I I I I 
I I I I I I 
9. to.baccn and Alcoholic I 3.62 I 1. 59. 8 I 159.6 I 178.5 I 186.0 I 197.2 I I I I I I 
Beverages 
+----------------------~-------------------------------------------------------------------+ 
Source Department of Business Economics, Ministry of Commerce 
** CPI for medicine = 2.6 
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Export of Pharmaceutical Products 
================================= 
( 1985 - 1987 ) 
+---------------------------------------------------------·------------+ 
1985 1986 1987 
:---------------------------------------------------------------------: 
Value Million Baht 213.3 23(>.5 267.1 
:----------------------------------------------------------~-----------: 
Growth I. 8.06 15.9 
+-------------------------------------------------.-------------------·-+ 
Market in l.987 Hong k:ong 
Singapore 
Laos 
ALlstral i a 
SoLlrce Department of Business Economics, Ministry of Commerce 
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